var images_info;if (!images_info) images_info =[]; images_info["83"]={"83000":{"type":"graphic_picture","displayName":"Inferior epigastric vessels round ligament","title":"Laparoscopic view of inferior epigastric vessels and round ligament","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Laparoscopic view of inferior epigastric vessels and round ligament</div><div class=\"cntnt\"><img style=\"width:504px; height:382px;\" src=\"images/OBGYN/83000_Inf_epigast_vess_rnd_SRC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laparoscopic view of the inferior epigastric vessels, located lateral to the medial umbilical ligaments (obliterated umbilical ligaments), and the round ligament entering the inguinal canal. It is important during placement of the lower abdominal trocars during laparoscopy to avoid the inferior epigastric vessels.</div><div id=\"graphicVersion\">Graphic 83000 Version 2.0</div></div></div>"},"83002":{"type":"graphic_picture","displayName":"Ovarian vessels","title":"Ovarian vessels at pelvic brim","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ovarian vessels at pelvic brim</div><div class=\"cntnt\"><img style=\"width:504px; height:385px;\" src=\"images/OBGYN/83002_Ovarian_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laparoscopic view of the ovarian vessels at the pelvic brim. The ovarian vessels supply the right ovary and tube, crossing over the pelvic brim and the bifurcation of the external and internal iliac vessels.</div><div id=\"graphicVersion\">Graphic 83002 Version 1.0</div></div></div>"},"83003":{"type":"graphic_figure","displayName":"Female pelvic lymph system","title":"Female pelvic lymph vessels and nodes","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Female pelvic lymph vessels and nodes</div><div class=\"cntnt\"><img style=\"width:594px; height:515px;\" src=\"images/OBGYN/83003_Female_pelvic_lymph_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphatic vessels and nodes. Posterior wall of abdomen and inguinal region.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83003 Version 1.0</div></div></div>"},"83004":{"type":"graphic_figure","displayName":"Time course of calcific aortic stenosis","title":"Time course of calcific aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Time course of calcific aortic stenosis</div><div class=\"cntnt\"><img style=\"width:523px; height:408px;\" src=\"images/CARD/83004_Time_crs_calci_aor_sten.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This conceptual framework for the natural history of calcific aortic valve disease illustrates the spectrum of disease from the 'at risk' patient to the patient with end-stage severe symptomatic aortic stenosis. Once aortic sclerosis is detectable, there is an increased risk of cardiovascular events, as shown by deviation of the survival curve (solid black line) from the expected event-free survival (dashed black line). At the onset of even mild symptoms, survival deviates even more from expected, with a dramatic decline in survival with severe symptomatic aortic stenosis. Aortic valve replacement (AVR) at the onset of early symptoms prevents these late adverse outcomes.</div><div class=\"graphic_reference\">Reproduced from: Otto CM. Calcific aortic valve disease: outflow obstruction is the end stage of a systemic disease process. Eur Heart J 2009; 30(16):1940-2. By permission of the European Society of Cardiology. Copyright Â© 2009 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 83004 Version 14.0</div></div></div>"},"83005":{"type":"graphic_picture","displayName":"Ureter at female pelvic brim","title":"Ureter at female pelvic brim","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ureter at female pelvic brim</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/OBGYN/83005_Ureter_fem_pelv_brim.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ureters are most easily identified at the pelvic brim, where they cross the bifurcation of the common iliac into the external and internal iliac vessels.</div><div id=\"graphicVersion\">Graphic 83005 Version 1.0</div></div></div>"},"83006":{"type":"graphic_picture","displayName":"Dyshidrotic eczema severe","title":"A severe form of dyshidrotic eczema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">A severe form of dyshidrotic eczema</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83006_Dyshidroticeczemasevere.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large bullae and signs of bacterial superinfection on the hands of a patient with severe dyshidrotic eczema.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83006 Version 5.0</div></div></div>"},"83007":{"type":"graphic_picture","displayName":"Dyshidrotic eczema large bullae","title":"Dyshidrotic eczema with large bullae","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic eczema with large bullae</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83007_Dyshidreczemalargebullae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large bullae resulting from coalescence of vesicles on the palms of a patient with severe dyshidrotic eczema.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83007 Version 7.0</div></div></div>"},"83008":{"type":"graphic_figure","displayName":"Female pelvic blood supply","title":"Female pelvic blood supply","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female pelvic blood supply</div><div class=\"cntnt\"><img style=\"width:439px; height:719px;\" src=\"images/OBGYN/83008_Female_pelvic_blood_supply.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The blood supply to the pelvis.<br />(A) The sagittal view of the pelvis without the viscera.<br />(B) The blood supply to one pelvic viscera.</div><div class=\"graphic_reference\">Reproduced with permission from: Berek JS. Berek &amp; Novak's Gynecology, 15th ed, Lippincott Williams &amp; Wikins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83008 Version 1.0</div></div></div>"},"83009":{"type":"graphic_figure","displayName":"Uterine and hypogastric artery ligation","title":"Uterine and hypogastric artery ligation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterine and hypogastric artery ligation</div><div class=\"cntnt\"><img style=\"width:438px; height:633px;\" src=\"images/OBGYN/83009_Uter_hypogast_art_ligation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical treatment of atonic uterine hemorrhage.<br />(A) Ligation of the uterine artery. The artery crosses over the ureter and is ligated beyond this point at the uterine corpus.<br />(B) Hypogastric artery ligation. Ligation of the anterior division of the internal iliac artery is performed after careful identification and retraction of the ureter, which usually overlies the bifurcation of the iliac artery into the external and internal iliac branches.</div><div class=\"graphic_reference\">Reproduced with permission from: Beckmann CRB, Ling FW, Laube DW, et al. Obstetrics and Gynecology, 4th ed, Lippincott Williams &amp; Wilkins, Baltimore 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83009 Version 1.0</div></div></div>"},"83010":{"type":"graphic_picture","displayName":"Dyshidrotic eczema mild","title":"Dyshidrotic eczema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic eczema</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83010_Dyshidrotic_eczema_mild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In mild forms of dyshidrotic eczema, tiny vesicles may be seen only on the lateral aspect of fingers.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83010 Version 3.0</div></div></div>"},"83011":{"type":"graphic_figure","displayName":"Avascular spaces female pelvis","title":"Avascular spaces of the female pelvis","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Avascular spaces of the female pelvis</div><div class=\"cntnt\"><img style=\"width:538px; height:511px;\" src=\"images/OBGYN/83011_Avascular-spaces-female-pelvis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic sectional drawing of the pelvis shows the firm connective tissue covering. The bladder, cervix, and rectum are surrounded by a connective tissue covering. The Mackenrodt ligament extends from the lateral cervix to the lateral abdominal pelvic wall. The vesicouterine ligament originating from the anterior edge of the Mackenrodt ligament leads to the covering of the bladder on the posterior side. The sagittal rectum column spreads both to the connective tissue of the rectum and the sacral vertebrae closely nestled against the back of the Mackenrodt ligament and lateral pelvic wall. Between the firm connective tissue bundles is loose connective tissue (paraspaces).</div><div class=\"graphic_reference\">Von Peham H, Amreich JA. Gynaekologische Operationslehre. S Karger, Berlin, Germany 1930.</div><div id=\"graphicVersion\">Graphic 83011 Version 2.0</div></div></div>"},"83013":{"type":"graphic_figure","displayName":"Indirect inguinal hernia","title":"Indirect inguinal hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Indirect inguinal hernia</div><div class=\"cntnt\"><img style=\"width:449px; height:608px;\" src=\"images/EM/83013_Indirect_inguinal_hernia_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Indirect hernias result from two anatomic defects: weakening of the fascia of the transversalis muscle fibers at the internal abdominal ring, and the potential space resulting from the a persistently patent processus vaginalis. In males, the obliteration of the processus vaginalis occurs during the first two years of life, but as many as 40 percent remain patent, 20 percent of which will later develop into inguinal hernias. The female counterpart of the processus vaginalis commonly disappears by eight months of gestation, although patency may persist into childhood. If patency persists, the patent processus is termed the canal of Nuck.</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss A, Wolfson AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83013 Version 1.0</div></div></div>"},"83015":{"type":"graphic_figure","displayName":"External view of a direct inguinal hernia ","title":"External view of a direct inguinal hernia ","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">External view of a direct inguinal hernia </div><div class=\"cntnt\"><img style=\"width:475px; height:608px;\" src=\"images/EM/83015_Ext_view_direct_ing_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct inguinal hernias protrude through Hesselbach's triangle above the inguinal ligament.</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss A, Wolfson AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83015 Version 1.0</div></div></div>"},"83016":{"type":"graphic_picture","displayName":"Ulcero-vegetative granuloma inguinale","title":"Ulcero-vegetative granuloma inguinale","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ulcero-vegetative granuloma inguinale</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/83016_Ulcero_veg_gran_inguinale.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ulcero-vegetative ulcers of granuloma inguinale start as pseudo-buboes that break down to form spreading ulcers, typically on the genitalia and in the inguinal region.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83016 Version 3.0</div></div></div>"},"83017":{"type":"graphic_picture","displayName":"Cystoscope components","title":"Cystoscope components","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Cystoscope components</div><div class=\"cntnt\"><img style=\"width:516px; height:525px;\" src=\"images/OBGYN/83017_Cystoscope_compon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The parts of a basic cystoscope: 1) lens; 2) bridge; 3) sheath.<BR>(B) Assembly of cystoscope parts.</div><div id=\"graphicVersion\">Graphic 83017 Version 1.0</div></div></div>"},"83018":{"type":"graphic_picture","displayName":"Cystoscope camera light source","title":"Cystoscope camera and light source","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystoscope camera and light source</div><div class=\"cntnt\"><img style=\"width:421px; height:334px;\" src=\"images/OBGYN/83018_Cysto_camera_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cystocope (A) camera and (B) light cord.</div><div id=\"graphicVersion\">Graphic 83018 Version 1.0</div></div></div>"},"83021":{"type":"graphic_table","displayName":"Psoralen drugs for PUVA","title":"Psoralens used with ultraviolet A light therapy (PUVA) for psoriasis and vitiligo","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Psoralens used with ultraviolet A light therapy (PUVA) for psoriasis and vitiligo</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Brand or generic</td> <td class=\"subtitle1\">Trade name(s)</td> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Preparation</td> <td class=\"subtitle1\">Suggested initial dose* (adult)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Methoxsalen<br /> (8-methoxypsoralen, 8-MOP)</td> <td>Brand</td> <td>Oxsoralen-Ultra</td> <td>Valeant Pharmaceuticals</td> <td>10 mg liquid filled soft-gelatin capsule</td> <td>0.4 mg/kg orally 1 hour prior to UVA<sup>&#182;</sup></td> </tr> <tr> <td>Generic</td> <td>N/A</td> <td>Oceanside Pharmaceuticals (a division of Valeant Pharmaceuticals)</td> <td>10 mg liquid filled soft-gelatin capsule</td> <td>0.4 mg/kg orally 1 hour prior to UVA<sup>&#182;</sup></td> </tr> <tr> <td>Generic</td> <td>N/A</td> <td>Strides Pharmaceuticals</td> <td>10 mg liquid filled soft-gelatin capsule</td> <td>0.4 mg/kg orally 1 hour prior to UVA<sup>&#182;</sup></td> </tr> <tr> <td>Brand<sup>&#916;</sup></td> <td>8-MOP</td> <td>Valeant Pharmaceuticals</td> <td>10 mg hard-gelatin capsule</td> <td>0.6 mg/kg orally 2 hours prior to UVA<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Brand</td> <td>Oxsoralen (lotion)</td> <td>Valeant Pharmaceuticals</td> <td>10 mg/mL lotion (in 71% ethanol)</td> <td>Diluted 1:10 with ethanol to deliver 0.1% strength; applied to affected area according to PUVA protocol (refer to text)</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Trioxsalen<br /> (4,5',8-trimethylpsoralen, trioxysalen, TMP)</p> Not available in the United States</td> <td>Brand</td> <td>Trisoralen (inactive trade name)</td> <td>ICN pharmaceuticals; Valeant (former United States&nbsp;manufacturer)</td> <td>5 mg</td> <td>0.6 mg/kg orally 2 hours prior to UVA</td> </tr> <tr> <td> <p>Bergapten<sup>&#9674;</sup><br /> (5-methoxypsoralen, 5-MOP)<sup>[1]</sup></p> Not available in the United States</td> <td>Brand</td> <td>Pentaderm, Psoraderm 5, Geralen</td> <td>May be available in some countries as an unlicensed product</td> <td>20 mg tablet<sup>&#9674;</sup></td> <td>1.2 mg/kg orally 2 hours prior to UVA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Doses must be given at least 48 hours apart.<br />Â¶ Weight-based doses are rounded to nearest 10 mg increment. <br />Î Older formulation having lower oral bioavailability and longer time to onset than newer Oxsoralen-Ultra.<br /><FONT class=lozenge>â</FONT> Micronized preparations appear to provide greater cutaneous absorption than unmicronized.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>McNeely W. 5-Methoxypsoralen: A review of its effects in psoriasis and vitiligo. Drugs 1998; 56:4.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 83021 Version 5.0</div></div></div>"},"83022":{"type":"graphic_figure","displayName":"Ankle sprains PI","title":"Ankle sprains","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Ankle sprains</div><div class=\"cntnt\"><img style=\"width:488px; height:686px;\" src=\"images/PI/83022_Ankle-sprains-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When a person sprains his or her ankle, the ankle joint turns too far in a particular direction. Inside the ankle are tough bands of tissue called ligaments, which hold the different bones together. During a sprain, one or more of those ligaments (shown in white) stretch too far or even tear.</div><div id=\"graphicVersion\">Graphic 83022 Version 1.0</div></div></div>"},"83023":{"type":"graphic_diagnosticimage","displayName":"Lytic lesions in the radius","title":"Multiple myeloma: Lytic lesions in the radius","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Multiple myeloma: Lytic lesions in the radius</div><div class=\"cntnt\"><img style=\"width:523px; height:584px;\" src=\"images/RADIOL/83023_Mult_myeloma_lytic_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The plain film of right radius in the AP projection is from a patient with multiple myeloma. The image reveals characteristic multiple punched out lesions in the proximal diaphysis of the right radius.<br />(B) A magnified view of the proximal radius.<br />(C) A magnified and enhanced view to exemplify the punched out, well defined nature of the lesions with no overt reaction by the surrounding bone.</div><div class=\"graphic_footnotes\">AP: Anteroposterior</div><div id=\"graphicVersion\">Graphic 83023 Version 2.0</div></div></div>"},"83025":{"type":"graphic_picture","displayName":"IgAV PI","title":"IgA vasculitis (Henoch-SchÃ¶nlein purpura)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">IgA vasculitis (Henoch-SchÃ¶nlein purpura)</div><div class=\"cntnt\"><img style=\"width:504px; height:352px;\" src=\"images/PI/83025_HSPPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Children with IgA vasculitis&nbsp;(Henoch-SchÃ¶nlein purpura)&nbsp;often develop a rash that looks like this on their legs and thighs.</div><div id=\"graphicVersion\">Graphic 83025 Version 4.0</div></div></div>"},"83026":{"type":"graphic_diagnosticimage","displayName":"Multiple myeloma effect on vertebral bodies","title":"Multiple myeloma: Osteopenia, compression fracture, and lytic disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple myeloma: Osteopenia, compression fracture, and lytic disease</div><div class=\"cntnt\"><img style=\"width:435px; height:511px;\" src=\"images/RADIOL/83026_Multiple_myeloma_osteopenia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The plain film of lumbar spine in the lateral projection is from a 38-year-old man with multiple myeloma. The image reveals evidence of decreased bone density, compression of L4 and T11 (arrows), and lytic disease with a soft tissue mass of the posterior elements of L2 (arrowhead).<br />(B) A correlative CT reconstruction in the sagittal projection of the thoracolumbar spine reveals multiple lytic changes in all of the visualized vertebral bodies, and reveals to better effect the destructive soft tissue process in the posterior elements of L2 (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Frymoyer JW, Wiesel SW, An HS, et al. The Adult and Pediatric Spine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83026 Version 3.0</div></div></div>"},"83028":{"type":"graphic_table","displayName":"Principles of prevention for exertional heat illness","title":"Principles of prevention for exertional heat illness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Principles of prevention for exertional heat illness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Ensure that appropriate medical care and equipment, including a cold water immersion tub or other effective tools for rapid cooling, are available at practices and games.</td> </tr> <tr> <td>Review and update emergency plans for exertional heat illness (EHI) annually with athletic directors, coaches, athletes, and medical personnel.</td> </tr> <tr> <td>Educate the medical staff, emergency personnel, athletes, coaches, and parents about EHI and proper acclimatization and hydration strategies.</td> </tr> <tr> <td>Include questions about EHI on pre-participation questionnaires and during examinations to identify \"high-risk\" individuals.</td> </tr> <tr> <td>Establish and follow heat acclimatization guidelines: These should allow individuals to acclimatize over the course of 10-14 days, progressively increasing the intensity and duration of activity and the amount of equipment.</td> </tr> <tr> <td>Establish and follow hot and humid weather activity guidelines that incorporate Wet Bulb Globe Temperature (WBGT) readings, time of day for activity, intensity and duration of activity, equipment, and rest and water breaks.</td> </tr> <tr> <td>Establish and follow clear policies to ensure proper hydration: Use appropriate rest to work ratios, weigh-ins before and after activity, and encourage drinking both water and sodium-containing fluids during activity.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83028 Version 2.0</div></div></div>"},"83029":{"type":"graphic_figure","displayName":"Atrial and ventricular septal defects PI","title":"Atrial and ventricular septal defects","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial and ventricular septal defects</div><div class=\"cntnt\"><img style=\"width:337px; height:333px;\" src=\"images/PI/83029_Atrial_vent_septal_defec_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a drawing of a normal heart. The heart has 4 chambers: right atrium, left atrium, right ventricle, and left ventricle. A child with an atrial septal defect has a hole between the right atrium and the left atrium. A child with an ventricular septal defect has a hole between the right ventricle and the left ventricle.</div><div id=\"graphicVersion\">Graphic 83029 Version 1.0</div></div></div>"},"83032":{"type":"graphic_figure","displayName":"Plantar fascia stretching","title":"Plantar fascia stretching exercise for plantar fasciitis","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Plantar fascia stretching exercise for plantar fasciitis</div><div class=\"cntnt\"><img style=\"width:515px; height:325px;\" src=\"images/RHEUM/83032_Plantar_fascia_stretch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise is performed seated, with the affected leg crossed over the contralateral leg. The hand on the affected side of the body is positioned with the fingers across the plantar aspect of the toes just distal to the metacarpophalangeal joints to pull the toes back (dorsally) toward the ankle and shin until feeling a stretching sensation in the arch of the foot (figure A). The tension in the plantar fascia should be confirmed by palpation (figure B). The stretch should be held for a count of 10 and repeated 10 times. The exercise should be performed three times each day.</div><div id=\"graphicVersion\">Graphic 83032 Version 2.0</div></div></div>"},"83041":{"type":"graphic_table","displayName":"Myths about exertional heat illness","title":"Myths about exertional heat illness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Myths about exertional heat illness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Misconception</td> <td class=\"subtitle1\">Explanation</td> </tr> <tr> <td>Athletes stop sweating when they develop exertional heat stroke (EHS)</td> <td>Since EHS occurs during intense exercise in the heat, athletes are almost always sweating profusely when they collapse. This widely held but completely <strong>inaccurate</strong> belief about EHS can delay diagnosis and is dangerous. </td> </tr> <tr class=\"divider_top\"> <td>Athletes must be severely dehydrated to develop EHS</td> <td>While dehydration may predispose athletes to exertional heat illness and can exacerbate EHS, it is <strong>not</strong> a necessary precondition. EHS can occur in as little as 20 minutes after the beginning of exercise, before severe fluid loss has occurred. Exercise intensity and environmental conditions (ie, heat and humidity) are the primary factors associated with EHS.</td> </tr> <tr class=\"divider_top\"> <td>Body temperature can be accurately determined using external means</td> <td>No external temperature assessment devices currently available have been proven accurate in athletes exercising in intense heat with a significant degree of hyperthermia. External temperature devices, including oral, tympanic, temporal, forehead sticker, and axillary devices, should <strong>never</strong> be used to diagnose EHS. The only device that is practical and accurate under these conditions is the rectal thermistor.</td> </tr> <tr class=\"divider_top\"> <td>Lucid mental status in a patient with severe heat illness means everything is okay</td> <td>Many patients with impending&nbsp;EHS appear lucid initially, only to progress to more severe disease. This initial period of normal mental function can mislead the clinician and obscure or delay the diagnosis. The lucid interval often coincides with minor central nervous system (CNS) dysfunction that is difficult to recognize.</td> </tr> <tr class=\"divider_top\"> <td>Shivering delays cooling</td> <td>Shivering does occur when a normothermic individual is placed in a cold water bath. However, this is seldom the case with hyperthermic individuals and rapid cooling occurs even in the few patients who manifest a shivering response.</td> </tr> <tr class=\"divider_top\"> <td>The onset of exertional heat stroke (EHS) is unpredictable</td> <td>Several predisposing factors for EHS are well documented. They include: environmental conditions (high temperature and/or high humidity), high intensity exercise, lack of acclimatization, poor physical fitness, equipment preventing heat loss, large mass to surface area ratio (eg, obesity), sleep deprivation, dehydration, and fever. </td> </tr> <tr class=\"divider_top\"> <td>Cold water immersion puts the patient at risk of drowning</td> <td>With proper precautions, there is almost no risk of drowning. Precautions include: supervising the patient at <strong>all</strong> times, obtaining adequate help from teammates and colleagues, and placing a sheet under the patient's armpits and across their chest to hold them upright and prevent their head from falling under water.</td> </tr> <tr class=\"divider_top\"> <td>Cold water immersion is unsanitary</td> <td>While unsanitary conditions may be present due to vomiting or diarrhea, an unsanitary tub is an acceptable tradeoff when providing a life-saving intervention. A dirty tub is easily cleaned.</td> </tr> <tr class=\"divider_top\"> <td>Hypothermic afterdrop (continued cooling following immersion) can occur</td> <td>Hypothermic afterdrop may be a concern if the athlete is cooled too long. However, if a proper measurement device (ie, rectal thermistor or rectal thermometer) is used, core body temperature can be closely monitored during treatment to prevent such an afterdrop.</td> </tr> <tr class=\"divider_top\"> <td>Peripheral vasoconstriction (PVC) delays cooling</td> <td>Although PVC may occur during cold water immersion, it has little impact compared to the large conductive and convective thermal transfer that rapidly cools the body. While initially PVC may increase core body temperature slightly even in an EHS patient, a rapid decrease in body temperature immediately follows. </td> </tr> <tr class=\"divider_top\"> <td>Ice water immersion is uncomfortable for the patient</td> <td>The physical comfort of the patient and staff is a secondary concern in the face of a life-threatening illness like EHS. No significant harm is sustained by the patient during appropriately managed ice water immersion therapy.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Recommendations are adapted from:<br /><OL>&#xD;&#xA;<LI>The Korey Stringer Institute (ksi.uconn.edu).</LI>&#xD;&#xA;<LI>Casa DJ, McDermott BM, Lee EC, et al. \"Cold-water immersion: The gold standard for exertional heat stroke treatment,\" Exercise and Sports Science Reviews 2007; 35:141.</LI></OL></div><div id=\"graphicVersion\">Graphic 83041 Version 2.0</div></div></div>"},"83042":{"type":"graphic_diagnosticimage","displayName":"Acute cholecystitis with pericholecystic fluid","title":"Acute cholecystitis with pericholecystic fluid seen on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Acute cholecystitis with pericholecystic fluid seen on ultrasound</div><div class=\"cntnt\"><img style=\"width:583px; height:491px;\" src=\"images/RADIOL/83042_Acut_cholecyst_perich_fluid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Longitudinal view of the gallbladder showing small shadowing stones in the dependent part of the gallbladder (arrow). The ultrasound also shows a thickened wall in both the longitudinal projection (small arrowhead) and transverse projection (B).<br />(B) A small amount of pericholecystic fluid is noted (large arrowhead).<br />(C) The Doppler study shows an increase in blood flow to the wall (dashed arrow) reminiscent of the hyperemia of an inflammatory process. These findings are consistent with acute calculous cholecystitis.</div><div id=\"graphicVersion\">Graphic 83042 Version 3.0</div></div></div>"},"83043":{"type":"graphic_diagnosticimage","displayName":"Decubitus x-ray intraperitoneal free air","title":"Decubitus x-ray of intraperitoneal free air","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Decubitus x-ray of intraperitoneal free air</div><div class=\"cntnt\"><img style=\"width:573px; height:448px;\" src=\"images/RADIOL/83043_Free_air_decubitus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain film examination of the abdomen in decubitus position reveals a large amount of free air collecting in the right flank, clearly outlining the bowel wall (open arrows). When air is present on both sides of the bowel, the wall is outlined with clear distinction because of the contrast differences created on both sides. This is called Rigler's sign and is pathognomonic for free air in the peritoneal cavity. The yellow arrows show air-fluid levels in distended bowel.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83043 Version 1.0</div></div></div>"},"83045":{"type":"graphic_figure","displayName":"Femoral hernia anatomy","title":"Femoral hernia anatomy","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Femoral hernia anatomy</div><div class=\"cntnt\"><img style=\"width:526px; height:502px;\" src=\"images/EM/83045_Femoral_hernia_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The femoral hernia protrudes below the inguinal ligament and medial to the femoral artery, often in the upper thigh area.</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss A, Wolfson AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83045 Version 1.0</div></div></div>"},"83046":{"type":"graphic_algorithm","displayName":"Management LCH in children","title":"Management of multisystem Langerhans cell histiocytosis in children","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Management of multisystem Langerhans cell histiocytosis in children</div><div class=\"cntnt\"><img style=\"width:618px; height:708px;\" src=\"images/HEME/83046_Management_LCH_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Risk organs include hematopoietic system, liver, and/or spleen.</div><div id=\"graphicVersion\">Graphic 83046 Version 1.0</div></div></div>"},"83047":{"type":"graphic_figure","displayName":"Congenital anomalies of the processus vaginalis","title":"Congenital anomalies of the processus vaginalis","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Congenital anomalies of the processus vaginalis</div><div class=\"cntnt\"><img style=\"width:458px; height:563px;\" src=\"images/EM/83047_Congenital_proc_vaginalis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Congenital hydrocele.<BR>(B) Encysted hydrocele of the spermatic cord.<BR>(C) Preformed hemial sac for indirect inguinal hernia.</div><div class=\"graphic_reference\">Reproduced with permission from: Snell RS. Clinical Anatomy By Regions, 8th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83047 Version 1.0</div></div></div>"},"83048":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of abdominal aortic aneurysm","title":"Ultrasound of an abdominal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Ultrasound of an abdominal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:586px; height:251px;\" src=\"images/RADIOL/83048_US_abdomin_aortic_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound examination of the abdominal aorta is shown in transverse projection (A) with Doppler interrogation (B) and reveals an abdominal aortic aneurysm measuring 4.75 cms in maximum transverse diameter. Turbulent flow in the aneurysm is reflected in the non-uniform heterogeneous Doppler pattern.</div><div id=\"graphicVersion\">Graphic 83048 Version 2.0</div></div></div>"},"83049":{"type":"graphic_picture","displayName":"Cystoscopy video monitor","title":"Cystoscopy light source and video monitor","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cystoscopy light source and video monitor</div><div class=\"cntnt\"><img style=\"width:504px; height:510px;\" src=\"images/OBGYN/83049_Cystoscopy_video_monitor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture of what a cystoscopy set-up may look like. Note the fluid medium at the upper left corner of the photo, the monitor at the top of the screen, and the inputs for the light source and camera in the middle of the screen. Also note the assembled cystoscope on top of the light box.</div><div id=\"graphicVersion\">Graphic 83049 Version 1.0</div></div></div>"},"83050":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph intraperitoneal free air","title":"Chest radiograph of intraperitoneal free air","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of intraperitoneal free air</div><div class=\"cntnt\"><img style=\"width:442px; height:448px;\" src=\"images/RADIOL/83050_Intraperitoneal_free_air.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain AP radiograph of the chest taken with the patient upright reveals a small amount of free air under the right hemidiaphragm confirming the diagnosis of a perforated abdominal viscus. The lucent, crescent shaped free air is noted between the arrows. The dome of the liver (arrow) and the soft tissue shadow of the right hemidiaphragm (arrowhead) border the free air.</div><div class=\"graphic_footnotes\">AP: anterior-posterior; PA: posterior-anterior.</div><div id=\"graphicVersion\">Graphic 83050 Version 3.0</div></div></div>"},"83051":{"type":"graphic_picture","displayName":"Blepharitis PI","title":"Blepharitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blepharitis</div><div class=\"cntnt\"><img style=\"width:432px; height:278px;\" src=\"images/PI/83051_Anterior_blepharitis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blepharitis is an inflammation of the eyelids that causes redness and swelling. The skin of the eyelids might also scale or flake, as in this picture.</div><div id=\"graphicVersion\">Graphic 83051 Version 1.0</div></div></div>"},"83053":{"type":"graphic_picture","displayName":"Dyshidrotic eczema mild 3","title":"Mild dyshidrotic eczema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mild dyshidrotic eczema</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83053_Dyshidrotic_eczema_mild_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mild forms of dyshidrotic eczema are clinically characterized by a small number of vesicles and mild erythema and desquamation.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83053 Version 3.0</div></div></div>"},"83055":{"type":"graphic_picture","displayName":"Dyshidrotic eczema severe 2","title":"Severe dyshidrotic eczema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Severe dyshidrotic eczema</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83055_Dyshidrotic_eczema_severe_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coalescing vesicles involve the entire palmar surface in this patient with severe dyshidrotic eczema.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83055 Version 4.0</div></div></div>"},"83056":{"type":"graphic_picture","displayName":"Dyshidrotic eczema moderate","title":"Dyshidrotic eczema of moderate severity","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic eczema of moderate severity</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83056_Dyshidroticeczemamoderate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In palmar acute dyshidrotic eczema, the vesicles are tense, deep-seated, and multilocular, resulting in a \"tapioca pudding\" appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83056 Version 6.0</div></div></div>"},"83071":{"type":"graphic_table","displayName":"MODY common gene mutations","title":"Maturity onset diabetes of the young: More commonly identified gene mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maturity onset diabetes of the young: More commonly identified gene mutations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Genetic defect</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Beta cell defect</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Risk of microvascular disease</td> <td class=\"subtitle1\">Optimal treatment</td> </tr> <tr> <td class=\"centered\">1</td> <td>Hepatocyte nuclear factor-4-alpha</td> <td>&#60;10%</td> <td>Reduced insulin secretory response to glucose</td> <td>Normal renal threshold for glucose</td> <td>Yes</td> <td>Sulfonylureas</td> </tr> <tr> <td class=\"centered\">2</td> <td>Glucokinase gene</td> <td>15 to 31%</td> <td>Defective glucokinase molecule (glucose sensor), increased plasma levels of glucose are necessary to elicit normal levels of insulin secretion</td> <td>Mild, stable, fasting hyperglycemia, often diagnosed during routine screening. Not progressive.</td> <td>Generally no</td> <td>Diet</td> </tr> <tr> <td class=\"centered\">3</td> <td>Hepatocyte nuclear factor-1-alpha</td> <td>52 to 65%</td> <td>Abnormal insulin secretion, low renal threshold for glucose</td> <td>Low renal threshold for glucose, +glycosuria</td> <td>Yes</td> <td>Sulfonylureas</td> </tr> <tr> <td class=\"centered\">4</td> <td>Insulin promoter factor 1</td> <td>Rare</td> <td>Reduced binding to the insulin gene promoter, reduced activation of insulin gene in response to hyperglycemia</td> <td>Rare, pancreatic agenesis in homozygotes, less severe mutations result in mild diabetes</td> <td>Yes</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">5</td> <td>Hepatocyte nuclear factor-1-beta</td> <td>Rare</td> <td>&nbsp;</td> <td>Pancreatic atrophy, renal dysplasia, renal cysts, renal insufficiency, hypomagnesemia</td> <td>Yes</td> <td>Insulin</td> </tr> <tr> <td class=\"centered\">6</td> <td>Neurogenic differentiation factor-1</td> <td>Rare</td> <td>Pancreatic development</td> <td>&nbsp;</td> <td>Yes</td> <td>Insulin</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Naylor R, Philipson LH. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf) 2011; 75:422.</LI>&#xD;&#xA;<LI>Ramesh SC, Marshall I. Clinical suspicion of Maturity Onset of Diabetes of the Young in pediatric patients diagnosed with diabetes mellitus, Indian J Pediatr 2012; 79:955.</LI>&#xD;&#xA;<LI>Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 2011; 343:d6044.</LI></OL></div><div id=\"graphicVersion\">Graphic 83071 Version 4.0</div></div></div>"},"83072":{"type":"graphic_table","displayName":"Clinical features distinguishing T1DM T2DM MODY","title":"Clinical features distinguishing type 1 diabetes, type 2 diabetes, and maturity onset diabetes of the young","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features distinguishing type 1 diabetes, type 2 diabetes, and maturity onset diabetes of the young</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Type 1 diabetes mellitus</td> <td class=\"subtitle1\">Type 2 diabetes mellitus</td> <td class=\"subtitle1\">MODY</td> </tr> <tr> <td>Age of diagnosis (years)</td> <td>Majority &#60;25, but may occur at any age</td> <td>Typically &#62;25 but incidence is increasing in adolescents, paralleling increasing rates of obesity in children and adolescents*</td> <td>&#60;25</td> </tr> <tr> <td>Weight</td> <td>Usually thin, but with obesity epidemic overweight and obesity at diagnosis becoming more common</td> <td>&#62;90 percent at least overweight</td> <td>Similar to general population</td> </tr> <tr> <td>Autoantibodies</td> <td>Present</td> <td>Absent</td> <td>Absent</td> </tr> <tr> <td>Insulin dependent</td> <td>Yes</td> <td>No</td> <td>No</td> </tr> <tr> <td>Insulin sensitivity</td> <td>Normal when controlled</td> <td>Decreased</td> <td>Normal (may be decreased if obese)</td> </tr> <tr> <td>Family history of diabetes</td> <td>Infrequent (5 to 10 percent)</td> <td>Frequent (75 to 90 percent)</td> <td>Multigenerational, ie, &#62;2 generations</td> </tr> <tr> <td>Risk of diabetic ketoacidosis</td> <td>High</td> <td>Low</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MODY: maturity onset diabetes of the young.<br />* In North America, type 2 diabetes predominates in Hispanic, African-American, Native American, Canadian First Nation, Pacific Islander, and Asian-American youth.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Naylor R, Philipson LH. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf) 2011; 75:422.</li>&#xD;&#xA;    <li>Ramesh SC, Marshall I. Clinical Suspicion of Maturity Onset of Diabetes of the Young in Pediatric Patients Diagnosed with Diabetes Mellitus. Indian J Pediatr 2011; Dec 10 [ePub].</li>&#xD;&#xA;    <li>Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 2011; 343:d6044.</li>&#xD;&#xA;    <li>Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005; 146:693.</li>&#xD;&#xA;    <li>De Ferranti SD, Osganian SK. Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. Diab Vasc Dis Res 2007; 4:285.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 83072 Version 2.0</div></div></div>"},"83076":{"type":"graphic_picture","displayName":"Cystoscope","title":"Cystoscope","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Cystoscope</div><div class=\"cntnt\"><img style=\"width:540px; height:370px;\" src=\"images/OBGYN/83076_Cystoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cystoscope with the parts fully assembled.</div><div id=\"graphicVersion\">Graphic 83076 Version 1.0</div></div></div>"},"83079":{"type":"graphic_table","displayName":"FISH classification MM","title":"Revised primary molecular cytogenetic classification of myeloma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised primary molecular cytogenetic classification of myeloma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">FISH abnormality</td> <td class=\"subtitle1\">Percentage of myeloma patients</td> </tr> <tr> <td>Trisomy(ies) without IgH abnormality</td> <td class=\"centered\">42</td> </tr> <tr> <td class=\"sublist1_start\">IgH abnormality without trisomy(ies)</td> <td class=\"sublist_other_start_centered\">30</td> </tr> <tr> <td class=\"sublist1\">t(11;14)</td> <td class=\"sublist_other_centered\">15</td> </tr> <tr> <td class=\"sublist1\">t(4;14)</td> <td class=\"sublist_other_centered\">6</td> </tr> <tr> <td class=\"sublist1\">t(14;16)</td> <td class=\"sublist_other_centered\">4</td> </tr> <tr> <td class=\"sublist1\">t(14;20)</td> <td class=\"sublist_other_centered\">&#60;1</td> </tr> <tr> <td class=\"sublist1\">Unknown partner/deletion of IgH region</td> <td class=\"sublist_other_centered\">5</td> </tr> <tr> <td class=\"sublist1_start\">IgH abnormality with trisomy(ies)</td> <td class=\"sublist_other_start_centered\">15</td> </tr> <tr> <td class=\"sublist1\">t(11;14)</td> <td class=\"sublist_other_centered\">3</td> </tr> <tr> <td class=\"sublist1\">t(4;14)</td> <td class=\"sublist_other_centered\">4</td> </tr> <tr> <td class=\"sublist1\">t(14;16)</td> <td class=\"sublist_other_centered\">1</td> </tr> <tr> <td class=\"sublist1\">t(6;14)</td> <td class=\"sublist_other_centered\">&#60;1</td> </tr> <tr> <td class=\"sublist1\">Unknown partner/deletion of IgH region</td> <td class=\"sublist_other_centered\">7</td> </tr> <tr> <td>Monosomy 14 in absence of IgH translocations or trisomy(ies)</td> <td class=\"centered\">4.5</td> </tr> <tr> <td>Other cytogenetic abnormalities in absence of IgH translocations or trisomy(ies) or monosomy 14*</td> <td class=\"centered\">5.5</td> </tr> <tr> <td>Normal</td> <td class=\"centered\">3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table describes the distribution of various abnormalities detected by fluorescent in situ hybridization (FISH) in a population of 484 patients with newly diagnosed symptomatic multiple myeloma.</div><div class=\"graphic_footnotes\">* These included primarily monosomy 13 and p53 abnormalities.</div><div class=\"graphic_reference\">This research was originally published in Blood. Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119:2100. Copyright &copy; 2012 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 83079 Version 4.0</div></div></div>"},"83081":{"type":"graphic_picture","displayName":"Cystoscopic view bladder tumor","title":"Cystoscopic view of a bladder cancer","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cystoscopic view of a bladder cancer</div><div class=\"cntnt\"><img style=\"width:504px; height:423px;\" src=\"images/OBGYN/83081_Cystosc_view_bladder_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cystoscopic view of a bladder tumor. Note the calcification.</div><div class=\"graphic_reference\">Courtesy of Marcus L Quek, MD.</div><div id=\"graphicVersion\">Graphic 83081 Version 1.0</div></div></div>"},"83086":{"type":"graphic_table","displayName":"Indications for posthumous reproduction","title":"Indications for posthumous reproduction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for posthumous reproduction</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Scenario</td>\r\n            <td class=\"subtitle1\">Gamete provider(s)</td>\r\n            <td class=\"subtitle1\">Requester(s)</td>\r\n            <td class=\"subtitle1\">Techniques</td>\r\n            <td class=\"subtitle1\">Considerations</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Possibility of death is anticipated</td>\r\n            <td>\r\n            <p>Military personel in combat zones or other high risk occupations<sup>[2]</sup></p>\r\n            <p>Patients with potentially fatal illness (eg, cancer)<sup>[2]</sup></p>\r\n            </td>\r\n            <td>The gamete provider and a surviving partner or family member</td>\r\n            <td>Gamete/embryo cryopreservation</td>\r\n            <td>Satisfies issues of informed consent from gamete provider prior to their death and respect for autonomy of the deceased</td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td>Fertility preservation</td>\r\n            <td>Patients are expected to survive a potentially gonadotoxic event, such as chemotherapy or radiation for cancer</td>\r\n            <td>Usually a surviving partner or family member</td>\r\n            <td>Cryopreservation of gametes, embryos, or reproductive tissues (eg, ovarian tissue)</td>\r\n            <td>\r\n            <p>Tissues are stored for future use in anticipation of probable cure</p>\r\n            <p>Disposition of reproductive tissues should be decided at the time of their collection<sup>[1]</sup></p>\r\n            <p>Legal minors may not be able to give informed consent</p>\r\n            </td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td>General infertility</td>\r\n            <td>Individuals/couples previously or currently using assisted reproductive technologies for routine indications</td>\r\n            <td>\r\n            <p>Usually a surviving partner or family member</p>\r\n            <p>Possibly an unknown recipient (in the case of gamete or embryo donation)<sup>[3]</sup></p>\r\n            </td>\r\n            <td>Gamete/embryo cryopreservation</td>\r\n            <td>\r\n            <p>Cryopreserved gametes or embryos already stored for use by the intended parents while living<sup>[3]</sup></p>\r\n            <p>Desire to reproduce while alive is explicit, but wishes concerning posthumous reproduction are not always considered</p>\r\n            <p>Disposition of gametes/embryos in case of death should be determined prior to freezing<sup>[1]</sup></p>\r\n            <p>Full disclosure and 3rd party consent required in cases of anonymous gamete/embryo donation<sup>[1]</sup></p>\r\n            </td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td>Sudden unexpected death or incapacitated state</td>\r\n            <td>Patients suffering recent death, coma, or irrecoverable illness rendering them unable to provide consent for PAR<sup>[4]</sup></td>\r\n            <td>Surviving partner or family member</td>\r\n            <td>Posthumous or perimortem gamete retrieval and cryopreservation</td>\r\n            <td>\r\n            <p>Often no opportunity to obtain consent from the prospective gamete donor</p>\r\n            <p>Gamete retrieval can be invasive and is usually time-sensitive</p>\r\n            <p>The act may be of emotionally therapeutic value for survivors even if the gametes are rarely if ever used</p>\r\n            </td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>ESHRE Task Force on Ethics and Law, Pennings G, de Wert G, et al. ESHRE Task Force on Ethics and Law 11: Posthumous assisted reproduction. Hum Reprod 2006; 21:3050.</li>&#xD;&#xA;    <li>Kindregan CP. Dead Dads: Thawing an Heir from the Freezer. William Mitchell Law Review 2009; 35:433.</li>&#xD;&#xA;    <li>Ethics Committee of the American Society for Reproductive Medicine. Posthumous reproduction. Fertil Steril 2004; 82 Suppl 1:S260.</li>&#xD;&#xA;    <li>Greer DM, Styer AK, Toth TL, et al. Case records of the Massachusetts General Hospital. Case 21-2010. A request for retrieval of oocytes from a 36-year-old woman with anoxic brain injury. N Engl J Med 2010; 363:276.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 83086 Version 2.0</div></div></div>"},"83087":{"type":"graphic_table","displayName":"Pseudorenal panel abnormalities paraproteinemia","title":"Pseudorenal panel abnormalities described with paraproteinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pseudorenal panel abnormalities described with paraproteinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Chemical</td> <td class=\"subtitle1\">Paraprotein type described</td> <td class=\"subtitle1\">Effect</td> <td class=\"subtitle1\">Mechanism</td> </tr> <tr> <td>Sodium</td> <td>IgG, IgM, IgA</td> <td>Hyponatremia</td> <td>Water exclusion effect*</td> </tr> <tr> <td>Chloride</td> <td>IgG</td> <td>Hypochloridemia</td> <td>Water exclusion effect</td> </tr> <tr> <td>CO<sub>2</sub></td> <td>IgG, IgM</td> <td>Hypobicarbonatemia</td> <td>Interaction between paraprotein and assay reagent</td> </tr> <tr> <td>Blood urea nitrogen</td> <td>IgM</td> <td>Low urea levels</td> <td>Paraprotein coats electrodes and interferes with ionic conductance</td> </tr> <tr> <td>Creatinine</td> <td>IgG</td> <td>Low creatinine levels</td> <td>Precipitation<sup>&#182;</sup></td> </tr> <tr> <td>Creatinine</td> <td>IgM</td> <td>High creatinine levels</td> <td>Interaction between paraprotein and assay reagent</td> </tr> <tr> <td>Calcium</td> <td>IgA, IgM</td> <td>Hypercalcemia</td> <td>Precipitation</td> </tr> <tr> <td>Phosphate</td> <td>IgG, IgM, IgA</td> <td>Hyperphosphatemia</td> <td>Precipitation in acid pH</td> </tr> <tr> <td>Phosphate</td> <td>IgG</td> <td>Hypophosphatemia</td> <td>Precipitation</td> </tr> <tr> <td>Albumin</td> <td>IgM</td> <td>Hypoalbuminemia</td> <td>Slowing of reaction</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Increased colloid phase decreases the aqueous phase per volume of sample resulting in plasma having lower levels of electrolytes per volume of sample.<br />Â¶ Immunoglobulins can precipitate or flocculate because of chemical interaction with the test reagents or to their inherent chemical structure.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Krish P, Jhaveri KD. Hyperbicarbonatemia in a patient with Waldenstrom's macroglobulinemia. Kidney Int 2012; 81:603. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 83087 Version 2.0</div></div></div>"},"83089":{"type":"graphic_picture","displayName":"Anaplastic large cell lymphoma skin 1","title":"Primary cutaneous anaplastic large cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous anaplastic large cell lymphoma</div><div class=\"cntnt\"><img style=\"width:401px; height:504px;\" src=\"images/DERM/83089_Anapla_lrg_cell_lym_skin_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary cutaneous anaplastic large cell lymphoma on the neck of a 24-year-old man.</div><div class=\"graphic_reference\">Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright Â© 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83089 Version 2.0</div></div></div>"},"83091":{"type":"graphic_picture","displayName":"Anaplastic large cell lymphoma skin 2","title":"Primary cutaneous anaplastic large cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous anaplastic large cell lymphoma</div><div class=\"cntnt\"><img style=\"width:504px; height:330px;\" src=\"images/DERM/83091_Anapla_lg_lymph_skin_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multicentric primary cutaneous anaplastic large cell lymphoma on the chest of a 36-year-old man.</div><div class=\"graphic_reference\">Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright Â© 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83091 Version 2.0</div></div></div>"},"83092":{"type":"graphic_picture","displayName":"Anaplastic large cell lymphoma skin 3","title":"Primary cutaneous anaplastic large cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous anaplastic large cell lymphoma</div><div class=\"cntnt\"><img style=\"width:330px; height:504px;\" src=\"images/DERM/83092_Anapla_lg_lymph_skin_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multicentric primary cutaneous anaplastic large cell lymphoma of skin on the face of a 47-year-old man.</div><div class=\"graphic_reference\">Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83092 Version 3.0</div></div></div>"},"83093":{"type":"graphic_picture","displayName":"Scabies nodular","title":"Nodular scabies","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nodular scabies</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83093_Scabiesnodular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous and excoriated nodules on the abdomen of a patient with nodular scabies.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83093 Version 6.0</div></div></div>"},"83094":{"type":"graphic_picture","displayName":"Drug eruption lymphomatoid","title":"Lymphomatoid drug eruption","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lymphomatoid drug eruption</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83094_drug_erupt_lymphomatoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83094 Version 3.0</div></div></div>"},"83095":{"type":"graphic_picture","displayName":"Hodgkin lymphoma skin","title":"Secondary skin lesions in Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Secondary skin lesions in Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83095_Hodgkin_lymph_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83095 Version 3.0</div></div></div>"},"83096":{"type":"graphic_picture","displayName":"Pityriasis lichenoides et varioliformis acuta 1","title":"Pityriasis lichenoides et varioliformis acuta","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pityriasis lichenoides et varioliformis acuta</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83096_PLEVA_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple inflammatory papules are present. Some lesions demonstrate necrosis and crusting.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83096 Version 5.0</div></div></div>"},"83098":{"type":"graphic_table","displayName":"Comparison of complement studies in angioedema disorders","title":"Comparison of complement studies in angioedema disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of complement studies in angioedema disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Angioedema disorder</td> <td class=\"subtitle1\">C4*</td> <td class=\"subtitle1\">C1INH level</td> <td class=\"subtitle1\">C1INH function</td> <td class=\"subtitle1\">C1q</td> <td class=\"subtitle1\">Other tests<br /> </td> </tr> <tr> <td>Hereditary angioedema with C1INH deficiency (C1INH-HAE<br /> type I)</td> <td>Low</td> <td>Low</td> <td>Low<br /> (usually &#60;50% of normal)</td> <td>Normal</td> <td>Genetic testing<br /> (not needed for diagnosis)</td> </tr> <tr> <td>Hereditary angioedema with C1INH deficiency (C1INH-HAE type&nbsp;II)</td> <td>Low</td> <td>Normal or elevated</td> <td>Low<br /> (usually &#60;50% of normal)</td> <td>Normal</td> <td>Genetic testing<br /> (not needed for diagnosis)</td> </tr> <tr> <td>Hereditary angioedema with factor XII mutations <br /> (FXII-HAE)</td> <td>Normal&nbsp;</td> <td>Normal&nbsp;</td> <td>Normal&nbsp;</td> <td>&nbsp;Normal</td> <td>Mutations in gene for factor XII </td> </tr> <tr> <td>Hereditary angioedema of unknown origin (U-HAE) </td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>&nbsp;</td> </tr> <tr> <td>Acquired angioedema with C1INH deficiency (C1INH-AAE)</td> <td>Low</td> <td>Normal or low</td> <td>Low<br /> (usually &#60;50% of normal)</td> <td>Normal or low<sup>&#182;</sup></td> <td>Anti-C1INH antibodies<br /> (not needed for diagnosis)</td> </tr> <tr> <td>Idiopathic acquired&nbsp;angioedema<br /> (histaminergic or nonhistaminergic)<br /> (IH-AAE or InH-AAE)</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>&nbsp;</td> </tr> <tr> <td>ACE inhibitor-associated angioedema</td> <td>Normal&nbsp;</td> <td>Normal</td> <td>Normal&nbsp;</td> <td>Normal&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">C1INH: C1 inhibitor; HAE: hereditary angioedema (also known as hereditary C1 inhibitor deficiency); AAE: acquired angioedema (also known as acquired C1 inhibitor deficiency); ACE: angiotensin-converting enzyme.<br />* In inherited angioedema types I and II, C4 is always low during an attack (with one published exception) and are chronically low in the majority of patients.<br />Â¶ There are rare forms of acquired angioedema in which C1q levels are normal. Refer to the&nbsp;UpToDate topics on acquired C1 inhibitor deficiency for details.</div><div id=\"graphicVersion\">Graphic 83098 Version 6.0</div></div></div>"},"83099":{"type":"graphic_table","displayName":"Conservative surgeries approach ","title":"Conservative surgeries approach: hypopharynx cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conservative surgeries approach: hypopharynx cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Patient selection</td> </tr> <tr> <td>Suprahyoid pharyngotomy</td> <td>A horizontal incision over the hyoid with anterior to posterior dissection exposing the posterior hypopharyngeal wall</td> <td>Tumors localized to the posterior hypopharyngeal wall</td> </tr> <tr> <td>Partial laryngopharyngectomy or extended supraglottic partial laryngectomy</td> <td>Approaches the tumor from the contralateral side through the aryepiglottic fold anterior to the arytenoids and then through the ventricle</td> <td>Posterior pharyngeal wall tumors; pyriform sinus tumors that are without vocal cord abnormality, extension to the apex of the pyriform sinus, or thyroid cartilage invasion</td> </tr> <tr> <td>Supracricoid hemilaryngopharyngectomy</td> <td>Removes the entire supraglottis, the false and true vocal cords, and the thyroid cartilage, including the paraglottic and preepiglottic spaces</td> <td>Pyriform sinus tumors without invasion of the apex, the postcricoid region, or posterior pharyngeal wall, and without fixation of true vocal cords</td> </tr> <tr> <td>Minimally invasive procedures</td> <td>Transoral approach with CO<sub>2</sub> laser resection or transoral robotic surgery</td> <td> <p>Tumors that are accessible and&nbsp;that are predicted to have good postoperative function</p> <p><span>â</span><span>â</span><span>â</span><span>â</span></p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Dr. Suisui Song, The University of Chicago Medical Center.</div><div id=\"graphicVersion\">Graphic 83099 Version 2.0</div></div></div>"},"83100":{"type":"graphic_picture","displayName":"Indirect inguinal hernia in a female infant","title":"Indirect inguinal hernia in a female infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Indirect inguinal hernia in a female infant</div><div class=\"cntnt\"><img style=\"width:360px; height:248px;\" src=\"images/EM/83100_Ind_inguin_hern_F_in.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One-month-old girl with bilateral inguinal hernias. Normal ovaries were found in the hernia sacs.</div><div class=\"graphic_reference\">Reproduced with permission from Allan R. De Jong, MD. Originally published in Visual Diagnosis in Pediatrics, Chung EK, Atkinson-McEvoy LR, Boom JA, Matz PS (Eds), Lippincott Williams &amp; Wilkins. Copyright &#169; 2010.</div><div id=\"graphicVersion\">Graphic 83100 Version 1.0</div></div></div>"},"83101":{"type":"graphic_picture","displayName":"Indirect inguinal hernia in a male","title":"Indirect inguinal hernia in a male","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Indirect inguinal hernia in a male</div><div class=\"cntnt\"><img style=\"width:504px; height:441px;\" src=\"images/EM/83101_Ind_inguin_hernia_M.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This infant has a large left inguinal hernia, seen as a bulge in the inguinal canal and a swelling of the left hemiscrotum.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83101 Version 1.0</div></div></div>"},"83102":{"type":"graphic_picture","displayName":"Esophageal candidiasis","title":"Esophageal candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal candidiasis</div><div class=\"cntnt\"><img style=\"width:365px; height:375px;\" src=\"images/ID/83102_Esophageal_candidiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive esophagitis due to Candida albicans in a patient with AIDS.</div><div class=\"graphic_reference\">Courtesy of Sameer Saini, MD.</div><div id=\"graphicVersion\">Graphic 83102 Version 2.0</div></div></div>"},"83104":{"type":"graphic_diagnosticimage","displayName":"Longitudinal fracture of the distal phalanx","title":"Longitudinal fracture of the distal phalanx","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Longitudinal fracture of the distal phalanx</div><div class=\"cntnt\"><img style=\"width:502px; height:360px;\" src=\"images/RADIOL/83104_Long_fracture_phalanx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The oblique examination of the distal phalanx of the right index finger reveals a longitudinal fracture through the base of the distal phalanx. Note the fracture traverses the distal interphalangeal joint space, and in this view the bony components are anatomically aligned.<BR>(B) The fracture is magnified and highlighted.</div><div id=\"graphicVersion\">Graphic 83104 Version 2.0</div></div></div>"},"83105":{"type":"graphic_diagnosticimage","displayName":"Longitudinal and transverse fractures of the phalanges ","title":"Longitudinal and transverse fractures of the phalanges","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal and transverse fractures of the phalanges</div><div class=\"cntnt\"><img style=\"width:442px; height:584px;\" src=\"images/RADIOL/83105_Two_separate_frac_phalanges.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This oblique examination&nbsp;of the right index finger reveals two separate fractures. There is a longitudinal fracture of the distal phalanx that traverses the joint. A second comminuted fracture in the proximal phalanx consists of a longitudinal component that traverses the proximal interphalangeal joint and a horizontal component through the mid to distal shaft.<BR>(B) The fractures are highlighted.</div><div id=\"graphicVersion\">Graphic 83105 Version 1.0</div></div></div>"},"83106":{"type":"graphic_diagnosticimage","displayName":"Vertebral burst fracture of the lumbar spine","title":"Vertebral burst fracture of the lumbar spine: Plain radiograph","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Vertebral burst fracture of the lumbar spine: Plain radiograph</div><div class=\"cntnt\"><img style=\"width:574px; height:480px;\" src=\"images/RADIOL/83106_Verte_burst_frac_lumb_spine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiographs are from a 37-year-old female drug addict who jumped from a building in a suicide attempt. The plain radiographs in lateral projection (A) and AP projection (B) of the lumbar spine show a burst fracture of L1 characterized by loss of height and malposition of the L1 vertebral body with posterior retropulsion into the spinal canal (arrow). The posterior elements are splayed as reflected in the widening of the pedicles (arrowheads).</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Reproduced with permission from: Frymoyer JW, Wiesel SW, et al. The Adult and Pediatric Spine. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83106 Version 2.0</div></div></div>"},"83107":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of acute calculous cholecystitis","title":"Ultrasound image of acute calculous cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of acute calculous cholecystitis</div><div class=\"cntnt\"><img style=\"width:466px; height:454px;\" src=\"images/RADIOL/83107_Acute_calculous_cholecyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are two shadowing gallstones (S)&nbsp;lying dependently at the base of the distended gallbladder, associated with diffuse thickening of the gallbladder wall (arrows). There is no definite fluid accumulation in the gallbladder fossa. In the presence of a positive sonographic Murphy's sign, or appropriate clinical setting, a diagnosis of acute calculous cholecystitis can be established.</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss A, Wolfson AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83107 Version 1.0</div></div></div>"},"83108":{"type":"graphic_figure","displayName":"Reitan Test - part A","title":"Reitan Test for hepatic encephalopathy (part A)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reitan Test for hepatic encephalopathy (part A)</div><div class=\"cntnt\"><img style=\"width:372px; height:708px;\" src=\"images/GAST/83108_Reitan_Test_A.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Reitan Test (number connection test) is a commonly used bedside test that is useful for screening for hepatic encephalopathy. &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Step 1: Make sure that the patient is alert enough to cooperate for this test, can see adequately, has a writing surface, is able to count, and can hold a pen or pencil.</LI>&#xD;&#xA;<LI>Step 2: Demonstrate to the patient how to connect the numbers on the sample for part A (lower box).</LI>&#xD;&#xA;<LI>Step 3: Inform the patient that you will be timing the test and to complete the number connections from 1 to 25 as fast as the patient can without lifting the pen or pencil from the paper.</LI>&#xD;&#xA;<LI>Step 4: If an error occurs, point it out immediately and allow the patient to correct the error. The total elapsed time to complete the test, including the time spent correcting errors, is the score.</LI>&#xD;&#xA;<LI>Step 5: Record the time spent to complete the test. If it takes longer than 3 minutes to complete test A, record \"&gt;3 minutes\" as the score.</LI></UL>An alert person without hepatic encephalopathy should be able to complete part A of the test in seconds similar to their age in years.</div><div id=\"graphicVersion\">Graphic 83108 Version 5.0</div></div></div>"},"83109":{"type":"graphic_figure","displayName":"Reitan Test - part B","title":"Reitan Test for hepatic encephalopathy (part B)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reitan Test for hepatic encephalopathy (part B)</div><div class=\"cntnt\"><img style=\"width:372px; height:708px;\" src=\"images/GAST/83109_Reitan_Test_B.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Reitan Test (number connection test) is a commonly used bedside test that is useful for screening for hepatic encephalopathy. Part B of the test may follow completion of part A, but is not used by all clinicians. &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Step 1: Make sure that the patient is alert enough to cooperate for this test, can see adequately, has a writing surface, is able to count, and can hold a pen or pencil.</LI>&#xD;&#xA;<LI>Step 2: Demonstrate to the patient how to connect the numbers and letters on the sample for part B (lower box), alternating between the numbers and letters (ie, 1-A-2-B-3-C, etc).</LI>&#xD;&#xA;<LI>Step 3: Inform the patient that you will be timing the test and to complete the number-letter connections from 1 to L as fast as the patient can without lifting the pen or pencil from the paper.</LI>&#xD;&#xA;<LI>Step 4: If an error occurs, point it out immediately and allow the patient to correct the error. The total elapsed time to complete the test, including the time spent correcting errors, is the score.</LI>&#xD;&#xA;<LI>Step 5: Record the time spent to complete the test. An average score is 75 seconds, while &gt;273 seconds is considered deficient.</LI></UL></div><div id=\"graphicVersion\">Graphic 83109 Version 3.0</div></div></div>"},"83112":{"type":"graphic_figure","displayName":"Ankle PI","title":"Ankle bones","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Ankle bones</div><div class=\"cntnt\"><img style=\"width:463px; height:577px;\" src=\"images/PI/83112_Ankle-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ankle is made up of 3 bones: the tibia (shinbone), fibula (calf bone), and talus (foot bone).</div><div id=\"graphicVersion\">Graphic 83112 Version 2.0</div></div></div>"},"83113":{"type":"graphic_diagnosticimage","displayName":"Distal femoral metaphyseal fracture in a child","title":"Distal femoral metaphyseal (supracondylar) fracture in a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal femoral metaphyseal (supracondylar) fracture in a child</div><div class=\"cntnt\"><img style=\"width:299px; height:582px;\" src=\"images/EM/83113_Distfemmetaphysupracondy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This 6-year-old patient sustained an unstable supracondylar fracture of the femur.<br />(B) The fracture was managed with immediate spica casting with the knee in 90 degrees of flexion, mandatory in such a case to prevent posterior angulation.<br />(C) Bayonet apposition is acceptable in a child this age.</div><div class=\"graphic_reference\">Reproduced with permission from: Flynn JM, Skaggs DL. Femoral shaft fractures. In: Beaty JH, Kasser JR. Rockwood and Wilkins' Fractures in Children, 7th edition, Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83113 Version 7.0</div></div></div>"},"83115":{"type":"graphic_table","displayName":"Long-term prophylaxis to prevent angioedema in people with HAE","title":"Long-term prophylaxis to prevent angioedema in adults and children with hereditary angioedema (HAE)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Long-term prophylaxis to prevent angioedema in adults and children with hereditary angioedema (HAE)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Prophylactic agent</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> <td class=\"subtitle1\">General points</td> </tr> <tr class=\"divider_bottom\"> <td>Androgens</td> <td> <ul> <li>Oral administration </li> <li>Effective in most patients </li> <li>Well-tolerated by many </li> <li>Inexpensive </li> </ul> </td> <td> <ul> <li>Side effects are prohibitive in some patients (elevated cholesterol, hypertension, mood effects, weight gain, others) </li> <li>Avoid in prepubertal children (premature closure of growth plate) and pregnant women (virilization of female fetus) </li> <li>Avoid in patients with liver disease or nephrotic syndrome </li> </ul> </td> <td> <p>May be started at a relatively high dose and gradually lowered once disease is controlled OR started at a low dose and gradually increased until disease is controlled. Over time, the lowest effective dose should be determined for each individual patient.</p> See additional treatments for breakthrough symptoms below.</td> </tr> <tr class=\"divider_bottom\"> <td>Antifibrinolytics: Tranexamic acid (preferred) or epsilon aminocaproic acid</td> <td> <ul> <li>Oral administration </li> <li>Safe in children </li> <li>Well-tolerated by most patients </li> </ul> </td> <td> <ul> <li>Less effective compared with androgens and C1 inhibitor concentrate </li> <li>Avoid in patients with history of thrombosis or thromboembolic disease or risk factor for thrombosis </li> </ul> </td> <td> <p>Most often used in children and some women.</p> See additional treatments for breakthrough symptoms below.</td> </tr> <tr class=\"divider_bottom\"> <td>C1 inhibitor concentrate</td> <td> <ul> <li><span style=\"color: black;\">Well-tolerated </span></li> <li><span style=\"color: black;\">Subcutaneous form available in some areas of the world </span></li> </ul> </td> <td> <ul> <li><span style=\"color: black;\">Expensive </span></li> <li><span style=\"color: black;\">Intravenous form: Requires reliable venous access (but indwelling ports are not recommended) </span></li> </ul> </td> <td>See additional treatments for breakthrough symptoms below.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Treatment for breakthrough symptoms <em>(required in combination with any of the options above)</em></td> </tr> <tr> <td class=\"indent1\">C1 inhibitor concentrate</td> <td> <ul> <li>As above </li> </ul> </td> <td> <ul> <li>As above </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Icatibant</td> <td> <ul> <li>Subcutaneous injection </li> <li>Approved for self-administration at home </li> </ul> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ecallantide</td> <td> <ul> <li>Subcutaneous injection </li> </ul> </td> <td> <ul> <li>Should be given under medical supervision due to possible hypersensitivity reactions usually within one hour </li> <li>Only available in the United States </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Plasma: Solvent/detergent-treated or fresh frozen</td> <td> <ul> <li>Widely available </li> </ul> </td> <td> <ul> <li>Efficacy not as well-established as other therapies </li> <li>Theoretical risk of transmission of blood-borne agents </li> <li>Requires visit to hospital or clinic for administration </li> </ul> </td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83115 Version 14.0</div></div></div>"},"83116":{"type":"graphic_diagnosticimage","displayName":"Distal femoral metaphyseal corner fracture","title":"Distal femoral metaphyseal corner fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal femoral metaphyseal corner fracture</div><div class=\"cntnt\"><img style=\"width:443px; height:504px;\" src=\"images/EM/83116_Dist_fem_metaph_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Metaphyseal \"corner\" fractures, as shown here (white arrows), are highly suggestive of child abuse.</div><div class=\"graphic_reference\">Courtesy of Kimberly P Stone, MD and Klane White, MD.</div><div id=\"graphicVersion\">Graphic 83116 Version 1.0</div></div></div>"},"83117":{"type":"graphic_table","displayName":"Short-term prophylaxis to prevent angioedema in HAE","title":"Short-term prophylaxis to prevent angioedema in hereditary angioedema (HAE)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Short-term prophylaxis to prevent angioedema in hereditary angioedema (HAE)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">High-risk&nbsp;procedures</td> <td class=\"subtitle1\">Lower-risk procedures&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Intubation, oral surgery (cutting of tissues), dental procedures involving injections of anesthetics, general surgery, other procedures that precipitated past attacks in that patient.</td> <td>Routine dental cleanings.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Option 1:</strong> Give plasma-derived C1 inhibitor&nbsp;concentrate one hour before procedure, with two additional doses available on demand*.</td> <td> <p>No additional treatment in advance but have treatment for acute angioedema immediately available if symptoms develop (ie, C1 inhibitor&nbsp;concentrate, ecallantide, or icatibant).&nbsp;</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Option 2:</strong> If option 1 is not possible, then give premedication with androgens for five days before and&nbsp;three days after.</p> <p>Example: Danazol, 10 mg/kg per day up to 600 mg daily or equivalent doses of another attenuated androgen </p> <p>&nbsp;</p> </td> <td>&nbsp; </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Ecallantide and icatibant have not been studied for use in prophylaxis, although they can be given if angioedema develops.</div><div id=\"graphicVersion\">Graphic 83117 Version 9.0</div></div></div>"},"83119":{"type":"graphic_figure","displayName":"Distal femoral Salter-Harris type II fracture","title":"Distal femoral Salter-Harris type II fracture","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Distal femoral Salter-Harris type II fracture</div><div class=\"cntnt\"><img style=\"width:456px; height:587px;\" src=\"images/EM/83119_DistalfemSHtypeIIfrac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In a Salter-Harris type II fracture, the side where the fracture occurred through the physis has associated disruption of the periosteum (black arrow). The side of the fracture that passes through the metaphysis usually has an intact periosteum that can be used for fracture reduction (red arrow).<br />(B) With fracture reduction, the periosteum may become interposed within the fracture site, preventing an anatomic reduction (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Herman MJ, Smith BG. Fractures of the Distal Femoral Physis. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright Â© 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83119 Version 9.0</div></div></div>"},"83120":{"type":"graphic_picture","displayName":"Slapped cheek rash PI","title":"Slapped cheek rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Slapped cheek rash</div><div class=\"cntnt\"><img style=\"width:432px; height:355px;\" src=\"images/PI/83120_Slapped_cheek_rash_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Children with erythema infectiosum (fifth disease) often have a rash on the face that looks like they were slapped.</div><div class=\"graphic_reference\">Courtesy of Moise L Levy, MD.</div><div id=\"graphicVersion\">Graphic 83120 Version 1.0</div></div></div>"},"83121":{"type":"graphic_diagnosticimage","displayName":"Distal femoral Salter-Harris type III fracture","title":"Distal femoral Salter-Harris type III fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal femoral Salter-Harris type III fracture</div><div class=\"cntnt\"><img style=\"width:374px; height:540px;\" src=\"images/EM/83121_DistalfemSHtypeIIIfrac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Salter-Harris type III fracture-separation of the distal femur. Note the vertical fracture line extending from the physis distally into the intercondylar notch with displacement.</div><div class=\"graphic_reference\">Reproduced with permission from: Price CT, Herrera-Soto J. Extra-articular injuries of the knee. In: Rockwood and Wilkins' Fractures in Children, 7th edition, Beaty JH, Kasser JR. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83121 Version 7.0</div></div></div>"},"83122":{"type":"graphic_picture","displayName":"Rash in erythema infectiosum PI","title":"Rash in erythema infectiosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rash in erythema infectiosum</div><div class=\"cntnt\"><img style=\"width:383px; height:252px;\" src=\"images/PI/83122_rash_erythema_infectios_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Children with erythema infectiosum can get a rash on the chest, back, arms, and legs.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div id=\"graphicVersion\">Graphic 83122 Version 3.0</div></div></div>"},"83123":{"type":"graphic_diagnosticimage","displayName":"Distal femoral Salter-Harris type IV fracture","title":"Distal femoral Salter-Harris type IV fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal femoral Salter-Harris type IV fracture</div><div class=\"cntnt\"><img style=\"width:368px; height:540px;\" src=\"images/EM/83123_DistfemSHtypeIVfrac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comminuted Salter-Harris type IV fracture of the distal femur in a 14-year-old boy involved in a motor vehicle collision.</div><div class=\"graphic_reference\">Reproduced with permission from: Herman MJ, Smith BG. Fractures of the Distal Femoral Physis. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright Â© 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83123 Version 7.0</div></div></div>"},"83124":{"type":"graphic_figure","displayName":"Deep brain stimulation","title":"Deep brain stimulation","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Deep brain stimulation</div><div class=\"cntnt\"><img style=\"width:523px; height:560px;\" src=\"images/PSYCH/83124_Deep-brain-stimulation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83124 Version 1.0</div></div></div>"},"83125":{"type":"graphic_picture","displayName":"Rubella rash PI","title":"Rubella rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rubella rash</div><div class=\"cntnt\"><img style=\"width:272px; height:396px;\" src=\"images/PI/83125_Rubella_rash_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rubella causes a red rash on the face and body. It is caused by infection with the rubella virus.</div><div class=\"graphic_reference\">Image from: Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 83125 Version 2.0</div></div></div>"},"83126":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image retroplacental hematoma","title":"Ultrasound image retroplacental hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound image retroplacental hematoma</div><div class=\"cntnt\"><img style=\"width:307px; height:255px;\" src=\"images/OBGYN/83126_Ultrasnd_retro_hema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">&nbsp;Posterior placenta with large retroplacental hematoma outlined by arrows.</div><div class=\"graphic_reference\">Courtesy of Martin R Chavez, MD.</div><div id=\"graphicVersion\">Graphic 83126 Version 1.0</div></div></div>"},"83127":{"type":"graphic_diagnosticimage","displayName":"Organizing intrauterine hematoma","title":"Organizing intrauterine hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Organizing intrauterine hematoma</div><div class=\"cntnt\"><img style=\"width:303px; height:219px;\" src=\"images/OBGYN/83127_Org_intraut_hematom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior heterogeneous collection (delineated by + signs) in the lower uterine segment representing an organized clot measuring 7 x 12 cm.</div><div class=\"graphic_reference\">Courtesy of Martin R Chavez, MD.</div><div id=\"graphicVersion\">Graphic 83127 Version 1.0</div></div></div>"},"83128":{"type":"graphic_figure","displayName":"Worldwide distribution of trichinellosis","title":"Worldwide distribution of trichinellosis","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">Worldwide distribution of trichinellosis</div><div class=\"cntnt\"><img style=\"width:740px; height:413px;\" src=\"images/ID/83128_Worldwide_trichinellosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">World map showing the distribution areas of <em>Trichinella nativa</em> (Tna), <em>Trichinella britovi</em> (Tb), <em>Trichinella murrelli</em> (Tm), <em>Trichinella nelsoni</em> (Tne), <em>Trichinella</em> genotype T6 (T6), <em>Trichinella</em> genotype T8 (T8), and <em>Trichinella</em> genotype T9 (T9). In some regions, the distribution areas of these encapsulated species and genotypes overlap between them.</div><div class=\"graphic_reference\">Reproduced with permission from: the International Trichinella Reference Center. Copyright &copy; 2014 Istituto Superiore di Sanit&agrave;.</div><div id=\"graphicVersion\">Graphic 83128 Version 1.0</div></div></div>"},"83130":{"type":"graphic_picture","displayName":"Skin tag thigh PI","title":"Skin tag on the thigh","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin tag on the thigh</div><div class=\"cntnt\"><img style=\"width:328px; height:347px;\" src=\"images/PI/83130_skin_tag_thigh_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin tags are small growths of normal skin that&nbsp;often grow on a short stalk or stem (as shown). Skin tags tend to form in places where the skin rubs together.</div><div class=\"graphic_reference\">Reproduced with permission from: Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 83130 Version 3.0</div></div></div>"},"83133":{"type":"graphic_table","displayName":"Variables included in valvular surgery risk scores","title":"Variables included in valvular surgery risk scores","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Variables included in valvular surgery risk scores</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">STS score</td> <td class=\"subtitle1\">EUROSCORE additive/logistic*</td> <td class=\"subtitle1\">Ambler score</td> </tr> <tr> <td class=\"sublist1_start subtitle2_left\" colspan=\"4\">Patient characteristics</td> </tr> <tr> <td class=\"indent1\">Age</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Gender</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Height</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Weight</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Body mass index</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ethnicity</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start subtitle2_left\" colspan=\"4\">Comorbid conditions</td> </tr> <tr> <td class=\"indent1\">Diabetes</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Chronic lung/pulmonary disease</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Extracardiac arteriopathy</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Peripheral vascular disease</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Neurological dysfunction</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cerebrovascular accident</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Serum creatinine</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Dialysis-dependent renal failure</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Immunosuppressive therapy</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start subtitle2_left\" colspan=\"4\">Cardiac history</td> </tr> <tr> <td class=\"indent1\">NYHA classification</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Unstable angina</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Recent myocardial infarction</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Arrhythmias</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Previous cardiac surgery</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Previous CABG</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Previous valvular surgery</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Previous PCI</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Active endocarditis</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Number of diseased coronary vessels</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Type and severity of valvular disease<br /> (stenosis/regurgitation, aortic/mitral)</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start subtitle2_left\" colspan=\"4\">Haemodynamic state</td> </tr> <tr> <td class=\"indent1\">Systolic pulmonary pressure &#62;60 mmHg</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ejection fraction</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Critical pre-operative state</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cardiogenic shock</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Resuscitation</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Inotropic agents</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Intra-aortic balloon pump</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start subtitle2_left\">Procedure</td> <td class=\"sublist_other_start_centered divider_bottom\">+</td> <td class=\"sublist_other_start_centered divider_bottom\">&nbsp;</td> <td class=\"sublist_other_start_centered divider_bottom\">+</td> </tr> <tr> <td class=\"indent1\">Emergency</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Surgery on thoracic aorta</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Aortic valve surgery<sup>&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Mitral valve surgery<sup>&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Aortic and mitral valve surgery<sup>&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Tricuspid surgery<sup>&#182;</sup></td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Surgery for congenital heart disease</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Rhythmologic surgery</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Concomitant CABG</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Concomitant tricuspid valve surgery</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Post-infarct septal rupture</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">STS: The Society of Thoracic Surgeons; CABG: coronary artery bypass grafting; NYHA: New York Heart Association; PCI: percutaneous coronary intervention.<br />* The same variables are used for the additive and logistic EuroSCORE.<br />Â¶ In the STS score, the type of valvular surgery (valve replacement or repair) is taken into account.</div><div class=\"graphic_reference\">Reproduced from: Rosenhek R, Lung B, Tornos P, et al. ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. Eur Heart J 2012; 33(7):822-8. By permission of the European Society of Cardiology. Copyright Â© 2012 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.escardio.org/\" target=_blank>www.escardio.org</A>.</div><div id=\"graphicVersion\">Graphic 83133 Version 18.0</div></div></div>"},"83134":{"type":"graphic_table","displayName":"Risks for congenital defects with maternal smoking","title":"Increased risk for selected congenital defects conferred by maternal smoking during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Increased risk for selected congenital defects conferred by maternal smoking during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Congenital defect</td> <td class=\"subtitle1\">Odds ratio</td> <td class=\"subtitle1\">95% confidence interval (CI)</td> </tr> <tr> <td>Gastroschisis</td> <td class=\"centered\">1.50</td> <td class=\"centered\">1.28-1.76</td> </tr> <tr> <td>Abdominal hernia (umbilical, inguinal, or ventral)</td> <td class=\"centered\">1.40</td> <td class=\"centered\">1.23-1.59</td> </tr> <tr> <td>Craniosynostosis</td> <td class=\"centered\">1.33</td> <td class=\"centered\">1.03-1.73</td> </tr> <tr> <td>Oral clefts</td> <td class=\"centered\">1.28</td> <td class=\"centered\">1.20-1.36</td> </tr> <tr> <td>Limb reduction </td> <td class=\"centered\">1.26</td> <td class=\"centered\">1.15-1.39</td> </tr> <tr> <td>Clubfoot</td> <td class=\"centered\">1.25</td> <td class=\"centered\">1.10-1.47</td> </tr> <tr> <td>Eye</td> <td class=\"centered\">1.25</td> <td class=\"centered\">1.11-1.40</td> </tr> <tr> <td>Digit anomaly</td> <td class=\"centered\">1.18</td> <td class=\"centered\">0.99-1.41</td> </tr> <tr> <td>Cryptorchidism</td> <td class=\"centered\">1.13</td> <td class=\"centered\">1.02-1.25</td> </tr> <tr> <td>Cardiovascular</td> <td class=\"centered\">1.09</td> <td class=\"centered\">1.02-1.17</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects:&nbsp;A systematic review based on 173,687 malformed cases and 11.7 million controls. Hum Reprod Update 2011; 17:589.</div><div id=\"graphicVersion\">Graphic 83134 Version 2.0</div></div></div>"},"83136":{"type":"graphic_picture","displayName":"Chickenpox oral 1","title":"Oral manifestation of varicella (chickenpox)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral manifestation of varicella (chickenpox)</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/83136_Chicken_pox_oral_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles on the hard palate of a child with chickenpox.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>.&nbsp;Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83136 Version 4.0</div></div></div>"},"83137":{"type":"graphic_picture","displayName":"Chickenpox oral 2","title":"Oral manifestations of varicella (chickenpox)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Oral manifestations of varicella (chickenpox)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83137_Chicken_pox_oral_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gingival vesicle in a patient with chickenpox.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83137 Version 3.0</div></div></div>"},"83138":{"type":"graphic_diagnosticimage","displayName":"Diffuse osteoblastic metastases in prostate cancer","title":"Diffuse osteoblastic metastases in prostate cancer","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Diffuse osteoblastic metastases in prostate cancer</div><div class=\"cntnt\"><img style=\"width:581px; height:491px;\" src=\"images/RADIOL/83138_Diffuse_osteoblastic_metast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bone scan and T2 weighted midsagittal image of the thoracic spine is from a 50-year-old male with known prostate carcinoma. The bone scan (A) shows extensive osteoblastic metastases involving almost all the visualized bones, including the entire spine, pubic symphysis, and probably sternum. The MRI (B) shows diffuse heterogeneity and a compression of T11 (arrow). The findings are consistent with extensive blastic metastasis from primary prostate carcinoma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 83138 Version 3.0</div></div></div>"},"83139":{"type":"graphic_diagnosticimage","displayName":"Osteoblastic metastases to the lumbar spine","title":"Prostate cancer: Osteoblastic metastases to the lumbar spine","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Prostate cancer: Osteoblastic metastases to the lumbar spine</div><div class=\"cntnt\"><img style=\"width:531px; height:538px;\" src=\"images/RADIOL/83139_Osteoblast_metast_lum_spine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is a 50-year-old man with metastatic prostate carcinoma. Image (A) is a CT reconstruction of the lumbar spine and shows extensive blastic metastases involving almost all the visualized bones with lytic and compressive changes in T11 (arrow). The T2 weighted MRI (B) shows heterogeneous changes within the bone marrow consistent with metastatic disease. The findings are consistent with extensive metastases from primary prostate carcinoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 83139 Version 3.0</div></div></div>"},"83140":{"type":"graphic_diagnosticimage","displayName":"Plain radiograph of thoracic compression fracture with kyphosis","title":"Plain radiograph of thoracic compression fracture with kyphosis","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of thoracic compression fracture with kyphosis</div><div class=\"cntnt\"><img style=\"width:582px; height:502px;\" src=\"images/RADIOL/83140_Plain_xray_thoracic_compr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is a 55-year-old female who fell and presented with back pain. The plain radiograph of the thoracic spine in the anterior posterior (A) and lateral (B) projections reveal a compression fracture of T5 (arrows) with about 70 percent loss of height of the vertebral body. A second compression fracture of T7 (arrowheads) has resulted in about 15 percent loss of height of the vertebral body. The fractures are better appreciated on the lateral examination in both instances. A kyphosis of the thoracic spine of about 30 degrees has resulted. Associated findings include mild osteopenia and chronic fractures of the left sided ribs 3, 4, 5, and 6.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 83140 Version 2.0</div></div></div>"},"83141":{"type":"graphic_diagnosticimage","displayName":"Extradural plasmacytoma","title":"Extradural plasmacytoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extradural plasmacytoma</div><div class=\"cntnt\"><img style=\"width:287px; height:584px;\" src=\"images/RADIOL/83141_Extradural_plasmacytoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This study is from a patient with known multiple myeloma. The MRI of the thoracic spine in the mid-sagittal plane reveals an extradural mass in the midthoracic spine. On the T2 weighted images (A and B) the spindle shaped mass is overlaid in green (B). The mass interrupts the posterior CSF column (arrow). The gadolinium enhanced T1 weighted images (C and D) reveal a more prominent area of involvement due to the associated hyperemia in the region (salmon overlay in D).</div><div id=\"graphicVersion\">Graphic 83141 Version 2.0</div></div></div>"},"83142":{"type":"graphic_diagnosticimage","displayName":"Lytic bone disease and PET positive scan","title":"Multiple myeloma: Lytic bone disease and PET positive scan","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Multiple myeloma: Lytic bone disease and PET positive scan</div><div class=\"cntnt\"><img style=\"width:584px; height:369px;\" src=\"images/RADIOL/83142_Lytic_bone_disease_PET_pos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This male patient is 81-years-old and has multiple myeloma. The CT scan (A and C) in the region of the cervicothoracic junction reveals an expansile and lytic process in the region of T1 (arrow). The correlative PET scan (B and D) shows a moderately hot area (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; PET: positron emission tomography.</div><div id=\"graphicVersion\">Graphic 83142 Version 2.0</div></div></div>"},"83143":{"type":"graphic_diagnosticimage","displayName":"Plasmacytoma CT scan","title":"Extramedullary plasmacytoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extramedullary plasmacytoma</div><div class=\"cntnt\"><img style=\"width:402px; height:583px;\" src=\"images/RADIOL/83143_Plasmacytoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan through the mid-chest region of an 80-year-old male patient reveals a destructive soft tissue mass in an anterior left rib (arrow). A core biopsy performed under CT guidance (B) confirmed a diagnosis of plasmacytoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 83143 Version 3.0</div></div></div>"},"83144":{"type":"graphic_diagnosticimage","displayName":"Open mouth view of C1 and C2 dislocation","title":"Open mouth (odontoid) view of C1/C2 dislocation","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Open mouth (odontoid) view of C1/C2 dislocation</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/RADIOL/83144_Open_mouth_C1_C2_disloc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The AP open mouth view of C1/C2 intervertebral joint space and the odontoid reveals an obvious offset of the right lateral mass of C1 (arrow) over the corresponding lateral mass of C2. There is more subtle malalignment of left C1 lateral mass (arrowhead) relative to C2. These findings suggest a Jefferson fracture of C1.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 83144 Version 2.0</div></div></div>"},"83145":{"type":"graphic_movie","displayName":"Push off demonstrating winging of scapula","title":"Wall push-off demonstrating winging of scapula","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Wall push-off demonstrating winging of scapula</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/83145_Pushoffdemowingingvideo.mp4\" style=\"width:480px;height:368px\"></div><img style=\"width:311px; height:401px;\" src=\"images/EM/83145_Pushoffdemowingingimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Having the patient push from a wall can help accentuate scapular winging, as demonstrated in this video clip. Note how the right scapula is elevated and protracted.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 83145 Version 1.0</div></div></div>"},"83146":{"type":"graphic_movie","displayName":"Scapular assistance maneuver","title":"Scapular assistance maneuver","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Scapular assistance maneuver</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/83146_Scapulassistmaneuvvideo.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:282px;\" src=\"images/EM/83146_Scapulassistmaneuvimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scapular assistance maneuver helps to identify dysfunction of the muscles that stabilize the scapula.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 83146 Version 1.0</div></div></div>"},"83163":{"type":"graphic_table","displayName":"Symptoms of acute rhinosinusitis ","title":"Symptoms of acute rhinosinusitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of acute rhinosinusitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"indent1\">Purulent anterior nasal discharge</td> </tr> <tr> <td class=\"indent1\">Purulent or discolored posterior nasal discharge</td> </tr> <tr> <td class=\"indent1\">Nasal congestion or obstruction</td> </tr> <tr> <td class=\"indent1\">Facial congestion or fullness</td> </tr> <tr> <td class=\"indent1\">Hyposmia or anosmia</td> </tr> <tr> <td class=\"indent1\">Fever</td> </tr> <tr> <td class=\"indent1\">Headache</td> </tr> <tr> <td class=\"indent1\">Ear pain, pressure, or fullness</td> </tr> <tr> <td class=\"indent1\">Halitosis</td> </tr> <tr> <td class=\"indent1\">Dental pain</td> </tr> <tr> <td class=\"indent1\">Fatigue</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Chow AW, Benninger MS, Brook I, et al. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. Clin Infect Dis 2012; 54:e72.</LI></OL>Original figure modified&nbsp;for this publication. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol 2004; 114:155. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83163 Version 7.0</div></div></div>"},"83165":{"type":"graphic_diagnosticimage","displayName":"MR fetus with agenesis of the corpus callosum","title":"Magnetic resonance image ofÂ fetus with agenesis of the corpus callosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of&nbsp;fetus with agenesis of the corpus callosum</div><div class=\"cntnt\"><img style=\"width:156px; height:148px;\" src=\"images/OBGYN/83165_MR_fetus_agenesis_crp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance image (coronal section) of a fetus with complete agenesis of the corpus callosum.</div><div class=\"graphic_reference\">Courtesy of Sarah S Milla, MD.</div><div id=\"graphicVersion\">Graphic 83165 Version 2.0</div></div></div>"},"83166":{"type":"graphic_diagnosticimage","displayName":"Fetus with absent septi pellucidi","title":"Fetus with absent septi pellucidi","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetus with absent septi pellucidi</div><div class=\"cntnt\"><img style=\"width:416px; height:243px;\" src=\"images/OBGYN/83166_Fetus_abs_sept_pell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional orthogonal planes of a fetus with absent septi pellucidi. (A) coronal; (B) median; and (C) axial. &#xD;&#xA;Magnetic resonance image of a fetus with absent cavum septi pellucidi. (D) coronal; and (E) axial.</div><div class=\"graphic_reference\">Courtesy of Sarah S Milla, MD.</div><div id=\"graphicVersion\">Graphic 83166 Version 1.0</div></div></div>"},"83167":{"type":"graphic_diagnosticimage","displayName":"Fetal bilateral schizencephaly","title":"Fetal bilateral schizencephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal bilateral schizencephaly</div><div class=\"cntnt\"><img style=\"width:398px; height:140px;\" src=\"images/OBGYN/83167_Fetal_bilat_schizen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance image of a fetus with bilateral schizencephaly and agenesis of the septi pellucidi.<br />(A) Axial section showing the bilateral defect (arrows).<br />(B) Anterior coronal section showing the left sided defect (arrow).<br />(C) More posterior coronal section showing the defect on the right side of the brain (arrow).</div><div class=\"graphic_reference\">Courtesy of Sarah S Milla, MD.</div><div id=\"graphicVersion\">Graphic 83167 Version 1.0</div></div></div>"},"83168":{"type":"graphic_table","displayName":"Criteria for acute kidney injury","title":"Criteria for acute kidney injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for acute kidney injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">RIFLE<sup>[1]</sup></td> <td class=\"subtitle1\">AKIN<sup>[2]</sup></td> <td class=\"subtitle1\">KDIGO<sup>[3]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Diagnostic criteria*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td>&nbsp;</td> <td> <p>Increase in serum creatinine of &#8805;0.3 mg/dL or &#8805;50% within 48 hours</p> <p>OR</p> Urine output of &#60;0.5 mL/kg/hour for &#62;6 hours</td> <td> <p>Increase in serum creatinine of &#8805;0.3 mg/dL within 48 hours or &#8805;50% within 7 days</p> <p>OR</p> Urine output of &#60;0.5 mL/kg/hour for &#62;6 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Staging criteria</td> </tr> <tr> <td class=\"indent1\">Risk (RIFLE) or stage 1 (AKIN/KDIGO)</td> <td> <p>Increase in serum creatinine of 50 to 99%</p> <p>OR</p> Urine output of &#60;0.5 mL/kg/hour for 6 to 12 hours</td> <td> <p>Increase in serum creatinine of &#8805;0.3 mg/dL or 50 to 100%</p> <p>OR</p> Urine output of &#60;0.5 mL/kg/hour for 6 to 12 hours</td> <td> <p>Increase in serum creatinine of &#8805;0.3 mg/dL or 50 to 99%</p> <p>OR</p> Urine output of &#60;0.5 mL/kg/hour for 6 to 12 hours</td> </tr> <tr> <td class=\"indent1\">Injury (RIFLE) or stage 2 (AKIN/KDIGO)</td> <td> <p>Increase in serum creatinine of 100 to 199%</p> <p>OR</p> Urine output of &#60;0.5 mL/kg/hour for 12 to 24 hours</td> <td> <p>Increase in serum creatinine of &#62;100 to 200%</p> <p>OR</p> Urine output of &#60;0.5 mL/kg/hour for 12 to 24 hours<br /> </td> <td> <p>Increase in serum creatinine of 100 to 199%</p> <p>OR</p> Urine output of &#60;0.5 mL/kg/hour for 12 to 24 hours</td> </tr> <tr> <td class=\"indent1\">Failure (RIFLE) or stage 3 (AKIN/KDIGO)</td> <td> <p>Increase in serum creatinine of &#8805;200%</p> <p>OR</p> <p>Increase in serum creatinine by &#62;0.5 mg/dL to &#62;4.0 mg/dL</p> <p>OR</p> <p>Urine output of &#60;0.3 mL/kg/hour for &#62;24 hours or anuria for &#62;12 hours</p> <p>OR</p> Initiation of renal replacement therapy</td> <td> <p>Increase in serum creatinine of &#62;200%</p> <p>OR</p> <p>Increase in serum creatinine by &#62;0.5 mg/dL to &#8805;4.0 mg/dL</p> <p>OR</p> <p>Urine output of &#60;0.3 mL/kg/hour for &#62;24 hours or anuria for &#62;12 hours</p> <p>OR</p> Initiation of renal replacement therapy</td> <td> <p>Increase in serum creatinine of &#8805;200%</p> <p>OR</p> <p>Increase in serum creatinine of &#8805;0.3 mg/dL to &#8805;4.0 mg/dL<sup>&#182;</sup></p> <p>OR</p> <p>Urine output of &#60;0.3 mL/kg/hour for &#8805;24 hours or anuria for &#8805;12 hours</p> <p>OR</p> Initiation of renal replacement therapy</td> </tr> <tr> <td class=\"indent1\">Loss (RIFLE)</td> <td>Need for renal replacement therapy for &#62;4 weeks</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">End stage (RIFLE)</td> <td>Need for renal replacement therapy for &#62;3 months</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RIFLE: risk, injury, failure, loss, ESRD;&nbsp;AKIN: Acute Kidney Injury Network; KDIGO: Kidney Disease: Improving Global Outcomes; ESRD: end-stage renal disease.<br />* AKIN and KDIGO provided both diagnostic and staging criteria. RIFLE provided a graded definition of AKI that is implicit in the staging criteria.<br />Â¶ In patients &lt;18 years, stage 3 AKI is also defined by KDIGO as a decrease in estimated glomerular filtration rate (eGFR) to &lt;35 mL/min/1.73 m<SUP>2</SUP>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:B204. Copyright &copy; 2004 BioMed Central Ltd.</li>&#xD;&#xA;    <li>Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31. Copyright &copy; 2007 BioMed Central Ltd.</li>&#xD;&#xA;    <li>Kidney Disease: Improving Global Outcomes (KDIGO). Acute Kidney Injury Work Group. KDIGO clinical practice guidelines for acute kidney injury. Kidney Int Suppl 2012; 2:1.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 83168 Version 11.0</div></div></div>"},"83173":{"type":"graphic_algorithm","displayName":"Algorithm for the maintenance of sinus rhythm","title":"Maintenance of sinus rhythm","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Maintenance of sinus rhythm</div><div class=\"cntnt\"><img style=\"width:592px; height:379px;\" src=\"images/CARD/83173_Algo_mainten_sinus_rhythm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation. Drugs are listed alphabetically and not in order of suggested use. The seriousness of heart disease progresses from left to right, and selection of therapy in patients with multiple conditions depends on the most serious condition present.</div><div class=\"graphic_footnotes\">LVH: left ventricular hypertrophy.</div><div class=\"graphic_reference\">Reproduced from: Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57:223. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83173 Version 1.0</div></div></div>"},"83179":{"type":"graphic_picture","displayName":"Labioplasty straight incision","title":"Labia minora labioplasty: Straight incision ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Labia minora labioplasty: Straight incision </div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/OBGYN/83179_Labiaminoraplastystr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83179 Version 6.0</div></div></div>"},"83180":{"type":"graphic_figure","displayName":"Valgus injury to distal femur in the adolescent","title":"Valgus injury to the distal femur in the adolescent","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Valgus injury to the distal femur in the adolescent</div><div class=\"cntnt\"><img style=\"width:588px; height:412px;\" src=\"images/EM/83180_Valgusinjurydistfemadol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Valgus and torsional stress across the knee may cause a physeal separation.<br />(B) In the skeletally immature athlete the medial collateral ligament remains intact and a Salter-Harris II (pictured) or III fracture occurs.</div><div class=\"graphic_reference\">Reproduced with permission from: Herman MJ, Smith BG. Fractures of the Distal Femoral Physis. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright Â© 2014 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83180 Version 6.0</div></div></div>"},"83181":{"type":"graphic_picture","displayName":"Clinical findings of a distal femoral fracture in a child","title":"Clinical findings of a distal femoral fracture in a child","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Clinical findings of a distal femoral fracture in a child</div><div class=\"cntnt\"><img style=\"width:466px; height:348px;\" src=\"images/EM/83181_Distalfemfracfindings.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This six year old girl has physical findings of a distal femoral fracture after a motor vehicle collision including swelling and&nbsp;posterior displacement of the distal femur (red arrow) and ecchymosis of the popliteal fossa (white arrow). Physical examination also revealed absent peroneal nerve function and a cold, pulseless foot.</div><div class=\"graphic_reference\">Reproduced with permission from: Herman MJ, Smith BG. Fractures of the Distal Femoral Physis. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright Â© 2014 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83181 Version 8.0</div></div></div>"},"83182":{"type":"graphic_picture","displayName":"Esophagogastric junction","title":"Esophagogastric junction","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Esophagogastric junction</div><div class=\"cntnt\"><img style=\"width:471px; height:402px;\" src=\"images/GAST/83182_Esophagogastric_junct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Esophagogastric junction as seen during esophagogastroduodenoscopy. The light pink mucosa (yellow arrow) represents the squamous lining of the esophagus, whereas the salmon-colored mucosa (white arrow) represents the columnar gastric mucosa. The squamocolumnar junction is also known as the \"z-line\".</div><div id=\"graphicVersion\">Graphic 83182 Version 1.0</div></div></div>"},"83183":{"type":"graphic_picture","displayName":"Hiatus hernia","title":"Hiatus hernia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hiatus hernia</div><div class=\"cntnt\"><img style=\"width:504px; height:339px;\" src=\"images/GAST/83183_Hiatus_hernia_G.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of a hiatus hernia seen from the stomach during retroflexion of the endoscope.</div><div id=\"graphicVersion\">Graphic 83183 Version 1.0</div></div></div>"},"83184":{"type":"graphic_figure","displayName":"Hepatitis B surface antigen seroclearance","title":"Hepatitis B surface antigen seroclearance following liver transplantation in patients receiving entecavir","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Hepatitis B surface antigen seroclearance following liver transplantation in patients receiving entecavir</div><div class=\"cntnt\"><img style=\"width:640px; height:627px;\" src=\"images/GAST/83184_HepB_surface_antigen_serocl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cumulative rate of HBsAg seroclearance.<BR>(B) Cumulative rate of HBsAg seroclearance in patients with and without HBV DNA level &lt;5 log copies/mL and HBsAg level &lt;3 log IU/mL.<BR>(C) Cumulative rate of HBsAg seroclearance in patients with and without detectable anti-HBs after liver transplant.<BR>(D) Cumulative rate of HBsAg relapse after initial seroclearance.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141:1212. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83184 Version 1.0</div></div></div>"},"83185":{"type":"graphic_figure","displayName":"Classification neuroendocrine tumors by embryonic derivation","title":"Anatomic location of neuroendocrine tumors based upon embryonic divisions of the alimentary tract","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Anatomic location of neuroendocrine tumors based upon embryonic divisions of the alimentary tract</div><div class=\"cntnt\"><img style=\"width:531px; height:667px;\" src=\"images/ONC/83185_Carcinoidtumors.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83185 Version 3.0</div></div></div>"},"83186":{"type":"graphic_diagnosticimage","displayName":"Comminuted distal femoral fracture","title":"Comminuted distal femoral fracture","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Comminuted distal femoral fracture</div><div class=\"cntnt\"><img style=\"width:525px; height:383px;\" src=\"images/EM/83186_Comm_distal_femoral_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Significantly comminuted fractures of the distal femur that do not involve the growth plate (A) are often best stabilized with plate fixation (B).</div><div class=\"graphic_reference\">Courtesy of Klane White, MD and Kimberly Stone, MD.</div><div id=\"graphicVersion\">Graphic 83186 Version 4.0</div></div></div>"},"83187":{"type":"graphic_diagnosticimage","displayName":"Extraosseous osteosarcoma with metastatic disease to the lungs","title":"Extraosseous osteosarcoma with metastatic disease to the lungs","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Extraosseous osteosarcoma with metastatic disease to the lungs</div><div class=\"cntnt\"><img style=\"width:584px; height:254px;\" src=\"images/RADIOL/83187_Extra_osteosarcoma_meta_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is a 38-year-old female found to have a calcified nodule in the left breast (A, arrow). The CT scan of the chest in the transverse projection reveals three densely calcified nodules in the left lung (B, arrowheads). Following surgical excision of the breast mass, pathological evaluation revealed a diagnosis of extraosseous osteosarcoma. The morphological similarity of the lung nodules to the primary tumor on CT suggests metastatic extraosseous osteosarcoma to the lungs.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 83187 Version 2.0</div></div></div>"},"83188":{"type":"graphic_diagnosticimage","displayName":"Comminuted Salter-Harris IV distal femoral fracture","title":"Comminuted Salter-Harris IV distal femoral fracture","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Comminuted Salter-Harris IV distal femoral fracture</div><div class=\"cntnt\"><img style=\"width:583px; height:426px;\" src=\"images/EM/83188_CommSHIVdistalfemfrac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Comminuted Salter-Harris IV fracture of the distal femur in a 14-year-old boy involved in a motor vehicle collision.<br />(B) Appearance six months after open reduction and internal fixation using cannulated screws in the metaphysis and epiphysis.</div><div class=\"graphic_reference\">Reproduced with permission from: Price CT, Herrera-Soto J. Extra-articular injuries of the knee. In: Rockwood and Wilkins' Fractures in Children, 7th edition, Beaty JH, Kasser JR. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83188 Version 7.0</div></div></div>"},"83189":{"type":"graphic_diagnosticimage","displayName":"Displaced distal metaphyseal femur fracture","title":"Displaced distal metaphyseal femur fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced distal metaphyseal femur fracture</div><div class=\"cntnt\"><img style=\"width:443px; height:584px;\" src=\"images/EM/83189_Displ_dist_metaphy_fem_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal femur fractures at or near the growth plate, such as this distal metaphyseal femur fracture (A: lateral radiograph; B: antero-posterior radiograph), generally require pin fixation after either closed or open reduction (C: antero-posterior view; D: lateral view).</div><div class=\"graphic_reference\">Courtesy of Klane White, MD and Kimberly Stone, MD.</div><div id=\"graphicVersion\">Graphic 83189 Version 3.0</div></div></div>"},"83190":{"type":"graphic_picture","displayName":"Neurovascular anatomy of the popliteal fossa","title":"Neurovascular anatomy of the popliteal fossa","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Neurovascular anatomy of the popliteal fossa</div><div class=\"cntnt\"><img style=\"width:514px; height:672px;\" src=\"images/EM/83190_Neurovasc-anat-pop-fossa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal femoral fractures and dislocations of the knee joint can cause injury to nerves and blood vessels that travel through the popliteal fossa including the popliteal artery and vein, tibial nerve, and common peroneal nerve.</div><div id=\"graphicVersion\">Graphic 83190 Version 4.0</div></div></div>"},"83191":{"type":"graphic_table","displayName":"Methoxsalen doses","title":"Dose schedule for methoxsalen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dose schedule for methoxsalen</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Patient weight</td> <td class=\"subtitle1\" rowspan=\"2\">Methoxsalen dose (mg)</td> </tr> <tr> <td class=\"subtitle2\">(lb)</td> <td class=\"subtitle2\">(kg)</td> </tr> <tr> <td class=\"centered\">&#60;66</td> <td class=\"centered\">&#60;30</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"centered\">66-143</td> <td class=\"centered\">30-65</td> <td class=\"centered\">20</td> </tr> <tr> <td class=\"centered\">144-200</td> <td class=\"centered\">65-90</td> <td class=\"centered\">30</td> </tr> <tr> <td class=\"centered\">&#62;200</td> <td class=\"centered\">&#62;90</td> <td class=\"centered\">40</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission of: Informa Healthcare, from Phototherapy and Photochemotherapy of Skin Disease, Morison WL, 3rd ed, New York 2005; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 83191 Version 4.0</div></div></div>"},"83192":{"type":"graphic_picture","displayName":"Allergic contact dermatitis interdigital","title":"Allergic contact dermatitis of the hand","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis of the hand</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83192_Allerg_contact_dermat_hand2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic allergic contact dermatitis of the hands presenting with erythema and scaling of the web spaces.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83192 Version 5.0</div></div></div>"},"83193":{"type":"graphic_table","displayName":"PUVA treatment schedule by skin type","title":"PUVA treatment schedule by skin type during the clearance phase","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PUVA treatment schedule by skin type during the clearance phase</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Skin type</td> <td class=\"subtitle1\" colspan=\"3\">UVA radiation dose (J/cm<sup>2</sup>)</td> </tr> <tr> <td class=\"subtitle2\">Initial</td> <td class=\"subtitle2\">Increments</td> <td class=\"subtitle2\">Maximum dose</td> </tr> <tr> <td class=\"centered\">I</td> <td class=\"centered\">1.5</td> <td class=\"centered\">0.5</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"centered\">II</td> <td class=\"centered\">2.5</td> <td class=\"centered\">0.5</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"centered\">III</td> <td class=\"centered\">3.5</td> <td class=\"centered\">0.5-1.0</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"centered\">IV</td> <td class=\"centered\">4.5</td> <td class=\"centered\">1.0</td> <td class=\"centered\">14</td> </tr> <tr> <td class=\"centered\">V</td> <td class=\"centered\">5.5</td> <td class=\"centered\">1.0</td> <td class=\"centered\">16</td> </tr> <tr> <td class=\"centered\">VI</td> <td class=\"centered\">6.5</td> <td class=\"centered\">1.0-1.5</td> <td class=\"centered\">20</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission of: Informa Healthcare, from Phototherapy and Photochemotherapy of Skin Disease, Morison WL, 3rd ed, New York 2005; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 83193 Version 4.0</div></div></div>"},"83194":{"type":"graphic_table","displayName":"Pulmonary complications of allogeneic HCT - Preengraftment","title":"Pulmonary complications of allogeneic hematopoietic cell transplantation: Preengraftment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary complications of allogeneic hematopoietic cell transplantation: Preengraftment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease process</td> <td class=\"subtitle1\">Risk factors</td> <td class=\"subtitle1\">Associated manifestations</td> <td class=\"subtitle1\">Radiographic findings</td> <td class=\"subtitle1\">Useful diagnostic tests</td> <td class=\"subtitle1\">Lung biopsy needed</td> </tr> <tr> <td>Bacterial pneumonia</td> <td>Mucositis, neutropenia</td> <td>Fever, cough, sputum</td> <td>Usually focal consolidation; becomes diffuse in acute lung injury</td> <td>Broad microbiologic testing; response to empiric antibiotics</td> <td>Generally not</td> </tr> <tr class=\"divider_top\"> <td>Fungal pneumonia</td> <td>Prolonged neutropenia; exposure to endemic fungi; prior treatment for invasive fungus</td> <td>Fever</td> <td>Focal nodular and consolidative opacities, \"halo sign,\" \"reverse halo sign\"</td> <td>Broad&nbsp;microbiologic testing&nbsp;including BAL; &#946;-D-glucan of the blood; Aspergillus galactomannan EIA of the blood and BAL fluid; response to empiric antifungal therapy</td> <td>Sometimes</td> </tr> <tr class=\"divider_top\"> <td>Aspiration pneumonia</td> <td>Impaired swallowing due to mucositis; opiate therapy</td> <td>Fever, dyspnea</td> <td>Diffuse or focal ground glass or consolidative opacities</td> <td>Cultures are often negative</td> <td>No</td> </tr> <tr class=\"divider_top\"> <td>Permeability pulmonary edema</td> <td>Aspiration, engraftment syndrome, hyperacute GVHD, sepsis syndrome</td> <td>Fever, dyspnea</td> <td>Diffuse ground glass opacities</td> <td>Normal BNP, normal LV function on echocardiogram</td> <td>No</td> </tr> <tr class=\"divider_top\"> <td>Cardiogenic pulmonary edema</td> <td>Cardiotoxic medications; copious intravenous fluid administration</td> <td>Dyspnea, weight gain, peripheral edema</td> <td>Perihilar opacities in butterfly distribution, septal thickening, pleural effusion, cardiomegaly</td> <td>Elevated BNP; echocardiogram showing reduced LV function</td> <td>No</td> </tr> <tr class=\"divider_top\"> <td>Engraftment syndrome</td> <td>&nbsp;</td> <td>Erythematous maculo-papular rash, fever &#62;38.3&#176;C, weight gain</td> <td>CT: bilateral ground-glass opacification, hilar or peribronchial consolidation, and thickening of interlobular septa</td> <td>Skin biopsy; BAL to exclude infection</td> <td>Sometimes to exclude other treatable causes, lung biopsy shows diffuse alveolar damage</td> </tr> <tr class=\"divider_top\"> <td>Hyperacute GVHD*</td> <td>HLA mismatch</td> <td>Rash, abdominal cramps, diarrhea, elevated bilirubin</td> <td>Diffuse ground glass consistent with acute lung injury</td> <td>Skin biopsy; BAL to exclude infection</td> <td>Sometimes to exclude other processes</td> </tr> <tr class=\"divider_top\"> <td>Diffuse alveolar hemorrhage&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>CT: patchy or diffuse opacities, may have air bronchograms&nbsp;</td> <td>BAL to exclude infection and to identify increasingly bloody return in sequential lavages and &#62;20 percent hemosiderin-laden macrophages&nbsp;</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage; EIA: enzyme immunoassay; BNP: brain natriuretic protein; LV: left ventricular; CT: computed tomography; GVHD: graft-versus-host-disease; HLA: human leukocyte antigens; CTPA: computed tomography pulmonary angiogram.<br />* Hyperacute GVHD is very rare preengraftment, but may rarely occur at the time of engraftment and overlaps clinically with engraftment syndrome.</div><div id=\"graphicVersion\">Graphic 83194 Version 2.0</div></div></div>"},"83195":{"type":"graphic_table","displayName":"Pulmonary complications of allogeneic HCT - Postengraftment","title":"Pulmonary complications of allogeneic hematopoietic cell transplantation: Postengraftment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary complications of allogeneic hematopoietic cell transplantation: Postengraftment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease process</td> <td class=\"subtitle1\">Risk factors</td> <td class=\"subtitle1\">Associated manifestations</td> <td class=\"subtitle1\">Radiographic findings</td> <td class=\"subtitle1\">Useful diagnostic tests</td> <td class=\"subtitle1\">Lung biopsy needed</td> </tr> <tr class=\"divider_top\"> <td>Bacterial pneumonia</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>Focal or patchy consolidation, may be peribronchial</p> <p>Occasionally mass-like \"round-pneumonia\"</p> </td> <td>Blood cultures, Legionella and pneumococcal urinary antigens, BAL for Gram stain and aerobic and anaerobic cultures, Legionella culture, Mycoplasma PCR, and modified AFB stain and culture for Nocardia</td> <td>Rarely</td> </tr> <tr class=\"divider_top\"> <td>Mycobacterial pneumonia</td> <td>Total body irradiation, chronic GVHD</td> <td>M. haemophilum is associated with skin nodules and/or joint inflammation</td> <td>Miliary pattern</td> <td>TST&nbsp;after HCT not helpful; AFB staining and cultures of induced sputum and BAL are helpful</td> <td>Rarely</td> </tr> <tr class=\"divider_top\"> <td>CMV pneumonitis</td> <td>Seropositive recipient with seronegative donor; delayed reconstitution, prior treatment for CMV</td> <td>&nbsp;</td> <td>CT: patchy or diffuse ground-glass opacities, patchy consolidation, small nodular opacities; rarely tree-in-bud pattern</td> <td>Serology, blood test for pp65 antigen or CMV PCR, BAL and endobronchial brush&nbsp;for cytologic examination for inclusion bodies and BAL shell vial cultures for CMV</td> <td>Rarely</td> </tr> <tr class=\"divider_top\"> <td>Respiratory viruses</td> <td>Exposure to someone with active viral infection</td> <td>URI symptoms prior to onset of lower respiratory tract symptoms</td> <td>Diffuse ground glass opacities are the most common</td> <td>PCR, culture, or rapid immunofluorescence of nasopharyngeal lavage or swab and BAL fluid</td> <td>Sometimes to completely exclude other possibilities</td> </tr> <tr class=\"divider_top\"> <td>Fungal infection (eg, invasive aspergillosis, Fusarium, agents of mucormycosis, Candida, Scedosporium, Pneumocystis)</td> <td>Presence and severity GVHD, older patient age, cytopenia, CMV infection</td> <td>&nbsp;</td> <td>Focal nodular and consolidative opacities, \"halo sign,\" \"reverse halo sign,\"&nbsp;sometimes subpleural wedge-shaped densities</td> <td>Broad&nbsp;microbiologic testing&nbsp;of blood and BAL; blood tests for &#946;-D-glucan and Aspergillus galactomannan EIA;&nbsp;BAL for Aspergillus&nbsp;galactomannan EIA; and induced sputum and BAL for Pneumocystis staining</td> <td>Sometimes when cultures are negative and no response to initial therapy</td> </tr> <tr class=\"divider_top\"> <td>Idiopathic pneumonia syndrome</td> <td>Busulfan, high dose cyclophosphamide, radiation, nonmyeloablative conditioning regimen</td> <td>&nbsp;</td> <td>Extensive opacities</td> <td>Negative stains, cultures, antigen testing, and PCR of blood, sputum, urine, and BAL</td> <td>Yes, either transbronchial or surgical</td> </tr> <tr class=\"divider_top\"> <td>Diffuse alveolar hemorrhage</td> <td>Underlying mucopolysaccharidosis</td> <td>&nbsp;</td> <td>CT: patchy or diffuse opacities, may have air bronchograms</td> <td>BAL showing increasingly bloody return in sequential lavages and &#62;20 percent hemosiderin-laden macrophages</td> <td>Not usually</td> </tr> <tr class=\"divider_top\"> <td>Connective tissue disease</td> <td>Myeloablative conditioning regimen</td> <td>Extrapulmonary manifestations such as dry mouth/dry eyes, joint pain/swelling, muscle weakness</td> <td>CT: subpleural, ground-glass opacities; septal thickening</td> <td>Autoantibody tests positive</td> <td>Often to identify specific type of interstitial pneumonitis</td> </tr> <tr class=\"divider_top\"> <td>Cryptogenic organizing pneumonia/organizing pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia)</td> <td>Irradiation, CMV infection, HCT associated connective tissue disease, chronic GVHD</td> <td>&nbsp;</td> <td>CT: patchy air-space consolidation, ground-glass opacities, small nodular opacities, \"reverse halo sign\"</td> <td>Lung biopsy</td> <td>Yes</td> </tr> <tr class=\"divider_top\"> <td>Bronchiolitis obliterans&nbsp;</td> <td>Chronic GVHD, postviral</td> <td>&nbsp;</td> <td>CT initially clear; as progresses, CT may show mosaic ground glass opacities and bronchiectasis</td> <td> <p>Spirometry showing airflow limitation</p> <p>Skin biopsy for GVHD</p> </td> <td>Sometimes, if diagnosis uncertain&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Malignancy</td> <td>Underlying lymphoma, EBV infection in posttransplant lymphoproliferative disorder</td> <td>&nbsp;</td> <td>Nodular opacities, lymphangitic pattern</td> <td>BAL cytology and flow cytometry, biopsy</td> <td>Biopsy usually needed</td> </tr> <tr class=\"divider_top\"> <td>Pulmonary alveolar proteinosis</td> <td>HCT for myeloid disorder</td> <td>&nbsp;</td> <td>Perihilar opacities in a \"bat-wing\" distribution often with air bronchograms</td> <td>Bronchoalveolar lavage showing characteristic milky appearance and positive stain for lipoproteins </td> <td>Not usually</td> </tr> <tr class=\"divider_top\"> <td>Pulmonary cytolytic thrombi</td> <td>Chronic GVHD is a risk factor</td> <td>Low grade fever, cough</td> <td>CT: peripheral nodules</td> <td>BAL to rule out infection; lung biopsy</td> <td>Yes, findings are basophilic cytolytic thrombi in the small to medium distal pulmonary vessels with entrapped monocytes</td> </tr> <tr class=\"divider_top\"> <td>Pulmonary veno-occlusive disease</td> <td>Onset after first 100 days, chronic GVHD</td> <td>Reduced DLCO</td> <td>CXR: pleural effusion and Kerley B lines; CT chest: centrilobular ground glass opacities; no emboli on CTPA</td> <td>Right heart catheterization; BAL showing occult hemorrhage</td> <td>For definitive diagnosis</td> </tr> <tr class=\"divider_top\"> <td>Drug toxicity</td> <td>History of pneumotoxic drug use (eg, busulfan, cyclophosphamide)</td> <td>May be associated with rash, peripheral eosinophilia</td> <td>Varied</td> <td>Increased BAL eosinophils may be seen; other processes excluded by negative blood and BAL stains and cultures, negative fungal studies</td> <td>Sometimes to completely exclude other possibilities</td> </tr> <tr class=\"divider_top\"> <td>Radiation pneumonitis</td> <td>History of radiation therapy involving lungs</td> <td> <p>Acute: onset usually 4 to 12 weeks following irradiation</p> <p>Late: onset after 6 to 12 months</p> </td> <td> <p>Acute CT: ground-glass attenuation within the area of irradiated lung</p> <p>Late CT: linear opacities (scarring) or an area of dense consolidation and volume loss</p> </td> <td>Other processes excluded by negative blood and BAL stains and cultures, negative fungal studies</td> <td>Sometimes to completely exclude other possibilities</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Selection of specific diagnostic tests is based on clinical features and results of prior testing.</div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage; PCR: polymerase chain reaction; AFB: acid-fast bacillus; GVHD: graft-versus-host disease; TST: tuberculin skin test; HCT: hematopoietic cell transplantation; CMV: cytomegalovirus; CT: computed tomography; URI: upper respiratory infection; EIA: enzyme immunoassay;&nbsp;EBV: Epstein-Barr virus; DLCO: diffusing capacity for carbon monoxide; CXR: chest radiograph; CTPA: computed tomography pulmonary angiography.</div><div id=\"graphicVersion\">Graphic 83195 Version 4.0</div></div></div>"},"83196":{"type":"graphic_diagnosticimage","displayName":"Acute subdural hematoma in an abused infant","title":"Acute subdural hematoma in an abused infant","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Acute subdural hematoma in an abused infant</div><div class=\"cntnt\"><img style=\"width:510px; height:544px;\" src=\"images/EM/83196_Acute_subdur_hemato_abused.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute subdural hematoma (arrows) in an abused infant with skin bruises and skull and rib fractures.</div><div class=\"graphic_reference\">Courtesy of Cindy Christian, MD.</div><div id=\"graphicVersion\">Graphic 83196 Version 2.0</div></div></div>"},"83197":{"type":"graphic_diagnosticimage","displayName":"Skull fracture in an abused infant","title":"Skull fracture in an abused infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skull fracture in an abused infant</div><div class=\"cntnt\"><img style=\"width:415px; height:615px;\" src=\"images/EM/83197_Skull_frac_abused_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph of the skull demonstrates a right parietal skull fracture (arrow) in an abused infant.</div><div class=\"graphic_reference\">Courtesy of Cindy Christian, MD.</div><div id=\"graphicVersion\">Graphic 83197 Version 1.0</div></div></div>"},"83198":{"type":"graphic_diagnosticimage","displayName":"Multiple healing rib fractures in an abused infant","title":"Multiple healing rib fractures in an abused infant","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Multiple healing rib fractures in an abused infant</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/EM/83198_Mult_heal_rib_frac_abus_inf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple healing rib fractures (arrows) in an infant who also had an acute subdural hematoma, linear parietal skull fracture, and skin bruising.</div><div class=\"graphic_reference\">Courtesy of Cindy Christian, MD.</div><div id=\"graphicVersion\">Graphic 83198 Version 1.0</div></div></div>"},"83200":{"type":"graphic_table","displayName":"PUVA indications","title":"PUVA indications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PUVA indications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">FDA approved indications</td> </tr> <tr> <td class=\"indent1\">Psoriasis*</td> </tr> <tr> <td class=\"indent1\">Vitiligo<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Off label dermatologic uses</td> </tr> <tr> <td class=\"sublist2_start\">Neoplastic</td> </tr> <tr> <td class=\"sublist2\">Mycosis fungoides/Sezary syndrome</td> </tr> <tr> <td class=\"sublist2\">Histiocytosis X (Langerhans cell histiocytosis)</td> </tr> <tr> <td class=\"sublist2_start\">Papulosquamous/dermatitis</td> </tr> <tr> <td class=\"sublist2\">Atopic dermatitis</td> </tr> <tr> <td class=\"sublist2\">Seborrheic dermatitis</td> </tr> <tr> <td class=\"sublist2\">Chronic hand dermatitis</td> </tr> <tr> <td class=\"sublist2\">Palmoplantar pustulosis</td> </tr> <tr> <td class=\"sublist2\">Lichen planus</td> </tr> <tr> <td class=\"sublist2\">Parapsoriasis</td> </tr> <tr> <td class=\"sublist2\">Pityriasis lichenoides</td> </tr> <tr> <td class=\"sublist2\">Lymphomatoid papulosis</td> </tr> <tr> <td class=\"sublist2_start\">Photosensitivity dermatoses</td> </tr> <tr> <td class=\"sublist2\">Polymorphous light eruption</td> </tr> <tr> <td class=\"sublist2\">Erythropoietic protoporphyria</td> </tr> <tr> <td class=\"sublist2\">Solar urticaria</td> </tr> <tr> <td class=\"sublist2\">Chronic actinic dermatitis</td> </tr> <tr> <td class=\"sublist2_start\">Other pruritic dermatoses</td> </tr> <tr> <td class=\"sublist2\">Dermographism</td> </tr> <tr> <td class=\"sublist2\">Aquagenic urticaria/pruritus</td> </tr> <tr> <td class=\"sublist2\">Chronic urticaria</td> </tr> <tr> <td class=\"sublist2\">Polycythemia vera</td> </tr> <tr> <td class=\"sublist2\">Idiopathic pruritus</td> </tr> <tr> <td class=\"sublist2\">Urticaria pigmentosa</td> </tr> <tr> <td class=\"sublist2\">Prurigo nodularis</td> </tr> <tr> <td class=\"sublist2_start\">Other immunologic dermatoses</td> </tr> <tr> <td class=\"sublist2\">Alopecia areata</td> </tr> <tr> <td class=\"sublist2\">Graft-versus-host disease</td> </tr> <tr> <td class=\"sublist2\">Morphea</td> </tr> <tr> <td class=\"sublist2\">Linear scleroderma</td> </tr> <tr> <td class=\"sublist2_start\">Miscellaneous dermatoses</td> </tr> <tr> <td class=\"sublist2\">Transient acantholytic dermatosis (Grover's disease)</td> </tr> <tr> <td class=\"sublist2\">Pigmented purpuric dermatoses</td> </tr> <tr> <td class=\"sublist2\">Ichthyosis linearis circumflexa</td> </tr> <tr> <td class=\"sublist2\">Scleromyxedema</td> </tr> <tr> <td class=\"sublist2\">Generalized granuloma annulare</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Methoxsalen capsules approved for this indication.<br />&para; Methoxsalen solution and trioxsalen are approved for this indication.</div><div class=\"graphic_reference\">Reproduced from: Morison WL. PUVA Photochemotherapy. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Saunders Elsevier, Philadelphia 2007. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83200 Version 3.0</div></div></div>"},"83203":{"type":"graphic_picture","displayName":"Strawberry tongue PI","title":"Strawberry tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strawberry tongue</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/PI/83203_Strawberry_tongue_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A person with scarlet fever might have a bright red tongue with small bumps, like a strawberry.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83203 Version 5.0</div></div></div>"},"83204":{"type":"graphic_figure","displayName":"Complications of acute mastoiditis","title":"Complications of acute mastoiditis","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Complications of acute mastoiditis</div><div class=\"cntnt\"><img style=\"width:533px; height:595px;\" src=\"images/PEDS/83204_Mastoiditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spread of infection from the mastoid to adjacent areas may lead to intratemporal and intracranial complications as depicted above.</div><div id=\"graphicVersion\">Graphic 83204 Version 1.0</div></div></div>"},"83205":{"type":"graphic_picture","displayName":"Mastoiditis infant","title":"Mastoiditis in an infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mastoiditis in an infant</div><div class=\"cntnt\"><img style=\"width:237px; height:178px;\" src=\"images/PEDS/83205_Mastoiditis_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mastoiditis in an infant, frontal view. The ear is displaced downward and outward.</div><div class=\"graphic_reference\">Reproduced with permission from Paul S. Matz, MD. Originally published in: Cronan K. Ear swelling. In: Visual Diagnosis in Pediatrics, Chung EK, Boom JA, Datto GA, Matz PS (Eds). Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006.</div><div id=\"graphicVersion\">Graphic 83205 Version 1.0</div></div></div>"},"83207":{"type":"graphic_table","displayName":"PUVA contraindications","title":"Contraindications to PUVA phototherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to PUVA phototherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absolute</td> </tr> <tr> <td>Xeroderma pigmentosum</td> </tr> <tr> <td>Lupus erythematosus with photosensitivity or positive Ro antibody</td> </tr> <tr> <td>Pregnancy (category C)</td> </tr> <tr> <td>Lactation</td> </tr> <tr> <td class=\"subtitle1_single\">Relative</td> </tr> <tr> <td>Photosensitivity and/photosensitizing medications</td> </tr> <tr> <td>History or family history of melanoma</td> </tr> <tr> <td>History of nonmelanoma skin cancer and/or extensive solar damage</td> </tr> <tr> <td>Previous treatment with ionizing radiation or arsenic</td> </tr> <tr> <td>Severe liver, renal, or cardiac disease</td> </tr> <tr> <td>Young age</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Morison WL. Phototherapy and Photochemotherapy of Skin Disease, 3rd ed, Taylor and Francis, New York 2005.</li>&#xD;&#xA;    <li>Morison WL. PUVA Photochemotherapy. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, Philadelphia 2007.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 83207 Version 2.0</div></div></div>"},"83209":{"type":"graphic_figure","displayName":"Larynx PI","title":"Larynx (voice box)","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Larynx (voice box)</div><div class=\"cntnt\"><img style=\"width:485px; height:613px;\" src=\"images/PI/83209_Larynx-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The larynx (voice box) is the top part of the windpipe. The larynx has the vocal cords in it, which are small structures that let people speak. The muscles that control the vocal cords in the voice box are called the \"laryngeal muscles.\"</div><div id=\"graphicVersion\">Graphic 83209 Version 3.0</div></div></div>"},"83210":{"type":"graphic_figure","displayName":"Throat PI","title":"Throat","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Throat</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/PI/83210_Throat-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a cross-section of the head and neck. The throat includes the area from the back of the nose and mouth to the windpipe and esophagus (the tube that carries food from the mouth to the stomach).</div><div id=\"graphicVersion\">Graphic 83210 Version 1.0</div></div></div>"},"83211":{"type":"graphic_picture","displayName":"Tongue cancer PI","title":"Tongue cancer","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tongue cancer</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/83211_Tongue_cancer_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an example of tongue cancer.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83211 Version 4.0</div></div></div>"},"83212":{"type":"graphic_table","displayName":"Dystonia PI","title":"Most common forms of dystonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Most common forms of dystonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Early-onset isolated dystonia</td> </tr> <tr> <td class=\"indent1\">When does it usually start?</td> <td>Childhood</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>Most of the time it starts in the leg, then moves to the trunk and other parts of the body</td> </tr> <tr> <td class=\"indent1\">What else do I need to know about it?</td> <td>It often starts with mild symptoms that get worse as time goes on</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Cervical dystonia (also called spasmodic torticollis)</td> </tr> <tr> <td class=\"indent1\">When does it usually start?</td> <td>Adulthood</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>Neck and shoulder muscles</td> </tr> <tr> <td class=\"indent1\">What else do I need to know about it?</td> <td>Some people also have a head tremor with cervical dystonia. About half the people with cervical dystonia have pain.</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Blepharospasm</td> </tr> <tr> <td class=\"indent1\">When does it usually start?</td> <td>Adulthood</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>Eyelid muscles</td> </tr> <tr> <td class=\"indent1\">What else do I need to know about it?</td> <td>Symptoms can include increased blinking and spasms that cause your eye to close. Both eyes are affected most of the time. Bright light or stress can make it worse. Most people do not have pain with blepharospasm.</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Oromandibular and facial dystonia</td> </tr> <tr> <td class=\"indent1\">When does it usually start?</td> <td>Adulthood</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>Face and throat muscles</td> </tr> <tr> <td class=\"indent1\">What else do I need to know about it?</td> <td> <p>Symptoms include problems with the jaw. For example, the jaw might clench, stay open, or be crooked. Some people cannot keep their tongue in their mouth. Some also have trouble speaking or swallowing.</p> This type of dystonia often happens in people who also have blepharospasm or cervical dystonia.</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Spasmodic dysphonia</td> </tr> <tr> <td class=\"indent1\">When does it usually start?</td> <td>Adulthood</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>Muscles of the voice box (called the \"laryngeal muscles\")</td> </tr> <tr> <td class=\"indent1\">What else do I need to know about it?</td> <td>Your voice might sound strained or you might only be able to whisper</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Arm dystonia</td> </tr> <tr> <td class=\"indent1\">When does it usually start?</td> <td>Adulthood</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>Arm and hand muscles</td> </tr> <tr> <td class=\"indent1\">What else do I need to know about it?</td> <td>Arm dystonia can cause your hand or arm to stay in odd positions. In many people, symptoms happen only when the arm is stretched out and go away when the arm is at rest.</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Occupational or task-specific dystonia</td> </tr> <tr> <td class=\"indent1\">When does it usually start?</td> <td>Adulthood</td> </tr> <tr> <td class=\"indent1\">Which muscles are affected most?</td> <td>This is a type of dystonia that happens only during certain activities. Writer's cramp is the most common form. Others include: <ul class=\"decimal_heading\"> <li>Typist's dystonia </li> <li>Golfer's dystonia </li> <li>Musician's dystonia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">What else do I need to know about it?</td> <td>Symptoms happen only when the person tries to do a specific task such as write, swing a golf club, or play a musical instrument. The person has no symptoms when doing anything else.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83212 Version 3.0</div></div></div>"},"83213":{"type":"graphic_figure","displayName":"Cleft lip and palate PI","title":"Baby with cleft lip and baby with cleft palate","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Baby with cleft lip and baby with cleft palate</div><div class=\"cntnt\"><img style=\"width:527px; height:543px;\" src=\"images/PI/83213_Cleft-lip-and-palate-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cleft lip is an opening or split in the upper lip (on left) A cleft palate is an opening or split the roof of the mouth, called the palate (on right). A baby can be born with one or both of these birth defects.</div><div id=\"graphicVersion\">Graphic 83213 Version 1.0</div></div></div>"},"83214":{"type":"graphic_diagnosticimage","displayName":"Pathological fracture in metastatic prostate carcinoma","title":"Plain radiograph of a pathological fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of a pathological fracture</div><div class=\"cntnt\"><img style=\"width:443px; height:593px;\" src=\"images/RADIOL/83214_Path_frac_metast_prost_carc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is an 89-year-old male with metastatic prostate carcinoma. The first set of plain radiograph images of the left humerus in the AP view with external rotation (A and magnified in B) reveal a mottled appearance of the medial surface of the diaphysis with an irregular erosion through the cortex (arrow) reminiscent of lytic metastatic disease. Two months later, the patient presented with a complete transverse pathological fracture through the midshaft of the humerus (C and magnified in D, with arrowhead).</div><div id=\"graphicVersion\">Graphic 83214 Version 2.0</div></div></div>"},"83215":{"type":"graphic_diagnosticimage","displayName":"HHV-6 encephalitis MRIs 1","title":"Post-transplant acute limbic encephalitis caused by HHV-6: Initial magnetic resonance imaging findings with days from symptom onset indicated","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Post-transplant acute limbic encephalitis caused by HHV-6: Initial magnetic resonance imaging findings with days from symptom onset indicated</div><div class=\"cntnt\"><img style=\"width:533px; height:660px;\" src=\"images/ID/83215_PALE_MRIs_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial FLAIR (top) and diffusion-weighted (bottom) sequences demonstrate limbic system involvement, including the uncus, amygdala, and anterior hippocampus in all patients. For Patient 6, only coronal FLAIR images from day 2 were available. An axial FLAIR image from day 6, with findings similar to those on day 2, is shown. The left side of each image corresponds to the right side of the brain.</div><div class=\"graphic_footnotes\">HHV-6: human herpesvirus 6; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">Reproduced with permission from: Seeley WW, Marty FM, Holmes TH, et al. Post-transplant acute limbic encephalitis: Clinical features and relationship to HHV6. Neurology 2007; 69:156. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83215 Version 10.0</div></div></div>"},"83216":{"type":"graphic_diagnosticimage","displayName":"HHV-6 encephalitis MRI 2","title":"Post-transplant acute limbic encephalitis caused by HHV-6: Coronal FLAIR magnetic resonance images","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Post-transplant acute limbic encephalitis caused by HHV-6: Coronal FLAIR magnetic resonance images</div><div class=\"cntnt\"><img style=\"width:513px; height:434px;\" src=\"images/ID/83216_PALE_MRI_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal FLAIR&nbsp;magnetic resonance&nbsp;images demonstrate the focality of the encephalitis, which can be traced bilaterally from the uncus through the hippocampal body and into the fornix. The amygdala is partly affected and the parahippocampal gyrus is conspicuously spared. The left side of each image corresponds to the right side of the brain.</div><div class=\"graphic_footnotes\">HHV-6: human herpesvirus 6; FLAIR: fluid attenuation inversion recovery.</div><div class=\"graphic_reference\">Reproduced with permission from: Seeley WW, Marty FM, Holmes TH, et al. Post-transplant acute limbic encephalitis: Clinical features and relationship to HHV6. Neurology 2007; 69:156. Copyright Â© 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83216 Version 8.0</div></div></div>"},"83217":{"type":"graphic_diagnosticimage","displayName":"Mild compression fracture of  L2","title":"Mild compression fracture of second lumbar vertebra","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mild compression fracture of second lumbar vertebra</div><div class=\"cntnt\"><img style=\"width:350px; height:584px;\" src=\"images/RADIOL/83217_Mild_compression_L2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The x-rays of the lumbar spine in the AP (A) and lateral projections (B), and magnified view of the lateral view (C), reveal a mild compression fracture of the superior endplate of L2 (arrowhead). The arrow shows a near normal appearing L2 in the AP projection with normal interpedicular distance. Note the step-off deformity of the anterior and superior aspect of the endplate of L2 (dashed arrow) which is a manifestation of the injury. There is less than 20 percent loss of vertebral height.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div id=\"graphicVersion\">Graphic 83217 Version 2.0</div></div></div>"},"83219":{"type":"graphic_table","displayName":"HHV-6 diagnostic tests","title":"Methods for diagnosing human herpesvirus 6 infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methods for diagnosing human herpesvirus 6 infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Assay</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td><strong>Culture</strong></td> <td> <p>Positive results represent active infection or replication</p> <p>Able to distinguish between HHV-6A and HHV-6B variants</p> </td> <td> <p>Technically difficult</p> <p>Long turn-around time</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">PCR</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">DNA PCR</td> </tr> <tr> <td class=\"indent2\">Plasma</td> <td> <p>Correlates well with diagnostic and clinical indicators of primary infection and with virus isolation after transplantation</p> <p>Able to distinguish between HHV-6A and HHV-6B variants</p> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">PBMC</td> <td> <p>Able to distinguish between HHV-6A and HHV-6B variants</p> </td> <td> <p>Requires quantitative cut-offs for established sensitivity threshold in order to distinguish latent from active infection</p> <p>Negative results may be difficult to interpret in lymphopenic patients (eg, HCT recipients early after transplantation)</p> </td> </tr> <tr> <td class=\"indent2\">CSF</td> <td>Able to distinguish between HHV-6A and HHV-6B variants</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\">Reverse transcription&nbsp;PCR</td> <td> <p>Positive results represent active infection or replication</p> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Serology</td> </tr> <tr> <td class=\"subtitle3_left\">Conventional</td> <td> <p>&nbsp;</p> </td> <td> <p>Does not reliably distinguish between active and latent infection</p> <p>There may be interference from maternal antibodies around the time of primary infection</p> <p>Immunocompromised patients do not reliably mount an antibody response</p> <p>Unable to distinguish between HHV-6A and HHV-6B variants</p> </td> </tr> <tr> <td class=\"subtitle3_left\">Avidity assays</td> <td> <p>Able to distinguish between antibody associated with primary versus established infection</p> </td> <td> <p>Unable to distinguish between reactivation and latent infection</p> <p>Unable to distinguish between HHV-6A and HHV-6B variants</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HHV-6: human herpesvirus 6; PCR: polymerase chain reaction; PBMC: peripheral blood mononuclear cells; HCT: hematopoietic cell transplantation; CSF: cerebrospinal fluid.</div><div class=\"graphic_reference\">Courtesy of Danielle Zerr, MD, MPH.</div><div id=\"graphicVersion\">Graphic 83219 Version 5.0</div></div></div>"},"83220":{"type":"graphic_figure","displayName":"Inherited HHV-6 from an HCT donor","title":"HHV-6 viral load kinetics in a hematopoietic cell transplant recipient whose donor had inherited HHV-6","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">HHV-6 viral load kinetics in a hematopoietic cell transplant recipient whose donor had inherited HHV-6</div><div class=\"cntnt\"><img style=\"width:515px; height:403px;\" src=\"images/ID/83220_Inherited_HHV6_HCT_donor.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Association between plasma versus whole blood HHV-6 DNA levels and total white cell count.</div><div class=\"graphic_footnotes\">HHV-6: human herpesvirus 6</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Kamble RT, Clark DA, Leong HN, et al. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40:563. Copyright &copy; 2007.</div><div id=\"graphicVersion\">Graphic 83220 Version 2.0</div></div></div>"},"83221":{"type":"graphic_figure","displayName":"Inherited HHV-6 in an HCT recipient","title":"HHV-6 viral load kinetics in an allogeneic hematopoietic cell transplant recipient with inherited HHV-6","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">HHV-6 viral load kinetics in an allogeneic hematopoietic cell transplant recipient with inherited HHV-6</div><div class=\"cntnt\"><img style=\"width:609px; height:395px;\" src=\"images/ID/83221_Inherit_HHV6_HCT_recipient.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HHV-6 viral load in whole blood expressed as log<SUB>10</SUB> genomic equivalent copies per milliliter of whole blood (<STRONG>X</STRONG>) and as log<SUB>10</SUB> genomic equivalent copies/10<SUP>6</SUP> cells (<STRONG>â¢</STRONG>), leukocyte count (â), and chimerism result in an allogeneic&nbsp;hematopoietic cell transplantation recipient.</div><div class=\"graphic_footnotes\">HHV-6: human herpesvirus 6; %: percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Jeulin H, Gu&eacute;ry M, Cl&eacute;ment L, et al. Chromosomally Integrated HHV-6: Slow Decrease of HHV-6 Viral Load After Hematopoietic Stem-Cell Transplantation. Transplantation 2009; 88:1142. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83221 Version 7.0</div></div></div>"},"83222":{"type":"graphic_figure","displayName":"Atherosclerosis PI","title":"Atherosclerosis","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Atherosclerosis</div><div class=\"cntnt\"><img style=\"width:457px; height:441px;\" src=\"images/PI/83222_Atherosclerosis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atherosclerosis is a condition in which fatty deposits called \"plaques\" build up in the lining of the blood vessels. As plaques get bigger, the blood vessels get narrow. This means the blood vessels cannot carry as much blood as before.</div><div class=\"graphic_reference\">Reproduced from: What Is Atherosclerosis? National Heart, Lung, and Blood Institute. Available at http://www.nhlbi.nih.gov/health/health-topics/topics/atherosclerosis/.</div><div id=\"graphicVersion\">Graphic 83222 Version 1.0</div></div></div>"},"83223":{"type":"graphic_table","displayName":"Partial list of seizure-inducing toxins","title":"Partial list of seizure-inducing toxins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Partial list of seizure-inducing toxins</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Anticholinergics</td> </tr> <tr> <td class=\"sublist1\">Diphenhydramine*</td> </tr> <tr> <td class=\"sublist1_start\">Anticonvulsants</td> </tr> <tr> <td class=\"sublist1\">Carbamazepine*</td> </tr> <tr> <td class=\"sublist1\">Phenytoin</td> </tr> <tr> <td class=\"sublist1_start\">Cholinergic agents</td> </tr> <tr> <td class=\"sublist1\">Organophosphates</td> </tr> <tr> <td class=\"sublist1\">Nerve agents</td> </tr> <tr> <td class=\"sublist1_start\">Hydrazines</td> </tr> <tr> <td class=\"sublist1\">Isoniazid</td> </tr> <tr> <td class=\"sublist1_start\">Hydrocarbons</td> </tr> <tr> <td class=\"sublist1\">Camphor</td> </tr> <tr> <td class=\"sublist1\">Lindane</td> </tr> <tr> <td class=\"sublist1_start\">Hypoglycemic agents</td> </tr> <tr> <td class=\"sublist1\">Insulin</td> </tr> <tr> <td class=\"sublist1\">Sulfonylureas</td> </tr> <tr> <td class=\"sublist1_start\">Methylxanthines</td> </tr> <tr> <td class=\"sublist1\">Theophylline*</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td class=\"sublist1_start\">Miscellaneous</td> </tr> <tr> <td class=\"sublist1\">Buproprion</td> </tr> <tr> <td class=\"sublist1\">Citalopram</td> </tr> <tr> <td class=\"sublist1\">Lithium</td> </tr> <tr> <td class=\"sublist1\">Venlafaxine*</td> </tr> <tr> <td class=\"sublist1_start\">Mitochondrial toxins</td> </tr> <tr> <td class=\"sublist1\">Carbon monoxide</td> </tr> <tr> <td class=\"sublist1\">Cyanide</td> </tr> <tr> <td class=\"sublist1_start\">Opioids</td> </tr> <tr> <td class=\"sublist1\">Meperidine</td> </tr> <tr> <td class=\"sublist1\">Propoxyphene*</td> </tr> <tr> <td class=\"sublist1_start\">Sodium channel blockers</td> </tr> <tr> <td class=\"sublist1\">Lidocaine*</td> </tr> <tr> <td class=\"sublist1\">Cyclic antidepressants*</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1_start\">Withdrawal</td> </tr> <tr> <td class=\"sublist1\">Ethanol</td> </tr> <tr> <td class=\"sublist1\">Sedative-hypnotic</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Toxins also associated with cardiotoxicity and dysrhythmias.</div><div class=\"graphic_reference\">Reproduced from: Sharma AN, Hoffman RH. Toxin-related seizures. Emerg Med Clin North Am 2011; 29:125. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83223 Version 1.0</div></div></div>"},"83224":{"type":"graphic_picture","displayName":"Rounded protracted shoulder posture","title":"Posture with rounded and protracted shoulders","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posture with rounded and protracted shoulders</div><div class=\"cntnt\"><img style=\"width:334px; height:504px;\" src=\"images/EM/83224_Round_pro_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The posture shown in the photograph, with the shoulders rounded and protracted, is common among those who spend a great deal of time working at a desk. In such cases, it is often associated with dysfunction of the scapular stabilizing muscles.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 83224 Version 1.0</div></div></div>"},"83225":{"type":"graphic_picture","displayName":"Palpation subscapular bursa","title":"Palpation of the subscapular bursa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Palpation of the subscapular bursa</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/EM/83225_Palpation_subscap_burs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The subscapular bursa can be palpated at the junction of the superior-medial angle of the scapula and the closest underlying rib.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 83225 Version 2.0</div></div></div>"},"83226":{"type":"graphic_picture","displayName":"Fungal OE","title":"Fungal otitis externa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fungal otitis externa</div><div class=\"cntnt\"><img style=\"width:504px; height:400px;\" src=\"images/PC/83226_Fungal_OE.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Daniel G Deschler, MD, FACS.</div><div id=\"graphicVersion\">Graphic 83226 Version 1.0</div></div></div>"},"83227":{"type":"graphic_picture","displayName":"Mild OE","title":"Mild otitis externa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mild otitis externa</div><div class=\"cntnt\"><img style=\"width:504px; height:402px;\" src=\"images/PC/83227_Mild_OE.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Daniel G Deschler, MD, FACS.</div><div id=\"graphicVersion\">Graphic 83227 Version 1.0</div></div></div>"},"83228":{"type":"graphic_picture","displayName":"Moderate OE","title":"Moderate otitis externa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Moderate otitis externa</div><div class=\"cntnt\"><img style=\"width:504px; height:401px;\" src=\"images/PC/83228_Moderate_OE.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Daniel G Deschler, MD, FACS.</div><div id=\"graphicVersion\">Graphic 83228 Version 1.0</div></div></div>"},"83232":{"type":"graphic_figure","displayName":"Psoralen mechanisms of action","title":"Mechanisms of action of psoralens","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Mechanisms of action of psoralens</div><div class=\"cntnt\"><img style=\"width:516px; height:652px;\" src=\"images/DERM/83232_PUVA-mechanisms-of-action.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83232 Version 4.0</div></div></div>"},"83233":{"type":"graphic_table","displayName":"Drugs inducing pseudoporphyria","title":"Drugs and chemicals inducing pseudoporphyria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs and chemicals inducing pseudoporphyria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antibiotics</td> </tr> <tr> <td>Nalidixic acid</td> </tr> <tr> <td>Tetracycline</td> </tr> <tr> <td>Ciprofloxacin</td> </tr> <tr> <td>Voriconazole</td> </tr> <tr> <td class=\"subtitle1_single\">Nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td>Naproxen</td> </tr> <tr> <td>Nabumetone</td> </tr> <tr> <td>Oxaprozin</td> </tr> <tr> <td>Ketoprofen</td> </tr> <tr> <td>Mefenamic acid</td> </tr> <tr> <td>Diflusinal</td> </tr> <tr> <td>Celecoxib</td> </tr> <tr> <td class=\"subtitle1_single\">Diuretics</td> </tr> <tr> <td>Furosemide </td> </tr> <tr> <td>Chlorthalidone</td> </tr> <tr> <td>Hydrochlorothiazide/triamterene</td> </tr> <tr> <td>Bumetanide</td> </tr> <tr> <td>Torsemide</td> </tr> <tr> <td class=\"subtitle1_single\">Retinoids</td> </tr> <tr> <td>Isotretinoin</td> </tr> <tr> <td>Etretinate</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Imatinib</td> </tr> <tr> <td>Cyclosporine</td> </tr> <tr> <td>5-Fluorouracil (intravenous)</td> </tr> <tr> <td>Carisoprodol/aspirin</td> </tr> <tr> <td>Pyridoxine</td> </tr> <tr> <td>Amiodarone</td> </tr> <tr> <td>Flutamide</td> </tr> <tr> <td>Metformin</td> </tr> <tr> <td>Dapsone</td> </tr> <tr> <td>Bakers' yeast</td> </tr> <tr> <td>Oral contraceptives</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83233 Version 3.0</div></div></div>"},"83237":{"type":"graphic_picture","displayName":"TdT staining ALL","title":"Lymph node biopsy of lymphoblastic leukemia/lymphoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lymph node biopsy of lymphoblastic leukemia/lymphoma</div><div class=\"cntnt\"><img style=\"width:504px; height:373px;\" src=\"images/HEME/83237_TdTstainingAll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node biopsy shows positive staining for terminal deoxytransferase (TdT). Immunoperoxidase, 100x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83237 Version 6.0</div></div></div>"},"83238":{"type":"graphic_figure","displayName":"Flow B cell ALL","title":"Flow cytometric histograms in B cell acute lymphoblastic leukemia","html":"<div class=\"graphic\"><div style=\"width: 906px\" class=\"figure\"><div class=\"ttl\">Flow cytometric histograms in B cell acute lymphoblastic leukemia</div><div class=\"cntnt\"><img style=\"width:886px; height:583px;\" src=\"images/HEME/83238_Flw_B_cll_ALL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Composite flow-cytometry histograms showing immunophenotypic profile of a precursor B-acute lymphoblastic leukemia. Note that the cells are dim CD45+ (A), TdT+ (B), CD34- (C), and coexpressing CD10 and CD19 (D).</div><div class=\"graphic_reference\">Reproduced with permission from: Lennerz JKM, Hassan A. The Bone Marrow. In: Stocker and Dehner's Pediatric Pathology, Stocker JT, Dehner LP, Husain AN, Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 83238 Version 4.0</div></div></div>"},"83239":{"type":"graphic_picture","displayName":"BM biopsy B cell ALL","title":"Bone marrow biopsy of a case of B cell acute lymphoblastic leukemia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bone marrow biopsy of a case of B cell acute lymphoblastic leukemia</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/83239_BMbiopsyBALL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow biopsy shows total replacement of normal hematopoietic cells with lymphoblasts that shows convoluted or folded nuclei. Hematoxylin and eosin, 100x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83239 Version 6.0</div></div></div>"},"83240":{"type":"graphic_picture","displayName":"Peripheral blood B cell ALL","title":"Peripheral blood smear of acute lymphoblastic leukemia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smear of acute lymphoblastic leukemia</div><div class=\"cntnt\"><img style=\"width:504px; height:424px;\" src=\"images/HEME/83240_Peripheralbloodball.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear shows small, uniform blasts with scant cytoplasm and inconspicuous nucleoli. Wright-Giemsa, 100x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83240 Version 7.0</div></div></div>"},"83241":{"type":"graphic_picture","displayName":"BM aspirate B cell ALL","title":"Bone marrow aspirate of acute lymphoblastic leukemia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bone marrow aspirate of acute lymphoblastic leukemia</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/83241_BMaspirateBall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate of acute lymphoblastic leukemia. Bone marrow aspirate shows lymphoblasts with variable sizes, scant cytoplasm with vacuolation in a few cells, and convoluted nucleus. (Wright-Giesma, 100x magnification)</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83241 Version 7.0</div></div></div>"},"83243":{"type":"graphic_picture","displayName":"BM aspirate T cell ALL","title":"Bone marrow aspirate in T cell acute lymphoblastic leukemia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bone marrow aspirate in T cell acute lymphoblastic leukemia</div><div class=\"cntnt\"><img style=\"width:504px; height:380px;\" src=\"images/HEME/83243_BMaspirateTall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate shows many lymphoblasts with different sizes, immature chromatin pattern, and inconspicuous nucleoli. A few lymphoblasts reveal vacuolated cytoplasm. Wright-Giemsa, 100x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83243 Version 6.0</div></div></div>"},"83244":{"type":"graphic_figure","displayName":"Flow T cell ALL","title":"Flow cytometric histograms in T cell acute lymphoblastic leukemia","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Flow cytometric histograms in T cell acute lymphoblastic leukemia</div><div class=\"cntnt\"><img style=\"width:784px; height:484px;\" src=\"images/HEME/83244_Flow_t_cell_all.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow cytometric histograms from a case of T cell ALL show that the tumor cells are positive for CD45, TDT, CD1A, CD3, and CD2. Neither CD8 nor CD4 is expressed.</div><div class=\"graphic_footnotes\">PE: phycoerythrin; FITC: fluorescein isothiocyanate; TdT: terminal deoxynucleotidyl transferase.</div><div id=\"graphicVersion\">Graphic 83244 Version 5.0</div></div></div>"},"83245":{"type":"graphic_picture","displayName":"Lymph node T cell LBL","title":"Lymph node biopsy of T cell lymphoblastic leukemia/lymphoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lymph node biopsy of T cell lymphoblastic leukemia/lymphoma</div><div class=\"cntnt\"><img style=\"width:504px; height:406px;\" src=\"images/HEME/83245_LymphnodeTLBL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node biopsy shows a \"starry sky\" histologic pattern with tangible-body macrophages and mitotic figures in the vacuoles. Hematoxylin and eosin, 60x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83245 Version 6.0</div></div></div>"},"83246":{"type":"graphic_figure","displayName":"Fetal alcohol syndrome PI","title":"Baby with fetal alcohol syndrome","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Baby with fetal alcohol syndrome</div><div class=\"cntnt\"><img style=\"width:465px; height:516px;\" src=\"images/PI/83246_FetalalcoholsyndromePI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Babies with fetal alcohol syndrome (FAS) have certain features that are different from babies without FAS. But a baby whose mother drank alcohol during pregnancy might have normal facial features and still have problems with thinking, learning, or behavior.</div><div id=\"graphicVersion\">Graphic 83246 Version 3.0</div></div></div>"},"83248":{"type":"graphic_figure","displayName":"Direct hernia repair","title":"Direct hernia repair","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Direct hernia repair</div><div class=\"cntnt\"><img style=\"width:520px; height:651px;\" src=\"images/SURG/83248_Direct-hernia-repair.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83248 Version 1.0</div></div></div>"},"83250":{"type":"graphic_table","displayName":"HIV medications affecting pituitary or adrenal function","title":"HIV medications affecting pituitary or adrenal function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">HIV medications affecting pituitary or adrenal function</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Clinical use</td> <td class=\"subtitle1\">Endocrine dysfunction</td> <td class=\"subtitle1\">Mechanism of action</td> </tr> <tr> <td>Glucocorticoids</td> <td>Antiinflammatory therapy</td> <td>Exogenous Cushing's syndrome; glucocorticoid deficiency upon discontinuation; hypogonadism</td> <td>Suppresses hypothalamic-pituitary-adrenal (HPA) axis and hypothalamic-pituitary-gonadal (HPG) axes</td> </tr> <tr> <td>HIV protease inhibitors</td> <td>Antiretroviral therapy&nbsp;(ART)</td> <td>Hyperprolactinemia</td> <td>May stimulate lactotrophs directly or inhibit metabolism of other medications</td> </tr> <tr class=\"divider_top\"> <td>Ketoconazole</td> <td>Antifungal therapy</td> <td>Adrenal insufficiency; hypogonadism</td> <td>Impairs steroid hormone synthesis</td> </tr> <tr class=\"divider_top\"> <td>Megestrol acetate</td> <td>Appetite stimulant</td> <td>Cushing's syndrome (rarely); hyperglycemia; hypogonadism; glucocorticoid deficiency upon discontinuation</td> <td>Intrinsic glucocorticoid-like and progestational activity</td> </tr> <tr class=\"divider_top\"> <td>Opiates</td> <td>Analgesic</td> <td>Impaired cortisol response to ACTH stimulation; hypogonadism</td> <td>Alterations in HPA&nbsp;and HPG axes</td> </tr> <tr class=\"divider_top\"> <td>Ritonavir (HIV&nbsp;protease inhibitor)</td> <td>ART pharmacologic booster</td> <td>Exogenous Cushing's syndrome (with concomitant use of inhaled fluticasone)</td> <td>Effects on hepatic cytochromes and drug metabolism</td> </tr> <tr class=\"divider_top\"> <td>Rifampin</td> <td>Antimycobacterial therapy</td> <td>Adrenal insufficiency</td> <td>Increases metabolic clearance of hormones</td> </tr> <tr class=\"divider_top\"> <td>Sulfonamides</td> <td>Antibiotic therapy</td> <td>Hyporeninemic hypoaldosteronism</td> <td>Interstitial nephritis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Melissa Weinberg, MD and Morris Schambelan, MD.</div><div id=\"graphicVersion\">Graphic 83250 Version 2.0</div></div></div>"},"83258":{"type":"graphic_table","displayName":"Pseudoporphyria and porphyria cutanea tarda differential","title":"Differential diagnosis of pseudoporphyria and porphyria cutanea tarda","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of pseudoporphyria and porphyria cutanea tarda</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Pseudoporphyria</td> <td class=\"subtitle1\">PCT</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Implicated drugs</strong></td> <td>Naproxen</td> <td>Alcohol</td> </tr> <tr> <td>Voriconazole</td> <td>Estrogens</td> </tr> <tr> <td>Tetracycline</td> <td>Iron</td> </tr> <tr> <td>Furosemide</td> <td>Tamoxifen</td> </tr> <tr> <td>Imatinib</td> <td>Chloroquine</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>Hydroxychloroquine</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sclerodermoid changes</strong></td> <td>No</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hypertrichosis</strong></td> <td>No</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hyperpigmentation</strong></td> <td>No</td> <td>Yes</td> </tr> <tr> <td><strong>Porphyrin abnormalities</strong></td> <td>No</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCT: porphyria cutanea tarda.</div><div id=\"graphicVersion\">Graphic 83258 Version 3.0</div></div></div>"},"83259":{"type":"graphic_picture","displayName":"Epidermolysis bullosa acquisita hand","title":"Epidermolysis bullosa acquisita","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa acquisita</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83259_Epiderm_bull_acqu_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83259 Version 3.0</div></div></div>"},"83260":{"type":"graphic_picture","displayName":"Pseudoporphyria histology","title":"Histologic features of pseudoporphyria","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Histologic features of pseudoporphyria</div><div class=\"cntnt\"><img style=\"width:540px; height:407px;\" src=\"images/DERM/83260_Pseudoporphyriahisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subepidermal blister with a scant perivascular lymphocytic infiltrate. </div><div class=\"graphic_reference\">Courtesy of Aleodor Andea, MD.</div><div id=\"graphicVersion\">Graphic 83260 Version 4.0</div></div></div>"},"83261":{"type":"graphic_picture","displayName":"Pseudoporphyria immunofluorescence","title":"Direct immunofluorescence findings in pseudoporphyria","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Direct immunofluorescence findings in pseudoporphyria</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/DERM/83261_pseudo_immunoflourescence.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct immunofluorescence shows deposition of IgG at the dermoepidermal junction and in the dermal vessels.</div><div class=\"graphic_reference\">Courtesy of Grant Anhalt, MD.</div><div id=\"graphicVersion\">Graphic 83261 Version 2.0</div></div></div>"},"83262":{"type":"graphic_picture","displayName":"Pseudoporphyria 2","title":"Pseudoporphyria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudoporphyria</div><div class=\"cntnt\"><img style=\"width:277px; height:429px;\" src=\"images/DERM/83262_Pseudoporphyria_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83262 Version 1.0</div></div></div>"},"83263":{"type":"graphic_table","displayName":"Example exposure hierarchy for snake phobia","title":"Example exposure hierarchy for snake phobia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example exposure hierarchy for snake phobia</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Step</td>\r\n            <td class=\"subtitle1\">Situation</td>\r\n            <td class=\"subtitle1\">Fear rating<br />\r\n            (0-100)</td>\r\n            <td class=\"subtitle1\">Avoidance rating<br />\r\n            (0-100)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">1</td>\r\n            <td>Hold a live snake</td>\r\n            <td class=\"centered\">100</td>\r\n            <td class=\"centered\">100</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">2</td>\r\n            <td>Touch a live snake being held by another person</td>\r\n            <td class=\"centered\">98</td>\r\n            <td class=\"centered\">100</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">3</td>\r\n            <td>Stand in front of someone holding a live snake</td>\r\n            <td class=\"centered\">95</td>\r\n            <td class=\"centered\">98</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">4</td>\r\n            <td>Stand 3 feet from someone holding a live snake</td>\r\n            <td class=\"centered\">90</td>\r\n            <td class=\"centered\">95</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">5</td>\r\n            <td>Stand 1 foot from an aquarium holding a live snake</td>\r\n            <td class=\"centered\">90</td>\r\n            <td class=\"centered\">90</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">6</td>\r\n            <td>Walk on a trail in the woods</td>\r\n            <td class=\"centered\">85</td>\r\n            <td class=\"centered\">100</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">7</td>\r\n            <td>Stand 3 feet from an aquarium holding a live snake</td>\r\n            <td class=\"centered\">85</td>\r\n            <td class=\"centered\">90</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">8</td>\r\n            <td>Watch a video of live snakes</td>\r\n            <td class=\"centered\">75</td>\r\n            <td class=\"centered\">80</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">9</td>\r\n            <td>Hold a rubber snake</td>\r\n            <td class=\"centered\">70</td>\r\n            <td class=\"centered\">80</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">10</td>\r\n            <td>Sit 3 feet away from a rubber snake</td>\r\n            <td class=\"centered\">65</td>\r\n            <td class=\"centered\">80</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">11</td>\r\n            <td>Touch a picture of a snake</td>\r\n            <td class=\"centered\">60</td>\r\n            <td class=\"centered\">80</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">12</td>\r\n            <td>Look at a picture of a snake </td>\r\n            <td class=\"centered\">55</td>\r\n            <td class=\"centered\">75</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"centered\">13</td>\r\n            <td>Say the word snake</td>\r\n            <td class=\"centered\">45</td>\r\n            <td class=\"centered\">75</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83263 Version 1.0</div></div></div>"},"83265":{"type":"graphic_figure","displayName":"Medial patellar plica test","title":"Medial patellar plica test","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Medial patellar plica test</div><div class=\"cntnt\"><img style=\"width:542px; height:421px;\" src=\"images/EM/83265_Medial_patellar_extension_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the patient supine, the examiner first applies pressure with the thumb over the inferior and medial apsect of the patellofemoral joint to interpose the medial plica between the medial patellar facet and the medial condyle. While maintaining this pressure, the knee is passively flexed from 0 to 90 degrees. Pain in extension that is relieved at 90 degrees of flexion constitutes a positive test. &nbsp;</div><div id=\"graphicVersion\">Graphic 83265 Version 2.0</div></div></div>"},"83266":{"type":"graphic_figure","displayName":"Knee extension test","title":"Knee extension test","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Knee extension test</div><div class=\"cntnt\"><img style=\"width:541px; height:377px;\" src=\"images/EM/83266_Knee-extension-test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the patient supine and the knee at 90 degrees of flexion, the examiner forces the patella medially while simultaneously internally rotating and slowly extending the knee. A positive test consists of pain and popping when the knee is between 45 and 60 degrees of flexion.</div><div id=\"graphicVersion\">Graphic 83266 Version 1.0</div></div></div>"},"83267":{"type":"graphic_figure","displayName":"Synovial plicae anatomy","title":"Synovial plicae anatomy","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Synovial plicae anatomy</div><div class=\"cntnt\"><img style=\"width:527px; height:458px;\" src=\"images/EM/83267_Synovial-plicae-anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four synovial plicae have been described: medial, suprapatellar, infrapatellar, and lateral. The \"shelf\" type medial patellar plica is most commonly associated with plica syndrome.</div><div id=\"graphicVersion\">Graphic 83267 Version 2.0</div></div></div>"},"83269":{"type":"graphic_diagnosticimage","displayName":"Gilula lines wrist radiograph","title":"Gilula lines wrist radiograph","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Gilula lines wrist radiograph</div><div class=\"cntnt\"><img style=\"width:597px; height:352px;\" src=\"images/RADIOL/83269_Gilula_lines_wrist_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The AP view of the wrist reveals a normal examination (A) with Gilula lines superimposed (B). The first arc outlines the proximal convexities of the scaphoid, lunate, and triquetrum. The second concave arc outlines the distal surfaces of the scaphoid, lunate, and triquetrum. The third arc traces the proximal curvatures of the capitate and hamate.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div id=\"graphicVersion\">Graphic 83269 Version 4.0</div></div></div>"},"83270":{"type":"graphic_diagnosticimage","displayName":"Ultrasound and Doppler images of placenta accreta","title":"Ultrasound and Doppler images of placenta accreta","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Ultrasound and Doppler images of placenta accreta</div><div class=\"cntnt\"><img style=\"width:599px; height:451px;\" src=\"images/RADIOL/83270_USDopplerplacaccreta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Placenta previa with accreta</strong> (A) Transvaginal image of the lower uterine segment in a patient with placenta previa shows a thin myometrium (arrows) in the region of prior cesarean delivery scar. This is either due to thinning in the region of prior cesarean scar or due to placenta accrete. In women with findings of a thinned myometrium we recommend measuring the extent of the thin myometrium in sagittal and transverse planes. (B) and (C) Transvaginal grey scale and color Doppler images of the lower uterine segment in a patient with placenta previa and prior cesarean delivery shows enlarged vascular spaces within the placenta and a focal mass invading the myometrium (dashed arrow) compatible with placenta accreta. Note the hypervascularity at the serosa-bladder interface.<br /><strong>Placenta previa without accreta</strong> (D) For comparison, color Doppler of the lower uterine segment in a patient with placenta previa and no accreta. Note the vascular structures between the placenta and the bladder wall. The flow appears normal, without turbulence and there is no crossing of vessels into the placental tissue. Also, note there are no placental sonolucencies and no evidence of a \"bulge\" into the bladder wall.</div><div id=\"graphicVersion\">Graphic 83270 Version 3.0</div></div></div>"},"83271":{"type":"graphic_diagnosticimage","displayName":"MRI of primary CNS lymphoma","title":"MRI of primary central nervous system (CNS) lymphoma","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">MRI of primary central nervous system (CNS) lymphoma</div><div class=\"cntnt\"><img style=\"width:522px; height:583px;\" src=\"images/RADIOL/83271_MRI_primary_CNS_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI examination in the transverse plane is from a 63-year-old female with primary CNS lymphoma. The T1 weighted sequence (A) reveals a single mass that infiltrates the splenium of corpus callosum [a relatively common location for primary CNS lymphoma] (arrow), abutting the third ventricle anteriorly. The mass enhances homogeneously following gadolinium administration (B), is relatively dark on T2 weighted images (C), and reveals restricted diffusion on the diffusion weighted sequence (bright, D). The reader should note the relative lack of edema on flair studies. These features are consistent with the diagnosis of primary lymphoma of the brain.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CNS: central nervous system.<br /></div><div id=\"graphicVersion\">Graphic 83271 Version 3.0</div></div></div>"},"83272":{"type":"graphic_table","displayName":"CHA2DS2-VASc score and risk factors","title":"Clinical risk factors for stroke, transient ischemic attack, and systemic embolism in the CHA<sub>2</sub>DS<sub>2</sub>-VASc score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical risk factors for stroke, transient ischemic attack, and systemic embolism in the CHA<sub>2</sub>DS<sub>2</sub>-VASc score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\">(A) The risk factor-based approach expressed as a point based scoring system, with the acronym CHA<sub>2</sub>DS<sub>2</sub>-VASc<br /> (NOTE: maximum score is 9 since age may contribute 0, 1, or 2 points)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">CHA<sub>2</sub>DS<sub>2</sub>-VASc risk factor</td> <td class=\"subtitle2_left\">Points</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Congestive heart failure <p class=\"indent2\">Signs/symptoms of heart failure or objective evidence of reduced left-ventricular ejection fraction</p> </td> <td class=\"indent1\">+1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Hypertension <p class=\"indent2\">Resting blood pressure &#62;140/90 mmHg on at least two occasions or current antihypertensive treatment</p> </td> <td class=\"indent1\">+1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Age 75 years or older</td> <td class=\"indent1\">+2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Diabetes mellitus <p class=\"indent2\">Fasting glucose &#62;125 mg/dL (7 mmol/L) or treatment with oral hypoglycaemic agent and/or insulin</p> </td> <td class=\"indent1\">+1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Previous stroke, transient ischaemic attack, or thromboembolism</td> <td class=\"indent1\">+2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Vascular disease <p class=\"indent2\">Previous myocardial infarction, peripheral artery disease, or aortic plaque</p> </td> <td class=\"indent1\">+1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Age 65-74 years</td> <td class=\"indent1\">+1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Sex category (female)</td> <td class=\"indent1\">+1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1 highlight_blue_text\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">(B) Adjusted stroke rate according to CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td> </tr> <tr> <td class=\"subtitle2_left\">CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td> <td class=\"subtitle2_left\">Patients<br /> (n = 73,538)</td> <td class=\"subtitle2_left\">Stroke and thromboembolism event rate at one-year follow-up (%)</td> </tr> <tr> <td class=\"indent1\">0</td> <td class=\"indent1\">6369</td> <td class=\"indent1\">0.78</td> </tr> <tr> <td class=\"indent1\">1</td> <td class=\"indent1\">8203</td> <td class=\"indent1\">2.01</td> </tr> <tr> <td class=\"indent1\">2</td> <td class=\"indent1\">12,771</td> <td class=\"indent1\">3.71</td> </tr> <tr> <td class=\"indent1\">3</td> <td class=\"indent1\">17,371</td> <td class=\"indent1\">5.92</td> </tr> <tr> <td class=\"indent1\">4</td> <td class=\"indent1\">13,887</td> <td class=\"indent1\">9.27</td> </tr> <tr> <td class=\"indent1\">5</td> <td class=\"indent1\">8942</td> <td class=\"indent1\">15.26</td> </tr> <tr> <td class=\"indent1\">6</td> <td class=\"indent1\">4244</td> <td class=\"indent1\">19.74</td> </tr> <tr> <td class=\"indent1\">7</td> <td class=\"indent1\">1420</td> <td class=\"indent1\">21.50</td> </tr> <tr> <td class=\"indent1\">8</td> <td class=\"indent1\">285</td> <td class=\"indent1\">22.38</td> </tr> <tr> <td class=\"indent1\">9</td> <td class=\"indent1\">46</td> <td class=\"indent1\">23.64</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CHA<sub>2</sub>DS<sub>2</sub>-VASc: Congestive heart failure, Hypertension, Age (&ge;75) (doubled), Diabetes, Stroke (doubled), Vascular disease, Age (65-74), Sex.</div><div class=\"graphic_reference\">Part A from: Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18(11):1609-1678. By permission of Oxford University Press on behalf of the European Society of Cardiology. Copyright Â© 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.escardio.org/\" target=_blank>www.escardio.org/</A>.</div><div id=\"graphicVersion\">Graphic 83272 Version 16.0</div></div></div>"},"83273":{"type":"graphic_figure","displayName":"Hydrocephalus PI","title":"Hydrocephalus treated with a shunt","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Hydrocephalus treated with a shunt</div><div class=\"cntnt\"><img style=\"width:512px; height:641px;\" src=\"images/PI/83273_Hydrocephalus-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hydrocephalus is a condition that causes too much spinal fluid to build up in the brain. Spinal fluid is fluid that surrounds and protects the brain and spinal cord. Normally, spinal fluid moves through the brain and drains into the bloodstream (see normal brain on the right). In a person with hydrocephalus, the fluid does not drain normally, or the body makes too much fluid. Doctors treat hydrocephalus with a shunt. A shunt is a long, flexible tube that a surgeon puts into a fluid-filled space inside the brain. The tube is placed under the skin and empties into the belly or heart. The shunt helps drain the extra spinal fluid from the brain.</div><div id=\"graphicVersion\">Graphic 83273 Version 2.0</div></div></div>"},"83274":{"type":"graphic_figure","displayName":"Kyphosis PI","title":"Kyphosis caused by osteoporosis","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Kyphosis caused by osteoporosis</div><div class=\"cntnt\"><img style=\"width:538px; height:424px;\" src=\"images/PI/83274_Kyphosis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kyphosis is the medical term for when the upper part of the spine curves forward, causing the back to look rounded or hunched. The most common cause of kyphosis in adults is osteoporosis, a condition that weakens bones. This picture shows a young woman on the left who does not have kyphosis. The woman in the middle is starting to show signs of it. The oldest woman on the right has kyphosis caused by osteoporosis. Besides making the spine curve, kyphosis also causes the belly to bulge.</div><div id=\"graphicVersion\">Graphic 83274 Version 2.0</div></div></div>"},"83275":{"type":"graphic_figure","displayName":"Rectovaginal fistula PI","title":"Rectovaginal fistula","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Rectovaginal fistula</div><div class=\"cntnt\"><img style=\"width:494px; height:507px;\" src=\"images/PI/83275_Rectovaginal-fistula-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A rectovaginal fistula is an abnormal connection between the lower part of the large intestine (rectum) and the vagina.</div><div id=\"graphicVersion\">Graphic 83275 Version 1.0</div></div></div>"},"83278":{"type":"graphic_figure","displayName":"Multiple sclerosis child PI","title":"Multiple sclerosis in children","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Multiple sclerosis in children</div><div class=\"cntnt\"><img style=\"width:482px; height:620px;\" src=\"images/PI/83278_Multiple-sclerosis-child-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In multiple sclerosis, the immune system attacks nerve cells in the brain and spinal cord. These nerve cells work kind of like electrical wires. They carry electrical signals and are wrapped in insulation that helps the electrical signal move quickly down the nerve. This \"insulation\" is made of a material called myelin. Multiple sclerosis damages this myelin, so the nerve cells cannot carry signals very well.</div><div id=\"graphicVersion\">Graphic 83278 Version 1.0</div></div></div>"},"83279":{"type":"graphic_picture","displayName":"Seborrheic keratosis PI","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:396px; height:270px;\" src=\"images/PI/83279_Seborrheic_keratosis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seborrheic keratosis is a condition that causes small growths on the skin. The growths can look like something was stuck on the skin.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 83279 Version 1.0</div></div></div>"},"83280":{"type":"graphic_picture","displayName":"Dermatosis papulosa PI","title":"Seborrheic keratosis on dark skin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis on dark skin</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/83280_Dermatosis_papulosa_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">People with dark skin can have a type of seborrheic keratosis that causes black growths.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83280 Version 5.0</div></div></div>"},"83282":{"type":"graphic_figure","displayName":"Cumulative incidence of hepatocellular carcinoma","title":"Cumulative incidence of hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Cumulative incidence of hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:616px; height:973px;\" src=\"images/GAST/83282_Cumu_incid_hepatocell_carc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence of hepatocellular carcinoma by:<br />(A) Group of long-term HBV DNA change.<br />(B) Long-term pattern of ALT.<br />Both P values for log-rank tests were &lt;0.001.</div><div class=\"graphic_footnotes\">* Data were not available for 326 participants because of &lt;2 measurements of ALT level.<BR><FONT class=bullet>â¢</FONT> ALT level â¥45 U/L in â¥50 percent of sequential ALT measurements.<BR>Î At least one ALT level â¥45 U/L but &lt;50 percent of sequential ALT measurements â¥45 U/L.<BR><FONT class=lozenge>â</FONT> All sequential ALT measurements &lt;45 U/L and at least one ALT level &gt;30 U/L.<BR>Â§ All sequential ALT measurements â¤30 U/L.</div><div class=\"graphic_reference\">Reproduced from: Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011; 141:1240. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83282 Version 1.0</div></div></div>"},"83283":{"type":"graphic_table","displayName":"Alliance-relevant aspects of personality disorder styles","title":"Aspects of personality disorder styles relevant to the therapeutic relationship","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aspects of personality disorder styles relevant to the therapeutic relationship</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Personality disorder/traits</td> <td class=\"subtitle1\">Alliance challenges</td> <td class=\"subtitle1\">Points of possible engagement in treatment</td> </tr> <tr> <td>Schizotypal</td> <td> <p>Suspiciousness/paranoia</p> <p>Profound interpersonal discomfort</p> Bizarre thinking</td> <td>Possible motivation for human connection</td> </tr> <tr> <td>Schizoid</td> <td> <p>Social detachment</p> Emotional aloofness</td> <td>Underlying neediness and sensitivity</td> </tr> <tr> <td>Paranoid</td> <td> <p>Expectations of harm or exploitation</p> <p>Hypersensitivity to perceived criticism</p> Inclination to withdraw or attack</td> <td>Underlying need for affirmation</td> </tr> <tr> <td>Borderline</td> <td> <p>Unstable emotional and cognitive states</p> <p>Extremely demanding</p> Proneness to acting-out</td> <td> <p>Relationship-seeking</p> Responds to warmth and support</td> </tr> <tr> <td>Narcissistic</td> <td> <p>Need for constant positive regard</p> <p>Contempt for others</p> Grandiose sense of entitlement</td> <td>Responds over time to empathy and affirmation</td> </tr> <tr> <td>Histrionic</td> <td> <p>Attempts to charm and entertain</p> <p>Emotionally labile</p> Unfocused cognitive style</td> <td> <p>Relationship-seeking</p> Responds to warmth and support</td> </tr> <tr> <td>Antisocial</td> <td> <p>Controlling</p> <p>Tendency to lie and manipulate</p> <p>No empathy or regard for others</p> Use of pseudoalliance to gain some advantage</td> <td>May engage in treatment if in self-interest or if Axis I symptoms cause sufficient distress</td> </tr> <tr> <td>Avoidant</td> <td> <p>Expectations of criticism or rejection</p> <p>Proneness to shame and humiliation</p> Reluctance to disclose information</td> <td> <p>Responds to warmth/empathy</p> Desire for relationships in spite of vulnerabilities</td> </tr> <tr> <td>Dependent</td> <td> <p>No value placed on independence/taking initiative</p> Submission leading to pseudoalliance</td> <td> <p>Friendly and compliant</p> Likely to stay in treatment</td> </tr> <tr> <td>Obsessive-compulsive</td> <td> <p>Need for control</p> <p>Perfectionistic toward self and others</p> <p>Fear of criticism from therapist</p> <p>Restricted affect</p> Stubbornness</td> <td> <p>Conscientious</p> <p>Use of intellectualization may be helpful at times</p> Will try to be a \"good patient\"</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the American Psychiatric Textbook of Personality Disorders, (Copyright &copy; 2005). American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 83283 Version 3.0</div></div></div>"},"83285":{"type":"graphic_table","displayName":"Causes of PALF in North America and Europe","title":"Etiology of acute liver failure in children in North America and Europe (final diagnosis as percent of cases in each age group)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of acute liver failure in children in North America and Europe (final diagnosis as percent of cases in each age group)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Final diagnosis</td> <td class=\"subtitle1\" colspan=\"6\">Percent of cases in each age group</td> </tr> <tr> <td class=\"subtitle2\">&#60;4 weeks</td> <td class=\"subtitle2\">4 to 8 weeks</td> <td class=\"subtitle2\">9 weeks to 1 year</td> <td class=\"subtitle2\">1 to 5 years</td> <td class=\"subtitle2\">6 to 10 years</td> <td class=\"subtitle2\">&#62;10 years</td> </tr> <tr> <td>Indeterminate</td> <td class=\"centered\">38*</td> <td class=\"centered\">41*</td> <td class=\"centered\">45*</td> <td class=\"centered\">67*</td> <td class=\"centered\">62*</td> <td class=\"centered\">32*</td> </tr> <tr> <td>Acetaminophen (paracetamol)</td> <td>&nbsp;</td> <td class=\"centered\">5</td> <td class=\"centered\">5</td> <td class=\"centered\">4</td> <td class=\"centered\">3</td> <td class=\"centered\"><span style=\"color: black;\">29*</span></td> </tr> <tr> <td>Metabolic </td> <td class=\"centered\">16*</td> <td class=\"centered\">27*</td> <td class=\"centered\">20*</td> <td class=\"centered\">5</td> <td class=\"centered\">8</td> <td class=\"centered\">9<sup>&#182;</sup></td> </tr> <tr> <td>Autoimmune</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">5</td> <td class=\"centered\">10*</td> </tr> <tr> <td>Viral hepatitis</td> <td class=\"centered\">22*</td> <td>&nbsp;</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">3</td> <td class=\"centered\">5</td> </tr> <tr> <td>Shock/ischemia</td> <td class=\"centered\">4</td> <td class=\"centered\">9</td> <td class=\"centered\">6</td> <td class=\"centered\">2</td> <td class=\"centered\">7</td> <td class=\"centered\">3</td> </tr> <tr> <td>Drug-induced</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">4</td> <td class=\"centered\">7</td> </tr> <tr> <td>Gestational alloimmune liver disease (neonatal hemochromatosis) </td> <td class=\"centered\">14*</td> <td class=\"centered\">14*</td> <td class=\"centered\">1 </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Veno-occlusive disease</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">4</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> </tr> <tr> <td>Hemophagocytic syndrome</td> <td class=\"centered\">1</td> <td>&nbsp;</td> <td class=\"centered\">6</td> <td class=\"centered\">2</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Budd-Chiari syndrome</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">1</td> <td>&nbsp;</td> </tr> <tr> <td>Other diagnosis</td> <td class=\"centered\">5</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">4</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> </tr> <tr> <td>Multiple diagnoses</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">1</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data from the Pediatric Acute Liver Failure Study Group, 2000-2007. </div><div class=\"graphic_footnotes\">* More common causes in this age group.<br />Â¶ In children 10 years or older, Wilson disease accounted for 90 percent of children with metabolic acute liver failure.</div><div class=\"graphic_reference\">Modified with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright Â© 2012 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 83285 Version 2.0</div></div></div>"},"83291":{"type":"graphic_table","displayName":"Cosmeceuticals","title":"Cosmeceuticals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cosmeceuticals</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cosmeceuticals</td> <td class=\"subtitle1\">Proposed mechanism of action</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Antioxidants</td> </tr> <tr> <td class=\"indent1\">Niacinamide (vitamin B3)</td> <td>Reduces transepidermal water loss, inhibits melanosome transfer, and increases collagen production</td> </tr> <tr> <td class=\"indent1\">Ascorbic acid (vitamin C)</td> <td>Protects from UVA-induced oxidative damage</td> </tr> <tr> <td class=\"indent1\">Coenzyme Q10</td> <td>Protects from UVA-induced oxidative damage, suppresses the expression of UVA-induced collagenase</td> </tr> <tr> <td class=\"indent1\">Vitamin E</td> <td>Reduces UV-induced erythema</td> </tr> <tr> <td class=\"indent1\">Retinyl esters, retinol, retinaldehyde, oxoretinoids</td> <td>Reduce matrix metalloproteinases, promote collagen production</td> </tr> <tr> <td class=\"indent1\">Alpha-lipoic acid</td> <td>Acts as a scavenger of reactive oxygen species, prevents lipid peroxidation, has anti-inflammatory properties, and acts as an exfoliant</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hydroxyacids</td> </tr> <tr> <td class=\"indent1\">Alpha-hydroxy acids (glycolic acid, lactic acid, citric acid, malic acid)<br /> Beta-hydroxy acids (salicylic acid)</td> <td>Reduce corneocyte adhesion, increase exfoliation, improve stratum corneum hydration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Plant extracts</td> </tr> <tr> <td class=\"indent1\">Green tea polyphenolic epicatechins</td> <td>Inhibit UV-induced erythema, reduce the formation of cyclobutane pyrimidine dimers, have antioxidant properties</td> </tr> <tr> <td class=\"indent1\">Soy isoflavones (genistein and daidzein)</td> <td>Act as antioxidants and phytoestrogens, inhibit UV-stimulated production of matrix metalloproteinase and melanosome transfer to keratinocytes</td> </tr> <tr> <td class=\"indent1\">Grape seeds (polyphenols)</td> <td>Have antioxidant and anti-inflammatory properties, promote wound healing</td> </tr> <tr> <td class=\"indent1\">Coffee berry (polyphenols, flavonoids, and flavonol glycosides)</td> <td>Has antioxidant properties</td> </tr> <tr> <td class=\"indent1\">Ginkgo biloba (polyphenols, flavonoids, and flavonol glycosides)</td> <td>Stimulate fibroblast proliferation and collagen production</td> </tr> <tr> <td class=\"indent1\">Ginseng (ginsenosides)</td> <td>Has antioxidant and anti-inflammatory properties</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UVA: ultraviolet A; UV: ultraviolet.</div><div id=\"graphicVersion\">Graphic 83291 Version 5.0</div></div></div>"},"83292":{"type":"graphic_table","displayName":"Pharmacology nonbenzodiazepines","title":"Nonbenzodiazepine hypnotics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonbenzodiazepine hypnotics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nonbenzodiazepine hypnotics</td> <td class=\"subtitle1\">US trade name</td> <td class=\"subtitle1\">Adult dose<br /> (usual)*</td> <td class=\"subtitle1\">Preparation</td> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Half-life<br /> (hours)</td> <td class=\"subtitle1\">Potential for drug interactions<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Zaleplon</td> <td>Sonata</td> <td>5 to 15 mg</td> <td>Capsule</td> <td>Sleep onset insomnia</td> <td>1</td> <td>Low</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Zolpidem</td> <td>Ambien </td> <td class=\"divider_bottom\" rowspan=\"3\">5 to 10 mg<sup>&#916;</sup></td> <td>Tablet</td> <td class=\"divider_bottom\" rowspan=\"3\">Sleep onset insomnia</td> <td>1.4 to 4.5</td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Low to moderate</p> Zolpidem is metabolized in part by CYP3A4</td> </tr> <tr> <td>Edluar</td> <td>Sublingual tablet</td> <td>1.6 to 6.7</td> </tr> <tr class=\"divider_bottom\"> <td>Zolpimist</td> <td>Oral liquid (each spray delivers 5 mg)</td> <td>1.7 to 8.4</td> </tr> <tr class=\"divider_bottom\"> <td>Zolpidem controlled release</td> <td>Ambien CR</td> <td>6.25 to 12.5 mg<sup>&#9674;</sup></td> <td>Coated tablet</td> <td>Sleep onset insomnia or sleep maintenance insomnia</td> <td>1.4 to 4.5, sustained release preparation<sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Zolpidem middle of night administration</td> <td>Intermezzo</td> <td>1.75 to 3.5 mg<sup>&#165;</sup></td> <td>Dissolvable tablet (sublingual)</td> <td>Sleep maintenance insomnia (middle night dose)</td> <td>1.4 to 6.7</td> </tr> <tr class=\"divider_bottom\"> <td>Eszopiclone</td> <td>Lunesta</td> <td> <p>1 mg initially for all patients</p> (may increase to 2 or3 mg if needed)<sup>&#135;</sup></td> <td>Tablet</td> <td>Sleep onset insomnia or sleep maintenance insomnia</td> <td>6 to 9</td> <td> <p>Moderate</p> Eszopiclone is metabolized in part by CYP3A4</td> </tr> <tr class=\"divider_bottom\"> <td>Zopiclone (not available in United States)</td> <td>Imovane (trade name in Canada)</td> <td>3.75 to 7.5 mg&#60;</td> <td>Tablet</td> <td>Sleep onset insomnia</td> <td>5 to 7</td> <td> <p>Moderate</p> Zopiclone is metabolized by CYP2C8 and 3A4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Other FDA-approved hypnotics</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ramelteon</td> <td>Rozerem</td> <td>8 mg</td> <td>Tablet</td> <td>Sleep onset insomnia</td> <td>1 to 2.6 (drug); 2 to 5 (active metabolite)</td> <td> <p>Moderate</p> <p>Ramelteon is metabolized in part by CYP1A2</p> Strong inhibitors of CYP1A2, including most fluoroquinolones, may interact. Use with fluvoxamine contraindicated.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Doxepin</td> <td>Silenor</td> <td>3 to 6 mg</td> <td>Tablet</td> <td>Sleep maintenance insomnia</td> <td>15 (drug); 31 (active metabolite)</td> <td> <p>Moderate</p> Doxepin is metabolized in part by CYP2D6</td> </tr> <tr> <td class=\"indent1\">Suvorexant</td> <td>Belsomra</td> <td>10 mg initially (may increase to 15 to 20 mg if needed)</td> <td>Tablet</td> <td>Sleep onset and/or maintenance insomnia</td> <td> <p>12</p> Clearance decreased in female patients who are obese; drug exposure increased by 46% relative to nonobese females</td> <td> <p>Significant drug interactions anticipated</p> <p>Suvorexant is metabolized by CYP3A</p> <p>If used in combination with moderate inhibitors of CYP3A, recommended dose is 5 mg; may increase to 10 mg</p> Avoid use of suvorexant with strong inhibitors or inducers of CYP3A<sup>&#134;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Initiate treatment using lowest dose shown for women, older adults, those with low body weight, debilitated patients, or those receiving treatment with opioid analgesics or other central nervous system or cardiorespiratory depressants.<br />Â¶ For specific drug interactions, including management recommendations and combinations that should be avoided, use Lexi-Interact drug interactions program included with UpToDate.<br />Î Recommended dose in women is 5 mg due to risk of impaired driving.<br /><FONT class=lozenge>â</FONT> Recommended dose in women is 6.25 mg due to risk of impaired driving.<br />Â¥ Recommended dose in women is 1.75 mg due to risk of impaired driving.<br />Â§ Duration of effect longer than predicted by half-life due to sustained release.<br />â¡ Increased risk of next-day&nbsp;impaired driving&nbsp;using 2 or 3 mg dose in both men and women.<br />â  A list of moderate and strong inhibitors and inducers of CYP3A is provided in a separate table.</div><div id=\"graphicVersion\">Graphic 83292 Version 11.0</div></div></div>"},"83293":{"type":"graphic_figure","displayName":"Hemisected male pelvis and perineum","title":"Hemisected male pelvis and perineum","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Hemisected male pelvis and perineum</div><div class=\"cntnt\"><img style=\"width:601px; height:452px;\" src=\"images/EM/83293_Hemisectedmalepelvisperi.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF, Agur AR. Pelvis and Perineum. In: Clinically Oriented Anatomy, 6th ed, Lippincott Williams &amp; Wilkins, New York 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83293 Version 6.0</div></div></div>"},"83296":{"type":"graphic_table","displayName":"Indications for colonoscopy","title":"Indications for colonoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for colonoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Signs/symptoms</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Abnormal imaging</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Lower gastrointestinal bleeding and unexplained iron deficiency anemia</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Lower gastrointestinal symptoms (eg, chronic diarrhea)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Screening/surveillance</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Colon polyp</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Colon cancer</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Inflammatory bowel disease</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Therapeutic</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Polypectomy</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Localization of lesion</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Foreign body removal</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Decompression of sigmoid volvulus</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Decompression of colonic pseudo-obstruction</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Balloon dilation of strictures</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Palliative treatment of bleeding or stenosed neoplasms</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Placement of percutaneous endoscopic cecostomy tube</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83296 Version 1.0</div></div></div>"},"83297":{"type":"graphic_figure","displayName":"Reported pertussis US 1922 to 2015","title":"Reported pertussis cases, United States, 1922 to 2015","html":"<div class=\"graphic\"><div style=\"width: 673px\" class=\"figure\"><div class=\"ttl\">Reported pertussis cases, United States, 1922 to 2015</div><div class=\"cntnt\"><img style=\"width:653px; height:417px;\" src=\"images/ID/83297_Reported_pertussis_cases_US.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DTP: diphtheria, tetanus toxoids, and pertussis vaccine; DTaP: diphtheria, tetanus toxoids, and acellular pertussis vaccine; Tdap: tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Pertussis (Whooping Cough): Surveillance &amp; Reporting. National Notifiable Diseases Surveillance System and Supplemental Pertussis Surveillance System and 1922-1949, passive reports to the Public Health Service. Available at: <a href=\"http://www.cdc.gov/pertussis/surv-reporting.html\" target=\"_blank\">http://www.cdc.gov/pertussis/surv-reporting.html</a> (Accessed on August 29, 2017).</div><div id=\"graphicVersion\">Graphic 83297 Version 6.0</div></div></div>"},"83298":{"type":"graphic_table","displayName":"Sample schedule for laboratory tests after lung transplantation","title":"Sample schedule for monitoring laboratory tests after lung transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample schedule for monitoring laboratory tests after lung transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Weeks 1 to 4</td> <td class=\"subtitle1\">Weeks 5 to 8</td> <td class=\"subtitle1\">Months 3 to 6</td> <td class=\"subtitle1\">After month 6</td> </tr> <tr> <td>Weekly</td> <td>Every two weeks</td> <td>Monthly</td> <td>Every three months</td> </tr> <tr> <td>CBC</td> <td>CBC</td> <td>CBC</td> <td>CBC</td> </tr> <tr> <td>Potassium</td> <td>Potassium</td> <td>Potassium</td> <td>Potassium</td> </tr> <tr> <td>Calcium</td> <td>Calcium</td> <td>Calcium</td> <td>Calcium</td> </tr> <tr> <td>Magnesium</td> <td>Magnesium</td> <td>Magnesium</td> <td>Magnesium</td> </tr> <tr> <td>Glucose</td> <td>Glucose</td> <td>Glucose</td> <td>Glucose</td> </tr> <tr> <td>BUN</td> <td>BUN</td> <td>BUN</td> <td>BUN</td> </tr> <tr> <td>Creatinine</td> <td>Creatinine</td> <td>Creatinine</td> <td>Creatinine</td> </tr> <tr> <td>AST, ALT, alkaline phosphatase</td> <td>AST, ALT, alkaline phosphatase</td> <td>AST, ALT, alkaline phosphatase</td> <td>AST, ALT, alkaline phosphatase</td> </tr> <tr> <td>Lipid panel*</td> <td>&nbsp;</td> <td>Lipid panel*</td> <td>Lipid panel</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Amylase</td> </tr> <tr> <td>CMV PCR</td> <td>CMV PCR</td> <td>CMV PCR</td> <td>CMV PCR</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Drug levels<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1\">Cyclosporine trough or C2<sup>&#916;</sup></td> <td class=\"sublist_other\">Cyclosporine trough or C2</td> <td class=\"sublist_other\">Cyclosporine trough or C2</td> <td class=\"sublist_other\">Cyclosporine trough or C2</td> </tr> <tr> <td class=\"sublist1\">Tacrolimus trough</td> <td class=\"sublist_other\">Tacrolimus trough</td> <td class=\"sublist_other\">Tacrolimus trough</td> <td class=\"sublist_other\">Tacrolimus trough</td> </tr> <tr> <td class=\"sublist1\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">Sirolimus trough</td> <td class=\"sublist_other\">Sirolimus trough</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The above table is a sample monitoring program. Each transplant center develops its own routine regarding the specific tests and their frequency. Some patients will need more frequent testing due to symptoms or prior abnormal values. CD3 cell counts are monitored initially following induction therapy with a polyclonal agent or alemtuzumab, but not on an ongoing basis.</div><div class=\"graphic_footnotes\">CBC: complete blood count; BUN: blood urea nitrogen; AST: aspartate aminotransferase (formerly SGOT); ALT: alanine aminotransferase (formerly SGPT); C2: cyclosporine level two hours post dose; CMV: cytomegalovirus; PCR: polymerase chain reaction.<br />* A lipid panel is assessed monthly for the first few months and then every three to six months.<br />&para; Drug levels are guided by the individual patient's drug regimen. Examples are given in the table.<br />&Delta; When monitoring cyclosporine, trough levels are used by most centers, although C2 levels are felt to be more accurate.</div><div id=\"graphicVersion\">Graphic 83298 Version 3.0</div></div></div>"},"83301":{"type":"graphic_figure","displayName":"Defibrillator pad placement PI","title":"Defibrillator pad placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Defibrillator pad placement</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/83301_Ant_lat_defb_pd_plcmnt_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hands-free defibrillator patches placed in the anterior (white lead) and lateral (red lead) positions.</div><div class=\"graphic_reference\">Reproduced with permission from: Taylor C, Lillis C, LeMone P, Lynn P. Fundamentals of Nursing, The Art And Science Of Nursing Care, 6th Ed. Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83301 Version 2.0</div></div></div>"},"83304":{"type":"graphic_table","displayName":"Timing of first ultrasound appearance of pregnancy landmarks","title":"Timing of first appearance of gestational landmarks on transvaginal ultrasound examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Timing of first appearance of gestational landmarks on transvaginal ultrasound examination</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Landmark</td>\r\n            <td class=\"subtitle1\">First appearance on transvaginal ultrasound examination</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Gestational sac</td>\r\n            <td>4.5 to 5 weeks</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Yolk sac</td>\r\n            <td>5 weeks</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cardiac activity</td>\r\n            <td>5.5 to 6 weeks</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Measurable crown-rump length</td>\r\n            <td>6 weeks</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_lgnd\">The yolk sac is visible when the mean gestational sac diameter (MSD) is 8 mm and fetal cardiac activity can be observed when MSD is 16 mm. For transabdominal sonograms, the corresponding MSDs are larger than 20 and 25 mm, respectively. MSD = (length+height+width of the gestational sac)/3. In addition, MSD(mm)+30 = gestational age(days).</div><div id=\"graphicVersion\">Graphic 83304 Version 5.0</div></div></div>"},"83305":{"type":"graphic_figure","displayName":"Timeline for diagnosis of pertussis","title":"Timeline for diagnosis of pertussis","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Timeline for diagnosis of pertussis</div><div class=\"cntnt\"><img style=\"width:532px; height:196px;\" src=\"images/ID/83305_Time_diag_pertussis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction.<br />* Presumed period of lower sensitivity.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Pertussis (Whooping Cough). Available at: <a href=\"http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-confirmation.html\" target=\"_blank\">http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-confirmation.html</a>.</div><div id=\"graphicVersion\">Graphic 83305 Version 3.0</div></div></div>"},"83306":{"type":"graphic_picture","displayName":"Sarcoid granuloma with Schaumann body","title":"Well-formed sarcoid granuloma with multinucleated giant cells and a Schaumann body","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Well-formed sarcoid granuloma with multinucleated giant cells and a Schaumann body</div><div class=\"cntnt\"><img style=\"width:504px; height:366px;\" src=\"images/PULM/83306_SarcoidgranSchaumbody.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Schaumann body consists of a fragmented, irregular, calcified, basophilic refractile structure in the cytoplasm of a multinucleated giant cell.</div><div class=\"graphic_reference\">Reproduced with permission from: Laga AC, Allen TC, Bedrossian C, et al. Noncellular structures. In: Color Atlas and Text of Pulmonary Pathology, 2nd Edition, Cagle PT, Allen TC, Barrios R, et al (Eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83306 Version 6.0</div></div></div>"},"83307":{"type":"graphic_picture","displayName":"Sarcoid granuloma with calcium oxalate crystal","title":"Sarcoid granuloma with calcium oxalate crystal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoid granuloma with calcium oxalate crystal</div><div class=\"cntnt\"><img style=\"width:420px; height:504px;\" src=\"images/PULM/83307_Sarcgrancalcoxcryst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This calcium oxalate crystal in the cytoplasm of a multinucleated giant cell in a sarcoid granuloma is highly birefringent under polarized light.</div><div class=\"graphic_reference\">Reproduced with permission from: Laga AC, Allen TC, Bedrossian C, et al. Noncellular structures. In: Color Atlas and Text of Pulmonary Pathology, 2nd Edition, Cagle PT, Allen TC, Barrios R, et al (Eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83307 Version 6.0</div></div></div>"},"83308":{"type":"graphic_picture","displayName":"Sarcoid granuloma with an asteroid body","title":"Sarcoid granuloma with an asteroid body","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Sarcoid granuloma with an asteroid body</div><div class=\"cntnt\"><img style=\"width:499px; height:504px;\" src=\"images/PULM/83308_Sarcgranasteroidbod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An asteroid body consists of a stellate arrangement of needle-shaped eosinophilic structures within the cytoplasm of a multinucleated giant cell.</div><div class=\"graphic_reference\">Reproduced with permission from: Laga AC, Allen TC, Bedrossian C, et al. Noncellular structures. In: Color Atlas and Text of Pulmonary Pathology, 2nd Edition, Cagle PT, Allen TC, Barrios R, et al (Eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83308 Version 6.0</div></div></div>"},"83309":{"type":"graphic_picture","displayName":"Loosely formed granuloma in hypersensitivity pneumonitis","title":"Loosely formed granuloma in hypersensitivity pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Loosely formed granuloma in hypersensitivity pneumonitis</div><div class=\"cntnt\"><img style=\"width:504px; height:403px;\" src=\"images/PULM/83309_Loosegranulhypsenspneu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A high power view shows a \"loose\" poorly-defined granuloma. Cholesterol clefts are seen in multinucleated giant cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Barrios R, Kerr KM. Hypersensitivity pneumonitis. In: Color Atlas and Text of Pulmonary Pathology, 2nd Edition, Cagle PT, Allen TC, Barrios R, et al (Eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83309 Version 6.0</div></div></div>"},"83338":{"type":"graphic_picture","displayName":"Keloids PI","title":"Keloids from acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keloids from acne</div><div class=\"cntnt\"><img style=\"width:396px; height:315px;\" src=\"images/PI/83338_Keloids_acne_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A keloid is a growth that forms where the skin has healed from a cut or other injury. These keloids formed on skin that healed from acne.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright Â© 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83338 Version 3.0</div></div></div>"},"83339":{"type":"graphic_picture","displayName":"Appendiceal orifice endoscopy","title":"Appendiceal orifice","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Appendiceal orifice</div><div class=\"cntnt\"><img style=\"width:504px; height:374px;\" src=\"images/GAST/83339_Append_orifice_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Appendiceal orifice seen during colonoscopy.</div><div id=\"graphicVersion\">Graphic 83339 Version 1.0</div></div></div>"},"83340":{"type":"graphic_form","displayName":"Worry record","title":"Worry record","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Worry record</div><div class=\"cntnt\"><img style=\"width:517px; height:609px;\" src=\"images/PSYCH/83340_Worry_record.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Craske MG, Barlow DH. Mastery of Your Anxiety and Worry, 2nd, Oxford University Press, New York 2006. p.17. By permission from Oxford University Press, Inc. (<A style=\"FONT-STYLE: italic\" href=\"http://www.oup.com/\" target=_blank>www.oup.com</A>).</div><div id=\"graphicVersion\">Graphic 83340 Version 6.0</div></div></div>"},"83341":{"type":"graphic_picture","displayName":"Hepatic flexure endoscopy","title":"Hepatic flexure","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hepatic flexure</div><div class=\"cntnt\"><img style=\"width:504px; height:373px;\" src=\"images/GAST/83341_Hepatic_flexure_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatic flexure seen during colonoscopy. The liver can be seen through the wall of the colon (arrow).</div><div id=\"graphicVersion\">Graphic 83341 Version 1.0</div></div></div>"},"83342":{"type":"graphic_picture","displayName":"Ileocecal valve endoscopy","title":"Ileocecal valve","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ileocecal valve</div><div class=\"cntnt\"><img style=\"width:504px; height:374px;\" src=\"images/GAST/83342_Ileocecal_valve_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ileocecal valve seen during colonoscopy. One defining characteristic of the ileocecal valve are the lipomatous lips (arrow).</div><div id=\"graphicVersion\">Graphic 83342 Version 1.0</div></div></div>"},"83343":{"type":"graphic_picture","displayName":"Rectum endoscopy","title":"Rectum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Rectum</div><div class=\"cntnt\"><img style=\"width:504px; height:374px;\" src=\"images/GAST/83343_Rectum_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rectum seen during colonoscopy. The colonoscope is in a retroflexed position, allowing for visualization of the lower rectum. The colonoscope is visible in the upper right corner of the image (arrow).</div><div id=\"graphicVersion\">Graphic 83343 Version 1.0</div></div></div>"},"83345":{"type":"graphic_picture","displayName":"Terminal ileum endoscopy","title":"Terminal ileum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Terminal ileum</div><div class=\"cntnt\"><img style=\"width:504px; height:375px;\" src=\"images/GAST/83345_Terminal_ileum_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Terminal ileum seen during colonoscopy. Numerous villi can be seen covering the surface of the terminal ileum.</div><div id=\"graphicVersion\">Graphic 83345 Version 1.0</div></div></div>"},"83346":{"type":"graphic_picture","displayName":"Transverse colon endoscopy","title":"Transverse colon","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Transverse colon</div><div class=\"cntnt\"><img style=\"width:504px; height:372px;\" src=\"images/GAST/83346_Transverse_colon_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse colon seen during colonoscopy. The triangular shape seen here is characteristic of the transverse colon.</div><div id=\"graphicVersion\">Graphic 83346 Version 1.0</div></div></div>"},"83347":{"type":"graphic_picture","displayName":"Cecum","title":"Cecum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cecum</div><div class=\"cntnt\"><img style=\"width:504px; height:388px;\" src=\"images/GAST/83347_Cecum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cecum seen during colonoscopy. The crescent-shaped structure is the appendiceal orifice (arrow).</div><div id=\"graphicVersion\">Graphic 83347 Version 1.0</div></div></div>"},"83348":{"type":"graphic_picture","displayName":"Magnetic endoscopic imaging display monitor","title":"Magnetic endoscopic imaging display monitor","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Magnetic endoscopic imaging display monitor</div><div class=\"cntnt\"><img style=\"width:540px; height:403px;\" src=\"images/GAST/83348_Magn_endosc_img_display_mon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Monitor displaying endoscopic images from a colonoscopy alongside a panel showing the configuration of the colonoscope.</div><div id=\"graphicVersion\">Graphic 83348 Version 1.0</div></div></div>"},"83349":{"type":"graphic_picture","displayName":"Equipment configuration for magnetic endoscopic imaging","title":"Equipment configuration for magnetic endoscopic imaging","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Equipment configuration for magnetic endoscopic imaging</div><div class=\"cntnt\"><img style=\"width:540px; height:403px;\" src=\"images/GAST/83349_Equip_config_magn_endo_img.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mobile integrated unit containing a magnetic field generator, central microprocessor unit, and sensor (receiver) coils (arrow). Images showing the colonoscope's configuration are displayed on a monitor alongside the live endoscopic images.</div><div id=\"graphicVersion\">Graphic 83349 Version 1.0</div></div></div>"},"83350":{"type":"graphic_table","displayName":"ESC classification of abnormalities of the athlete ECG","title":"European Society of Cardiology (ESC) classification of abnormalities (training-related or training-unrelated) of the athlete's electrocardiogram (ECG)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Society of Cardiology (ESC) classification of abnormalities (training-related or training-unrelated) of the athlete's electrocardiogram (ECG)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Group 1: Common and training-related ECG changes</td> </tr> <tr> <td class=\"indent1\">Sinus bradycardia</td> </tr> <tr> <td class=\"indent1\">First-degree AV block</td> </tr> <tr> <td class=\"indent1\">Incomplete RBBB</td> </tr> <tr> <td class=\"indent1\">Early repolarization</td> </tr> <tr> <td class=\"indent1\">Isolated QRS voltage criteria for left ventricular hypertrophy</td> </tr> <tr> <td class=\"subtitle1_single\">Group 2: Uncommon and training-unrelated ECG changes</td> </tr> <tr> <td class=\"indent1\">T-wave inversion</td> </tr> <tr> <td class=\"indent1\">ST-segment depression</td> </tr> <tr> <td class=\"indent1\">Pathological Q-waves</td> </tr> <tr> <td class=\"indent1\">Left atrial enlargement</td> </tr> <tr> <td class=\"indent1\">Left-axis deviation/left anterior hemiblock</td> </tr> <tr> <td class=\"indent1\">Right-axis deviation/left posterior hemiblock</td> </tr> <tr> <td class=\"indent1\">Right ventricular hypertrophy</td> </tr> <tr> <td class=\"indent1\">Ventricular pre-excitation</td> </tr> <tr> <td class=\"indent1\">Complete LBBB or RBBB</td> </tr> <tr> <td class=\"indent1\">Long- or short-QT interval</td> </tr> <tr> <td class=\"indent1\">Brugada-like early repolarization</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: atrioventricular; RBBB: right bundle branch block; LBBB: left bundle branch block.</div><div class=\"graphic_reference\">Reproduced from: Corrado D, Pelliccia A, Heidbuchel H, et al. Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J 2010; 31:243. By permission of the European Society of Cardiology. Copyright Â© 2013 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.escardio.org/\" target=_blank>www.escardio.org/</A>.</div><div id=\"graphicVersion\">Graphic 83350 Version 14.0</div></div></div>"},"83351":{"type":"graphic_picture","displayName":"Atypical nevus 1","title":"Clinically atypical nevus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Clinically atypical nevus</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/DERM/83351_Atypical_nevus_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this atypical nevus, note the ill-defined borders, variegated color, and asymmetry (one half of the lesion does not match the other in terms of color).</div><div id=\"graphicVersion\">Graphic 83351 Version 3.0</div></div></div>"},"83352":{"type":"graphic_table","displayName":"Physiologic parameters based on pediatric age","title":"Physiologic parameters based on pediatric age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic parameters based on pediatric age</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Age group</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Heart rate, beats/min</td>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Respiratory rate, breaths/min</td>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Leukocyte count, leukocytes x 10<sup>3</sup>/mm<sup>3</sup></td>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Systolic blood pressure, mmHg</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">Tachycardia</td>\r\n            <td class=\"subtitle2\">Bradycardia</td>\r\n        </tr>\r\n        <tr>\r\n            <td>0 days to 1 wk</td>\r\n            <td class=\"centered\">&#62;180</td>\r\n            <td class=\"centered\">&#60;100</td>\r\n            <td class=\"centered\">&#62;50</td>\r\n            <td class=\"centered\">&#62;34</td>\r\n            <td class=\"centered\">&#60;65</td>\r\n        </tr>\r\n        <tr>\r\n            <td>1 wk to 1 mo</td>\r\n            <td class=\"centered\">&#62;180</td>\r\n            <td class=\"centered\">&#60;100</td>\r\n            <td class=\"centered\">&#62;40</td>\r\n            <td class=\"centered\">&#62;19.5 or &#60;5</td>\r\n            <td class=\"centered\">&#60;75</td>\r\n        </tr>\r\n        <tr>\r\n            <td>1 mo to 1 yr</td>\r\n            <td class=\"centered\">&#62;180</td>\r\n            <td class=\"centered\">&#60;90</td>\r\n            <td class=\"centered\">&#62;34</td>\r\n            <td class=\"centered\">&#62;17.5 or &#60;5</td>\r\n            <td class=\"centered\">&#60;100</td>\r\n        </tr>\r\n        <tr>\r\n            <td>2-5 yrs</td>\r\n            <td class=\"centered\">&#62;140</td>\r\n            <td class=\"centered\">NA</td>\r\n            <td class=\"centered\">&#62;22</td>\r\n            <td class=\"centered\">&#62;15.5 or &#60;6</td>\r\n            <td class=\"centered\">&#60;94</td>\r\n        </tr>\r\n        <tr>\r\n            <td>6-12 yrs</td>\r\n            <td class=\"centered\">&#62;130</td>\r\n            <td class=\"centered\">NA</td>\r\n            <td class=\"centered\">&#62;18</td>\r\n            <td class=\"centered\">&#62;13.5 or &#60;4.5</td>\r\n            <td class=\"centered\">&#60;105</td>\r\n        </tr>\r\n        <tr>\r\n            <td>13 to &#60;18 yrs</td>\r\n            <td class=\"centered\">&#62;110</td>\r\n            <td class=\"centered\">NA</td>\r\n            <td class=\"centered\">&#62;14</td>\r\n            <td class=\"centered\">&#62;11 or &#60;4.5</td>\r\n            <td class=\"centered\">&#60;117</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">NA: not applicable.</div><div class=\"graphic_reference\">Reproduced with permission from: Goldstein B, Giroir B, Randolph B, Members of the International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2. Copyright Â© 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83352 Version 5.0</div></div></div>"},"83353":{"type":"graphic_table","displayName":"Heart rate control of atrial fib in COPD","title":"Intravenous pharmacologic agents for acute heart rate control in patients with atrial fibrillation and chronic obstructive pulmonary disease*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous pharmacologic agents for acute heart rate control in patients with atrial fibrillation and chronic obstructive pulmonary disease*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Loading dose</td> <td class=\"subtitle1\">Onset</td> <td class=\"subtitle1\">Maintenance dose (for initial 24 to 72 hours)</td> <td class=\"subtitle1\">Major side effects</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">There is evidence and/or general agreement that the following drugs are effective for acute heart rate control in patients with AF who do NOT have an accessory pathway or heart failure</td> </tr> <tr> <td class=\"indent1\">Verapamil<sup>&#182;</sup></td> <td>0.075 to 0.15 mg/kg (max 10 mg per dose) IV over 2 minutes, may repeat dose in 15 to 30 minutes if inadequate response to initial dose</td> <td>3 to 5 minutes</td> <td>&nbsp;</td> <td>Hypotension, heart block, heart failure</td> </tr> <tr> <td class=\"indent1\">Diltiazem<sup>&#182;</sup></td> <td>0.25 mg/kg IV over 2 minutes (max 25 mg initial dose), may repeat with higher dose (0.35 mg/kg IV) in 15 to 30 minutes if inadequate response to initial dose</td> <td>2 to 7 minutes</td> <td>5 to 15 mg/hour IV infusion titrated according to ventricular heart rate</td> <td>Hypotension, heart block, heart failure</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Metoprolol<sup>&#182;</sup><sup>&#916;</sup><sup>&#9674;</sup></td> <td>2.5 to 5 mg IV over 2 minutes; up to 3 doses (maximum 15 mg total) administered 5 to 10 minutes apart may be given</td> <td>5 minutes</td> <td>&nbsp;</td> <td>Hypotension, heart block, bradycardia, heart failure, bronchoconstriction</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">For acute heart rate control in patients with AF and an accessory pathway</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Amiodarone<sup>&#182;</sup><sup>&#167;</sup></td> <td>150 mg IV over 30 minutes, followed by 1 mg/minute IV infusion for 6 hours, followed by 0.5 mg/minute IV infusion for 18 hours</td> <td>1 to 30 minutes</td> <td>0.5 mg/minute IV infusion for up to additional 48 hours</td> <td>Hypotension, sinus bradycardia, heart block, QT prolongation, ventricular arrhythmias, pulmonary toxicity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">For acute heart rate control in patients with AF and heart failure but not an accessory pathway</td> </tr> <tr> <td class=\"indent1\">Digoxin<sup>&#182;</sup><sup>&#165;</sup><sup>&#135;</sup></td> <td>0.25 mg IV every 2 hours, up to a total dose of 1.5 mg</td> <td>15 to 30 minutes, peak effect in 1 to 5 hours</td> <td>0.125 to 0.25 mg orally once a day</td> <td>Digitalis toxicity, heart block, bradycardia</td> </tr> <tr> <td class=\"indent1\">Amiodarone<sup>&#182;</sup><sup>&#167;</sup></td> <td>150 mg IV over 30 minutes, followed by 1 mg/minute IV infusion for 6 hours, followed by 0.5 mg/minute IV infusion for 18 hours</td> <td>1 to 30 minutes</td> <td>0.5 mg/minute IV infusion for up to additional 48 hours</td> <td>Hypotension, sinus bradycardia, heart block, QT prolongation, ventricular arrhythmias, pulmonary toxicity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For patients with hemodynamic instability due to atrial fibrillation, direct current cardioversion is the treatment of choice. For all patients with COPD and atrial fibrillation with a rapid ventricular response, correction of hypoxemia, acidosis, and other metabolic disturbances is recommended. Theophylline can increase the ventricular response, so dosing should be regulated to keep the serum level in the range of 8 to 12 mg/mL; discontinuation of the medication should be considered.<br />&para; Electrocardiographic (ECG or telemetry) and blood pressure monitoring should be continuously performed during initial loading dose and frequently (eg, every 4 hours) during maintenance intravenous dosing.<br /><span class=\"lozenge\">&loz;</span> Representative of the type of selective beta-1 blockers that could be used but similar drugs could be given in appropriate doses.<br />&Delta; Nondihydropyridine calcium channel antagonists (eg, verapamil, diltiazem) are preferred over metoprolol for heart rate control of atrial fibrillation in patients with COPD due to concerns about exacerbating bronchoconstriction.<br />&sect; Amiodarone can be useful when other measures are unsuccessful or contraindicated. For patients with an accessory pathway, intravenous amiodarone can be given if the rhythm cannot be converted or ablated and rate control is needed. <br />&yen; There is evidence and/or general agreement that digoxin is effective in patients with heart failure but not an accessory pathway.<br />&Dagger; Dosing shown is for normal renal function and normal body weight. Reduced doses are needed for renal insufficiency or low body weight. Refer to topic on \"Method of digitalization\".</div><div id=\"graphicVersion\">Graphic 83353 Version 3.0</div></div></div>"},"83358":{"type":"graphic_table","displayName":"Heart rate control of MAT in COPD","title":"Pharmacologic agents for acute heart rate control in patients with multifocal atrial tachycardia and chronic obstructive pulmonary disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic agents for acute heart rate control in patients with multifocal atrial tachycardia and chronic obstructive pulmonary disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Initial dose</td> <td class=\"subtitle1\">Onset</td> <td class=\"subtitle1\">Subsequent doses</td> <td class=\"subtitle1\">Maintenance dose</td> <td class=\"subtitle1\">Side effects</td> </tr> <tr class=\"divider_bottom\"> <td>Verapamil*<sup>&#182;</sup><sup>&#9674;</sup></td> <td>1 mg IV</td> <td>1 to 2 minutes</td> <td>4 mg over 5 minutes; then 5 mg over 5 minutes up to 3 additional doses</td> <td>120 to 480 mg daily</td> <td>Hypotension, heart block, heart failure</td> </tr> <tr> <td>Metoprolol<sup>&#916;</sup><sup>&#182;</sup><sup>&#9674;</sup></td> <td>5 mg IV over 5 minutes</td> <td>5 minutes</td> <td>5 mg IV over 5 minutes at 10 minute intervals for 2 to 3 additional doses</td> <td>50 to 100 mg orally twice daily</td> <td>Hypotension, heart block, bradycardia, heart failure, bronchoconstriction</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MAT: multifocal atrial tachycardia; COPD: chronic obstructive pulmonary disease.<br />* For all patients with COPD and MAT and a rapid ventricular response, correction of hypoxemia, acidosis, and other metabolic disturbances is recommended. Theophylline can increase the ventricular response, so dosing should be regulated to keep the serum level in the range of 8 to 12 mg/mL; discontinuation of the medication should be considered.<br />Â¶ Verapamil is preferred over metoprolol for heart rate control of MAT in patients with COPD due to concerns about exacerbating bronchoconstriction.<br />Î Representative of the type of selective beta-1 blockers that could be used, but similar drugs could be given in appropriate doses.<br /><FONT class=lozenge>â</FONT> Verapamil and beta blockers should not be given to patients with sinus node dysfunction or preexisting second- or third-degree block unless a temporary or permanent pacemaker has been implanted. Verapamil and beta blockers should be administered cautiously in patients with decompensated heart failure or hypotension to avoid worsening these conditions.</div><div id=\"graphicVersion\">Graphic 83358 Version 5.0</div></div></div>"},"83371":{"type":"graphic_picture","displayName":"Keratoderma in SÃ©zary syndrome","title":"Keratoderma in SÃ©zary syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratoderma in SÃ©zary syndrome</div><div class=\"cntnt\"><img style=\"width:300px; height:727px;\" src=\"images/HEME/83371_Keratoderma_Sezary.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A thickened retention of keratin on the palms and soles, so-called keratoderma is a common finding and one that can also help to differentiate&nbsp;SÃ©zary syndrome from other causes of erythroderma.</div><div id=\"graphicVersion\">Graphic 83371 Version 2.0</div></div></div>"},"83372":{"type":"graphic_picture","displayName":"Follicular involvement in mycosis fungoides","title":"Follicular involvement in mycosis fungoides","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Follicular involvement in mycosis fungoides</div><div class=\"cntnt\"><img style=\"width:440px; height:300px;\" src=\"images/HEME/83372_Follicular_invol_SS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflamed follicular-based papules or scale may signal follicular involvement in mycosis fungoides and SÃ©zary syndrome.</div><div id=\"graphicVersion\">Graphic 83372 Version 4.0</div></div></div>"},"83373":{"type":"graphic_picture","displayName":"Localized alopecia in follicular mycosis fungoides","title":"Localized alopecia in follicular mycosis fungoides","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Localized alopecia in follicular mycosis fungoides</div><div class=\"cntnt\"><img style=\"width:512px; height:433px;\" src=\"images/HEME/83373_Loc_alopecia_fol_MF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alopecia is common in patients with mycosis fungoides and can present as reduced hair density diffusely over the scalp and body or as patches of alopecia.</div><div id=\"graphicVersion\">Graphic 83373 Version 3.0</div></div></div>"},"83374":{"type":"graphic_picture","displayName":"Diffuse alopecia in SS","title":"Diffuse alopecia in SÃ©zary syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse alopecia in S&#233;zary syndrome</div><div class=\"cntnt\"><img style=\"width:288px; height:306px;\" src=\"images/HEME/83374_Diffuse_alopecia_SS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alopecia is common in patients with mycosis fungoides and S&#233;zary syndrome and can present as reduced hair density diffusely over the scalp and body or as patches of alopecia.</div><div id=\"graphicVersion\">Graphic 83374 Version 2.0</div></div></div>"},"83376":{"type":"graphic_table","displayName":"Inhaled medications that require specific nebulizers","title":"Inhaled medications that require specific nebulizers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inhaled medications that require specific nebulizers</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Medication</td>\r\n            <td class=\"subtitle1\">Specialized nebulizer</td>\r\n            <td class=\"subtitle1\">Comments</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Aztreonam</td>\r\n            <td>Mesh: Altera<sup>&#174;</sup> Nebulizer System</td>\r\n            <td>&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Budesonide</td>\r\n            <td>Jet or mesh nebulizers, but NOT ultrasonic</td>\r\n            <td>Ultrasonic nebulizers cannot be used for budesonide</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Dornase alpha (DNase)</td>\r\n            <td>Jet: Pulmo-Aide<sup>&#174;</sup>, Pari-Proneb<sup>&#174;</sup>, Mobilaire<sup>&#174;</sup>, Porta-Neb<sup>&#174;</sup>, Pari-Baby&#8482;</td>\r\n            <td>&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Iloprost</td>\r\n            <td>Jet: Prodose AAD (respironics)<br />\r\n            Mesh: I-neb AAD (respironics)</td>\r\n            <td>Specialized nebulizer needed for accurate dosing</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Pentamidine</td>\r\n            <td>Jet: Respirgard II<sup>&#174;</sup></td>\r\n            <td>Small volume, one-way valve to prevent contamination of ambient environment</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ribavirin</td>\r\n            <td>Jet: Viratek Small-Particle Aerosol Generator (SPAG-2<sup>&#174;</sup>)</td>\r\n            <td>Small particle size; scavenging system to minimize contamination of the ambient environment</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Tobramycin</td>\r\n            <td>Jet: PARI-LC PLUS&#8482;</td>\r\n            <td>&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Treprostinil</td>\r\n            <td>Ultrasonic: Optineb</td>\r\n            <td>Specialized nebulizer needed for accurate dosing</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83376 Version 1.0</div></div></div>"},"83378":{"type":"graphic_picture","displayName":"Abduction exercise for frozen shoulder","title":"Abduction exercise for frozen shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abduction exercise for frozen shoulder</div><div class=\"cntnt\"><img style=\"width:314px; height:235px;\" src=\"images/EM/83378_Abduct_exer_frozen_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To stretch the inferior portion of the shoulder capsule, the seated patient places their elbow and forearm on a table and gently abducts the shoulder by sliding the forearm away from their body.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 83378 Version 1.0</div></div></div>"},"83379":{"type":"graphic_picture","displayName":"External rotation exercise for frozen shoulder","title":"External rotation exercise for frozen shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External rotation exercise for frozen shoulder</div><div class=\"cntnt\"><img style=\"width:235px; height:272px;\" src=\"images/EM/83379_Ext_rot_ex_frozen_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To stretch the anterior portion of the shoulder capsule, the patient stands in a door frame with their elbow bent at approximately 90 degrees and the inside of their distal forearm resting against the frame, and then externally rotates the shoulder by turning their body away from the forearm. The forearm is kept in place by the door frame.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 83379 Version 1.0</div></div></div>"},"83380":{"type":"graphic_picture","displayName":"Internal rotation exercise for frozen shoulder","title":"Internal rotation exercise for frozen shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Internal rotation exercise for frozen shoulder</div><div class=\"cntnt\"><img style=\"width:179px; height:309px;\" src=\"images/EM/83380_Int_rot_ex_frozen_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To stretch the posterior portion of the shoulder capsule, the patient stands in a door frame with their hand behind their lower back and their forearm against the frame and then internally rotates the shoulder by turning their body toward the arm. The door frame keeps the forearm in place.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 83380 Version 1.0</div></div></div>"},"83381":{"type":"graphic_picture","displayName":"Abduction external rotation exercise for frozen shoulder","title":"Abduction and external rotation exercise for frozen shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abduction and external rotation exercise for frozen shoulder</div><div class=\"cntnt\"><img style=\"width:314px; height:229px;\" src=\"images/EM/83381_Abd_ext_rot_exer_froz_sh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise helps to improve both abduction and external rotation in patients with frozen shoulder. To perform the exercise, the patient lies down and, using the unaffected arm and a pillow as needed, gently abducts and externally rotates the shoulder.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 83381 Version 1.0</div></div></div>"},"83382":{"type":"graphic_movie","displayName":"Abduction adduction exercise for frozen shoulder","title":"Abduction adduction exercise for frozen shoulder","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Abduction adduction exercise for frozen shoulder</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/83382_Abdaddfrozshouldervideo.mp4\" style=\"width:512px;height:304px\"></div><img style=\"width:468px; height:261px;\" src=\"images/EM/83382_Abdaddfrozshoulderimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise to improve shoulder mobility and strength is performed by patients with frozen shoulder after their motion has begun to improve.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 83382 Version 1.0</div></div></div>"},"83384":{"type":"graphic_movie","displayName":"Active flexion extension exercise for frozen shoulder","title":"Active flexion extension exercise for frozen shoulder","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Active flexion extension exercise for frozen shoulder</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/83384_Actflexextenfrozenvideo.mp4\" style=\"width:288px;height:528px\"></div><img style=\"width:285px; height:465px;\" src=\"images/EM/83384_Actflexextenfrozenimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exericse to improve shoulder mobility and strength in patients with frozen shoulder is performed after motion has begun to improve.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 83384 Version 1.0</div></div></div>"},"83385":{"type":"graphic_movie","displayName":"Seated external rotation exercise for frozen shoulder","title":"Seated external rotation exercise for frozen shoulder","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Seated external rotation exercise for frozen shoulder</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/83385_Seatedextrotfrozenvideo.mp4\" style=\"width:512px;height:304px\"></div><img style=\"width:459px; height:333px;\" src=\"images/EM/83385_Seatedextrotfrozenimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise for the external rotators of the shoulder can be added to a rehabilitation regimen once shoulder motion begins to improve.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 83385 Version 1.0</div></div></div>"},"83388":{"type":"graphic_picture","displayName":"Caterpillar bodies","title":"Caterpillar bodies in porphyria cutanea tarda and pseudoporphyria","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Caterpillar bodies in porphyria cutanea tarda and pseudoporphyria</div><div class=\"cntnt\"><img style=\"width:504px; height:363px;\" src=\"images/DERM/83388_Caterpillar_bodies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear arrangement of segmented eosinophilic deposits parallel to the epidermal surface above the subepidermal blister.</div><div class=\"graphic_reference\">Reproduced with permission from: Raso DS, Greene WB, Maize JC, et al. Caterpillar bodies of porphyria cutanea tarda ultrastructurally represent a unique arrangement of colloid and basement membrane bodies. Am J Dermatopathol 1996; 18:24. Copyright Â© 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83388 Version 4.0</div></div></div>"},"83389":{"type":"graphic_figure","displayName":"Course of BK-induced nephropathy","title":"Graph showing typical course of viruria, viremia, and BK-induced nephropathy","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Graph showing typical course of viruria, viremia, and BK-induced nephropathy</div><div class=\"cntnt\"><img style=\"width:534px; height:327px;\" src=\"images/NEPH/83389_Crs_BK_ind_nephropath.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prototypical course of PVAN and opportunities for timely intervention. The vast majority of cases of PVAN are preceded by an asymptomatic period of persistent and significant Vr. This can be demonstrated by PCR-based studies (&gt;10E+05 viral copies/mL) or by urine cytology (decoy cells present for&nbsp;two or more&nbsp;months). Both BK and JC Vr manifest with decoy cells, but only BK Vr increases the risk for graft loss or shortened graft survival. Sustained BK Vr is typically followed within weeks by the development of Vm. Significant, sustained Vm (&gt;5000 BK copies/mL for three consecutive weeks) characterizes patients with high, uncontrolled viral replication, leading to parenchymal injury. Progression of PVAN leads to eventual deterioration of&nbsp;the graft function. In patients with uncomplicated PVAN, appearance of Vr and Vm precede the increase in serum creatinine (Cr) by weeks or months.<br />Histologic diagnosis of PVAN (Bx+). The statistical possibility to achieve a histologic diagnosis by needle graft biopsy (Bx) is directly proportional to the time elapsed from the initiation of the Vm and correlates with the overall level of viral loads (Vr, Vm). Negative biopsy samples are common in early PVAN due to heterogeneous renal involvement. Longer and more pronounced Vm is associated with more severe histologic disease/pattern and larger number of cells with viral cytopathic changes (SV40+ cells).<br />(E-G) options for clinical intervention in PVAN: <br />(E) Preemptive intervention. In patients with Vr and Vm, progressive and customized decrease in immunosuppression before significant renal scarring has occurred leads to resolution of the infection in 85 to 90 percent of cases, with long-term preservation of graft function. Risk of acute rejection is low (10 to 15 percent). Intervention is not indicated in the absence of Vm (ie, Vr only). <br />(F) Obligatory intervention. Late diagnosis and intervention once graft dysfunction is evident decreases the likelihood of viral clearance and is associated with higher rates of premature graft loss (30 versus 10 percent). <br />(G) Ineffectual, late intervention. The late stage of PVAN resembles clinically and hitologically end stage renal disease from other causes. With progressive obliteration of the renal tubules (the primary target of BK infection) there is progressive decrease of Vr and Vm.</div><div class=\"graphic_footnotes\">PVAN: polyomavirus-associated nephropathy; Vr: viruria; PCR: polymerace chain reaction; Vm: viremia.</div><div class=\"graphic_reference\">Reproduced with permission from: Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: State of affairs. Transplantation 2009; 87:621. Copyright Â© 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83389 Version 8.0</div></div></div>"},"83390":{"type":"graphic_picture","displayName":"Variegate porphyria","title":"Chronic skin changes in variegate porphyria","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chronic skin changes in variegate porphyria</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83390_Variegate_porphyria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions, scarring, and hyperpigmentation in a patient with variegate porphyria.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83390 Version 3.0</div></div></div>"},"83391":{"type":"graphic_picture","displayName":"Pseudoporphyria and vitiligo","title":"Pseudoporphyria in a patient with vitiligo","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pseudoporphyria in a patient with vitiligo</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83391_pseudoporphyria_vitiligo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient with vitiligo, bullae developed in areas of pigment loss.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83391 Version 3.0</div></div></div>"},"83400":{"type":"graphic_figure","displayName":"US ovarian ca incidence age race","title":"US ovarian cancer incidence by age and race/ethnicity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US ovarian cancer incidence by age and race/ethnicity</div><div class=\"cntnt\"><img style=\"width:444px; height:492px;\" src=\"images/OBGYN/83400_US_ovar_ca_in_age_race.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cancer sites include invasive cases only unless otherwise noted.<br />Hispanics and Non-Hispanics are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.</div><div class=\"graphic_reference\">Reproduced from: Surveillance, Epidemiology and End Results (SEER). National Cancer Institute. More information available at: <a href=\"http://seer.cancer.gov/\" style=\"font-style: italic;\" target=\"_blank\">http://seer.cancer.gov/</a>.</div><div id=\"graphicVersion\">Graphic 83400 Version 2.0</div></div></div>"},"83401":{"type":"graphic_figure","displayName":"Intestinal sites of nutrient absorption","title":"Intestinal sites of nutrient absorption","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Intestinal sites of nutrient absorption</div><div class=\"cntnt\"><img style=\"width:527px; height:663px;\" src=\"images/PEDS/83401_Intestinal-sites-of-nutrient-absorption.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83401 Version 1.0</div></div></div>"},"83402":{"type":"graphic_picture","displayName":"Bone marrow findings in parvovirus B19 infection","title":"Bone marrowÂ findings in parvovirus B19 infection","html":"<div class=\"graphic\"><div style=\"width: 886px\" class=\"figure\"><div class=\"ttl\">Bone marrow&nbsp;findings in parvovirus B19 infection</div><div class=\"cntnt\"><img style=\"width:866px; height:372px;\" src=\"images/ID/83402_Bn_mrw_bpsy_prvrs_B19_infc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power micrograph of a bone marrow aspirate and biopsy&nbsp;from a patient with parvovirus B19 infection. The giant pronormoblast&nbsp;with prominent nuclear inclusions is characteristic of parvovirus B19 infection.</div><div class=\"graphic_reference\">Reproduced with permission from: German Pihan, MD. Copyright &copy; 2015.</div><div id=\"graphicVersion\">Graphic 83402 Version 8.0</div></div></div>"},"83403":{"type":"graphic_table","displayName":"Phenotypes of vancomycin-resistant enterococci","title":"Phenotypes of vancomycin-resistant enterococci (VRE)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phenotypes of vancomycin-resistant enterococci (VRE)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"12%\"></colgroup><colgroup width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Phenotype</td> <td class=\"subtitle1\">Ligase gene</td> <td class=\"subtitle1\">Ending of peptidoglycan*</td> <td class=\"subtitle1\">MIC vancomycin<br /> (mcg/mL)</td> <td class=\"subtitle1\">MIC teicoplanin<br /> (mcg/mL)</td> <td class=\"subtitle1\">Transferability between strains</td> <td class=\"subtitle1\">Species</td> </tr> <tr> <td class=\"centered\">VanA</td> <td class=\"centered\"><em>vanA</em></td> <td class=\"centered\">D-Ala-D-Lac</td> <td class=\"centered\">64 to 1000</td> <td class=\"centered\">16 to 512</td> <td class=\"centered\">YES</td> <td><em>E. faecium, E. faecalis, E. durans, E. hirae, E. gallinarum, E. casseliflavus, E. raffinosus, E. avium, E. mundtii</em></td> </tr> <tr> <td class=\"centered\">VanB</td> <td class=\"centered\"><em>vanB</em></td> <td class=\"centered\">D-Ala-D-Lac</td> <td class=\"centered\">4 to 32</td> <td class=\"centered\">0.5 to 1</td> <td class=\"centered\">YES</td> <td><em>E. faecium, E. faecalis, E. durans, E. gallinarum</em></td> </tr> <tr> <td class=\"centered\">VanC</td> <td class=\"centered\"><em>vanC</em></td> <td class=\"centered\">D-Ala-D-Ser</td> <td class=\"centered\">8 to 32</td> <td class=\"centered\">0.5 to 1</td> <td class=\"centered\">NO</td> <td><em>E. gallinarum, E. casseliflavus</em></td> </tr> <tr> <td class=\"centered\">VanD</td> <td class=\"centered\"><em>vanD</em></td> <td class=\"centered\">D-Ala-D-Lac</td> <td class=\"centered\">64 to 128</td> <td class=\"centered\">4 to 64</td> <td class=\"centered\">NO</td> <td><em>E. faecium, E. faecalis, E. raffinosus</em></td> </tr> <tr> <td class=\"centered\">VanE</td> <td class=\"centered\"><em>vanE</em></td> <td class=\"centered\">D-Ala-D-Ser</td> <td class=\"centered\">8 to 32</td> <td class=\"centered\">0.5 to 1</td> <td class=\"centered\">NO</td> <td><em>E. faecalis</em></td> </tr> <tr> <td class=\"centered\">VanG</td> <td class=\"centered\"><em>vanG</em></td> <td class=\"centered\">D-Ala-D-Ser</td> <td class=\"centered\">8 to 16</td> <td class=\"centered\">0.5 to 1</td> <td class=\"centered\">YES</td> <td><em>E. faecalis</em></td> </tr> <tr> <td class=\"centered\">VanL</td> <td class=\"centered\"><em>vanL</em></td> <td class=\"centered\">D-Ala-D-Ser<sup>&#182;</sup></td> <td class=\"centered\">8</td> <td class=\"centered\">0.5</td> <td class=\"centered\">NO</td> <td><em>E. faecalis</em></td> </tr> <tr> <td class=\"centered\">VanM</td> <td class=\"centered\"><em>vanM</em></td> <td class=\"centered\">D-Ala-D-Lac<sup>&#182;</sup></td> <td class=\"centered\">&#62;256</td> <td class=\"centered\">64&nbsp;to &#62;256</td> <td class=\"centered\">YES</td> <td><em>E. faecium</em></td> </tr> <tr> <td class=\"centered\">VanN</td> <td class=\"centered\"><em>vanN</em></td> <td class=\"centered\">D-Ala-D-Ser<sup>&#182;</sup></td> <td class=\"centered\">8</td> <td class=\"centered\">0.5</td> <td class=\"centered\">YES</td> <td><em>E. faecium</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">D-Ala-D-Lac: D-alanine-D-lactate; D-Ala-D-Ser: D-alanine-D-serine; MIC: minimal inhibitory concentration.<br />* Refers to the last two amino acids of peptidoglycan precursors, which are normally D-Ala-D-Ala; in some phenotypes, the ending is deduced from the amino acid sequence of the corresponding ligase.<br />Â¶&nbsp;Predicted but not actually confirmed.</div><div class=\"graphic_reference\">Courtesy of Cesar Arias, MD, and Barbara Murray, MD.</div><div id=\"graphicVersion\">Graphic 83403 Version 5.0</div></div></div>"},"83404":{"type":"graphic_figure","displayName":"Reading items figure for PedNIHSS","title":"Reading items figure for PedNIHSS","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Reading items figure for PedNIHSS</div><div class=\"cntnt\"><img style=\"width:581px; height:224px;\" src=\"images/NEURO/83404_PedNIHSS_2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Words to test reading for Item 9 (Best language) of PedNIHSS.</div><div class=\"graphic_reference\">Reproduced with permission from: Ichord RN, Bastian R, Abraham L, et al. Interrater reliability of the Pediatric National Institutes of Health Stroke Scale (PedNIHSS) in a multicenter study. Stroke 2011; 42:613. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83404 Version 4.0</div></div></div>"},"83405":{"type":"graphic_figure","displayName":"Picture naming figure for PedNIHSS","title":"Picture naming figure for PedNIHSS","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Picture naming figure for PedNIHSS</div><div class=\"cntnt\"><img style=\"width:545px; height:500px;\" src=\"images/NEURO/83405_PedNIHSS_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pictures to test naming for Item 9 (Best language) of PedNIHSS.</div><div class=\"graphic_reference\">Reproduced with permission from: Ichord RN, Bastian R, Abraham L, et al. Interrater reliability of the Pediatric National Institutes of Health Stroke Scale (PedNIHSS) in a multicenter study. Stroke 2011; 42:613. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83405 Version 4.0</div></div></div>"},"83406":{"type":"graphic_figure","displayName":"Cookie theft picture for NIHSS and PedNIHSS","title":"Cookie theft picture for NIHSS and PedNIHSS","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Cookie theft picture for NIHSS and PedNIHSS</div><div class=\"cntnt\"><img style=\"width:596px; height:450px;\" src=\"images/NEURO/83406_PedNIHSS_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cookie theft picture to test story-telling for Item 9 Best language of NIHSS and&nbsp;PedNIHSS.</div><div class=\"graphic_reference\">Reproduced with permission from: Ichord RN, Bastian R, Abraham L, et al. Interrater reliability of the Pediatric National Institutes of Health Stroke Scale (PedNIHSS) in a multicenter study. Stroke 2011; 42:613. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83406 Version 4.0</div></div></div>"},"83407":{"type":"graphic_picture","displayName":"Ground glass nodule","title":"Ground-glass solitary pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ground-glass solitary pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:323px; height:504px;\" src=\"images/PULM/83407_Ground_glass_nod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A ground-glass solitary pulmonary nodule in the right middle lobe (arrow), most likely representing a focus of atypical alveolar hyperplasia.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 83407 Version 1.0</div></div></div>"},"83408":{"type":"graphic_table","displayName":"Complications sinusitis children","title":"Complications of acute bacterial rhinosinusitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of acute bacterial rhinosinusitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Complication</td> <td class=\"subtitle1\">Clinical manifestations</td> </tr> <tr class=\"divider_bottom\"> <td>Preseptal (periorbital) cellulitis</td> <td> <ul> <li>Swelling of eyelids/periorbital area </li> <li>Erythema of eyelids/periorbital area </li> <li>Absence of proptosis </li> <li>Normal eye movements </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Orbital cellulitis</td> <td> <ul> <li>Periorbital swelling </li> <li>Erythema of eyelids </li> <li>Pain with eye movement </li> <li>Conjunctival swelling (chemosis) </li> <li>Proptosis </li> <li>Limitation of eye movements </li> <li>Double vision </li> <li>Vision loss </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Orbital subperiosteal abscess</td> <td> <ul> <li>Periorbital swelling </li> <li>Erythema of eyelids </li> <li>Pain with eye movement </li> <li>Conjunctival swelling (chemosis) </li> <li>Proptosis </li> <li>Limitation of eye movements </li> <li>Double vision </li> <li>Vision loss </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Septic cavernous sinus thrombosis</td> <td> <ul> <li>Ptosis </li> <li>Proptosis </li> <li>Limitation of eye movements </li> <li>Periorbital edema </li> <li>Headache </li> <li>Change in mental status </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Meningitis</td> <td> <ul> <li>Fever </li> <li>Headache </li> <li>Nuchal rigidity </li> <li>Change in mental status </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Osteomyelitis of the frontal bone with subperiosteal abscess (Pott puffy tumor)</td> <td> <ul> <li>Fever </li> <li>Forehead or scalp swelling and tenderness </li> <li>Headache </li> <li>Photophobia </li> <li>Vomiting </li> <li>Lethargy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Epidural abscess</td> <td> <ul> <li>Focal neurologic signs </li> <li>Headache </li> <li>Lethargy </li> <li>Nausea </li> <li>Vomiting </li> <li>Papilledema </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Subdural abscess</td> <td> <ul> <li>Fever </li> <li>Severe headache </li> <li>Meningeal irritation </li> <li>Progressive neurologic deficits </li> <li>Seizures </li> <li>Vomiting </li> <li>Papilledema </li> </ul> </td> </tr> <tr> <td>Brain abscess</td> <td> <ul> <li>Headache </li> <li>Neck stiffness </li> <li>Change in mental status </li> <li>Vomiting </li> <li>Focal neurologic deficits </li> <li>Papilledema </li> <li>Third and sixth cranial nerve deficits </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83408 Version 4.0</div></div></div>"},"83409":{"type":"graphic_picture","displayName":"Miliary lesions","title":"Miliary lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Miliary lesions</div><div class=\"cntnt\"><img style=\"width:332px; height:420px;\" src=\"images/ID/83409_Miliary_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Millet seeds are small grains (average diameter &lt;2 mm) that are consumed without their outer layer being removed. Pearl millet (<em>Pennisetum typhoides</em>, bajra) is shown here. These grains (inset, upper right) correspond to the approximate size of miliary lesions on the high-resolution computer tomography scan of the chest (inset, lower left).</div><div class=\"graphic_reference\">Reproduced from: Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis 2005; 5:415. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83409 Version 2.0</div></div></div>"},"83410":{"type":"graphic_table","displayName":"Chronologic appearance and characteristics of organisms in burns","title":"Chronologic appearance and characteristics of organisms in burns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronologic appearance and characteristics of organisms in burns</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organism, chronology</td> <td class=\"subtitle1\">Characteristics</td> </tr> <tr> <td>Commensal skin organisms (gram positive) result in early colonization of burns</td> <td> <ul> <li>Streptococcus and Staphylococcus species primarily </li> <li>Other sources are upper respiratory tract and environment </li> <li>Topical antimicrobials help decrease colonization </li> </ul> </td> </tr> <tr> <td>Gram-negative species dominant &#62;5 days</td> <td> <ul> <li>2 to 4 days post-burn, gram-negative bacteria colonize wound </li> <li>Patient skin, upper respiratory tract, gastrointestinal tract, and hospital environment are typical sources </li> <li>Pseudomonas aeruginoasa, Acinetobacter baumannii, E. Coli, Klebsiella pneumoniae, Enterobacter cloacae</li> </ul> </td> </tr> <tr> <td>If gram-negative cover is initiated, yeast often appears</td> <td> <ul> <li>Yeast and fungi colonization follows </li> <li>Majority are Candida&nbsp;species, other fungi are increasing in frequency </li> </ul> </td> </tr> <tr> <td>Finally, more resistant bacteria and fungi invade the wound</td> <td> <ul> <li>MRSA, VRE, multi-drug-resistant Pseudomonas and Acinetobacter species, and fungi </li> <li>Usually secondary to broad-spectrum antibiotics, or inadequate host response or therapeutic measures (excision burn, topical and systemic antibiotics) </li> <li>Transition from colonization to invasion </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRSA:&nbsp; methicillin-resistant Staphylococcus aureus, VRE: vancomycin-resistant Enterococcus</div><div id=\"graphicVersion\">Graphic 83410 Version 2.0</div></div></div>"},"83411":{"type":"graphic_table","displayName":"Appearance of infected burns","title":"Appearance of infected burns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Appearance of infected burns</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Organism type</td>\r\n            <td class=\"subtitle1\">Appearance</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Staphylococcal infection</td>\r\n            <td>&nbsp;Previously re-epithelialized areas \"melting away\"</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Pseudomonas aeruginosa</td>\r\n            <td>\r\n            <ul>\r\n                <li>Blue-green&nbsp;(pyocyanin), fluorescent yellow-green (pyvoverdine) color and sweet smell </li>\r\n                <li>Invasive pseudomonas appear purple, punched-out lesions in burns or donor sites </li>\r\n            </ul>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Candida</td>\r\n            <td>&nbsp;Small white pustules on the skin</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Herpes simplex-1</td>\r\n            <td>&nbsp;Punched-out holes in previously healed skin (2 to 3 mm in diameter)</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83411 Version 1.0</div></div></div>"},"83412":{"type":"graphic_figure","displayName":"Causes of liver allograft dysfunction","title":"Causes of liver allograft dysfunction","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Causes of liver allograft dysfunction</div><div class=\"cntnt\"><img style=\"width:484px; height:265px;\" src=\"images/GAST/83412_Cause_liver_allograft_dys.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83412 Version 1.0</div></div></div>"},"83413":{"type":"graphic_table","displayName":"Transjugular liver biopsy indications","title":"Specific indications for transjugular liver biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Specific indications for transjugular liver biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td>Severe coagulopathy or thrombocytopenia</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Large-volume ascites</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Morbid obesity</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Suspected vascular tumor</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Failure of previous percutaneous liver biopsy</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Simultaneous indication for hepatic venous pressure gradient measurement</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Simultaneous indication for transjugular intrahepatic portosystemic shunt placement</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83413 Version 1.0</div></div></div>"},"83414":{"type":"graphic_table","displayName":"Transjugular liver biopsy complications","title":"Complications of transjugular liver biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of transjugular liver biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td>Fever</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Abdominal pain</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Neck hematoma</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Transient Horner's syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Transient dysphonia</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cardiac arrhythmias</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Pneumothorax</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Perforation of the liver capsule</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Fistulas between hepatic vein, hepatic artery, portal vein and/or biliary system</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hemoperitoneum</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hepatic hematoma</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hemobilia</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hepatic vein thrombosis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Inadvertent biopsy of an adjacent organ</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Death</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83414 Version 1.0</div></div></div>"},"83415":{"type":"graphic_diagnosticimage","displayName":"Hepatic venogram","title":"Hepatic venogram obtained during transjugular liver biopsy","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Hepatic venogram obtained during transjugular liver biopsy</div><div class=\"cntnt\"><img style=\"width:457px; height:504px;\" src=\"images/GAST/83415_Hepatic_venogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatic venogram after selective catheterization of the right hepatic vein.</div><div id=\"graphicVersion\">Graphic 83415 Version 2.0</div></div></div>"},"83416":{"type":"graphic_diagnosticimage","displayName":"Hepatic vein cannulation mid vein","title":"Transjugular liver biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transjugular liver biopsy</div><div class=\"cntnt\"><img style=\"width:428px; height:500px;\" src=\"images/GAST/83416_Hepatic_vein_cann_mid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic image of the right upper quadrant of the abdomen showing a catheter with a metallic cannula (arrow) in the mid portion of the right hepatic vein.</div><div id=\"graphicVersion\">Graphic 83416 Version 2.0</div></div></div>"},"83417":{"type":"graphic_diagnosticimage","displayName":"Hepatic vein cannulation rotated","title":"Transjugular liver biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transjugular liver biopsy</div><div class=\"cntnt\"><img style=\"width:423px; height:504px;\" src=\"images/GAST/83417_Hepat_vein_cann_rot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic image of the right upper quadrant of the abdomen showing a catheter with a metallic cannula (arrow) rotated away from the center of the vein pointing toward the liver parenchyma.</div><div id=\"graphicVersion\">Graphic 83417 Version 2.0</div></div></div>"},"83418":{"type":"graphic_diagnosticimage","displayName":"Needle advancement into liver","title":"Transjugular liver biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transjugular liver biopsy</div><div class=\"cntnt\"><img style=\"width:420px; height:503px;\" src=\"images/GAST/83418_Needle_adv_into_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic image of the right upper quadrant of the abdomen showing the biopsy needle (arrow) advanced into the liver parenchyma.</div><div id=\"graphicVersion\">Graphic 83418 Version 2.0</div></div></div>"},"83419":{"type":"graphic_diagnosticimage","displayName":"Surgical specimen of extraosseous osteosarcoma ","title":"Mammogram and x-ray of surgical specimen of an extraosseous osteosarcoma arising in the breast","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Mammogram and x-ray of surgical specimen of an extraosseous osteosarcoma arising in the breast</div><div class=\"cntnt\"><img style=\"width:584px; height:392px;\" src=\"images/RADIOL/83419_Surg_spec_extraos_osteosarc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The mammogram of the left breast reveals a 2 cm mass with dense calcifications (arrow).<BR>(B) X-ray of the surgical specimen showing a densely calcified mass with the needle localizer traversing the mass. The x-ray confirms the heavy calcification, and histopathology confirmed the diagnosis of an extraosseous osteosarcoma.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 83419 Version 1.0</div></div></div>"},"83420":{"type":"graphic_waveform","displayName":"Timing of intraaortic balloon pump inflation and deflation","title":"Timing of intraaortic balloon pump inflation and deflation","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Timing of intraaortic balloon pump inflation and deflation</div><div class=\"cntnt\"><img style=\"width:620px; height:571px;\" src=\"images/CARD/83420_Timinintraaorballoonpump.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The timing of balloon inflation is adjusted until it occurs late in diastole, uncovering the dicrotic notch. Subsequently, inflation timing is moved earlier in the cardiac cycle until the dicrotic notch on the central aortic tracing just disappears (beat #4). The augmented pressure will rise as inflation timing is moved earlier.<br />(B) Deflation knob is moved toward the right (later in the cardiac cycle) until the end diastolic dip is 10 to 15 mmHg below the patient's unassisted diastolic pressure. This will produce a maximal lowering of the patient's unassisted systolic pressure.<br />(C) The balloon console is triggering on an atrial pacing artifact. This is corrected by changing the console to a mode that will discriminate between a pacing spike and an R wave.</div><div class=\"graphic_reference\">Reproduced with permission from: Aroesty J. Percutaneous intraaortic balloon insertion. In: Cardiac Catheterization and Angiography, 3rd ed, Grossman W (Ed), Lea &amp; Febiger, Philadelphia 1986. Copyright Â© 1986 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83420 Version 7.0</div></div></div>"},"83421":{"type":"graphic_figure","displayName":"Intraaortic balloon pressure tracings","title":"Intraaortic balloon pressure tracings","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Intraaortic balloon pressure tracings</div><div class=\"cntnt\"><img style=\"width:610px; height:556px;\" src=\"images/CARD/83421_Intraaorballoonpresstrac.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One minute following temporary discontinuation of counterpulsation in a patient with three-vessel coronary artery disease, left main coronary artery stenosis, and severe unstable angina, there is a prompt increase in left ventricular systolic and end-diastolic pressure with rapid return of ischemic pain (A). Left ventricular (LV) and pulmonary capillary wedge (PCW) tracings without (B) and with (C) intraaortic balloon counterpulsation in a 45-year-old woman in cardiogenic shock from ruptured chordae of the mitral valve.</div><div class=\"graphic_reference\">Reproduced with permission from: Aroesty J. Percutaneous intraaortic balloon insertion. In: Cardiac Catheterization and Angiography, 3rd ed, Grossman W (Ed), Lea &amp; Febiger, Philadelphia 1986. Copyright Â© 1986 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83421 Version 6.0</div></div></div>"},"83422":{"type":"graphic_table","displayName":"Pregnancy outcomes in women with mitral stenosis","title":"Summary of pregnancy outcomes in women with mitral stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of pregnancy outcomes in women with mitral stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Severity of MS</td> <td class=\"subtitle1\">Number of pregnancies</td> <td class=\"subtitle1\">Congestive heart failure or pulmonary edema</td> <td class=\"subtitle1\">Arrhythmia</td> <td class=\"subtitle1\">Preterm delivery</td> <td class=\"subtitle1\">Small for gestational age or intrauterine growth restriction</td> <td class=\"subtitle1\">Still birth or fetoneonatal death</td> </tr> <tr> <td>Mild</td> <td class=\"centered\">61</td> <td class=\"centered\">20 percent</td> <td class=\"centered\">8 percent</td> <td class=\"centered\">11 percent</td> <td class=\"centered\">8 percent</td> <td class=\"centered\">2 percent</td> </tr> <tr> <td>Moderate</td> <td class=\"centered\">47</td> <td class=\"centered\">45 percent</td> <td class=\"centered\">15 percent</td> <td class=\"centered\">27 percent</td> <td class=\"centered\">19 percent</td> <td class=\"centered\">2 percent</td> </tr> <tr> <td>Severe</td> <td class=\"centered\">18</td> <td class=\"centered\">67 percent</td> <td class=\"centered\">33 percent</td> <td class=\"centered\">39 percent</td> <td class=\"centered\">17 percent</td> <td class=\"centered\">11 percent</td> </tr> <tr class=\"divider_top\"> <td><strong>Overall</strong></td> <td class=\"centered\"> <p><strong>126</strong></p> </td> <td class=\"centered\"><strong>36 percent</strong></td> <td class=\"centered\"><strong>14 percent</strong></td> <td class=\"centered\"><strong>21 percent</strong></td> <td class=\"centered\"><strong>13 percent</strong></td> <td class=\"centered\"><strong>3 percent</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol><li>Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 2001; 37:89</li>&#xD;&#xA;<li>Silversides CK, Colman JM, Sermer M, Siu SC. Cardiac risk in pregnant women with rheumatic mitral stenosis. Am J Cardiol 2003; 91:1382.</li></ol></div><div id=\"graphicVersion\">Graphic 83422 Version 4.0</div></div></div>"},"83423":{"type":"graphic_figure","displayName":"IgE structure","title":"Structure of immunoglobulin E (IgE)","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Structure of immunoglobulin E (IgE)</div><div class=\"cntnt\"><img style=\"width:494px; height:482px;\" src=\"images/ALLRG/83423_IgE_structure.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; Îµ: epsilon.</div><div class=\"graphic_reference\">Adapted from:<br /><ol>&#xD;&#xA;    <li>Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125:S41.</li>&#xD;&#xA;    <li>Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 83423 Version 3.0</div></div></div>"},"83424":{"type":"graphic_figure","displayName":"IgE levels with age","title":"Normal total IgE levels with age (in the United States population)","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Normal total IgE levels with age (in the United States population)</div><div class=\"cntnt\"><img style=\"width:570px; height:529px;\" src=\"images/ALLRG/83424_IgE_levels_with_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Based on 2005 to 2006 data from the National Health and Nutrition Examination Survey (NHANES).</div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div class=\"graphic_reference\">Data from: Gergen PT, Arbes SJ Jr, Calatroni A, et al. Total IgE levels and asthma prevalence in the US population: Results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2009; 124:447.</div><div id=\"graphicVersion\">Graphic 83424 Version 2.0</div></div></div>"},"83425":{"type":"graphic_table","displayName":"Equipment for pleural manometry","title":"Equipment needed for pleural manometry and large volume thoracentesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Equipment needed for pleural manometry and large volume thoracentesis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td>Mask, protective eyewear</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Sterile gowns, gloves, drapes</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Chlorhexidine 2 percent, or povidone-iodine</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Local anesthetic (eg, lidocaine 1 or 2 percent)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Needles (usually 25G 1.5 inch and 21G) and syringe (3 or 5 mL) for anesthetizing the skin and subcutaneous tissues</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Gauze pads</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Thoracentesis catheter (10 to 12 French)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Stopcock (two stopcocks if an electronic system is used in addition to a water manometer)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Syringe for fluid removal (30 to 50 mL) with luer lock tip</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Two intravenous tubing extension sets and a 22G needle to use as resistor between them</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Normal saline (0.9 percent) to prefill intravenous tubing</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ruler or measuring tape</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Drainage bag</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Bandage (eg, petroleum gauze, 4x4 gauze pads, elastic tape)</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83425 Version 1.0</div></div></div>"},"83429":{"type":"graphic_picture","displayName":"Giardia cyst - trichrome stain","title":"<EM>Giardia intestinalis</EM> cyst stained with trichrome","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\"><EM>Giardia intestinalis</EM> cyst stained with trichrome</div><div class=\"cntnt\"><img style=\"width:511px; height:258px;\" src=\"images/ID/83429_Giardia_cyst_tri_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Giardia</EM> cysts measure 8 to 19 mcm (average 10 to 14 mcm). </div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Giardiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/giardiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/giardiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 83429 Version 7.0</div></div></div>"},"83430":{"type":"graphic_picture","displayName":"Giardia cyst - iodine","title":"<EM>Giardia</EM> intestinalis cyst in wet mount stained with iodine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Giardia</EM> intestinalis cyst in wet mount stained with iodine</div><div class=\"cntnt\"><img style=\"width:300px; height:300px;\" src=\"images/ID/83430_Giardia_cyst_iodine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Giardia</EM> cysts measure 8 to 19 mcm (average 10 to 14 mcm).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Giardiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/giardiasis/index.html\">http://www.cdc.gov/dpdx/giardiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 83430 Version 5.0</div></div></div>"},"83433":{"type":"graphic_diagnosticimage","displayName":"Shoulder OA radiograph","title":"Glenohumeral joint osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glenohumeral joint osteoarthritis</div><div class=\"cntnt\"><img style=\"width:313px; height:350px;\" src=\"images/RHEUM/83433_Should_OA_radio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film radiography demonstrates joint space narrowing and osteophyte formation (arrow) consistent with osteoarthritis.</div><div class=\"graphic_reference\">Courtesy of Shahla Modaressi, MD, and Cecilia Jude, MD.</div><div id=\"graphicVersion\">Graphic 83433 Version 1.0</div></div></div>"},"83442":{"type":"graphic_table","displayName":"Diagnostic criteria for Carney complex","title":"Diagnostic criteria for Carney complex","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for Carney complex</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major diagnostic criteria</td> </tr> <tr> <td>Spotty skin pigmentation with typical distribution (lips, conjunctiva and inner or outer canthi, vaginal and penile mucosa)</td> </tr> <tr> <td>Myxoma* (cutaneous and mucosal)</td> </tr> <tr> <td>Cardiac myxoma*</td> </tr> <tr> <td>Breast myxomatosis* or fat-suppressed MRI findings suggestive of this diagnosis</td> </tr> <tr> <td>PPNAD* or paradoxical positive response of urinary glucocorticoid excretion to dexamethasone administration during Liddle's test</td> </tr> <tr> <td>Acromegaly due to GH-producing adenoma*</td> </tr> <tr> <td>LCCSCT* or characteristic calcification on testicular ultrasound</td> </tr> <tr> <td>Thyroid carcinoma* or multiple, hypoechoic nodules on thyroid ultrasound in a young patient</td> </tr> <tr> <td>Psammomatous melanotic schwannomas*</td> </tr> <tr> <td>Blue nevus, epithelioid blue nevus*</td> </tr> <tr> <td>Breast ductal adenoma*</td> </tr> <tr> <td>Osteochondromyxoma*</td> </tr> <tr> <td class=\"subtitle1_single\">Supplemental criteria</td> </tr> <tr> <td>Affected first-degree relative</td> </tr> <tr> <td>Inactivating mutation of the <em>PRKAR1A</em> gene</td> </tr> <tr> <td class=\"subtitle1_single\">Findings suggestive of or possibly associated with CNC, but not diagnostic for the disease</td> </tr> <tr> <td>Intense freckling (without darkly pigmented spots or typical distribution)</td> </tr> <tr> <td>Blue nevus, common type (if multiple)</td> </tr> <tr> <td>Caf&#233;-au-lait spots or other \"birthmarks\"</td> </tr> <tr> <td>Elevated IGF-1 levels, abnormal GTT, or paradoxical GH response to TRH testing in the absence of clinical acromegaly</td> </tr> <tr> <td>Cardiomyopathy</td> </tr> <tr> <td>Pilonidal sinus</td> </tr> <tr> <td>History of Cushing's syndrome, acromegaly, or sudden death in extended family</td> </tr> <tr> <td>Multiple skin tags or other skin lesions, lipomas</td> </tr> <tr> <td>Colonic polyps (usually in association with acromegaly)</td> </tr> <tr> <td>Hyperprolactinemia (usually mild and almost always combined with clinical or subclinical acromegaly)</td> </tr> <tr> <td>Single, benign thyroid nodule in a young patient; multiple thyroid nodules in an older patient (detected on ultrasound)</td> </tr> <tr> <td>Family history of carcinoma, in particular of the thyroid, colon, pancreas, and ovary; other multiple benign or malignant tumors</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; PPNAD: primary pigmented nodular adrenocortical disease; GH: growth hormone; LCCSCT: large cell calcifying Sertoli cell tumor; PRKAR1A: protein kinase A regulatory subunit 1-alpha; CNC: Carney complex; IGF-1: insulin-like growth factor 1; GTT: glucose tolerance test; TRH: thyrotropin-releasing hormone.<br />* After histologic confirmation.</div><div class=\"graphic_reference\">Reproduced from: Almeida MQ, Stratakis CA. Carney complex and other conditions associated with micronodular adrenal hyperplasias. Best Pract Res Clin Endocrinol Metab 2010; 24:907. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83442 Version 3.0</div></div></div>"},"83453":{"type":"graphic_table","displayName":"Sinusitis clinical severity score","title":"Clinical severity score for acute bacterial rhinosinusitis in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical severity score for acute bacterial rhinosinusitis in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom or sign</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Abnormal nasal or postnasal discharge</td> </tr> <tr> <td class=\"sublist1\">Minimal</td> <td class=\"sublist_other_centered\">1</td> </tr> <tr> <td class=\"sublist1\">Severe</td> <td class=\"sublist_other_centered\">2</td> </tr> <tr> <td>Nasal congestion</td> <td class=\"centered\">1</td> </tr> <tr> <td>Cough</td> <td class=\"centered\">2</td> </tr> <tr> <td>Malodorous breath</td> <td class=\"centered\">1</td> </tr> <tr> <td>Facial tenderness</td> <td class=\"centered\">3</td> </tr> <tr> <td>Erythematous nasal mucosa</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Fever*</td> </tr> <tr> <td class=\"sublist1\">&#60;38.5&#176;C</td> <td class=\"sublist_other_centered\">1</td> </tr> <tr> <td class=\"sublist1\">&#8805;38.5&#176;C</td> <td class=\"sublist_other_centered\">2</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Headache (retro-orbital)/irritability</td> </tr> <tr> <td class=\"sublist1\">Severe</td> <td class=\"sublist_other_centered\">3</td> </tr> <tr> <td class=\"sublist1\">Mild</td> <td class=\"sublist_other_centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A total score &lt;8 indicates mild/moderate disease. A total score â¥8 indicates severe disease.<BR>* Within 24 hours of presentation, either observed or according to history and documented with thermometer.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 124, Pages 9-15, Copyright Â© 2009 by the AAP.</div><div id=\"graphicVersion\">Graphic 83453 Version 10.0</div></div></div>"},"83454":{"type":"graphic_table","displayName":"Antimicrobial regimens sinusitis children","title":"Antimicrobial regimens for acute bacterial rhinosinusitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial regimens for acute bacterial rhinosinusitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Initial therapy</td> <td class=\"subtitle1\">Second line therapy(s)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Outpatient therapy</td> </tr> <tr> <td class=\"indent1\">Mild/moderate disease<sup>&#182;</sup></td> <td> <p><strong>Preferred:</strong> Amoxicillin-clavulanate 45 mg/kg<sup>&#916;</sup> per day orally divided in 2 doses (maximum 1.75 g/day)</p> <strong>Alternative</strong><sup>&#9674;</sup><strong>:</strong> Amoxicillin 90 mg/kg per day orally divided in 2 doses (maximum 4 g/day)</td> <td>Amoxicillin-clavulanate 90 mg/kg<sup>&#167;</sup> per day orally divided in 2 doses (maximum 4 g/day)</td> </tr> <tr> <td class=\"indent1\">Severe disease or risk for antibiotic resistance<sup>&#182;</sup></td> <td> <p><strong>Preferred:</strong> Amoxicillin-clavulanate 90 mg/kg<sup>&#167;</sup> per day orally divided in 2 doses (maximum 4 g/day)</p> <p><strong>Alternatives</strong><sup>&#9674;</sup><strong>:</strong> Cefpodoxime 10 mg/kg per day orally divided in 2 doses (maximum 400 mg/day), or</p> <p>Cefdinir 14 mg/kg per day orally divided in 1 or 2 doses (maximum 600 mg/day), or</p> Levofloxacin<sup>&#165;</sup> 10 to 20 mg/kg per day orally divided in 1 or 2 doses (maximum 500 mg/day)</td> <td> <p>Ceftriaxone 50 mg/kg once per day IV or IM&nbsp;(maximum 2 g/day) for 1 to 3 days followed by appropriate oral regimen, or</p> <p>Cefpodoxime 10 mg/kg per day orally divided in 2 doses (maximum 400 mg/day), or</p> <p>Cefdinir 14 mg/kg per day orally divided in 1 or 2 doses (maximum 600 mg/day), or</p> Levofloxacin<sup>&#165;</sup> 10 to 20 mg/kg per day orally divided in 1 or 2 doses (maximum 500 mg/day)</td> </tr> <tr> <td class=\"indent1\">Penicillin allergy (anaphylaxis)</td> <td>Levofloxacin<sup>&#165;</sup> 10 to 20 mg/kg per day orally divided in 1 or 2 doses (maximum 500 mg/day)</td> <td>Inpatient therapy (see below)</td> </tr> <tr> <td class=\"indent1\">Penicillin allergy (nonanaphylaxis)</td> <td> <p>Cefpodoxime 10 mg/kg per day orally divided in 2 doses (maximum 400 mg/day), or</p> Cefdinir 14 mg/kg per day orally divided in 1 or 2 doses (maximum 600 mg/day)</td> <td>Levofloxacin<sup>&#165;</sup> 10 to 20 mg/kg per day orally divided in 1 or 2 doses (maximum 500 mg/day)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vomiting</td> <td>Ceftriaxone 50 mg/kg per day IV or IM once (maximum&nbsp;1 g/day), followed 24 hours later by appropriate oral therapy</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Inpatient therapy</td> </tr> <tr> <td class=\"indent1\">ABRS requiring hospitalization<sup>&#182;</sup></td> <td> <p>Ampicillin-sulbactam 200 to 400 mg/kg per day IV divided every 6 hours (maximum 8 g ampicillin component/day), or</p> <p>Ceftriaxone 100 mg/kg per day IV divided every 12 hours (maximum 2 g/day), or</p> <p>Cefotaxime 100 to 200 mg/kg per day IV divided every 6 hours (maximum 8 g/day), or</p> Levofloxacin<sup>&#165;</sup> 10 to 20 mg/kg per day IV divided every 12 or 24 hours (maximum 500 mg/day)</td> <td> <p>Addition of vancomycin (60 mg/kg per day IV) divided every 6 hours (maximum 4 g/day)<sup>&#134;</sup> and possibly,</p> Metronidazole** (30 mg/kg per day IV) divided every 6 hours (maximum 4 g/day)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp pediatric drug monograph for renal dose adjustments.</div><div class=\"graphic_footnotes\">IV: intravenously; IM: intramuscularly; ABRS: acute bacterial rhinosinusitis.<br />* Second-line therapies are indicated for children who worsen within three days or fail to improve after three days of initial therapy and in whom no pathogen is identified. If a pathogen is identified, antimicrobial therapy should be adjusted according to susceptibilities.<br />Â¶ Refer to UpToDate topic on treatment of acute bacterial rhinosinusitis in children for definitions.<br />Î Based on amoxicillin component; in the United States, use 200 or 400 mg/5 mL suspension or 200 or 400 mg chewable tablet for appropriate clavulanate ratio.<br /><FONT class=lozenge>â</FONT> Alternative regimens may not cover resistant pathogens as well as the suggested initial regimen.<br />Â§ Based on amoxicillin component; in the United States, use 600 mg/5 mL suspension or 1000 mg/62.5 mg extended-release tablet for appropriate clavulanate ratio.<br />Â¥ Levofloxacin should be reserved for cases in which there is no other safe and effective alternative.<br />â  Individualize vancomycin dose and interval based on serum concentration monitoring, when indicated.<br />** Metronidazole may be warranted for anaerobic coverage.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72.</LI>&#xD;&#xA;<LI>Jackson MA, Schutze GE, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics 2016; 138.</LI></OL></div><div id=\"graphicVersion\">Graphic 83454 Version 13.0</div></div></div>"},"83455":{"type":"graphic_picture","displayName":"Photoaging histology","title":"Comparison of photodamaged and normal skin on histologic examination","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Comparison of photodamaged and normal skin on histologic examination</div><div class=\"cntnt\"><img style=\"width:513px; height:436px;\" src=\"images/DERM/83455_Photoaging_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sun-protected skin.<BR>(B) Photoaged skin. <BR>Photoaged skin shows atypical keratinocytes, flattening of dermal papillae, and deposition of amorphous basophilic material in the dermis&nbsp;(solar elastosis).</div><div id=\"graphicVersion\">Graphic 83455 Version 2.0</div></div></div>"},"83457":{"type":"graphic_table","displayName":"Conditions associated with elevated serum IgE","title":"Conditions associated with elevated serum IgE","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with elevated serum IgE</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"65%\"></colgroup> <tbody> <tr> <td rowspan=\"8\"><strong>Infectious diseases</strong></td> <td rowspan=\"3\">Parasitic</td> <td>Ascariasis</td> </tr> <tr> <td>Schistosomiasis</td> </tr> <tr> <td>Strongyloidiasis</td> </tr> <tr> <td colspan=\"2\">Human immunodeficiency virus (HIV) infection</td> </tr> <tr> <td colspan=\"2\"><em>Mycobacterium tuberculosis</em></td> </tr> <tr> <td colspan=\"2\">Cytomegalovirus</td> </tr> <tr> <td colspan=\"2\">Epstein-Barr virus (EBV)</td> </tr> <tr> <td colspan=\"2\">Candidiasis</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Atopic diseases</strong></td> <td colspan=\"2\">Allergic bronchopulmonary aspergillosis (ABPA)</td> </tr> <tr> <td colspan=\"2\">Allergic fungal rhinosinusitis</td> </tr> <tr> <td colspan=\"2\">Atopic dermatitis</td> </tr> <tr> <td colspan=\"2\">Allergic asthma</td> </tr> <tr> <td colspan=\"2\">Allergic rhinitis</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>Immunodeficiencies</strong></td> <td colspan=\"2\">Hyperimmunoglobulin E syndrome</td> </tr> <tr> <td colspan=\"2\">Wiskott-Aldrich syndrome</td> </tr> <tr> <td colspan=\"2\">Netherton disease</td> </tr> <tr> <td colspan=\"2\">Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX)</td> </tr> <tr> <td colspan=\"2\">Omenn syndrome</td> </tr> <tr> <td colspan=\"2\">Atypical complete DiGeorge syndrome</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Inflammatory diseases</strong></td> <td colspan=\"2\">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> </tr> <tr> <td colspan=\"2\">Kimura disease</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Neoplasms</strong></td> <td colspan=\"2\">Hodgkin lymphoma</td> </tr> <tr> <td colspan=\"2\">IgE myeloma</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Others</strong></td> <td colspan=\"2\">Tobacco smokers</td> </tr> <tr> <td colspan=\"2\">Cystic fibrosis</td> </tr> <tr> <td colspan=\"2\">Nephrotic syndrome</td> </tr> <tr> <td colspan=\"2\">Bone marrow transplantation</td> </tr> <tr> <td colspan=\"2\">Bullous pemphigoid</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 83457 Version 11.0</div></div></div>"},"83459":{"type":"graphic_diagnosticimage","displayName":"CT acute appendicitis","title":"CT acute appendicitis","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">CT acute appendicitis</div><div class=\"cntnt\"><img style=\"width:549px; height:250px;\" src=\"images/RADIOL/83459_CT_acute_appendicitis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute appendicitis. Images of the pelvis (A and B) from a CT with intravenous and oral contrast shows an thickened appendix (arrow) containing an appendicolith and surrounding fluid indicating inflammation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 83459 Version 3.0</div></div></div>"},"83460":{"type":"graphic_diagnosticimage","displayName":"CT normal appendix","title":"CT normal appendix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT normal appendix</div><div class=\"cntnt\"><img style=\"width:311px; height:312px;\" src=\"images/RADIOL/83460_CT_normal_appendix_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal appendix. Images of the pelvis from a CT with intravenous and oral contrast shows an appendix (arrow) that is air-filled with double-layer wall thickness of &lt;6 mm.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 83460 Version 3.0</div></div></div>"},"83461":{"type":"graphic_diagnosticimage","displayName":"Appendicolith on abdominal films","title":"Appendicolith on abdominal films","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Appendicolith on abdominal films</div><div class=\"cntnt\"><img style=\"width:464px; height:576px;\" src=\"images/RADIOL/83461_Appendicolith_abdomin_films.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain film of the abdomen reveals a 1.2 cm calcific density, an appendicolith. The patient presented with right lower quadrant pain and was diagnosed with acute appendicitis.</div><div id=\"graphicVersion\">Graphic 83461 Version 1.0</div></div></div>"},"83462":{"type":"graphic_table","displayName":"Mgmt of clopidogrel hypersensitivity without drug interruption","title":"Management of clopidogrel hypersensitivity without drug interruption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of clopidogrel hypersensitivity without drug interruption</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Initial therapy</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Glucocorticoid taper</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Example: Methylprednisolone taper* </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Long-acting nonsedating antihistamine</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Example: Fexofenadine 180 mg orally each day</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Short-acting antihistamine</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Example: Diphenhydramine 25 to 50 mg orally before bed</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Secondary therapy (for symptom relapse)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Longer course of glucocorticoids</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Example: Prednisone 60 mg initially per day, taper by 10 mg every three days</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Leukotriene inhibitor</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Example: Montelukast 10 mg orally each day</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Referral to allergist</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_lgnd\">Protocol used at Thomas Jefferson University Hospital.</div><div class=\"graphic_footnotes\">* Dosing of glucocorticoids was left to the discretion of the supervising cardiologist.&nbsp;A commonly used regimen was a&nbsp;six-day tapering course&nbsp;beginning with 24 mg daily (divided into three doses) with total daily dose decreasing by 4 mg&nbsp;per day (Medrol Dosepak).</div><div class=\"graphic_reference\">Reproduced from: Campbell KL, Cohn JR, Fischman DL, et al. Management of clopidogrel hypersensitivity without drug interruption. Am J Cardiol 2011; 107:812. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83462 Version 4.0</div></div></div>"},"83466":{"type":"graphic_picture","displayName":"Atypical nevus - fried egg","title":"Atypical nevus with a \"fried egg\" appearance","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atypical nevus with a \"fried egg\" appearance</div><div class=\"cntnt\"><img style=\"width:504px; height:337px;\" src=\"images/DERM/83466_Atypical_nevus_fried_egg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This atypical nevus is characterized by a peripheral macular component and a papular center, resulting in a \"fried egg\" appearance.</div><div id=\"graphicVersion\">Graphic 83466 Version 3.0</div></div></div>"},"83469":{"type":"graphic_diagnosticimage","displayName":"X-ray fracture of lumbar transverse process","title":"X-ray fracture of lumbar transverse process","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">X-ray fracture of lumbar transverse process</div><div class=\"cntnt\"><img style=\"width:379px; height:576px;\" src=\"images/RADIOL/83469_Xray_frac_lumbar_trans_proc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain film tomogram of the left sided transverse processes of the lumbar spine in the AP projection reveals transverse fractures of the L3 and L4 vertebra (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, 3rd Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83469 Version 1.0</div></div></div>"},"83470":{"type":"graphic_diagnosticimage","displayName":"CT transverse process fracture","title":"CT transverse process fracture","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">CT transverse process fracture</div><div class=\"cntnt\"><img style=\"width:507px; height:507px;\" src=\"images/RADIOL/83470_CT_transverse_process_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan of lumbar spine in the transverse projection reveals an acute incomplete fracture of the left transverse process (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 83470 Version 2.0</div></div></div>"},"83471":{"type":"graphic_figure","displayName":"Lymphatic drainage of the esophagus","title":"Lymphatic drainage of the esophagus","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Lymphatic drainage of the esophagus</div><div class=\"cntnt\"><img style=\"width:456px; height:687px;\" src=\"images/SURG/83471_Lymphatic-drainage-of-the-esophagus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83471 Version 1.0</div></div></div>"},"83472":{"type":"graphic_figure","displayName":"Venous drainage of the esophagus","title":"Venous drainage of the esophagus","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Venous drainage of the esophagus</div><div class=\"cntnt\"><img style=\"width:490px; height:694px;\" src=\"images/SURG/83472_Venous-drainage-of-the-esophagus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83472 Version 1.0</div></div></div>"},"83473":{"type":"graphic_figure","displayName":"Blood supply of the esophagus","title":"Blood supply of the esophagus","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Blood supply of the esophagus</div><div class=\"cntnt\"><img style=\"width:469px; height:683px;\" src=\"images/SURG/83473_Blood-supply-of-the-esophagus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83473 Version 1.0</div></div></div>"},"83474":{"type":"graphic_diagnosticimage","displayName":"Bilateral laminar fractures of cervical spine","title":"Bilateral laminar fractures of cervical spine","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Bilateral laminar fractures of cervical spine</div><div class=\"cntnt\"><img style=\"width:597px; height:579px;\" src=\"images/RADIOL/83474_Xray_bilateral_laminar_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral radiograph (A) demonstrates posterior impaction with multiple comminuted laminar and spinous processes fractures from C2 to C6 (white arrows). The acute vacuum disc (black arrow) with abnormal widening of the anterior C6-7 disc space is a sign of anterior and middle column distraction. The corresponding CT images (B and C) demonstrate displacement of the spinous processes and bilateral comminuted laminar fractures (white arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Schwartz ED, Flander AE. Spinal Trauma: Imaging, Diagnosis, and Management, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83474 Version 2.0</div></div></div>"},"83475":{"type":"graphic_diagnosticimage","displayName":"Radiograph fracture of the coronoid process","title":"Radiograph fracture of the coronoid process","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph fracture of the coronoid process</div><div class=\"cntnt\"><img style=\"width:439px; height:576px;\" src=\"images/RADIOL/83475_Xray_frac_coronoid_process.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient incurred a fracture of the coronoid process following a hyperextension injury. The radiograph of elbow in the lateral projection reveals the fracture line through the tip of the coronoid process.</div><div class=\"graphic_reference\">Courtesy of Dr. Sandra O'Connor. Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, 3rd Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83475 Version 3.0</div></div></div>"},"83477":{"type":"graphic_figure","displayName":"Urinary system anatomy","title":"Urinary system anatomy","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Urinary system anatomy</div><div class=\"cntnt\"><img style=\"width:494px; height:694px;\" src=\"images/EM/83477_Genitourinary_syst_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2012 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 83477 Version 2.0</div></div></div>"},"83478":{"type":"graphic_figure","displayName":"Urinary system location anterior view","title":"Urinary system location: Anterior perspective","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Urinary system location: Anterior perspective</div><div class=\"cntnt\"><img style=\"width:586px; height:421px;\" src=\"images/EM/83478_Genitoursystlocaantview.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture above depicts the urinary system in situ and its relationship to the skeleton from an anterior perspective.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83478 Version 4.0</div></div></div>"},"83479":{"type":"graphic_figure","displayName":"Urinary system location anterolateral view","title":"Urinary system location: Anterolateral perspective","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Urinary system location: Anterolateral perspective</div><div class=\"cntnt\"><img style=\"width:586px; height:532px;\" src=\"images/EM/83479_GenitoursystlocationALV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts the urinary system in situ from an&nbsp;anterolateral perspective.&nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83479 Version 4.0</div></div></div>"},"83480":{"type":"graphic_figure","displayName":"Foot and toe bones PI","title":"Foot and toe bones","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Foot and toe bones</div><div class=\"cntnt\"><img style=\"width:492px; height:445px;\" src=\"images/PI/83480_Foot-and-toe-bones-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the foot and toe bones. The foot bones include the tarsals and metatarsals.</div><div id=\"graphicVersion\">Graphic 83480 Version 1.0</div></div></div>"},"83481":{"type":"graphic_picture","displayName":"Thigh sleeve PI","title":"Thigh sleeve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thigh sleeve</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/83481_Thigh_sleeve_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wearing a thigh sleeve (the blue fabric band around the thigh) can help ease symptoms of a muscle strain.</div><div id=\"graphicVersion\">Graphic 83481 Version 1.0</div></div></div>"},"83482":{"type":"graphic_figure","displayName":"Pavlik harness PI","title":"Pavlik harness","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pavlik harness</div><div class=\"cntnt\"><img style=\"width:424px; height:542px;\" src=\"images/PI/83482_Pavlik_harness_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a device called a \"Pavlik harness\" that doctors can use to treat developmental dysplasia of the hip in babies.</div><div id=\"graphicVersion\">Graphic 83482 Version 2.0</div></div></div>"},"83483":{"type":"graphic_picture","displayName":"Skin biopsy mycosis fungoides","title":"Mycosis fungoides: Architectural patterns of epidermotropism","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides: Architectural patterns of epidermotropism</div><div class=\"cntnt\"><img style=\"width:516px; height:339px;\" src=\"images/HEME/83483_SkinbiopsyMF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Papillary dermal interstitial infiltrate associated with linear aggregation of neoplastic lymphocytes along the dermal-epidermal junction.<BR>(B) Adjacent section stained for CD4 emphasizing this linear pattern of early epidermotropism.<BR>(C) Early plaque-stage disease with single cell epidermotropism by atypical lymphocytes into a \"passive\" epidermal layer.<BR>(D) Plaque-stage disease characterized by prominent clusters of atypical lymphocytes within the epidermis (Pautrier microabscesses).</div><div class=\"graphic_reference\">Reproduced with permission from: Hsu MY, Murphy GF. Cutaneous lymphomas and leukemias. In: Lever's Histopathology of the Skin, 10th ed, Elder DE, Elenitsas RE, Johnson BL Jr, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright Â© 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83483 Version 9.0</div></div></div>"},"83484":{"type":"graphic_picture","displayName":"Haloed lymphocytes of MF","title":"Haloed lymphocytes of mycosis fungoides","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Haloed lymphocytes of mycosis fungoides</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/83484_HaloedlymphoMF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy from a patient with&nbsp;mycosis fungoides shows many single haloed lymphocytes. Hematoxylin and eosin, 40x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83484 Version 7.0</div></div></div>"},"83485":{"type":"graphic_table","displayName":"Rapid overview for hypoglycemia in children","title":"Rapid overview for hypoglycemia in adolescents and children, other than neonates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview for hypoglycemia in adolescents and children, other than neonates</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td><strong>Any</strong> patient with acute lethargy or coma should have an immediate measurement of blood glucose to determine if hypoglycemia is a possible cause</td> </tr> <tr> <td>Other findings of hypoglycemia are nonspecific* and vary by age:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li><strong>Infants</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Irritability </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Lethargy </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Jitteriness </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Feeding problems </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Hypothermia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Hypotonia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Tachypnea </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Cyanosis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Apnea </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Seizures </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><strong>Older children and adolescents</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Autonomic response (tends to occur with blood glucose &#60;50 to 65 mg/dL) </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Sweating </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Tachycardia </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Palpitations </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Tremor </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Nervousness </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Hunger </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Paresthesias </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Pallor </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Neuroglycopenia </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Irritability </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Confusion </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Uncharacteristic behavior </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Weakness </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Seizures </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Coma </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"> <ul style=\"list-style-type: circle;\"> <li>Occasionally, transient focal neurologic deficits </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Diagnosis</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obtain rapid bedside blood glucose concentration (and &#946;-hydroxybutyrate, if available as a point-of-care measurement) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Confirm the presence of hypoglycemia with a simultaneously drawn plasma glucose </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Treat, as outlined below, if the bedside value is low (&#60;70 mg/dL [3.89 mmol/L]) in symptomatic patients </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Obtain a blood sample for additional diagnostic studies prior to glucose administration, if possible, and collect the first voided urine after the hypoglycemic event in all infants and young children who are not being treated for diabetes mellitus or do not have a known cause for hypoglycemia<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"indent1\"> <ul> <li><strong>Do not delay</strong> treatment if symptomatic hypoglycemia is suspected. However, every reasonable effort should be made to obtain a rapid blood glucose measurement <strong>prior</strong> to administering glucose. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><strong>Give glucose based upon the patients level of consciousness and ability to swallow safely (ie, alert enough to do so and with intact gag reflex) as follows:</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent3\"><strong>Conscious and able to drink and swallow safely:</strong></td> </tr> <tr> <td class=\"indent4\">Administer 0.3 g/kg (10 to 20 g) of a rapidly-absorbed carbohydrate. 15 g is supplied by 3 glucose tablets, a tube of gel with 15 g, 4 oz (120 mL) sweetened fruit juice, 6 oz non-diet soda, or a tablespoon (15 mL) of honey or table sugar. May repeat in 10 to 15 minutes.</td> </tr> <tr> <td class=\"indent3\"><strong>Altered mental status, unable to swallow, or does not respond to oral glucose administration within 15 minutes:</strong></td> </tr> <tr> <td class=\"indent4\">Give an initial IV bolus of glucose of 0.25 g/kg of dextrose (maximum single dose 25 g).<sup>&#916;</sup> The volume and concentration of glucose bolus is infused slowly at 2 to 3 mL per minute and based upon age:</td> </tr> <tr> <td class=\"indent5\">2.5 mL/kg of 10% dextrose solution (D10W) in infants and children up to 12 years of age (10% dextrose is 100 mg/mL)</td> </tr> <tr> <td class=\"indent5\">1 mL/kg of 25% dextrose (D25W) or 0.5 mL/kg of 50% dextrose (D50W) in adolescents (25% dextrose is 250 mg/mL; 50% dextrose is 500 mg/mL)</td> </tr> <tr> <td class=\"indent3\"><strong>Unable to receive oral glucose and unable to obtain IV access:</strong></td> </tr> <tr> <td class=\"indent4\">Give glucagon 0.03 mg/kg IM or SQ (maximum dose 1 mg):<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent5\">Perform blood glucose monitoring every 10 to 15 minutes as the effects of glucagon may be transient</td> </tr> <tr> <td class=\"indent5\">Establish vascular access as soon as possible</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>After initial hypoglycemia is reversed, provide additional glucose and treatment based upon suspected etiology: </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Give children and adolescents with type I diabetes mellitus a normal diet </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Give patients with an unknown cause of hypoglycemia intravenous infusion of dextrose 10% (6 to 9 mg/kg per minute) titrated to maintain blood glucose in a safe and appropriate range (70 to 150 mg/dL [3.89 to 8.33 mmol/L]) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Give patients, who have ingested a sulfonylurea and have recurrent hypoglycemia, octreotide (dose: 1 to 1.5 mcg/kg IM or SQ, maximum dose 150 mcg every 6 hours) in addition to glucose. (Refer to UpToDate topic on sulfonylurea poisoning.) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Measure a rapid blood and plasma glucose 15 to 30 minutes after the initial IV glucose bolus and then monitor every 30 to 60 minutes until stable (minimum of four hours) to ensure that plasma glucose concentration is maintained in the normal range (&#62;70 to 100 mg/dL [&#62;3.89 to 5.55 mmol/L]) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obtain pediatric endocrinology consultation for patients with hypoglycemia of unknown cause </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obtain medical toxicology consultation for patients with ingestion of oral hypoglycemic agents by calling the United States Poison Control Network at <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-222-1222<a href=\"#\" title=\"Call: 1-800-222-1222\"><img alt=\"\" title=\"Call: 1-800-222-1222\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> or access the World Health Organization's list of <a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" spellcheck=\"true\">international poison centers </a></li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Admit the following patients: </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Cannot maintain normoglycemia with oral intake </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Hypoglycemia of unknown cause </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Ingestion of long-acting hypoglycemic agents </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Recurrent hypoglycemia during the period of observation </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; IM: intramuscular; SQ: subcutaneous; D10W: 10% dextrose in water; D25W: 25% dextrose in water; D50W: 50% dextrose in water.<br />* These findings may also occur in infants with sepsis, congenital heart disease, respiratory distress syndrome, intraventricular hemorrhage, other metabolic disorders, and in children and adolescents with a variety of underlying conditions.<br />&para; Specific laboratory studies to obtain in children include blood samples for glucose, insulin, C-peptide, beta-hydroxybutyrate, lactate (free flowing blood must be obtained without a tourniquet), plasma acylcarnitines, free fatty acids, growth hormone, and cortisol.<br />&Delta; Higher doses of glucose (eg, 0.5 to 1 g/kg [5 to 10 mL/kg of 10% dextrose in water <strong>or</strong> 2 to 4 mL/kg of 25% dextrose in water]) may be needed to correct hypoglycemia caused by sulfonylurea ingestion. (For more detail, refer to UpToDate topic on sulfonylurea agent poisoning.)<br /><span class=\"lozenge\">&loz;</span> Glucagon will reverse hypoglycemia caused by excess endogenous or exogenous insulin and will not be effective in patients with inadequate glycogen stores (prolonged fasting), ketotic hypoglycemia, or are unable to mobilize glycogen (glycogen storage diseases). Of note, children may exhaust their glycogen stores in as little as 12 hours. Other conditions in which glycogen cannot be effectively mobilized include ethanol intoxication in children, adrenal insufficiency, and certain inborn errors of metabolism (eg, a disorder of glycogen synthesis and glycogen storage diseases).</div><div id=\"graphicVersion\">Graphic 83485 Version 7.0</div></div></div>"},"83486":{"type":"graphic_diagnosticimage","displayName":"X-ray scaphoid fracture AP","title":"X-ray scaphoid fracture AP","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">X-ray scaphoid fracture AP</div><div class=\"cntnt\"><img style=\"width:583px; height:363px;\" src=\"images/RADIOL/83486_Xray_scaphoid_fracture_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The AP view of the left wrist (A, highlighted and magnified in B) reveals a complex fracture through the mid-portion of the scaphoid. The fracture fragments appear to be in anatomic alignment in this view.</div><div id=\"graphicVersion\">Graphic 83486 Version 1.0</div></div></div>"},"83487":{"type":"graphic_diagnosticimage","displayName":"X-ray scaphoid fracture oblique view","title":"X-ray scaphoid fracture oblique view","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">X-ray scaphoid fracture oblique view</div><div class=\"cntnt\"><img style=\"width:582px; height:432px;\" src=\"images/RADIOL/83487_Xray_scaphoid_frac_oblique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The oblique view of the left wrist (A, magnified in B) reveals a fracture through the mid portion of the scaphoid (arrow). The fracture fragments appear to be in anatomic alignment in this view.</div><div id=\"graphicVersion\">Graphic 83487 Version 1.0</div></div></div>"},"83488":{"type":"graphic_diagnosticimage","displayName":"X-ray scaphoid fracture lateral view","title":"X-ray scaphoid fracture lateral view","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">X-ray scaphoid fracture lateral view</div><div class=\"cntnt\"><img style=\"width:583px; height:539px;\" src=\"images/RADIOL/83488_Xray_scaphoid_frac_lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral view of the left wrist (A, magnified in B) reveals a fracture through the scaphoid (arrow). A small fragment has been displaced from the fracture line.</div><div id=\"graphicVersion\">Graphic 83488 Version 1.0</div></div></div>"},"83490":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray of polymyositis interstitial lung disease","title":"ChestÂ radiograph of polymyositis interstitial lung disease","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Chest&nbsp;radiograph of polymyositis interstitial lung disease</div><div class=\"cntnt\"><img style=\"width:598px; height:272px;\" src=\"images/RADIOL/83490_Chest_xray_polymyositis_ILD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest&nbsp;radiograph is from a 62-year-old female patient with polymyositis and interstitial lung disease. The anterior-posterior view (A) shows a reticular pattern dominantly at the bases of the lungs. Image B is a magnified view of the reticular changes in the right lower lung zone. While these findings are non-specific, they are consistent with interstitial lung disease and in a patient with polymyositis, NSIP is most characteristic. The interstitium is best evaluated by high resolution CT scanning of the lungs.</div><div class=\"graphic_footnotes\">CT: computed tomography; NSIP: nonspecific interstitial pneumonia.</div><div class=\"graphic_reference\">Courtesy of Peter LaCamera, MD.</div><div id=\"graphicVersion\">Graphic 83490 Version 2.0</div></div></div>"},"83491":{"type":"graphic_diagnosticimage","displayName":"Polymyositis interstitial lung disease","title":"CT scan of lung bases with interstitial lung disease","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">CT scan of lung bases with interstitial lung disease</div><div class=\"cntnt\"><img style=\"width:600px; height:307px;\" src=\"images/RADIOL/83491_Polymyositis_ILD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The high resolution CT scan of the bases of the lungs in the axial projection (A) reveals bibasilar reticular pattern with traction bronchiectasis at the right base (highlighted and magnified in green with arrow in B, and blue in C); ground glass changes better seen in the left base (D, yellow arrow). Image E (magnified with red overlay) reveals a secondary lobule with thickened interlobular septa and centrally placed arteriole. While not pathognomonic, the changes are consistent with NSIP associated with polymyositis and dermatomyositis.</div><div class=\"graphic_footnotes\">CT: computed tomography; NSIP: nonspecific interstitial pneumonia.</div><div class=\"graphic_reference\">Courtesy of Peter LaCamera, MD.</div><div id=\"graphicVersion\">Graphic 83491 Version 2.0</div></div></div>"},"83492":{"type":"graphic_diagnosticimage","displayName":"CT blastic lytic and mixed metastases","title":"CT blastic lytic and mixed metastases","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">CT blastic lytic and mixed metastases</div><div class=\"cntnt\"><img style=\"width:598px; height:351px;\" src=\"images/RADIOL/83492_CT_blastic_lytic_mixed_met.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The reconstructed CT images are from three different patients and reflect different patterns of metastatic bone disease. The bone windows of the spine are projected as sagittal reconstructions. The first (A) is a patient with breast carcinoma complicated by blastic metastatic disease of the thoracolumbar spine (arrow). The second (B) is a patient with multiple myeloma and multiple lytic lesions in the thoracolumbar spine (arrowhead). The third (C) is a patient with breast carcinoma with both blastic (arrow) and lytic (arrowhead) disease.</div><div id=\"graphicVersion\">Graphic 83492 Version 2.0</div></div></div>"},"83493":{"type":"graphic_picture","displayName":"Cat scratch disease PI","title":"Cat scratch disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cat scratch disease</div><div class=\"cntnt\"><img style=\"width:371px; height:278px;\" src=\"images/PI/83493_CSD_typ_papular_lesion_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cat scratch disease causes redness, swelling, and small round bumps at the site of the bite or scratch, as shown on this finger.</div><div id=\"graphicVersion\">Graphic 83493 Version 1.0</div></div></div>"},"83495":{"type":"graphic_table","displayName":"Differential diagnosis clinical hyperandrogenism","title":"Differential diagnosis of clinical hyperandrogenism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of clinical hyperandrogenism</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Diagnosis</td>\r\n            <td class=\"subtitle1_single\">Frequency (percent)</td>\r\n            <td class=\"subtitle1_single\">Age of onset years</td>\r\n            <td class=\"subtitle1_single\">Time of onset to presentation</td>\r\n            <td class=\"subtitle1_single\">Menstrual disturbance</td>\r\n            <td class=\"subtitle1_single\">Virilization</td>\r\n        </tr>\r\n        <tr>\r\n            <td>PCOS and related disorders</td>\r\n            <td>&#62;95</td>\r\n            <td>15 to 25</td>\r\n            <td>Years</td>\r\n            <td>+/-</td>\r\n            <td>Rare</td>\r\n        </tr>\r\n        <tr>\r\n            <td>CAH</td>\r\n            <td>1 to 2</td>\r\n            <td>Congenital</td>\r\n            <td>Birth/adolescence/adulthood</td>\r\n            <td>+</td>\r\n            <td>+/-</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Adrenal tumor</td>\r\n            <td>&#60;1</td>\r\n            <td>Any time</td>\r\n            <td>Weeks-months</td>\r\n            <td>+</td>\r\n            <td>+</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ovarian tumor</td>\r\n            <td>&#60;1</td>\r\n            <td>Any time</td>\r\n            <td>Weeks-months</td>\r\n            <td>+</td>\r\n            <td>+</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cushing's syndrome</td>\r\n            <td>&#60;1</td>\r\n            <td>Any time</td>\r\n            <td>Months-years</td>\r\n            <td>+</td>\r\n            <td>+/-</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hyperthecosis ovary</td>\r\n            <td>&#60;1</td>\r\n            <td>Pre- to post-menopause</td>\r\n            <td>Months-years</td>\r\n            <td>+</td>\r\n            <td>+</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome; CAH: congenital adrenal hyperplasia; (+): present; (-): absent; (+/-): present or absent.</div><div class=\"graphic_reference\">From: Dennedy MC, Smith D, O'Shea D, McKenna TJ. Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma. Eur J Endocrinol 2010; 162:213. Copyright &copy; Society of the European Journal of Endocrinology 2010. Reproduced by permission.</div><div id=\"graphicVersion\">Graphic 83495 Version 1.0</div></div></div>"},"83496":{"type":"graphic_picture","displayName":"Perianal condyloma acuminatum in child","title":"Condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83496_Perianal_condy_acum_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several soft brown papules are present on the perianal skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83496 Version 3.0</div></div></div>"},"83497":{"type":"graphic_picture","displayName":"Penile condyloma acuminatum in a child","title":"Condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83497_Penile_condy_acum_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Soft brown papules are present on the penis of this child.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83497 Version 3.0</div></div></div>"},"83498":{"type":"graphic_picture","displayName":"Condyloma acuminatum papules and plaques in a child","title":"Condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83498_Condylom_acum_pap_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Soft papules and plaques are present in the perianal and genital regions.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\">www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83498 Version 3.0</div></div></div>"},"83499":{"type":"graphic_diagnosticimage","displayName":"Pelvic radiograph - AP view demonstrating osteopenia","title":"Pelvic radiograph: Anteroposterior view demonstrating osteopenia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pelvic radiograph: Anteroposterior view demonstrating osteopenia</div><div class=\"cntnt\"><img style=\"width:504px; height:409px;\" src=\"images/EM/83499_AP_pelv_xray_osteopenia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior plain radiograph of the pelvis was obtained in an elder female patient with low back pain. The radiograph reveals diffuse osteopenia of the pelvic bones but no fracture. When symptoms persisted, a magnetic resonance imaging (MRI) study was obtained that revealed an insufficiency fracture of the sacral ala.</div><div class=\"graphic_reference\">Courtesy of Jim Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 83499 Version 2.0</div></div></div>"},"83500":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph nondisplaced posterior rib fractures","title":"Chest radiograph nondisplaced posterior rib fractures","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Chest radiograph nondisplaced posterior rib fractures</div><div class=\"cntnt\"><img style=\"width:582px; height:387px;\" src=\"images/RADIOL/83500_Chest_xray_nondisp_post_rib.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph is from an 80-year-old female who complained of chest pain following trauma. Nondisplaced posterior fractures of right sided ribs 6, 7, and 8 are noted (magnified and red arrows, image B). There is no evidence of pneumothorax.</div><div id=\"graphicVersion\">Graphic 83500 Version 3.0</div></div></div>"},"83501":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph rib fractures","title":"Chest radiograph rib fractures","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Chest radiograph rib fractures</div><div class=\"cntnt\"><img style=\"width:597px; height:282px;\" src=\"images/RADIOL/83501_Chest_xray_rib_fractures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The PA chest radiograph is from a 43-year-old man with right sided chest pain following trauma. The conventional PA view (image A) reveals a subtle nondisplaced fracture of the lateral aspect of the ninth rib on the right side (arrow). Image B is a magnified and highlighted view of the fracture.</div><div class=\"graphic_footnotes\">PA: posterior-anterior.</div><div id=\"graphicVersion\">Graphic 83501 Version 2.0</div></div></div>"},"83503":{"type":"graphic_diagnosticimage","displayName":"Radiograph angulated fracture of proximal phalanx","title":"Radiograph angulated fracture of proximal phalanx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph angulated fracture of proximal phalanx</div><div class=\"cntnt\"><img style=\"width:333px; height:656px;\" src=\"images/RADIOL/83503_Xray_ang_frac_prox_phalanx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The AP (A, and magnified in B) and oblique radiograph (C, and magnified in D) reveal a ventrally angulated displaced fracture of the proximal shaft of the fifth proximal phalanx of the left hand (red arrows).</div><div class=\"graphic_footnotes\">AP: anterior-posterior.</div><div id=\"graphicVersion\">Graphic 83503 Version 2.0</div></div></div>"},"83504":{"type":"graphic_diagnosticimage","displayName":"Radiograph incomplete stable fracture proximal phalanx","title":"RadiographÂ incomplete stable fracture of proximal phalanx","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Radiograph&nbsp;incomplete stable fracture of proximal phalanx</div><div class=\"cntnt\"><img style=\"width:454px; height:598px;\" src=\"images/RADIOL/83504_Xray_inc_stab_frac_phalanx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior-posterior (AP) view of the left fourth proximal phalanx (A, magnified in B) reveals an incomplete complex fracture of the proximal diaphysis with mild overlying soft tissue swelling. The oblique image confirms a nondisplaced fracture that is barely visible (D, red arrow). The fracture was not obvious on the lateral examination.</div><div id=\"graphicVersion\">Graphic 83504 Version 2.0</div></div></div>"},"83505":{"type":"graphic_diagnosticimage","displayName":"Linear skull fracture x-ray","title":"Linear skull fracture plain x-ray","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Linear skull fracture plain x-ray</div><div class=\"cntnt\"><img style=\"width:597px; height:341px;\" src=\"images/RADIOL/83505_Xray_skull_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain films of the skull in the AP Towne's view (A) and lateral view (B) reveal a linear fracture of the right occipital bone (arrows A). The lateral view shows the fracture involving the parietal bone as well (arrows B).</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83505 Version 2.0</div></div></div>"},"83506":{"type":"graphic_diagnosticimage","displayName":"Skull fracture CT scan","title":"Skull fracture CT scan","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Skull fracture CT scan</div><div class=\"cntnt\"><img style=\"width:597px; height:375px;\" src=\"images/RADIOL/83506_Skull_fracture_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axial image of the skull in the transverse plane using bone windows (A) is displayed alongside the 3D reconstructed view (B). A linear fracture of the right occipital bone (arrow) is noted just to the right of midline. The 3D view shows the fracture extending from the right side of the lambdoid suture to the inferior margin of the right occipital bone.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 83506 Version 2.0</div></div></div>"},"83507":{"type":"graphic_figure","displayName":"Buddy taping toe PI","title":"Buddy taping of the toes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Buddy taping of the toes</div><div class=\"cntnt\"><img style=\"width:180px; height:257px;\" src=\"images/PI/83507_Buddy_taping_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Buddy taping involves taping the injured toe to the toe next to it. Some cotton or other soft material should be put between the toes so they don't rub together.</div><div id=\"graphicVersion\">Graphic 83507 Version 1.0</div></div></div>"},"83508":{"type":"graphic_diagnosticimage","displayName":"Radiograph shear fracture T12","title":"RadiographÂ shear fracture T12","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph&nbsp;shear fracture T12</div><div class=\"cntnt\"><img style=\"width:314px; height:656px;\" src=\"images/RADIOL/83508_Xray_shear_fracture_T12.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph of the thoracolumbar spine in anterior posterior (A and B) and lateral projections (C and D) reveals a fracture dislocation centered around T11/T12. The arrowheads define the spinous processes on the frontal film and demonstrate the abrupt angulation centered at the dislocated level. The arrows point to the posterior cortices of the vertebral bodies and highlight the extent of abnormal translation.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 83508 Version 2.0</div></div></div>"},"83509":{"type":"graphic_figure","displayName":"Kyphosis children PI","title":"Kyphosis in a child","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Kyphosis in a child</div><div class=\"cntnt\"><img style=\"width:498px; height:577px;\" src=\"images/PI/83509_Kyphosos-children-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A normal spine (left) has a slight curve. In a child with kyphosis, the upper part of the spine curves more than normal (right), causing a rounded or hunched back.</div><div id=\"graphicVersion\">Graphic 83509 Version 1.0</div></div></div>"},"83510":{"type":"graphic_figure","displayName":"Lymphatic drainage of the stomach","title":"Lymphatic drainage of the stomach","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Lymphatic drainage of the stomach</div><div class=\"cntnt\"><img style=\"width:519px; height:418px;\" src=\"images/SURG/83510_Lymphatic-drainage-of-the-stomach.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83510 Version 1.0</div></div></div>"},"83511":{"type":"graphic_figure","displayName":"Pelvis PI","title":"Pelvis","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Pelvis</div><div class=\"cntnt\"><img style=\"width:509px; height:660px;\" src=\"images/PI/83511_Pelvis-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the location of the pelvis.</div><div id=\"graphicVersion\">Graphic 83511 Version 1.0</div></div></div>"},"83512":{"type":"graphic_table","displayName":"Intravenous agents for pediatric procedural sedation","title":"Commonly used intravenous agents for pediatric procedural sedation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used intravenous agents for pediatric procedural sedation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"6\"><strong>These agents should ONLY be administered by clinicians trained and experienced in pediatric procedural sedation using continuous non-invasive electronic monitoring of oxygenation, heart rate, blood pressure and, whenever, possible,&nbsp;end-tidal carbon dioxide monitoring. Resuscitation equipment, medications, and personnel skilled in advanced pediatric life support and knowledgeable of sedatives and reversal agents must be present. Unstable patients, patients with airway anomalies, and those with life-threatening severe systemic disease warrant consultation with an anesthesiologist or pediatric critical care specialist prior to procedural sedation. Please refer to UpToDate topics on procedural sedation in children for more details.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Initial intravenous dose*</td> <td class=\"subtitle1\">Repeat intravenous dose (as needed to achieve desired level of sedation)</td> <td class=\"subtitle1\">Onset (minutes)</td> <td class=\"subtitle1\">Duration (minutes)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Ketamine</td> <td> <p>1 to 2 mg/kg; some experts do not exceed 1.5 mg/kg per dose.</p> <p>&nbsp;</p> When given with propofol, reduce initial dose to 0.5 mg/kg.</td> <td>0.5 to 1 mg/kg repeat every 5 to&nbsp;10 minutes, titrating to desired level of sedation.</td> <td>1 to 2</td> <td>15 to 30</td> <td> <ul> <li>Provides sedation AND analgesia for moderately to severely painful procedures. Less respiratory depression and complications than propofol alone or combinations of opioids with midazolam or with propofol. </li> <li>Common adverse events: Vomiting, emergence reaction, frequency of vomiting is reduced by premedication with ondansetron (0.15 mg/kg, typical dose 4 mg) or by co-administration of propofol. </li> <li>Laryngospasm and apnea occur rarely and are more common with intramuscular administration. </li> <li>Relative contraindications and precautions: Age younger than 12 months, active pulmonary infections (including URI), known or suspected cardiac disease, suspected increased intracranial pressure (eg, head trauma with signs or symptoms, intracranial mass, or obstructive hydrocephalus), glaucoma or acute eye injury (open globe), porphyria, thyroid disease, or seizures </li> <li>Absolute contraindications: Age younger than 3 months or patients with known or suspected psychosis. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Propofol<sup>&#182;</sup></td> <td> <p>Initiate infusion at&nbsp;100 mcg/kg per minute and titrate gradually to response (range 50 to 200 mcg/kg per minute).</p> <p>OR</p> <p>6 months to 2 years: 1 to 2 mg/kg IV bolus dose.</p> 2 years of age and older: 0.5 to 1 mg/kg IV bolus dose.</td> <td> <p>Not applicable for continuous IV infusion, titrate infusion rate as needed.</p> <p>OR</p> Additional IV bolus dose 0.5 mg/kg every 3 to 5 minutes, titrating as needed up to 3 mg/kg. Wait at least 3 to 5 minutes between doses to assess effect.</td> <td>&#8804;0.5</td> <td>5 to 15 after single bolus dose, longer after prolonged infusion or when repeated bolus doses are given</td> <td> <ul> <li>Provides deep sedation, but can produce general anesthesia, especially with multiple bolus doses or high continuous infusion rate. </li> <li>Provides sedation but NO analgesia. For painful procedures, an analgesic agent (eg, ketamine, fentanyl), regional anesthetic, or local anesthetic should be co-administered. Commonly used for diagnostic imaging (CT, MRI). </li> <li>Rapid onset of sedation with good neurologic recovery. Reduces intracranial pressure. </li> <li>Peripheral injection site pain.<sup>&#916;</sup> </li> <li>Common adverse events: Respiratory depression, oxygen desaturation, apnea, hypotension, and/or rapid transition to deeper levels of sedation, especially with overly rapid administration of bolus injection. </li> <li>Absolute contraindications: Porphyria, propofol should be avoided in patients with cardiac compromise. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Dexmedetomidine</td> <td> <p>1 to 3 mcg/kg loading dose (over 10 minutes), followed by 0.5 to 1 mcg/kg per <strong>hour</strong> continuous infusion.</p> Children younger than 5 years of age may require maintenance infusion rates at the higher end of the range shown.</td> <td>Not applicable for continuous infusion, titrate infusion rate as needed.</td> <td>5 to 10</td> <td>30 to 70</td> <td> <ul> <li>Sedation and modest analgesia without respiratory depression. Commonly used for diagnostic imaging (CT, MRI). </li> <li>Common adverse events: Bradycardia, hypertension, or, especially with loading dose, hypotension. </li> <li>Relative contraindications: Children who are inadequately hydrated, or have reduced cardiac output. </li> <li>Absolute contraindication: Dexmedetomidine should be avoided in patients receiving digoxin or other medications acting on the&nbsp;atrioventricular node or with cardiac conduction abnormalities (eg, sinus node dysfunction) unless provided by physicians with training and expertise in pediatric cardiac anesthesiology. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Fentanyl</td> <td> <p>1 to 2 mcg/kg</p> <p>Some experts prefer to not exceed 50 mcg per dose.</p> </td> <td> <p>Repeat 0.5 to 1 mcg/kg every 3 to 5 minutes.</p> <p>Some experts prefer to not exceed&nbsp;25 mcg per dose.</p> </td> <td>&#60;3 to 5</td> <td>30 to 60 after a single dose</td> <td> <ul> <li>May cause respiratory depression and hypotension. </li> <li>Chest wall rigidity may occur, especially with rapid IV infusion. </li> <li>When combined with propofol, may produce a state of general anethesia. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Midazolam</td> <td> <p>6 months to 5 years: 0.05 to 0.1 mg/kg IV, maximum single dose 2 mg.</p> <p>6 to 12 years: 0.025 to 0.05 mg/kg IV, maximum single dose 2 mg.</p> Over 12 years: 1 to 2 mg IV.</td> <td> <p>After initial IV dose, repeat after 2 to 5 minutes, titrating to desired level of sedation as follows:</p> <p>6 months to 5 years: 0.2 mg/kg per dose (maximum total dose 6 mg).</p> <p>6 to 12 years: 0.1 mg/kg (maximum total dose 6 mg).</p> Over 12 years: 1 to 2 mg (maximum total dose 10 mg).</td> <td>1 to 3</td> <td>15 to 60, depending upon total dose administered</td> <td> <ul> <li>Provides sedation but NO analgesia. For painful procedures, an analgesic agent (eg, ketamine, fentanyl) should be co-administered. </li> <li>Provides amnesia, mild anxiolysis, and mild sedation for procedures that do not require full immobility (eg, laceration repair with local topical anesthesia). </li> <li>When combined with fentanyl can produce moderate or deep sedation, but less effective and more adverse respiratory events reported when compared to sedation with ketamine alone or combined with propofol. </li> <li>Flumazenil can reverse effects but should be avoided in patients with seizure disorder or who are chronically maintained on benzodiazepines. </li> <li>Common adverse effects: Respiratory depression, and apnea, especially when combined with opioid medications (eg, fentanyl); paradoxical reactions, including hyperactivity, aggressive behavior, and inconsolable crying. </li> </ul> </td> </tr> <tr> <td>Etomidate</td> <td> <p>0.1 to 0.3 mg/kg IV.</p> Lower dose in children with renal or hepatic insufficiency.</td> <td>0.05 mg/kg every 3 to 5 minutes, titrate up to 0.6 mg/kg total dose to desired sedation.</td> <td>&#8804;0.5</td> <td>5 to 15</td> <td> <ul> <li>Rapid onset and recovery. Commonly used for brief diagnostic imaging (eg, head CT). </li> <li>Reduces intracranial pressure. Hemodynamic and respiratory stability maintained in most patients making it a good choice if cardiovascular status is unknown or compromised (eg, trauma patient). </li> <li>Common adverse effects: Pain at the injection site, transient nonepileptiform myoclonus, vomiting. Myoclonus and vomiting reduced by premedication with midazolam. </li> <li>Relatively contraindicated in children with severe illness such as suspected sepsis. </li> <li>Absolutely contraindications: Children with congenital or acquired adrenal insufficiency. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">URI: upper respiratory tract infection; IV: intravenous; CT: computed tomography; MRI: magnetic resonance imaging.<br />* Doses are given as a suggested range for the initial dose. Children may differ markedly with respect to efficacy of any single dose and careful titration to effect by using repetitive dosing to achieve the desired depth and duration of sedation is necessary for any individual patient.<br />Â¶ In some institutions, propofol is ONLY approved for use by anesthesiologists or others with specialized pediatric procedural sedation training. Check local recommendations.<br />Î A higher dose of dexmedetomidine (1 to 3 mcg/kg loading dose) followed by a continuous infusion of 0.5 to 1 mcg/kg per hour is proposed by some experts for successful sedation during magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 83512 Version 11.0</div></div></div>"},"83517":{"type":"graphic_diagnosticimage","displayName":"Radiograph and magnetic resonance imaging lunate fracture","title":"Radiograph and magnetic resonance imagingÂ lunate fracture","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Radiograph and magnetic resonance imaging&nbsp;lunate fracture</div><div class=\"cntnt\"><img style=\"width:583px; height:481px;\" src=\"images/RADIOL/83517_Xray_MRI_lunate_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images of the right wrist are from a 25-year-old male who presented with wrist pain following trauma. The initial plain films were negative. Follow-up radiographs in the AP (A) and oblique (B) projections of the right wrist reveal a subacute nondisplaced fracture through the mid-portion of the lunate (highlighted in A and B). Subtle heterogeneity of the trabecular pattern is noted in A, while the fracture is obvious in image B. The T1 weighted MRI arthrogram in coronal projection (C) confirms the diagnosis of a subacute fracture (arrow).</div><div class=\"graphic_footnotes\">AP: anteroposterior; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD and Anthony Romano, MD.</div><div id=\"graphicVersion\">Graphic 83517 Version 2.0</div></div></div>"},"83518":{"type":"graphic_table","displayName":"Diff diag tubulointerstitial nephropathies urothelial carcinoma","title":"Differential diagnosis of some forms of chronic tubulointerstitial nephropathies associated with urothelial carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of some forms of chronic tubulointerstitial nephropathies associated with urothelial carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Aristolochic acid nephropathy</td>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Analgesic nephropathy</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">Chinese herb nephropathy</td>\r\n            <td class=\"subtitle2\">Balkan endemic nephropathy</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Etiology</td>\r\n            <td class=\"centered\" colspan=\"2\">Aristolochic acid</td>\r\n            <td>Analgesics + addictive substances</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Progression to ESRD</td>\r\n            <td>6 months to 2 years</td>\r\n            <td>&#62;20 years</td>\r\n            <td>&#62;10 to 15 years</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Kidney imaging</td>\r\n            <td>\r\n            <p>Shrunken</p>\r\n            <p>Irregular contours</p>\r\n            <p>No calcifications</p>\r\n            </td>\r\n            <td>\r\n            <p>Shrunken</p>\r\n            <p>Smooth surface</p>\r\n            <p>No calcifications</p>\r\n            </td>\r\n            <td>\r\n            <p>Shrunken</p>\r\n            <p>Irregular contours</p>\r\n            <p>Papillary necrosis-calcifications</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\" colspan=\"4\">Histology</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Cellular infiltration</td>\r\n            <td class=\"sublist_other_centered\">+</td>\r\n            <td class=\"sublist_other_centered\">+</td>\r\n            <td class=\"sublist_other_centered\">++</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Fibrosis</td>\r\n            <td class=\"sublist_other_centered\">++</td>\r\n            <td class=\"sublist_other_centered\">++</td>\r\n            <td class=\"sublist_other_centered\">++</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Atrophy</td>\r\n            <td class=\"sublist_other_centered\">++</td>\r\n            <td class=\"sublist_other_centered\">+++</td>\r\n            <td class=\"sublist_other_centered\">++</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Capillarosclerosis</td>\r\n            <td class=\"centered\">+</td>\r\n            <td class=\"centered\">+</td>\r\n            <td class=\"centered\">+</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Apoptosis</td>\r\n            <td class=\"centered\">++</td>\r\n            <td class=\"centered\">++</td>\r\n            <td class=\"centered\">?</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Urothelial malignancies</td>\r\n            <td class=\"centered\">\r\n            <p>+</p>\r\n            <p>Upper tract</p>\r\n            </td>\r\n            <td class=\"centered\">\r\n            <p>+</p>\r\n            <p>Upper tract</p>\r\n            </td>\r\n            <td class=\"centered\">+ (*)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Familial occurrence</td>\r\n            <td class=\"centered\">-</td>\r\n            <td class=\"centered\">+</td>\r\n            <td class=\"centered\">-</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">ESRD: end-stage renal disease.<br />* As long as phenacetin was part of the analgesic mixtures.</div><div class=\"graphic_reference\">Adapted by permission from: Macmillan Publishers Ltd: De Broe ME. Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int 2012; 81:513. Copyright Â© 2012.</div><div id=\"graphicVersion\">Graphic 83518 Version 2.0</div></div></div>"},"83519":{"type":"graphic_picture","displayName":"Callus PI","title":"Calluses on the hands","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calluses on the hands</div><div class=\"cntnt\"><img style=\"width:374px; height:270px;\" src=\"images/PI/83519_Callus_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows calluses on a person's hands. These form when something repeatedly rubs or presses on the skin. Over time, using gardening tools or sports equipment can cause calluses to appear on the hands.</div><div id=\"graphicVersion\">Graphic 83519 Version 1.0</div></div></div>"},"83520":{"type":"graphic_picture","displayName":"Corns PI","title":"Corns","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Corns</div><div class=\"cntnt\"><img style=\"width:515px; height:197px;\" src=\"images/PI/83520_Corns_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Corns can appear on the feet when something repeatedly rubs or presses on the skin, such as shoes that don't fit well. <BR>Picture A (on&nbsp;the left) shows a corn on the outside of the fifth (pinky) toe. <BR>Picture B (on the right) shows a corn on the bottom of the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83520 Version 4.0</div></div></div>"},"83521":{"type":"graphic_picture","displayName":"Molluscum contagiosum pediatric genital","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83521_Mollusc_contag_pediat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple umbilicated small papules are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83521 Version 3.0</div></div></div>"},"83522":{"type":"graphic_picture","displayName":"Condylomata lata of syphilis","title":"Condylomata lata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Condylomata lata</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/PC/83522_Condylom_lat_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Moist, gray papules that resemble condylomata acuminata are present on the perianal skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83522 Version 3.0</div></div></div>"},"83532":{"type":"graphic_figure","displayName":"Loiasis prevalence map","title":"Map of the estimated prevalence of eye worm history in Africa","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Map of the estimated prevalence of eye worm history in Africa</div><div class=\"cntnt\"><img style=\"width:576px; height:409px;\" src=\"images/ID/83532_Loiasis_prev_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: Zour&eacute; HG, Wanji S, Noma M, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 2011; 5:e1210. Copyright &copy; 2011 Public Library of Science (PLoS).</div><div id=\"graphicVersion\">Graphic 83532 Version 1.0</div></div></div>"},"83533":{"type":"graphic_picture","displayName":"Calabar swelling","title":"Calabar swelling","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Calabar swelling</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/83533_Calabar_swelling.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83533 Version 3.0</div></div></div>"},"83534":{"type":"graphic_table","displayName":"Clinical features of nevi and melanoma","title":"Clinical features of common nevi, atypical nevi, and melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of common nevi, atypical nevi, and melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Feature</td>\r\n            <td class=\"subtitle1\">Common nevi</td>\r\n            <td class=\"subtitle1\">Atypical nevi</td>\r\n            <td class=\"subtitle1\">Melanoma</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Symmetry</td>\r\n            <td>Symmetric</td>\r\n            <td>Variable</td>\r\n            <td>Usually asymmetric</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Border</td>\r\n            <td>Regular; well defined</td>\r\n            <td>Irregular; ill defined</td>\r\n            <td>Irregular; sometimes sharp</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Color</td>\r\n            <td>Uniform and few colors (tan/brown)</td>\r\n            <td>Variegated; tan/brown/black/red</td>\r\n            <td>Variegated; tan/brown/black/red/ white/blue</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Diameter</td>\r\n            <td>&#8804;6 mm</td>\r\n            <td>&#62;5 mm</td>\r\n            <td>Usually &#62;5mm</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Change over time</td>\r\n            <td>Slow then stable; many will regress</td>\r\n            <td>Slow then stable; some will regress</td>\r\n            <td>Faster (over months)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Surface</td>\r\n            <td>Uniformly macular or elevated</td>\r\n            <td>Macular or elevated with peripheral macular \"shoulder\"</td>\r\n            <td>Macular and/or elevated</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">Reproduced from: Marghoob AA, Kovalyshyn I, Halpern AC. Management of Dysplastic Nevi and Melanomas. In: Surgery of the Skin, 2nd ed, Robinson JK (Ed), Elsevier 2010. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83534 Version 1.0</div></div></div>"},"83537":{"type":"graphic_table","displayName":"Grading system predicting vascular invasion by pancreatic cancer","title":"Grading system* for predicting vascular invasion by a pancreatic cancer on dual-phase contrast-enhanced CT ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading system* for predicting vascular invasion by a pancreatic cancer on dual-phase contrast-enhanced CT </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Grade 0</td> <td>No contiguity of tumor with a vessel</td> <td>Vascular invasion in 0 percent of cases</td> </tr> <tr> <td>Grade 1</td> <td>Tumor contiguous with &#60;25 percent of the circumference of a vessel</td> <td>Vascular invasion in 0 percent of cases</td> </tr> <tr> <td>Grade 2</td> <td>Tumor contiguous with 25 to 50 percent of the circumference of a vessel</td> <td>Vascular invasion in 57 percent of cases</td> </tr> <tr> <td>Grade 3</td> <td>Tumor contiguous with 50 to 75 percent of the circumference of a vessel</td> <td>Vascular invasion in 88 percent of cases</td> </tr> <tr> <td>Grade 4</td> <td>Tumor contiguous with &#62;75 percent of the circumference of a vessel or any vessel constriction</td> <td>Vascular invasion in all cases</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* Proposed by Lu DSK, et al. AJR Am J Roentgenol 1997; 168:1439.</div><div class=\"graphic_reference\">Reproduced from: Wong JC, Raman S. Surgical resectability of pancreatic adenocarcinoma: CTA. Abdom Imaging 2010; 35:471. Copyright Â© 2010; with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 83537 Version 3.0</div></div></div>"},"83542":{"type":"graphic_figure","displayName":"Disease-specific survival MF SS","title":"Disease-specific survival for mycosis fungoides/SÃ©zary syndrome by stage","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Disease-specific survival for mycosis fungoides/SÃ©zary syndrome by stage</div><div class=\"cntnt\"><img style=\"width:526px; height:414px;\" src=\"images/HEME/83542_Dis_spec_surv_MF_SS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Disease-specific survival according to (A) clinical stage and (B) T classification (International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer).</div><div class=\"graphic_reference\">From: Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/S&eacute;zary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28:4730. Reprinted with permission. Copyright &copy; 2010 American Society of Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83542 Version 3.0</div></div></div>"},"83544":{"type":"graphic_figure","displayName":"Melanoma dermoscopy features","title":"Pattern analysis: Dermoscopic features of melanoma","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Pattern analysis: Dermoscopic features of melanoma</div><div class=\"cntnt\"><img style=\"width:509px; height:272px;\" src=\"images/DERM/83544_Melan_derm_featur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Diffuse reticular pattern with focal atypical pigment network.<br />(B) Patchy reticular pattern with focal atypical pigment network.<br />(C) Diffuse reticular pattern with peripheral tan structureless area.<br />(D) Diffuse reticular pattern with off-center blotch.<br />(E) Homogeneous pattern with off-center blotches.<br />(F) Diffuse reticular pattern with atypical globules.<br />(G) Globular pattern with atypical globules.<br />(H) Multicomponent pattern with regression structures, atypical globules, off-center blotch.</div><div class=\"graphic_reference\">Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 83544 Version 4.0</div></div></div>"},"83545":{"type":"graphic_picture","displayName":"Melanoma in atypical nevus 1","title":"Melanoma arising in atypical nevus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Melanoma arising in atypical nevus</div><div class=\"cntnt\"><img style=\"width:504px; height:332px;\" src=\"images/DERM/83545_Melanoma_atypical_nevus_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A rapid change in size, color,&nbsp;and shape in&nbsp;a preexisting nevus over months should raise the suspicion of melanoma and prompt surgical excision for histopathologic examination.</div><div id=\"graphicVersion\">Graphic 83545 Version 3.0</div></div></div>"},"83546":{"type":"graphic_picture","displayName":"Melanoma in atypical nevus 2","title":"Melanoma arising in atypical nevus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Melanoma arising in atypical nevus</div><div class=\"cntnt\"><img style=\"width:504px; height:358px;\" src=\"images/DERM/83546_Melanoma_atypical_nevus_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymmetry, border irregularity, irregular pigment distribution, and rapid change over months suggest melanoma and should prompt surgical excision for histopathologic examinaton.</div><div id=\"graphicVersion\">Graphic 83546 Version 3.0</div></div></div>"},"83549":{"type":"graphic_picture","displayName":"Pigmented basal cell carcinoma","title":"Pigmented superficial basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pigmented superficial basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83549_Pig_basal_skin_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pigmented basal cell carcinoma presenting as a pink/brownish macule with slightly atrophic center and&nbsp;irregular, elevated, hyperpigmented&nbsp;borders.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83549 Version 4.0</div></div></div>"},"83550":{"type":"graphic_picture","displayName":"Seborrheic keratosis irregular pigmentation","title":"Seborrheic keratosis with irregular pigmentation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis with irregular pigmentation</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83550_Seborrheic_kera_irr_pig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seborrheic keratosis with typical&nbsp;dull surface and stuck on\" appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83550 Version 5.0</div></div></div>"},"83551":{"type":"graphic_figure","displayName":"Surgical Robot Side Docking","title":"Surgical Robot: Docking set up on side of patient","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Surgical Robot: Docking set up on side of patient</div><div class=\"cntnt\"><img style=\"width:476px; height:609px;\" src=\"images/OBGYN/83551_Surgical-Robot-Side-Docking.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83551 Version 1.0</div></div></div>"},"83552":{"type":"graphic_figure","displayName":"Surgical Robot Between the Legs Docking","title":"Surgical Robot: Docking set up between patient's legs","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Surgical Robot: Docking set up between patient's legs</div><div class=\"cntnt\"><img style=\"width:488px; height:644px;\" src=\"images/OBGYN/83552_Surgical-Robot-Between-the-Legs-Docking.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83552 Version 1.0</div></div></div>"},"83553":{"type":"graphic_picture","displayName":"Cutaneous arteriovenous malformation","title":"Cutaneous arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83553_Cutan_arterioven_malform.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arteriovenous malformation presenting as an erythematous patch on the leg of a young child. Superficial veins are visible.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83553 Version 4.0</div></div></div>"},"83556":{"type":"graphic_diagnosticimage","displayName":"Acute appendicitis ultrasound","title":"Acute appendicitis ultrasound","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Acute appendicitis ultrasound</div><div class=\"cntnt\"><img style=\"width:604px; height:275px;\" src=\"images/RADIOL/83556_Acute_appendicitis_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is a 19-year-old female who presented to the emergency department with right lower quadrant pain. The gray scale ultrasound of the appendix is projected in the longitudinal (A) and transverse planes (B). A noncompressible appendix measures almost 20 mm in diameter, consistent with a diagnosis of acute appendicitis. The echogenic mucosal and submucosal portions of the wall have become discontinuous (arrows) suggesting disruption as a result of sloughing. Luminal air (arrowheads) results in posterior shadowing.</div><div id=\"graphicVersion\">Graphic 83556 Version 2.0</div></div></div>"},"83557":{"type":"graphic_diagnosticimage","displayName":"Normal appendix by ultrasound imaging","title":"Normal appendix by ultrasound imaging","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Normal appendix by ultrasound imaging</div><div class=\"cntnt\"><img style=\"width:607px; height:475px;\" src=\"images/RADIOL/83557_Normal_appendix_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The gray scale ultrasound (A, and magnified in B) and Doppler image (C) of the appendix are projected in the transverse plane. Images A and B show a normal appendix measuring almost 6 mm in maximum transverse dimension (arrow). The appendix was compressible and no hyperemia was demonstrated (arrow) on the Doppler image (C). These findings are consistent with a normal appendix by ultrasound.</div><div id=\"graphicVersion\">Graphic 83557 Version 1.0</div></div></div>"},"83558":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of incarcerated uterus","title":"Ultrasound of incarcerated uterus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ultrasound of incarcerated uterus</div><div class=\"cntnt\"><img style=\"width:504px; height:465px;\" src=\"images/OBGYN/83558_Ultrasnd_incarc_uterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal ultrasound image at 18 weeks of gestation shows an incarcerated uterus. The cervix is stretched anteriorly (arrows), and the uterine fundus is posterior to the cervix. Note fetal head (H) and free fluid in the cul-de-sac (ff).</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 83558 Version 1.0</div></div></div>"},"83559":{"type":"graphic_picture","displayName":"Proteus syndrome","title":"Proteus syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Proteus syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83559_Proteus_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proteus syndrome presenting in a newborn&nbsp;with an asymmetric enlargement of the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83559 Version 5.0</div></div></div>"},"83560":{"type":"graphic_picture","displayName":"Thumbs up sign for radial nerve motor function","title":"Thumbs up sign for radial nerve motor function","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Thumbs up sign for radial nerve motor function</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/83560_Thumbs_up_radial_nerv_motor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Motor function of the radial nerve can be tested by asking the patient to make the thumbs up sign, as shown in the photograph.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD</div><div id=\"graphicVersion\">Graphic 83560 Version 1.0</div></div></div>"},"83561":{"type":"graphic_picture","displayName":"Thumb extension against resistance","title":"Thumb extension against resistance","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Thumb extension against resistance</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/83561_Thum_ext_against_resistance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Resisted thumb extension can be used to assess radial nerve function and the strength of thumb extensors.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD</div><div id=\"graphicVersion\">Graphic 83561 Version 1.0</div></div></div>"},"83562":{"type":"graphic_picture","displayName":"Weak OK sign","title":"Weak OK sign","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Weak OK sign</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/83562_Weak_OK_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior interosseus nerve injury causes flattening of the OK sign due to the loss of thumb and index finger flexion.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD</div><div id=\"graphicVersion\">Graphic 83562 Version 1.0</div></div></div>"},"83563":{"type":"graphic_picture","displayName":"Peace sign to assess ulnar nerve motor function","title":"Peace sign to assess ulnar nerve motor function","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Peace sign to assess ulnar nerve motor function</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/83563_Peace_sign_ulnar_nerv_motor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Injury to the ulnar nerve impairs function of the dorsal and palmar interossei making patients unable to abduct and adduct their fingers. This can be tested by having the patient make a peace sign, as shown in the photograph.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD</div><div id=\"graphicVersion\">Graphic 83563 Version 1.0</div></div></div>"},"83564":{"type":"graphic_picture","displayName":"Resisted peace sign for ulnar nerve motor function","title":"Resisted peace sign for ulnar nerve motor function","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Resisted peace sign for ulnar nerve motor function</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/83564_Resist_peace_sign_ulna_nerv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulnar nerve function can be assessed by having the patient make a peace sign and then maintain it against resistance, as shown in the photograph.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD</div><div id=\"graphicVersion\">Graphic 83564 Version 1.0</div></div></div>"},"83565":{"type":"graphic_picture","displayName":"Kleinert finger splint","title":"Kleinert finger splint","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Kleinert finger splint</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/83565_Kleinert_finger_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Kleinert splint, pictured above, does not place pressure at the distal interphalangeal joint because the middle third of the padding has been removed.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD</div><div id=\"graphicVersion\">Graphic 83565 Version 1.0</div></div></div>"},"83566":{"type":"graphic_picture","displayName":"Kleinert finger splint in place","title":"Kleinert finger splint in place","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Kleinert finger splint in place</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/83566_Kleinert_fing_splint_place.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows the Kleinert splint in position. The splint should keep the distal interphalangeal joint in slight hyperextension without placing any direct pressure on the joint itself.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD</div><div id=\"graphicVersion\">Graphic 83566 Version 1.0</div></div></div>"},"83568":{"type":"graphic_diagnosticimage","displayName":"Shoulder fracture dislocation","title":"Shoulder fracture dislocation","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Shoulder fracture dislocation</div><div class=\"cntnt\"><img style=\"width:515px; height:538px;\" src=\"images/EM/83568_Shoulder_fract_dislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph above shows a fracture-dislocation of the glenohumeral joint. The humeral head is clearly dislodged from the glenoid fossa and the dislocation is accompanied by a fracture at the surgical neck.</div><div class=\"graphic_reference\">Courtesy of Scott Sherman, MD.</div><div id=\"graphicVersion\">Graphic 83568 Version 1.0</div></div></div>"},"83569":{"type":"graphic_table","displayName":"Drug-induced linear IgA bullous dermatosis","title":"Drug-induced linear IgA bullous dermatosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug-induced linear IgA bullous dermatosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td class=\"indent1\">Vancomycin</td> </tr> <tr> <td class=\"subtitle1_single\">Less common</td> </tr> <tr> <td class=\"indent1\">Penicillins</td> </tr> <tr> <td class=\"indent1\">Cephalosporins</td> </tr> <tr> <td class=\"indent1\">Captopril &#62;other ACE inhibitors</td> </tr> <tr> <td class=\"indent1\">NSAIDs: diclofenac, naproxen, oxaprozin, piroxicam</td> </tr> <tr> <td class=\"subtitle1_single\">Uncommon</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Sulfonamide antibiotics: sulfamethoxazole, sulfisoxazole</td> </tr> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"indent1\">Angiotensin receptor blockers: candesartan, eprosartan</td> </tr> <tr> <td class=\"indent1\">Atorvastatin</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Cyclosporine</td> </tr> <tr> <td class=\"indent1\">Furosemide</td> </tr> <tr> <td class=\"indent1\">Gemcitabine</td> </tr> <tr> <td class=\"indent1\">Glyburide</td> </tr> <tr> <td class=\"indent1\">Granulocyte colony-stimulating factor</td> </tr> <tr> <td class=\"indent1\">Interferon-&#945; and interferon-&#947;</td> </tr> <tr> <td class=\"indent1\">Interleukin-2</td> </tr> <tr> <td class=\"indent1\">Lithium carbonate</td> </tr> <tr> <td class=\"indent1\">PUVA</td> </tr> <tr> <td class=\"indent1\">Rifampin</td> </tr> <tr> <td class=\"indent1\">Somatostatin</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin converting enzyme; NSAIDs: nonsteroidal antiinflammatory drugs.</div><div class=\"graphic_reference\">Reproduced from: Zone JJ. Dermatitis herpetiformis and linear IgA bullous dermatosis. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier, 2008. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83569 Version 3.0</div></div></div>"},"83570":{"type":"graphic_figure","displayName":"Urocortins","title":"Urocortins and their interactions in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Urocortins and their interactions in pregnancy</div><div class=\"cntnt\"><img style=\"width:559px; height:367px;\" src=\"images/OBGYN/83570_Urocortins.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CRH: Corticotropin-releasing hormone; ACTH: Adrenocorticotropic hormone; Ucn: Urocortin; Ucn2: Urocortin 2; Ucn3: Urocortin 3; DHEA-S: Dehydroepiandrosterone sulfate.</div><div class=\"graphic_reference\">Courtesy of Felice Petraglia, MD.</div><div id=\"graphicVersion\">Graphic 83570 Version 2.0</div></div></div>"},"83571":{"type":"graphic_diagnosticimage","displayName":"Portable chest radiograph rib fractures","title":"Portable chest radiograph rib fractures","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Portable chest radiograph rib fractures</div><div class=\"cntnt\"><img style=\"width:598px; height:294px;\" src=\"images/RADIOL/83571_Portab_chest_xray_rib_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The AP portable film of the chest (image A, and magnified in image B) reveals acute fractures of the lateral aspects of left sided ribs 2, 3, and 4 (red arrows) following trauma. No pneumothorax is present.</div><div class=\"graphic_footnotes\">AP: anterior-posterior.</div><div id=\"graphicVersion\">Graphic 83571 Version 3.0</div></div></div>"},"83572":{"type":"graphic_movie","displayName":"Fares technique for shoulder reduction","title":"Fares technique for shoulder reduction","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Fares technique for shoulder reduction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/83572_Faresshoulderreducvideo.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/83572_Faresshoulderreducimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from Simon and Sherman, Emergency Orthopedics, 6th edition DVD Â© Scott Sherman, all rights reserved.</div><div id=\"graphicVersion\">Graphic 83572 Version 3.0</div></div></div>"},"83573":{"type":"graphic_diagnosticimage","displayName":"Coalescent mastoiditis","title":"Coalescent mastoiditis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Coalescent mastoiditis</div><div class=\"cntnt\"><img style=\"width:504px; height:434px;\" src=\"images/PEDS/83573_Coalescent_mastoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal computed tomography with contrast of coalescent mastoiditis with loss of definition of the bony septae that define the mastoid air cells on the left (arrow) and soft tissue swelling (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 83573 Version 2.0</div></div></div>"},"83574":{"type":"graphic_diagnosticimage","displayName":"Coalescent mastoiditis with cortical disruption","title":"Coalescent mastoiditis with cortical disruption","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Coalescent mastoiditis with cortical disruption</div><div class=\"cntnt\"><img style=\"width:504px; height:483px;\" src=\"images/PEDS/83574_Coal_mastd_corti_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal computed tomography with contrast of 10-month-old with coalescent mastoiditis (arrow) and disruption of the mastoid cortex (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 83574 Version 2.0</div></div></div>"},"83576":{"type":"graphic_picture","displayName":"Arteriovenous malformation gluteus","title":"Arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83576_Arterio_malform_gluteus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arteriovenous malformation presenting as a vascular patch on the gluteus of a child.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83576 Version 6.0</div></div></div>"},"83577":{"type":"graphic_picture","displayName":"Arteriovenous malformation hand","title":"Arteriovenous malformation of the hand","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation of the hand</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83577_Arteriovenous_malfrm_ hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arteriovenous malformation presenting as a vascular mass on the hand of a child. Note the prominent draining veins on the wrist.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83577 Version 4.0</div></div></div>"},"83578":{"type":"graphic_picture","displayName":"Linear scleroderma face","title":"Linear scleroderma (morphea): Early manifestation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear scleroderma (morphea): Early manifestation</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83578_Linear_scleroderma_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A white, shiny, indurated area surrounded by an erythematous halo on the face of a child with linear scleroderma.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83578 Version 6.0</div></div></div>"},"83579":{"type":"graphic_picture","displayName":"Linear scleroderma face 2","title":"Linear scleroderma (morphea) of the face: Advanced lesion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear scleroderma (morphea) of the face: Advanced lesion</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83579_Linear_scleroderma_face_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Advanced linear morphea presenting as a&nbsp;firm, indurated, waxy plaque surrounded by a red-violaceous border&nbsp;on the face of a child.&nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83579 Version 5.0</div></div></div>"},"83580":{"type":"graphic_picture","displayName":"Nevus simplex salmon patch forehead","title":"Nevus simplex (salmon patch) of the forehead","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nevus simplex (salmon patch) of the forehead</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83580_Nevus_simpl_salmon_fore.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This splotchy pink mark fades with age.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83580 Version 4.0</div></div></div>"},"83581":{"type":"graphic_table","displayName":"Common street names cocaine PI","title":"Common street names for cocaine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common street names for cocaine</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td>Cocaine base (smokable)</td>\r\n            <td>Base, black rock, crack, electric kool-aid, rock, gravel, purple caps, Scotty, scramble, supercoke, twinkie, window pane, yam</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine HCl</td>\r\n            <td>Aspirin, Big C, blow, coconut, coke, devil's dandruff, flake, Florida snow, foo-foo dust, happy dust, lady, nose candy, white dragon, white lady, yao</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine paste</td>\r\n            <td>Basuco, bazooka, pasta</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine in vagina</td>\r\n            <td>Balling</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + heroin</td>\r\n            <td>Belushi, bipping, blanco, boy-girl, dynamite, goof ball, he-she, murder one, sandwich, snowball, speedball</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + marijuana</td>\r\n            <td>51, banano, bazooka, blunt, C &#38; M, candy sticks, caviar, champagne, cocktail, cocoa puff, crack bash, dirties, geek-joint, Greek, lace, P-dogs, premos, primo, Sherman stick, woo blunts, woolie</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + MDMA (ecstasy)</td>\r\n            <td>Bumping up</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + MDMA + LSD</td>\r\n            <td>Candy flipping on a string</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + methamphetamine</td>\r\n            <td>Croak, shabu</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + methcathinone</td>\r\n            <td>Wild cat</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + morphine</td>\r\n            <td>C &#38; M</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + PCP</td>\r\n            <td>Beam me up Scottie, space ball, space base, space dust</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + tobacco</td>\r\n            <td>Cigamos, coolie, geek-joint</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + marijuana + PCP</td>\r\n            <td>Jim Jones, speed boat, squirrel, wickie</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + heroin + tobacco</td>\r\n            <td>Flamethrowers, primos</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Cocaine + heroin + methamphetamine + flunitrazepam + alcohol</td>\r\n            <td>Five-way</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_lgnd\">Note that street names change over time and may differ by location. The same name might refer to more than one drug.</div><div id=\"graphicVersion\">Graphic 83581 Version 1.0</div></div></div>"},"83582":{"type":"graphic_table","displayName":"Causes of inguinal swelling in children","title":"Causes of inguinal swelling in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of inguinal swelling in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Male or Female</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Inguinal hernia (direct or indirect)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Inguinal lymphadenopathy or lymphadenitis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Granuloma inguinale</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Femoral hernia</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Appendicitis within the hernial sac (Amyand hernia)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Benign or malignant tumor*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Male only</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hydrocele of the spermatic cord</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Retractile testis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ectopic or undescended testis</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Traumatically dislocated testis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Female only</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Herniation of the ovary or fallopian tube</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">* Benign lesions of the inguinal canal can include, but are not limited to: lipomas, hematomas, mesothelial cyst , dermoid cysts. Soft tissue sarcomas comprise the most common malignant tumors of the groin.</div><div id=\"graphicVersion\">Graphic 83582 Version 1.0</div></div></div>"},"83583":{"type":"graphic_algorithm","displayName":"Inguinal swelling in a boy","title":"Inguinal swelling in a boy","html":"<div class=\"graphic\"><div style=\"width: 994px\" class=\"figure\"><div class=\"ttl\">Inguinal swelling in a boy</div><div class=\"cntnt\"><img style=\"width:974px; height:610px;\" src=\"images/EM/83583_Inguinal_swelling_boy_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LGV: lymphogranuloma venereum.<br />* Ultrasound should be performed.<br />Â¶ Ultrasound may provide additional diagnostic information.</div><div id=\"graphicVersion\">Graphic 83583 Version 4.0</div></div></div>"},"83584":{"type":"graphic_algorithm","displayName":"Inguinal swelling in a girl","title":"Inguinal swelling in a girl","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Inguinal swelling in a girl</div><div class=\"cntnt\"><img style=\"width:712px; height:362px;\" src=\"images/EM/83584_Inguinal_swell_girl.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Ultrasound should be performed.</div><div id=\"graphicVersion\">Graphic 83584 Version 2.0</div></div></div>"},"83585":{"type":"graphic_picture","displayName":"Bleeding ileum capsule endoscopy","title":"Bleeding in the ileum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bleeding in the ileum</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/GAST/83585_Bleeding_in_ileum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capsule endoscopy image showing bleeding in the ileum.</div><div id=\"graphicVersion\">Graphic 83585 Version 1.0</div></div></div>"},"83586":{"type":"graphic_picture","displayName":"Celiac disease capsule endoscopy","title":"Celiac disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Celiac disease</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/GAST/83586_Celiac_disease_caps_endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capsule endoscopy image in a patient with celiac disease. The findings are notable for villous blunting, leading to a scalloped mucosal appearance.</div><div id=\"graphicVersion\">Graphic 83586 Version 1.0</div></div></div>"},"83587":{"type":"graphic_table","displayName":"AIP response to treatment","title":"Autoimmune pancreatitis: Response to treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Autoimmune pancreatitis: Response to treatment</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">&nbsp;</td>\r\n            <td class=\"subtitle1\">Initial response to corticosteroids</td>\r\n            <td class=\"subtitle1\">Relapse</td>\r\n            <td class=\"subtitle1\">Response to azathioprine</td>\r\n            <td class=\"subtitle1\">Bile duct strictures - response to azathioprine</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>Raina 2009<sup>[1]</sup></strong></td>\r\n            <td class=\"centered\">15/19</td>\r\n            <td class=\"centered\">9/15</td>\r\n            <td class=\"centered\">9/15</td>\r\n            <td class=\"centered\">6/9</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>Ghazale 2008<sup>[2]</sup></strong></td>\r\n            <td class=\"centered\">29/30<br />\r\n            IAC</td>\r\n            <td class=\"centered\">12/17</td>\r\n            <td class=\"centered\">7/12</td>\r\n            <td>&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>Sandanayake 2009<sup>[3]</sup></strong></td>\r\n            <td class=\"centered\">23/28<br />\r\n            IAC</td>\r\n            <td class=\"centered\">13/23</td>\r\n            <td class=\"centered\">7/23</td>\r\n            <td>&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>Overall response</strong></td>\r\n            <td class=\"centered\">67/77<br />\r\n            (87 percent)</td>\r\n            <td class=\"centered\">34/55<br />\r\n            (61.8 percent)</td>\r\n            <td class=\"centered\">23/50<br />\r\n            (46 percent)</td>\r\n            <td>&nbsp;</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">IAC: IgG4 associated cholangitis.</div><div class=\"graphic_reference\">References:<br /><ol><li>Raina A, Yadav D, Krasinskas AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009; 104:2295.</li>&#xD;&#xA;<li>Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134:706.</li>&#xD;&#xA;<li>Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009; 7:1089.</li></ol></div><div id=\"graphicVersion\">Graphic 83587 Version 1.0</div></div></div>"},"83588":{"type":"graphic_picture","displayName":"NSAID stricture capsule endoscopy","title":"Small bowel stricture due to nonsteroidal anti-inflammatory drug use","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Small bowel stricture due to nonsteroidal anti-inflammatory drug use</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/GAST/83588_NSAID_strict_cap_endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capsule endoscopy image showing a stricture due to NSAID use.</div><div id=\"graphicVersion\">Graphic 83588 Version 1.0</div></div></div>"},"83589":{"type":"graphic_picture","displayName":"Crohn disease capsule endoscopy II","title":"Crohn disease of the small bowel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn disease of the small bowel</div><div class=\"cntnt\"><img style=\"width:447px; height:447px;\" src=\"images/GAST/83589_Crohns_capsule_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capsule endoscopy image from a patient with small bowel Crohn disease. The image is notable for edematous villi and erythematous small bowel mucosa around a stenosis.</div><div id=\"graphicVersion\">Graphic 83589 Version 2.0</div></div></div>"},"83590":{"type":"graphic_figure","displayName":"Acetaminophen poisoning nomogram","title":"Acetaminophen poisoning nomogram","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Acetaminophen poisoning nomogram</div><div class=\"cntnt\"><img style=\"width:470px; height:590px;\" src=\"images/EM/83590_Acetaminophen_poison_nomogr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This nomogram should only be used after a single acute acetaminophen ingestion. The line indicates the level at which toxicity is possible after acetaminophen overdose. A serum acetaminophen level should be obtained four or more hours after an ingestion to ensure that a peak level has occurred. Patients who ingest extended-release preparations should have a second level drawn four hours after the first level to assess for an additional rise in serum concentration. The level should be plotted in relationship to the time of ingestion to determine the likelihood of toxicity and the need for treatment. Caution should be used in assessing the reliability of the time of ingestion. This nomogram cannot be used for ingestions that occurred greater than 24 hours prior to presentation, repeated supratherapeutic oral ingestions, or iatrogenic intravenous overdose.</div><div class=\"graphic_footnotes\">* Note that mg/L is the same concentration as mcg/mL.</div><div class=\"graphic_reference\">Original nomogram from: Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975; 55:871. Copyright &copy; 1975 by the AAP. Updated version reproduced with permission from: Dart RC, Rumack BH. Acetaminophen (Paracetamol). In: Medical Toxicology, 3rd ed, Dart RC (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83590 Version 8.0</div></div></div>"},"83591":{"type":"graphic_picture","displayName":"PTCL-NOS histology","title":"Peripheral T-cell lymphoma, not otherwise specified histology","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Peripheral T-cell lymphoma, not otherwise specified histology</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/HEME/83591_PTCLNOShistology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node biopsy of a&nbsp;peripheral T cell lymphoma&nbsp;shows tumor cells with clear cytoplasm and pleomorphic nuclei. There are two high endothelial venules present in this field. Hematoxylin and eosin, 40x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83591 Version 6.0</div></div></div>"},"83592":{"type":"graphic_picture","displayName":"PTCL NOS pathology","title":"Peripheral T cell lymphoma, not otherwise specified","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Peripheral T cell lymphoma, not otherwise specified</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/83592_Lymphoepithelioidlymph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node biopsy showing a peripheral T cell lymphoma, not otherwise specified with a high content of epitheliod histiocytes and eosinophils&nbsp;intermixing with lymphoma cells. Hematoxylin and eosin, 50x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83592 Version 7.0</div></div></div>"},"83593":{"type":"graphic_table","displayName":"US prehospital provider scope of practice","title":"United States responder and emergency medical technician scope of practice","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">United States responder and emergency medical technician scope of practice</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Provider (current designation)</td>\r\n            <td class=\"subtitle1\">Provider (future designation)*</td>\r\n            <td class=\"subtitle1\">Scope of practice</td>\r\n        </tr>\r\n        <tr>\r\n            <td>First responder</td>\r\n            <td>Emergency medical responder (EMR)</td>\r\n            <td>\r\n            <ul>\r\n                <li>Ensure environment is safe to enter and provide care</li>\r\n                <li>Gather initial history</li>\r\n                <li>Appropriate physical examination</li>\r\n                <li>Remove patient(s) from immediate danger</li>\r\n                <li>Basic cardiopulmonary resuscitation</li>\r\n                <li>Operate an automated external defibrillator</li>\r\n                <li>Oxygen administration</li>\r\n                <li>Insert oropharyngeal airway</li>\r\n                <li>Suction airway</li>\r\n                <li>Provide bag-mask ventilation</li>\r\n                <li>Apply direct pressure for control of bleeding</li>\r\n                <li>Administer unit dose auto-injectors (eg, epinephrine)</li>\r\n                <li>Perform bandaging</li>\r\n                <li>Provide manual C-spine and fracture stabilization</li>\r\n                <li>Assist uncomplicated delivery of newborn</li>\r\n            </ul>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Emergency medical technician-Basic (EMT-B)</td>\r\n            <td>Emergency medical technician (EMT)</td>\r\n            <td>As for first responder and:\r\n            <ul>\r\n                <li>Obtain consent for or refusal of care</li>\r\n                <li>Perform basic on-scene triage</li>\r\n                <li>Access and extricate trapped victims</li>\r\n                <li>Apply traction splint</li>\r\n                <li>Perform spine immobilization (C-spine and backboard)</li>\r\n                <li>Apply tourniquet</li>\r\n                <li>Apply pneumatic antishock garment if indicated</li>\r\n                <li>Irrigate eyes</li>\r\n                <li>Provide basic burn management</li>\r\n                <li>Perform basic poisoning management (administration of activated charcoal)</li>\r\n                <li>Assist patient in taking their own prescribed medications (eg, nitroglycerin SL)</li>\r\n                <li>Administer limited types of oral medications (eg, aspirin, glucose paste)</li>\r\n                <li>Assist complicated delivery of newborn</li>\r\n            </ul>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Emergency medical technician-Intermediate (EMT-I)</td>\r\n            <td>Advanced emergency medical technician (AEMT)</td>\r\n            <td>As for first responder, EMT-B and:\r\n            <ul>\r\n                <li>Insert esophageal-tracheal or multi-lumen airway</li>\r\n                <li>Suction already intubated patients</li>\r\n                <li>Obtain peripheral IV access</li>\r\n                <li>Perform IO access</li>\r\n                <li>Administer IV fluids</li>\r\n                <li>Administer limited medications (eg, nitroglycerine SL, IM or SC epinephrine, IV dextrose, IM or IV naloxone)</li>\r\n                <li>Administer inhaled beta agonists</li>\r\n            </ul>\r\n            </td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">C-spine: cervical spine; SL: sublingual; IO: intraosseous; IV: intravenous; IM: intramuscular; SC: subcutaneous.<br />* Proposed in United States document, EMS Education Agenda for the Future: A Systems Approach (www.nhtsa.gov/people/injury/ems/FinalEducationAgenda.pdf [Accessed on May 08, 2012]).</div><div id=\"graphicVersion\">Graphic 83593 Version 1.0</div></div></div>"},"83594":{"type":"graphic_diagnosticimage","displayName":"Identification of mitral valve prolapse","title":"Identification of mitral valve prolapse","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Identification of mitral valve prolapse</div><div class=\"cntnt\"><img style=\"width:501px; height:504px;\" src=\"images/CARD/83594_Id_mitral_valve_pro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The current accepted echocardiographic definition of mitral valve prolapse is billowing of any portion of the mitral leaflets at least 2 mm above the annular plane in the long axis views (parasternal or apical three-chamber). On this parasternal long axis there is pronounced prolapse of the posterior leaflet (arrows) above the annular plane (line).</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; Ao: aorta.</div><div id=\"graphicVersion\">Graphic 83594 Version 3.0</div></div></div>"},"83595":{"type":"graphic_figure","displayName":"Nonclassic and classic MVP","title":"Nonclassic mitral valve prolapse (with fibroelastic deficiency) and classic mitral valve prolapse (Barlow's disease)","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Nonclassic mitral valve prolapse (with fibroelastic deficiency) and classic mitral valve prolapse (Barlow's disease)</div><div class=\"cntnt\"><img style=\"width:513px; height:486px;\" src=\"images/CARD/83595_Nonclass_class_MVP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>(A and B) Non-classic MVP (fibroelastic deficiency)</strong><br />(A) Parasternal long axis view demonstrating presence of a flail segment of the posterior leaflet (arrow).<br />(B) 3D TEE of the same patient shows focal involvement of the P2 scallop with evidence of ruptured chords (arrow).<br /><strong>(C and D) Classic MVP (Barlow's disease)</strong><br />(C) Apical long axis view shows diffusely thickened anterior and posterior mitral leaflets (arrows).<br />(D) 3D TEE of the same patient shows massive prolapse of the P2-P3 scallops.</div><div id=\"graphicVersion\">Graphic 83595 Version 2.0</div></div></div>"},"83597":{"type":"graphic_figure","displayName":"Deaths from cardiovascular disease","title":"Deaths from cardiovascular disease, United States, 1900 to 2008","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Deaths from cardiovascular disease, United States, 1900 to 2008</div><div class=\"cntnt\"><img style=\"width:550px; height:290px;\" src=\"images/CARD/83597_Deathscardiovascdisease.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CVD: cardiovascular disease; CHD: coronary heart disease.</div><div class=\"graphic_reference\">Reproduced from: NHLBI Fact Book, 2011. National Heart Lung and Blood Institute. Available at: http://www.nhlbi.nih.gov/about/factbook/toc.htm.</div><div id=\"graphicVersion\">Graphic 83597 Version 3.0</div></div></div>"},"83598":{"type":"graphic_table","displayName":"ART for PEP after exposure to HIV","title":"Antiretroviral regimens for post-exposure prophylaxis following an exposure to HIV","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antiretroviral regimens for post-exposure prophylaxis following an exposure to HIV</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preferred regimen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Tenofovir disoproxil fumarate-emtricitabine* plus one of the following:</p> <ul> <li>Raltegravir 400 mg twice daily </li> <li>Dolutegravir 50 mg once daily </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Alternative regimens</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate&#182; </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tenofovir disoproxil fumarate-emtricitabine* plus a pharmacologically boosted protease inhibitor<sup>&#182;&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rilpivirine-emtricitabine-tenofovir disoproxil fumarate*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Antiretroviral agents separated by \"-\" are available in single-tablet coformulations</div><div class=\"graphic_footnotes\">*For individuals with an estimated glomerular filtration rate &lt;50 mL/min, the dosage of tenofovir disoproxil fumarate and emtricitabine should be adjusted based upon kidney function, and coformulated tablets cannot be used. For specific dosing recommendations, refer to the individual Lexicomp drug monographs available in UpToDate.<br />Â¶ There is an increased risk of drug interactions if a regimen using a boosting agent (ie, cobicistat or ritonavir) is administered. In addition, regimens that contain tenofovir disoproxil fumarate and cobicistat should only be administered to individuals with an estimated glomerular filtration rate â¥70 mL/min.<br />Î In general, we prefer darunavir boosted with ritonavir or the coformulated tablet darunavir-cobicistat if a protease inhibitor is used. However, darunavir should generally be avoided in patients with a sulfonamide allergy. Atazanavir boosted with ritonavir or the coformulated tablet atazanavir-cobicistat can be used as an alternative.</div><div id=\"graphicVersion\">Graphic 83598 Version 9.0</div></div></div>"},"83599":{"type":"graphic_figure","displayName":"Age-adjusted death rates for CHD","title":"Age-adjusted death rates for coronary heart disease by race/ethnicity and sex, United States, 1999 to 2008","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Age-adjusted death rates for coronary heart disease by race/ethnicity and sex, United States, 1999 to 2008</div><div class=\"cntnt\"><img style=\"width:570px; height:419px;\" src=\"images/CARD/83599_Age_adjust_death_rates_CHD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Non-Hispanic.</div><div class=\"graphic_reference\">Reproduced from: NHLBI Fact Book, 2011. National Heart Lung and Blood Institute. Available at: http://www.nhlbi.nih.gov/about/factbook/toc.htm.</div><div id=\"graphicVersion\">Graphic 83599 Version 2.0</div></div></div>"},"83601":{"type":"graphic_picture","displayName":"Port wine stain midline demarcation","title":"Port wine stain in an infant","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Port wine stain in an infant</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83601_Port_wine_stain__mid_dema.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83601 Version 4.0</div></div></div>"},"83602":{"type":"graphic_movie","displayName":"PLAX view of nonclassic MVP","title":"Parasternal long-axis echocardiographic view of nonclassic mitral valve prolapse with flail posterior leaflet","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Parasternal long-axis echocardiographic view of nonclassic mitral valve prolapse with flail posterior leaflet</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/83602_PLAXnonclassicMVPvideo.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:514px; height:354px;\" src=\"images/CARD/83602_PLAXnonclassicMVPimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images from a patient with fibroelastic deficiency with flail P2 scallop. Note focal involvement of the middle posterior scallop.</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 83602 Version 1.0</div></div></div>"},"83603":{"type":"graphic_movie","displayName":"3D SHAX view of nonclassic MVP","title":"Three-dimensional short-axis echocardiographic view of nonclassic mitral valve prolapse with flail posterior leaflet","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Three-dimensional short-axis echocardiographic view of nonclassic mitral valve prolapse with flail posterior leaflet</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/83603_3DSHAXnonclassMVPvideo.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:514px; height:368px;\" src=\"images/CARD/83603_3DSHAXnonclassMVPimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images from a patient with fibroelastic deficiency with flail P2 scallop. Note focal involvement of the middle posterior scallop.</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 83603 Version 1.0</div></div></div>"},"83604":{"type":"graphic_movie","displayName":"Three-chamber view of classic MVP","title":"Apical three chamber echocardiographic view of classic mitral valve prolapse with bileaflet prolapse","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Apical three chamber echocardiographic view of classic mitral valve prolapse with bileaflet prolapse</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/83604_ThreechambclassMVPvideo.mp4\" style=\"width:512px;height:368px\"></div><img style=\"width:504px; height:343px;\" src=\"images/CARD/83604_ThreechambclassMVPimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images from a patient with classic Barlow's disease. Note diffusely thickened anterior and posterior leaflets, with massive prolapse mostly of the P2-P3 scallops.</div><div id=\"graphicVersion\">Graphic 83604 Version 1.0</div></div></div>"},"83605":{"type":"graphic_movie","displayName":"3D SHAX view of classic MVP","title":"Three-dimensional short-axis echocardiographic view of classic mitral valve prolapse with bileaflet prolapse","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Three-dimensional short-axis echocardiographic view of classic mitral valve prolapse with bileaflet prolapse</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/83605_3DSHAXclassicMVPvideo.mp4\" style=\"width:512px;height:368px\"></div><img style=\"width:524px; height:344px;\" src=\"images/CARD/83605_3DSHAXclassicMVPimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images from a patient with classic Barlow's disease. Note diffusely thickened anterior and posterior leaflets, with massive prolapse mostly of the P2-P3 scallops.</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 83605 Version 1.0</div></div></div>"},"83606":{"type":"graphic_movie","displayName":"PLAX view of classic MVP with annular disjunction","title":"Parasternal long-axis echocardiographic view of classic mitral valve prolapse with annular disjunction","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Parasternal long-axis echocardiographic view of classic mitral valve prolapse with annular disjunction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/83606_PLAXVPannuldisjuncvideo.mp4\" style=\"width:512px;height:368px\"></div><img style=\"width:504px; height:343px;\" src=\"images/CARD/83606_PLAXVPannuldisjuncimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mitral annular disjunction in patient with MVP. During systole, a small gap appears between the postero-lateral basal myocardial segment and the mitral annulus.</div><div id=\"graphicVersion\">Graphic 83606 Version 1.0</div></div></div>"},"83607":{"type":"graphic_figure","displayName":"iCycleBeads","title":"iCycleBeads software application","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">iCycleBeads software application</div><div class=\"cntnt\"><img style=\"width:504px; height:350px;\" src=\"images/OBGYN/83607_iCycleBeads.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After the&nbsp;woman enters the start date of her most recent period into her private account, the web app shows her where she is in her cycle and whether she is on a day when pregnancy is&nbsp;possible (fertile day)&nbsp;or&nbsp;unlikely (non-fertile day)&nbsp;according to the Standard Days Method of family planning. The information is provided both on a color coded calendar and on a virtual representation of CycleBeadsÂ®. She can also receive alerts telling her the day is a fertile&nbsp;or non-fetile day and&nbsp;reminding her&nbsp;when she is about to get her next period.</div><div class=\"graphic_reference\">Copyright &copy; 2002-2012 Cycle Technologies. Photo reproduced with permission.</div><div id=\"graphicVersion\">Graphic 83607 Version 2.0</div></div></div>"},"83608":{"type":"graphic_figure","displayName":"Central spinal cord syndrome PI","title":"Central spinal cord syndrome","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Central spinal cord syndrome</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/PI/83608_Central-spinal-cord-syndrome-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">People with central spinal cord syndrome lose some sensation in the upper part of the body (the shaded part in the drawing). Sometimes they also have weakness in those body parts or trouble moving them.</div><div id=\"graphicVersion\">Graphic 83608 Version 1.0</div></div></div>"},"83609":{"type":"graphic_figure","displayName":"Psoralens","title":"Psoralens","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Psoralens</div><div class=\"cntnt\"><img style=\"width:481px; height:669px;\" src=\"images/DERM/83609_Psoralens.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83609 Version 2.0</div></div></div>"},"83618":{"type":"graphic_figure","displayName":"Colon cancer on CT and colonoscopy","title":"Colon cancer seen on CT scan and colonoscopy","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Colon cancer seen on CT scan and colonoscopy</div><div class=\"cntnt\"><img style=\"width:513px; height:227px;\" src=\"images/GAST/83618_Col_cancer_CT_clnscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Computed tomographic (CT) scan showing a filling defect in the ascending colon (red arrow) along with an involved lymph node (yellow arrow). <BR>(B) Colon cancer identified in the ascending colon on subsequent colonoscopy.</div><div id=\"graphicVersion\">Graphic 83618 Version 1.0</div></div></div>"},"83625":{"type":"graphic_figure","displayName":"Effect of CPAP on CSA associated with HF","title":"Effect of CPAP therapy on heart transplant-free survival in patients who have central sleep apnea associated with heart failure","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Effect of CPAP therapy on heart transplant-free survival in patients who have central sleep apnea associated with heart failure</div><div class=\"cntnt\"><img style=\"width:530px; height:522px;\" src=\"images/PULM/83625_eff_cpap_csa_assoc_hf.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival plots demonstrating that compared with the control group, the CPAP-CSA-suppressed group had significantly improved heart transplant-free survival (* unadjusted p = 0.043), whereas the CPAP-CSA-unsuppressed group did not (unadjusted p = 0.260).</div><div class=\"graphic_reference\">Reproduced with permission from: Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: A post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure trial (CANPAP). Circulation 2007; 115:3173. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83625 Version 4.0</div></div></div>"},"83630":{"type":"graphic_algorithm","displayName":"Management of acute symptomatic nephrolithiasis","title":"Management of acute symptomatic nephrolithiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of acute symptomatic nephrolithiasis</div><div class=\"cntnt\"><img style=\"width:405px; height:500px;\" src=\"images/NEPH/83630_Manageacutesympnephrol.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; ESWL: extracorporeal shock wave lithotripsy; URS: ureteroscopy.</div><div id=\"graphicVersion\">Graphic 83630 Version 4.0</div></div></div>"},"83631":{"type":"graphic_picture","displayName":"Urine sediment with bacteria budding yeast and hyphae","title":"Urine sediment showing bacteria, budding yeast, and hyphae","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Urine sediment showing bacteria, budding yeast, and hyphae</div><div class=\"cntnt\"><img style=\"width:504px; height:339px;\" src=\"images/NEPH/83631_Urin_bact_yeast_hyph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The background contains budding yeast and hyphae (white arrow), as well as a bacteria (yellow arrows). There is also a broad hyaline cast.&nbsp;(Bright-field microscopy, 3100.)</div><div class=\"graphic_reference\">Reproduced with permission from: McClatchey KD. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83631 Version 1.0</div></div></div>"},"83632":{"type":"graphic_picture","displayName":"Urine sediment showing squamous epithelial cells","title":"Urine sediment showing squamous epithelial cells","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Urine sediment showing squamous epithelial cells</div><div class=\"cntnt\"><img style=\"width:498px; height:336px;\" src=\"images/NEPH/83632_Urine_sed_squam_epith_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A group of squamous epithelial cells in urine. The cells are large and flat and have some granules in their cytoplasm. The central nucleus is approximately the size of a large lymphocyte. (Bright-field microscopy, 3160.)</div><div class=\"graphic_reference\">Reproduced with permission from: McClatchey KD. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83632 Version 1.0</div></div></div>"},"83635":{"type":"graphic_table","displayName":"Questions that are helpful in detecting possible narcolepsy","title":"Questions that are helpful in detecting possible narcolepsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Questions that are helpful in detecting possible narcolepsy</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Question</td>\r\n            <td class=\"subtitle1\">Implication</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Are you sleepy most of the day?</td>\r\n            <td>Sleepiness present, but could be caused by a variety of conditions</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Do you feel rested upon waking in the morning? Are your naps refreshing?</td>\r\n            <td>Sleepiness probably not caused by poor quality sleep (eg, sleep apnea, etc)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Do you have vivid dreams during daytime naps?</td>\r\n            <td>Possible REM sleep during naps</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Do you ever have muscle weakness when you tell a joke or laugh?</td>\r\n            <td>Cataplexy</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Do you ever see, hear, or feel things that you know aren't there as you are falling asleep?</td>\r\n            <td>Hypnagogic hallucinations</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Are you ever unable to move when you first awake or just before falling asleep?</td>\r\n            <td>Sleep paralysis</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83635 Version 1.0</div></div></div>"},"83636":{"type":"graphic_picture","displayName":"Endodermal sinus tumor histo","title":"Ovarian endodermal sinus tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ovarian endodermal sinus tumor</div><div class=\"cntnt\"><img style=\"width:374px; height:576px;\" src=\"images/ONC/83636_Endoderm_sinus_tumor_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yolk sac (endodermal sinus tumor). The tumor is composed of dilated tubular spaces lined by flattened cells with an edematous stroma.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83636 Version 1.0</div></div></div>"},"83637":{"type":"graphic_picture","displayName":"Clopidogrel hypersensitivity: Generalized rash","title":"Clopidogrel hypersensitivity: Generalized rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clopidogrel hypersensitivity: Generalized rash</div><div class=\"cntnt\"><img style=\"width:441px; height:514px;\" src=\"images/ALLRG/83637_Clopidogrelgenexanth.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Cheema AN, Mohammad A, Hong T, et al. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J Am Coll Cardiol 2011; 58:1445. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83637 Version 4.0</div></div></div>"},"83638":{"type":"graphic_table","displayName":"Clopidogrel desensitization protocol","title":"Clopidogrel desensitization protocol","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clopidogrel desensitization protocol</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Dose (mg)</td> <td class=\"subtitle1\">Concentration (mg/mL)*</td> <td class=\"subtitle1\">Amount given (mL)</td> </tr> <tr class=\"centered\"> <td>8:00 AM</td> <td>0</td> <td>0</td> <td>0.01</td> </tr> <tr class=\"centered\"> <td>8:30 AM</td> <td>0.005</td> <td>0.5</td> <td>0.01</td> </tr> <tr class=\"centered\"> <td>9:00 AM</td> <td>0.01</td> <td>0.5</td> <td>0.02</td> </tr> <tr class=\"centered\"> <td>9:30 AM</td> <td>0.02</td> <td>0.5</td> <td>0.04</td> </tr> <tr class=\"centered\"> <td>10:00 AM</td> <td>0.04</td> <td>0.5</td> <td>0.08</td> </tr> <tr class=\"centered\"> <td>10:30 AM</td> <td>0.08</td> <td>0.5</td> <td>0.16</td> </tr> <tr class=\"centered\"> <td>11:00 AM</td> <td>0.16</td> <td>0.5</td> <td>0.32</td> </tr> <tr class=\"centered\"> <td>11:30 AM</td> <td>0.3</td> <td>0.5</td> <td>0.6</td> </tr> <tr class=\"centered\"> <td>12:00 PM</td> <td>0.6</td> <td>0.5</td> <td>1.2</td> </tr> <tr class=\"centered\"> <td>12:30 PM</td> <td>1.2</td> <td>5</td> <td>0.24</td> </tr> <tr class=\"centered\"> <td>1:00 PM</td> <td>2.5</td> <td>5</td> <td>0.5</td> </tr> <tr class=\"centered\"> <td>1:30 PM</td> <td>5</td> <td>5</td> <td>1</td> </tr> <tr class=\"centered\"> <td>2:00 PM</td> <td>10</td> <td>5</td> <td>2</td> </tr> <tr class=\"centered\"> <td>2:30 PM</td> <td>20</td> <td>5</td> <td>4</td> </tr> <tr class=\"centered\"> <td>3:00 PM</td> <td>40</td> <td>5</td> <td>8</td> </tr> <tr class=\"centered\"> <td>3:30 PM</td> <td>75</td> <td>75 mg tablet</td> <td>N/A</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">Refer to the UpToDate topic on hypersensitivity reactions to clopidogrel&nbsp;</SPAN><SPAN style=\"COLOR: black\">for specific </SPAN>information about the types of reactions for which clopidogrel desensitization has been performed, preparation of the patient, and risks and benefits of the procedure.</div><div class=\"graphic_footnotes\">* Clopidogrel can be solubilized by different methods. (1) Finely crushed clopidogrel may be combined with a small amount of Ora-Plus compounding agent and then diluted with Ora-Sweet to final concentrations of 0.5 and 5 mg/mL. (2) Ethanol may be used as a solvent to dissolve finely crushed clopidogrel, which is then titrated to 0.5 and 5 mg/mL using purified drinking water. All solutions should be prepared just before use.</div><div class=\"graphic_reference\">Reproduced from: von Tiehl KF, Price MJ, Valencia R, et al. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007; 50:2039. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83638 Version 7.0</div></div></div>"},"83639":{"type":"graphic_picture","displayName":"Balloon dilation of eustachian tube","title":"Balloon dilation of eustachian tube","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Balloon dilation of eustachian tube</div><div class=\"cntnt\"><img style=\"width:513px; height:477px;\" src=\"images/PC/83639_Ball_dilat_eust_tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Preoperative 30 degree angled rigid endoscopic view of left eustachian tube nasopharyngeal orifice showing inflamed, edematous mucosa circumferentially and especially at the posterior cushion. The lumen is swollen closed.<br />(B) Intraoperative inflation of a 7 mm diameter by 16 mm long balloon placed within the cartilaginous eustachian tube.<br />(C) Immediate postdilation view of the eustachian tube lumen showing some minor mucosal laceration and significant persistent widening of the lumen.</div><div class=\"graphic_reference\">Figures reprinted with permission from: Dennis S Poe, MD, Childrenâs Hospital Boston.</div><div id=\"graphicVersion\">Graphic 83639 Version 1.0</div></div></div>"},"83640":{"type":"graphic_figure","displayName":"Cross section of female pelvis","title":"Cross section of female pelvis","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Cross section of female pelvis</div><div class=\"cntnt\"><img style=\"width:593px; height:444px;\" src=\"images/EM/83640_Crosssectionfemalepelvis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF, Agur AMR. Pelvis and perineum. In: Clinically Oriented Anatomy, 6th ed, Lippincott Williams &amp; Wilkins, Baltimore, 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83640 Version 7.0</div></div></div>"},"83641":{"type":"graphic_table","displayName":"Giftedness characteristics","title":"Presentation and characteristics of giftedness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presentation and characteristics of giftedness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Characteristics of giftedness</td> <td class=\"subtitle1\">Example</td> </tr> <tr> <td>Early language development</td> <td>A two-year-old who speaks in complex sentences</td> </tr> <tr> <td>Early reading and writing skills</td> <td>A preschooler who reads text with comprehension or writes in sentences with minimal or no instruction</td> </tr> <tr> <td>Complaints of boredom at school, in the presence of clear academic success</td> <td>\"Why do I have to do the same thing over and over again?\"</td> </tr> <tr> <td>Unusual academic skills in math</td> <td>Self-acquired ability and interest in numbers (eg, learning to multiply numbers mentally before formal schooling)</td> </tr> <tr> <td>Intense interests</td> <td>A strong preoccupation with an area of interest, academic or nonacademic (eg, airplanes)</td> </tr> <tr> <td>Clearly advanced skills in academic or nonacademic areas, especially when identified by a teacher or a professional in an academic or nonacademic domain</td> <td>Highly advanced drawing skills, athletic abilities, musical ability, etc</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"2\">Characteristics NOT indicative of school-house giftedness</td> </tr> <tr> <td colspan=\"2\">Advanced motor skills, especially before&nbsp;two years of age*</td> </tr> <tr> <td colspan=\"2\">High scores on a developmental assessment tool, especially when administered before&nbsp;three years of age</td> </tr> <tr> <td colspan=\"2\">Advanced rote learning skills, such as letter identification, number identification, or reading decoding without text comprehension</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Advanced motor skills may be associated with giftedness in athletics or other kinesthetic domains.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Robinson NM, Olszewski-Kubilius PM. Gifted and talented children: Issues for pediatricians. Pediatr Rev 1996; 17:427.</LI>&#xD;&#xA;<LI>Ruf DL. 5 Levels of Gifted: School Issues and Educational Options, Great Potential Press, Scottsdale, AZ 2009.</LI>&#xD;&#xA;<LI>Webb TJ, Amend ER, Webb NE, et al. Misdiagnosis and Dual Diagnosis of Gifted Children and Adults: ADHD, Bipolar, OCD, Aspergerâs, Depression, and Other Disorders, Great Potential Press, Scottsdale, AZ 2005.</LI>&#xD;&#xA;<LI>Winner E. Gifted Children: Myths and Realities, Basic Books, New York 1996.</LI>&#xD;&#xA;<LI>Winner E. Exceptionally high intelligence and schooling. American Psychologist 1997; 52:1070.</LI></OL></div><div id=\"graphicVersion\">Graphic 83641 Version 2.0</div></div></div>"},"83643":{"type":"graphic_table","displayName":"Giftedness definitions","title":"Commonly used definitions for giftedness/outstanding talent","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used definitions for giftedness/outstanding talent</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">United States Department of Education</td> </tr> <tr> <td class=\"indent1\">\"Children and youth with outstanding talent perform or show the potential for performing at remarkably high levels of accomplishment when compared with others of their age, experience, or environment. These children and youth exhibit high capability in intellectual, creative, and/or artistic areas, possess an unusual leadership capacity, or excel in specific academic fields. They require services or activities not ordinarily provided by the schools. Outstanding talents are present in children and youth from all cultural groups, across all economic strata, and in all areas of human endeavor.\"</td> </tr> <tr> <td class=\"subtitle1_single\">The National Association for Gifted Children</td> </tr> <tr> <td class=\"indent1\">\"Gifted individuals are those who demonstrate outstanding levels of aptitude (defined as an exceptional ability to reason and learn) or competence (documented performance or achievement in top 10 percent or rarer) in one or more domains. Domains include any structured area of activity with its own symbol system (eg, mathematics, music, language) and/or set of sensorimotor skills (eg, painting, dance, sports).\"</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>National Excellence:A case for developing America's talent. 1993. www.eric.ed.gov/PDFS/ED372580.pdf (Accessed on April 11, 2012).</li>&#xD;&#xA;    <li>National Association for Gifted Children Position Paper: Redefining Giftedness for a New Century: Shifting the Paradigm. March 2010. Available at: www.nagc.org/index2.aspx?id=6404 (Accessed on April 11, 2012).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 83643 Version 2.0</div></div></div>"},"83644":{"type":"graphic_table","displayName":"Giftedness resources","title":"Resources for clinicians and families of gifted children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for clinicians and families of gifted children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">National organizations</td> </tr> <tr> <td>The Association for the Gifted<br /> cectag.com</td> <td>A division of the Council of Exceptional Children; dedicated to helping parents and professionals work together successfully.</td> </tr> <tr> <td>Davidson Institute for Talent Development<br /> <a href=\"http://www.ditd.org/\" target=\"_new\">www.ditd.org</a></td> <td>Focuses on the needs of highly and profoundly gifted young people.</td> </tr> <tr> <td>Duke University Talent Identification Program<br /> <a href=\"http://www.tip.duke.edu/\" target=\"_new\">www.tip.duke.edu</a></td> <td>Provides information and resources about the identification and support of academically gifted students.</td> </tr> <tr> <td>The Gifted Child Society<br /> <a href=\"http://www.gifted.org/\" target=\"_new\">www.gifted.org</a></td> <td>Provides educational enrichment and support services, assistance to parents, and professional training.</td> </tr> <tr> <td>Hoagie's Gifted Page<br /> <a href=\"http://www.hoagiesgifted.org/\" target=\"_new\">www.hoagiesgifted.org</a></td> <td>Provides a variety of information and resources.</td> </tr> <tr> <td>National Association for Gifted Children<br /> <a href=\"http://www.nagc.org/\" target=\"_new\">www.nagc.org</a></td> <td>Nonprofit organization of parents, teachers, and other professionals; provides position papers and local contact information for parents of gifted children. Focus is on schoolhouse giftedness.</td> </tr> <tr> <td>National Research Center on the Gifted and Talented<br /> <a href=\"http://nrcgt.uconn.edu/\" spellcheck=\"true\" target=\"_blank\">nrcgt.uconn.edu</a></td> <td>Provides research and informational resources.</td> </tr> <tr> <td>Supporting the Emotional Needs of the Gifted<br /> <a href=\"http://sengifted.org/\" spellcheck=\"true\" target=\"_blank\">sengifted.org</a></td> <td>Focuses on the social and emotional needs of the gifted.</td> </tr> <tr> <td>Twice-Exceptional Newsletter<br /> www.2enewsletter.com</td> <td>Provides information and resources for parents, teachers, and counselors of gifted children with learning difficulties.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"2\">Books</td> </tr> <tr> <td colspan=\"2\">A Parent's Guide to Gifted Children by James T Webb, Janet L Gore, Edward R Amend, and Arlene R De Vries (2007)</td> </tr> <tr> <td colspan=\"2\">Freeing Our Families From Perfectionism by Thomas S Greenspon (2001)</td> </tr> <tr> <td colspan=\"2\">Gifted Grownups: The Mixed Blessing of Extraordinary Potential by Marylou Kelly Streznewski (1999)</td> </tr> <tr> <td colspan=\"2\">Gifted Kids Speak Out: Hundreds of Kids Ages 6-13 Talk About School, Friends, Their Families, and the Future by James R Delisle (1987)</td> </tr> <tr> <td colspan=\"2\">Gifted Kids Survival Guide series of books by Judy Galbraith (2009 and 2011)</td> </tr> <tr> <td colspan=\"2\">Guiding the Gifted Child by James T Webb, Elizabeth A Meckstroth, and Stephanie S Tolan (1994)</td> </tr> <tr> <td colspan=\"2\">Helping Gifted Children Soar: A Practical Guide for Parents and Teachers, 2<sup>nd</sup> ed. by Carol Strip Whitney and Gretchen Hirsch (2011)</td> </tr> <tr> <td colspan=\"2\">Keys to Parenting the Gifted Child, 3<sup>rd</sup> ed. by Sylvia B Rimm (2006)</td> </tr> <tr> <td colspan=\"2\">Parents' Guide to Raising a Gifted Child: Recognizing and Developing Your Child's Potential from Preschool to Adolescence by James Alvino (1996)</td> </tr> <tr> <td colspan=\"2\">Stand Up for Your Gifted Child: How to Make the Most of Kids' Strengths at School and at Home by Joan F Smutny (2000)</td> </tr> <tr> <td colspan=\"2\">The Survival Guide for Parents of Gifted Kids: How to Understand, Live With, and Stick Up for Your Gifted Child by Sally Yahnke Walker (2002)</td> </tr> <tr> <td colspan=\"2\">Perfectionism: What's Bad About Being Too Good by Jan Goldberg and Miriam Elliot (1992)</td> </tr> <tr> <td colspan=\"2\">Why Bright Kids Get Poor Grades: And What You Can Do About It: A Six-Step Program for Parents and Teachers By Sylvia B Rimm (2008)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83644 Version 6.0</div></div></div>"},"83645":{"type":"graphic_diagnosticimage","displayName":"Cervical spine unilateral facet dislocation","title":"Cervical spine unilateral facet dislocation with bow tie sign","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Cervical spine unilateral facet dislocation with bow tie sign</div><div class=\"cntnt\"><img style=\"width:460px; height:595px;\" src=\"images/RADIOL/83645_Cerv_spine_unilat_facet_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain x-ray of the cervical spine in the lateral projection reveals unilateral malalignment of the facets of C3 (arrowheads) compared with subjacent column which are widely separated resulting in the bow tie appearance of the posterior elements as they line up (D, red overlay). Associated mild subluxation is present. The arrows show normal alignment of the facet joints of C4, C5, and C6. These findings are reminiscent of a unilateral facet dislocation.</div><div id=\"graphicVersion\">Graphic 83645 Version 2.0</div></div></div>"},"83646":{"type":"graphic_diagnosticimage","displayName":"CT scan rib fractures","title":"CT scan rib fractures","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">CT scan rib fractures</div><div class=\"cntnt\"><img style=\"width:596px; height:509px;\" src=\"images/RADIOL/83646_CT_scan_rib_fractures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is a 41-year-old man who sustained trauma and was complaining of left sided back pain. The findings on plain film are not obvious (image A). The CT scan through the lower chest in the axial plane (image B) reveals an obvious minimally displaced left sided posterior rib fracture (arrow) which is magnified in image C. There is an associated small effusion or hemothorax (small arrowhead), minor atelectasis at the left base (large arrowhead), and a small amount of extrapleural hemorrhage (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 83646 Version 3.0</div></div></div>"},"83647":{"type":"graphic_figure","displayName":"Gifted writing sample 1","title":"Writing sample of gifted child at age 5 years, 0 months","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Writing sample of gifted child at age 5 years, 0 months</div><div class=\"cntnt\"><img style=\"width:378px; height:495px;\" src=\"images/PEDS/83647_Gifted_writing_samp_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">I like to play with Dermot.</div><div id=\"graphicVersion\">Graphic 83647 Version 1.0</div></div></div>"},"83648":{"type":"graphic_figure","displayName":"Gifted writing sample 2","title":"Writing sample of gifted child at age 5 years, 1 month","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Writing sample of gifted child at age 5 years, 1 month</div><div class=\"cntnt\"><img style=\"width:385px; height:514px;\" src=\"images/PEDS/83648_Gifted_writing_samp_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">What did you do over the weekend? I celebrated Diwali on Friday with my teacher from Balivhar.</div><div id=\"graphicVersion\">Graphic 83648 Version 1.0</div></div></div>"},"83649":{"type":"graphic_figure","displayName":"Gifted writing sample 3","title":"Writing sample of gifted child during kindergarten","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Writing sample of gifted child during kindergarten</div><div class=\"cntnt\"><img style=\"width:392px; height:509px;\" src=\"images/PEDS/83649_Gifted_writing_samp_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fractions mean a part of something. An example is half a pizza or a quarter of a pie.</div><div id=\"graphicVersion\">Graphic 83649 Version 1.0</div></div></div>"},"83650":{"type":"graphic_figure","displayName":"Gifted writing sample 4","title":"Writing sample of gifted child at age 5 years, 10 months","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Writing sample of gifted child at age 5 years, 10 months</div><div class=\"cntnt\"><img style=\"width:385px; height:504px;\" src=\"images/PEDS/83650_Gifted_writing_Samp_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When we learned about space we learned about Neptune. A fact is that Neptune has a storm cloud scooter and it chases all the other storms. I also enjoyed being with Nicholas and Nadia.</div><div id=\"graphicVersion\">Graphic 83650 Version 1.0</div></div></div>"},"83653":{"type":"graphic_table","displayName":"Categories of antituberculous agents","title":"Antituberculous agents for treatment of drug-resistant tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antituberculous agents for treatment of drug-resistant tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>A. Fluoroquinolones*</strong></td> <td colspan=\"2\"> <p>Levofloxacin</p> <p>Moxifloxacin</p> Gatifloxacin<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>B. Second-line injectable agents</strong></td> <td colspan=\"2\"> <p>Amikacin</p> <p>Capreomycin</p> <p>Kanamycin<sup>&#916;</sup></p> Streptomycin<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>C. Other core second-line agents*</strong></td> <td colspan=\"2\"> <p>Ethionamide/prothionamide</p> <p>Cycloserine/terizidone</p> <p>Linezolid</p> Clofazimine<sup>&#167;</sup></td> </tr> <tr> <td rowspan=\"3\"><strong>D. Add-on agents</strong> (not part of the core MDR-TB regimen)</td> <td class=\"divider_bottom\"><strong>D1</strong></td> <td class=\"divider_bottom\"> <p>Pyrazinamide</p> <p>Ethambutol</p> High-dose isoniazid</td> </tr> <tr class=\"divider_bottom\"> <td><strong>D2</strong></td> <td> <p>Bedaquiline</p> Delamanid</td> </tr> <tr> <td><strong>D3</strong></td> <td> <p>Para-aminosalicyclic acid</p> <p>Imipenem-cilastatin<sup>&#165;</sup></p> <p>Meropenem<sup>&#165;</sup></p> <p>Amoxicillin-clavulanate<sup>&#165;</sup></p> (Thioacetazone)<sup>&#135;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The approach to selecting an antituberculous regimen is discussed in the UpToDate text on diagnosis, treatment, and prevention of drug-resistant tuberculosis. If a minimum number of core second-line TB medicines cannot be reached by using agents from groups A, B, and C alone, drugs from group D2 or, if not possible, from group D3 are added. Agents from group D1 may be used if they are considered to add benefit (eg, high-dose isoniazid in patients without high-level isoniazid resistance).</div><div class=\"graphic_footnotes\">MDR-TB: multidrug-resistant tuberculosis.<br />* Medicines in groups A and C are shown by decreasing order of usual preference for use (subject to other considerations; refer to the UpToDate topic on diagnosis, treatment, and prevention of drug-resistant tuberculosis).<br />Â¶ Gatifloxacin is associated with dysglycemia and is no longer commercially available.<br />Î Kanamycin is not available in the United States.<br />â&nbsp;In general, use of streptomycin should be avoided, given widespread resistance; its use should be restricted to the setting of known in vitro susceptibility, no history of prior use, and contraindication to amikacin (which is the preferred injectable agent).<br />Â§ In the United States, use of clofazimine for treatment of drug-resistant TB requires submission of an investigational new drug (IND) application to the US Food and Drug Administration (FDA).<br />Â¥&nbsp;Carbapenems and clavulanate are meant to be used together; clavulanate is only available in formulations combined with amoxicillin.<br />â¡&nbsp;HIV status must be tested and confirmed to be negative before thioacetazone is started.</div><div class=\"graphic_reference\">Adapted from WHO Treatment guidelines for drug-resistant tuberculosis â 2016 update. World Health Organization 2016 (<A href=\"http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/\" target=_blank>http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/</A>, accessed 2 June 2016). Copyright Â© 2016.</div><div id=\"graphicVersion\">Graphic 83653 Version 19.0</div></div></div>"},"83654":{"type":"graphic_figure","displayName":"Schematic and 3D echo of mitral valve leaflets    ","title":"Schematic and 3D echocardiographic image of mitral valve leaflets","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Schematic and 3D echocardiographic image of mitral valve leaflets</div><div class=\"cntnt\"><img style=\"width:517px; height:293px;\" src=\"images/CARD/83654_Schem_3D_echo_mit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomically, the mitral valve is formed by a long and narrow&nbsp;anterior leaflet&nbsp;and a shorter posterior leaflet occupying a larger portion of the annular circumference.<BR>(A) Anatomical description proposed by Carpentier, with the posterior leaflet divided into anterolateral (P1), middle (P2), and postero-medial (P3) scallops. While the anterior leaflet does not have obvious anatomical divisions, corresponding segments are labeled similarly A1 to A3. <BR>(B) Corresponding 3D TEE image of the mitral valve as viewed from the left atrial side.</div><div class=\"graphic_footnotes\">Ao: aortic valve.</div><div id=\"graphicVersion\">Graphic 83654 Version 2.0</div></div></div>"},"83655":{"type":"graphic_table","displayName":"Etiologies of MVP","title":"Etiologies of mitral valve prolapse and mechanisms of regurgitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of mitral valve prolapse and mechanisms of regurgitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Mechanism of regurgitation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Primary MVP</td> </tr> <tr> <td class=\"indent1\">Fibroelastic deficiency</td> <td> <p>Isolated prolapse of the mitral leaflet (commonly P2 scallop)</p> <p>Frequent chordal rupture</p> Mild annular enlargement</td> </tr> <tr> <td class=\"indent1\">Forme fruste Barlow disease</td> <td>Intermediate</td> </tr> <tr> <td class=\"indent1\">Barlow disease</td> <td> <p>Diffusely thickened, redundant mitral leaflets</p> <p>Chordal elongation/rupture</p> Severe annular enlargement</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Secondary MVP</td> </tr> <tr> <td class=\"indent1\">Associated with connective tissue disease*</td> <td> <p>Diffusely thickened, redundant mitral leaflets</p> <p>Chordal elongation/rupture</p> Severe annular enlargement</td> </tr> <tr> <td class=\"indent1\">Associated with congenital heart disease<sup>&#182;</sup></td> <td> <p>Thickened, redundant mitral leaflets</p> Chordal elongation/rupture possible</td> </tr> <tr> <td class=\"indent1\">Acute myocardial ischemia</td> <td>Papillary muscle dysfunction with secondary prolapse/papillary muscle rupture</td> </tr> <tr> <td class=\"indent1\">Acute rheumatic fever</td> <td>Chordal and leaflet destruction by acute inflammatory process</td> </tr> <tr> <td class=\"indent1\">Endocarditis</td> <td>Chordal and leaflet destruction by infectious process; vegetations</td> </tr> <tr> <td class=\"indent1\">Other (trauma, severe mitral annular calcification, hypertrophic cardiomyopathy)</td> <td>Ruptured chordae, no myxomatous changes of mitral valve leaflets</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Associated with Marfan and Ehlers-Danlos syndromes, osteogenesis imperfecta, and pseudoxanthoma elasticum. Macroscopical and microscopical appearance similar to primary Barlow disease.<br />&para; Most common congenital disease associations are Ebstein's anomaly and atrial septal defect.</div><div id=\"graphicVersion\">Graphic 83655 Version 2.0</div></div></div>"},"83656":{"type":"graphic_figure","displayName":"ARDS mortality trend","title":"ARDS mortality from 1981 to 2006","html":"<div class=\"graphic\"><div style=\"width: 635px\" class=\"figure\"><div class=\"ttl\">ARDS mortality from 1981 to 2006</div><div class=\"cntnt\"><img style=\"width:615px; height:285px;\" src=\"images/PULM/83656_ARDS_mortality_trend.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annual pooled weighted mortality from 1981 to 2006 for all included studies, by year of conduct. The solid points show data for observational studies; the open points show data for randomized controlled trials. Upper and lower confidence intervals are shown for observational studies and randomized controlled trials, respectively. Interpolation lines are included to facilitate visual interpretation and do not indicate trends between point estimates.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2012 American Thoracic Society. Phua J, Badia JR, Adhikari NK, et al, 2009. Has mortality from acute respiratory distress syndrome decreased over time? A systematic review. American Journal of Respiratory and Critical Care Medicine; 179:220. Official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 83656 Version 1.0</div></div></div>"},"83657":{"type":"graphic_table","displayName":"BAV and associated CV conditions","title":"Bicuspid aortic valve and associated cardiovascular conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bicuspid aortic valve and associated cardiovascular conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Incidence of BAV (percent)</td> </tr> <tr> <td>Coarctation of the aorta</td> <td>50</td> </tr> <tr> <td>Turner syndrome</td> <td>30</td> </tr> <tr> <td>Supravalvular aortic stenosis</td> <td>30</td> </tr> <tr> <td>Subvalvular aortic stenosis</td> <td>23</td> </tr> <tr> <td>Patent ductus arteriosus</td> <td>Unknown</td> </tr> <tr> <td>Sinus of Valsalva aneurysm</td> <td>15 to 20</td> </tr> <tr> <td>Ventricular septal defect</td> <td>30</td> </tr> <tr> <td>Shone complex</td> <td>60 to 85</td> </tr> <tr> <td>Ascending aortic aneurysm</td> <td>Common</td> </tr> <tr> <td>Loeys-Dietz syndrome</td> <td>2.5 to 17</td> </tr> <tr> <td>ACTA2 mutation familial thoracic aortic aneurysm syndrome</td> <td>3</td> </tr> <tr> <td>MAT2A mutation familial thoracic aortic aneurysm syndrome</td> <td>Unknown</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAV: bicuspid aortic valve.</div><div id=\"graphicVersion\">Graphic 83657 Version 3.0</div></div></div>"},"83658":{"type":"graphic_figure","displayName":"Mortality ESRD patients 2007 USRDS","title":"All-cause mortality among ESRD patients from 2007 USRDS data","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">All-cause mortality among ESRD patients from 2007 USRDS data</div><div class=\"cntnt\"><img style=\"width:507px; height:385px;\" src=\"images/NEPH/83658_MortalityESRD2007USRDS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ESRD: prevalent ESRD patients, 2007. General Medicare: non-ESRD patients with at least one month of Medicare eligibility in 2007. Adjusted for gender and race. Medicare patients, 2007, used as reference cohort.</div><div class=\"graphic_footnotes\">ESRD: end-stage renal disease; USRDS: United States Renal Data System.</div><div class=\"graphic_reference\">Reproduced from: U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009. The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.</div><div id=\"graphicVersion\">Graphic 83658 Version 2.0</div></div></div>"},"83659":{"type":"graphic_picture","displayName":"Chalazion eyelid PI","title":"Chalazion in the eyelid","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Chalazion in the eyelid</div><div class=\"cntnt\"><img style=\"width:515px; height:197px;\" src=\"images/PI/83659_Chalazion_upp_eye_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chalazion is a firm, painless bump that can form in the upper eyelid (A) or the lower eyelid (B).</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83659 Version 4.0</div></div></div>"},"83660":{"type":"graphic_figure","displayName":"Five-year survival ESRD patients 2007 USRDS data","title":"Five-year survival among ESRD patients from 2007 USRDS data","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Five-year survival among ESRD patients from 2007 USRDS data</div><div class=\"cntnt\"><img style=\"width:583px; height:324px;\" src=\"images/NEPH/83660_5yearsurvESRD2007data.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incident dialysis patients and patients receiving a first transplant in the calendar year, 1993 to 1997 and 1998 to 2002 combined; adjusted for age, gender, race, and primary diagnosis. Incident ESRD patients, 2005, used as reference cohort. Dialysis patients are followed from day 90 after initiation; transplant patients are followed from the transplant date.</div><div class=\"graphic_footnotes\">ESRD: end-stage renal disease; USRDS: United States Renal Data System; PD: peritoneal dialysis; Tx: transplant; HD: hemodialysis.</div><div class=\"graphic_reference\">Reproduced from: U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009. The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.</div><div id=\"graphicVersion\">Graphic 83660 Version 2.0</div></div></div>"},"83661":{"type":"graphic_figure","displayName":"Range of neutrophil count in term neonates","title":"Range of neutrophil count for newborn infants born with a gestational age >36 weeks during the first 72 hours of life","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Range of neutrophil count for newborn infants born with a gestational age &gt;36 weeks during the first 72 hours of life</div><div class=\"cntnt\"><img style=\"width:512px; height:358px;\" src=\"images/PEDS/83661_Range_neutro_term_neo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neutrophils per microL of blood during the first 72 hours after the birth of term and near-term (&gt;36 weeks of gestation) neonates. A total of 12,149 values were obtained for the analysis. The 5th percentile, the mean, and the 95th percentile values are shown.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Schmutz N, Henry E, Jopling J, Christensen RD. Expected ranges for blood neutrophil concentrations of neonates: the Manroe and Mouzinho charts revisited. J Perinatol 2008; 28:275. <a href=\"http://www.nature.com/jp/index.html\" target=\"_blank\">http://www.nature.com/jp/index.html</a>. Copyright &copy; 2008.</div><div id=\"graphicVersion\">Graphic 83661 Version 2.0</div></div></div>"},"83662":{"type":"graphic_table","displayName":"Evaluation of BAV","title":"Recommendations for evaluation of the unoperated patient with bicupsid aortic valve","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for evaluation of the unoperated patient with bicupsid aortic valve</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class I</td> </tr> <tr> <td>Primary imaging and hemodynamic assessment of AS and aortic valve disease are recommended by echocardiography-Doppler to evaluate the presence and severity of AS or AR; LV size, function, and mass; and dimensions and anatomy of the ascending aorta and associated lesions (level of evidence: B)</td> </tr> <tr> <td>Echocardiography is recommended for re-evaluation of patients with AS who experience a change in signs or symptoms and for assessment of changes in AS hemodynamics during pregnancy (level of evidence: B)</td> </tr> <tr> <td>In asymptomatic adolescents and young adults, echocardiography-Doppler is recommended yearly for AS with a mean Doppler gradient greater than 30 mmHg or peak instantaneous gradient greater than 50 mmHg and every two years for patients with lesser gradients (level of evidence: C)</td> </tr> <tr> <td>Cardiac catheterization is recommended when noninvasive measurements are inconclusive or discordant with clinical signs (level of evidence: C)</td> </tr> <tr> <td>Coronary angiography is recommended before aortic valve surgery for coronary angiography in adults at risk for coronary artery disease (level of evidence: B)</td> </tr> <tr> <td>Coronary angiography is recommended before a Ross procedure if noninvasive imaging of the coronary arteries is inadequate (level of evidence: C)</td> </tr> <tr> <td>A yearly ECG is recommended in young adults less than 30 years of age with mean Doppler gradients greater than 30 mmHg or peak Doppler gradients greater than 50 mmHg (level of evidence: C)</td> </tr> <tr> <td>An ECG is recommended every other year in young adults less than 30 years of age with mean Doppler gradients less than 30 mmHg or peak Doppler gradients less than 50 mmHg (level of evidence: C)</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIa</td> </tr> <tr> <td>In asymptomatic young adults less than 30 years of age, exercise stress testing is reasonable to determine exercise capability, symptoms, and blood pressure response (level of evidence: C)</td> </tr> <tr> <td>Exercise stress testing is reasonable for patients with a mean Doppler gradient greater than 30 mmHg or peak Doppler gradient greater than 50 mmHg if the patient is interested in athletic participation or if clinical findings differ from noninvasive measurements (level of evidence: C)</td> </tr> <tr> <td>Exercise stress testing is reasonable for the evaluation of an asymptomatic young adult with a mean Doppler gradient greater than 40 mmHg or a peak Doppler gradient greater than 64 mmHg or when the patient anticipates athletic participation or pregnancy (level of evidence: C)</td> </tr> <tr> <td>Dobutamine stress testing can be beneficial in the evaluation of a mild aortic valve gradient in the face of low LV ejection fraction and reduced cardiac output (level of evidence: C)</td> </tr> <tr> <td>MRI/CT can be beneficial to add important information about the anatomy of the thoracic aorta (level of evidence: C)</td> </tr> <tr> <td>Exercise stress testing can be useful to evaluate blood pressure response or elicit exercise-induced symptoms in asymptomatic older adults with AS (level of evidence: B)</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIb</td> </tr> <tr> <td>Magnetic resonance angiography may be beneficial in quantifying AR when other data are ambiguous or borderline (level of evidence: C)</td> </tr> <tr> <td class=\"subtitle1_single\">Class III</td> </tr> <tr> <td>Exercise stress testing should not be performed in symptomatic patients with AS or those with repolarization abnormality on ECG or systolic dysfunction on echocardiography (level of evidence: C)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. Circulation 2008; 118:e714. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83662 Version 4.0</div></div></div>"},"83663":{"type":"graphic_table","displayName":"BAV AoV surgery and Ao root replacement","title":"Recommendations for aortic valve repair/replacement and aortic root replacement in patients with bicuspid aortic valve","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for aortic valve repair/replacement and aortic root replacement in patients with bicuspid aortic valve</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Class I</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Aortic valvuloplasty, AVR, or Ross repair is indicated in patients with severe AS or chronic severe AR while they undergo coronary artery bypass grafting, surgery on the aorta, or surgery on other heart valves (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>AVR is indicated for patients with severe AS and LV dysfunction (LV ejection fraction less than 50 percent) (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">AVR is indicated in adolescents or young adults with severe AR who have:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Development of symptoms (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Development of persistent LV dysfunction (LV ejection fraction less than 50 percent) or progressive LV dilatation (LV end-diastolic diameter four standard deviations above normal) (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Surgery to repair or replace the ascending aorta in a patient with a BAV is recommended when the ascending aorta diameter is 5.0 cm or more or when there is progressive dilatation at a rate greater than or equal to 5 mm per year (level of evidence: B)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Class IIa</td>\r\n        </tr>\r\n        <tr>\r\n            <td>AVR is reasonable for asymptomatic patients with severe AR and normal systolic function (ejection fraction greater than 50 percent) but with severe LV dilatation (LV end-diastolic diameter greater than 75 mm or end-systolic dimension greater than 55 mm) (level of evidence: B)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Surgical aortic valve repair or replacement is reasonable in patients with moderate AS undergoing coronary artery bypass grafting or other cardiac or aortic root surgery (level of evidence: B)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Class IIb</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">AVR may be considered for asymptomatic patients with any of the following indications:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Severe AS and abnormal response to exercise (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Evidence of rapid progression of AS or AR (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Mild AS while undergoing coronary artery bypass grafting or other cardiac surgery and evidence of a calcific aortic valve (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Extremely severe AS (aortic valve area less than 0.6 cm and/or mean Doppler systolic AV gradient greater than 60 mmHg) in an otherwise good operative candidate (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Moderate AR undergoing coronary artery bypass grafting or other cardiac surgery (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Severe AR with rapidly progressive LV dilation when the degree of LV dilation exceeds an end-diastolic dimension of 70 mm or end-systolic dimension of 50 mm, with declining exercise tolerance, or with abnormal hemodynamic responses to exercise (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Surgical repair may be considered in adults with AS or AR and concomitant ascending aortic dilatation (ascending aorta diameter greater than 4.5 cm) coexisting with AS or AR (level of evidence: B)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1_start\">Early surgical repair may be considered in adults with the following indications:</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">AS and a progressive increase in ascending aortic size (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">Mild AR if valve-sparing aortic root replacement is being considered (level of evidence: C)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Class III</td>\r\n        </tr>\r\n        <tr>\r\n            <td>AVR is not useful for prevention of sudden death in asymptomatic adults with AS who have none of the findings listed under the Class IIa/IIb indications (level of evidence: B)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>AVR is not indicated in asymptomatic patients with AR who have normal LV size and function (level of evidence: B)</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. Circulation 2008; 118:e714. Copyright Â© 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83663 Version 4.0</div></div></div>"},"83664":{"type":"graphic_table","displayName":"Aortic balloon valvotomy in youg adults with congenital AS","title":"Recommendations for aortic balloon valvotomy for young adults with congenital aortic stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for aortic balloon valvotomy for young adults with congenital aortic stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class I</td> </tr> <tr> <td class=\"sublist2_start\">In young adults and others without significantly calcified aortic valves and no AR, aortic balloon valvotomy is indicated in the following patients:</td> </tr> <tr> <td class=\"sublist2\">Those with symptoms of angina, syncope, dyspnea on exertion, and peak-to-peak gradients at catheterization greater than 50 mmHg (level of evidence: C)</td> </tr> <tr> <td class=\"sublist2\">Asymptomatic adolescents or young adults who demonstrate ST or T-wave abnormalities in the left precordial leads on ECG at rest or with exercise and a peak-to-peak catheter gradient greater than 60 mmHg (level of evidence: C)</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIa</td> </tr> <tr> <td class=\"indent1\">Aortic balloon valvotomy is reasonable in the asymptomatic adolescent or young adult with AS and a peak-to-peak gradient on catheterization greater than 50 mmHg when the patient is interested in playing competitive sports or becoming pregnant (level of evidence: C)</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIb</td> </tr> <tr> <td class=\"indent1\">Aortic balloon valvotomy may be considered as a bridge to surgery in hemodynamically unstable adults with AS, adults at high risk for AVR, or when AVR cannot be performed secondary to significant comorbidities (level of evidence: C)</td> </tr> <tr> <td class=\"subtitle1_single\">Class III</td> </tr> <tr> <td class=\"indent1\">In older adults, aortic balloon valvotomy is not recommended as an alternative to AVR, although certain younger patients may be an exception and should be referred to a center with experience in aortic balloon valvuloplasties (level of evidence: B)</td> </tr> <tr> <td class=\"indent1\">In asymptomatic adolescents and young adults, aortic balloon valvotomy should not be performed with a peak-to-peak gradient less than 40 mmHg without symptoms or ECG changes (level of evidence: B)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. Circulation 2008; 118:e714. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83664 Version 7.0</div></div></div>"},"83670":{"type":"graphic_table","displayName":"Manual defibrillation performance bundle","title":"Manual defibrillation performance bundle","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Manual defibrillation performance bundle</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td>\r\n            <ol>\r\n                <li>Attach and charge the defibrillator while continuing excellent chest compressions. </li>\r\n                <li>Stop compressions and assess rhythm (should take no more than 5 seconds).</li>\r\n                <li>If VF or VT is present, deliver shock; if non-shockable rhythm is present, resume excellent CPR. </li>\r\n                <li>Resume excellent chest compressions and CPR <strong>immediately</strong> after the shock is delivered. </li>\r\n            </ol>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Critical point: Interruptions in excellent chest compressions must be kept to a minimum: Do <strong>NOT</strong> stop compressions while defibrillator is charged.</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83670 Version 2.0</div></div></div>"},"83671":{"type":"graphic_table","displayName":"Key principles in the performance of ACLS","title":"Key principles in the performance of ACLS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key principles in the performance of ACLS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Excellent CPR is crucial.</td> </tr> <tr> <td> <ul> <li>Excellent chest compressions <strong>must</strong> be performed throughout the resuscitation without interruption, using proper timing (100 to 120 compressions per minute) and force (5 to 6 cm depth), and allowing for complete chest recoil. </li> <li>Do&nbsp;<strong>not</strong> stop compressions until the defibrillator is fully charged. </li> <li>Anything short of excellent CPR does not achieve adequate cerebral and coronary perfusion. </li> <li>Excellent chest compressions take priority over ventilation. If a second rescuer is present, ventilations must be performed using proper timing (6 to 8 breaths per minute in the intubated patient; ratio of 30 compressions to 2 ventilations if not intubated) and force (each breath delivered over&nbsp;one second); avoid hyperventilation. </li> </ul> </td> </tr> <tr> <td>Defibrillate VF and pulseless VT as rapidly as possible.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Rapidly</strong> identify and treat causes of non-shockable arrest (PEA, asystole).</td> </tr> <tr> <td> <ul> <li>Important causes include the 5 H's and 5 T's: Hypoxia, Hypovolemia, Hydrogen ions (acidosis), Hyper/Hypo-kalemia, Hypothermia; Tension pneumothorax, Tamponade-cardiac, Toxins, Thrombosis-coronary (MI), Thrombosis-pulmonary (PE). </li> <li>If reversible causes are not corrected rapidly, the patient has little chance of survival. </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83671 Version 3.0</div></div></div>"},"83681":{"type":"graphic_picture","displayName":"Endoscopy showing ulcers","title":"Upper endoscopy showing shallow ulcers in the esophagus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Upper endoscopy showing shallow ulcers in the esophagus</div><div class=\"cntnt\"><img style=\"width:504px; height:411px;\" src=\"images/ID/83681_Endoscopy_show_ulcers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing multiple discrete shallow ulcers in the distal third of the esophagus.</div><div class=\"graphic_reference\">Reproduced with permission from: Canalejo E, Duran FG, Cabello N, Martinez JG. Herpes esophagitis in healthy adults and adolescents: report of 3 cases and review of the literature. Medicine 2010; 89:204. Copyright Â© 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83681 Version 4.0</div></div></div>"},"83682":{"type":"graphic_picture","displayName":"Viral exanthem close view","title":"Viral exanthem","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Viral exanthem</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/83682_Viral_exanthem_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous macules are present on the skin of this patient with a viral exanthem.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83682 Version 4.0</div></div></div>"},"83683":{"type":"graphic_table","displayName":"NCCN risk factors for cutaneous SCC recurrence","title":"Features identified by the National Comprehensive Cancer Network as risk factors for recurrence of cutaneous squamous cell carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features identified by the National Comprehensive Cancer Network as risk factors for recurrence of cutaneous squamous cell carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td>Location/size*</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Poorly-defined borders</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Recurrent tumors</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Immunosuppressed patient</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Site of previous radiation therapy or chronic inflammation</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Rapidly growing tumor</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Neurologic symptoms</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Moderately or poorly differentiated tumor</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Adenoid (acantholytic), adenosquamous, or desmoplastic subtypes</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Depth &#8805;2 mm or Clark level IV or V</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Perineural or vascular involvement</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">* Size â¥20 mm on trunk or extremities (excluding pretibia, hands, feet, nail units, and ankles); size â¥10 mm on cheeks, forehead, scalp, neck, or pretibia; size â¥6 mm on \"mask areas\" of the face (central face, eyelids, eyebrows, periorbital nose, lips [cutaneous and vermilion], chin, mandible, preauricular and postauricular skin/sulci, temple, ear, genitalia, hands, and feet).</div><div class=\"graphic_reference\">Source: Bichakjian CK, Alam M, Andersen J, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Basal Cell and Squamous Cell Skin Cancers, Version I.2013, National Comprehensive Cancer Network, 2013.</div><div id=\"graphicVersion\">Graphic 83683 Version 4.0</div></div></div>"},"83685":{"type":"graphic_picture","displayName":"Large volume nebulizer","title":"Large volume nebulizer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large volume nebulizer</div><div class=\"cntnt\"><img style=\"width:264px; height:504px;\" src=\"images/ALLRG/83685_Large_volume_nebulizer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large volume nebulizer, such as the HEART nebulizer shown here, can generate approximately 30 mL/hour of aerosol.</div><div class=\"graphic_reference\">Photo courtesy of Westmed, Inc. Reproduced with permission. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83685 Version 3.0</div></div></div>"},"83687":{"type":"graphic_picture","displayName":"Port wine stain pyogenic granuloma","title":"Pyogenic granuloma occurring in a port wine stain","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma occurring in a port wine stain</div><div class=\"cntnt\"><img style=\"width:464px; height:504px;\" src=\"images/DERM/83687_Port_wine_stain_pyo_gran.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 5-year-old boy with a small port wine stain on the side of his right cheek extending onto the ear developed a 4 mm pyogenic granuloma within the capillary malformation.</div><div class=\"graphic_reference\">Copyright Â© Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 83687 Version 5.0</div></div></div>"},"83689":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum on penis","title":"Pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/83689_Pyoderma_gangren_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A purulent ulcer is present on the penis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83689 Version 3.0</div></div></div>"},"83690":{"type":"graphic_picture","displayName":"Pustular pyoderma gangrenosum","title":"Pustular pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pustular pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83690_Pust_pyoderma_gangrenosum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple pustules with peripheral erythema consistent with pustular pyoderma gangrenosum are on the extremity. Scattered hemorrhagic macules are also present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83690 Version 3.0</div></div></div>"},"83691":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum large ulcer","title":"Pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83691_Pyoderm_gangren_lrg_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large ulcer with undermined borders and a purulent base is present on the lower extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83691 Version 3.0</div></div></div>"},"83692":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum localized","title":"Pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83692_Pyoderma_gangrenos_local.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A purulent ulcer is present on the extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83692 Version 3.0</div></div></div>"},"83694":{"type":"graphic_table","displayName":"Risk factors breast ca 40 to 49","title":"Factors significantly associated with increased breast cancer risk for women aged 40 to 49 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors significantly associated with increased breast cancer risk for women aged 40 to 49 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\">Breast cancer risk ratio<br /> (95% CI)</td> <td class=\"subtitle1\">Source<br /> (reference)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">&#8805;2-fold increased risk</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">First-degree relatives with breast cancer</td> </tr> <tr> <td class=\"sublist2\">1</td> <td class=\"sublist_other_centered\">2.14 (1.92-2.38)</td> <td class=\"sublist_other_centered\">1</td> </tr> <tr> <td class=\"sublist2\">2</td> <td class=\"sublist_other_centered\">3.84 (2.37-6.22)</td> <td class=\"sublist_other_centered\">1</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Age of first-degree relative with breast cancer</td> </tr> <tr> <td class=\"sublist2\">&#60;40 years</td> <td class=\"sublist_other_centered\">3.0 (1.8-4.9)</td> <td class=\"sublist_other_centered\">1</td> </tr> <tr> <td class=\"sublist2\">&#60;50 years</td> <td class=\"sublist_other_centered\">2.17 (1.86-2.53)</td> <td class=\"sublist_other_centered\">BCSC</td> </tr> <tr> <td class=\"indent1\">Breast density BI-RADS category 4</td> <td class=\"centered\">2.04 (1.84-2.26)</td> <td class=\"centered\">2*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">1.5- to 2.0-fold increased risk</td> </tr> <tr> <td class=\"indent1\">Prior benign breast biopsy result</td> <td class=\"centered\">1.87 (1.64-2.13)</td> <td class=\"centered\">3*</td> </tr> <tr> <td class=\"indent1\">Second-degree relative with breast cancer</td> <td class=\"centered\">1.7 (1.4-2.0)</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Breast density BI-RADS category 3</td> <td class=\"centered\">1.62 (1.51-1.75)</td> <td class=\"centered\">2*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">1.0- to 1.5-fold increased risk</td> </tr> <tr> <td class=\"indent1\">Current oral contraceptive use</td> <td class=\"centered\">1.30 (1.13-1.49)</td> <td class=\"centered\">BCSC</td> </tr> <tr> <td class=\"indent1\">Nulliparity<sup>&#182;</sup></td> <td class=\"centered\">1.25 (1.08-1.46)</td> <td class=\"centered\">5-9</td> </tr> <tr> <td class=\"indent1\">Age at first birth &#8805;30 years<sup>&#916;</sup></td> <td class=\"centered\">1.20 (1.02-1.42)</td> <td class=\"centered\">5-9</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BCSC: Breast Cancer Surveillance Consortium; BI-RADS: Breast Imaging Reporting and Data System.<br />* BCSC estimates from published analyses.<br />Â¶ Nulliparity was calculated in two ways. Estimates indicating significantly increased risk for nonparous compared with parous women were similar for the meta-analysis and the BCSC data. Estimates comparing ages at first birth that included nonparous women provided significant results for the meta-analysis only.<br />Î Results were not statistically significant for the BCSC data.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001; 358:1389.</li>&#xD;&#xA;    <li>Kerlikowske K, Cook AJ, Buist DS, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 2010; 28:3830.</li>&#xD;&#xA;    <li>Ashbeck EL, Rosenberg RD, Stauber PM, Key CR. Benign breast biopsy diagnosis and subsequent risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:467.</li>&#xD;&#xA;    <li>Pharoah PD, Day NE, Duffy S, et al. Family history and the risk of breast cancer: A systematic review and meta-analysis. Int J Cancer 1997; 71:800.</li>&#xD;&#xA;    <li>McCredie M, Paul C, Skegg DC, Williams S. Reproductive factors and breast cancer in New Zealand. Int J Cancer 1998; 76:182.</li>&#xD;&#xA;    <li>Chen CL, White E, Malone KE, Daling JR. Leisure-time physical activity in relation to breast cancer among young women (Washington, United States). Cancer Causes Control 1997; 8:77.</li>&#xD;&#xA;    <li>Althuis MD, Brogan DD, Coates RJ, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control 2003; 14:151.</li>&#xD;&#xA;    <li>Sweeney C, Baumgartner KB, Byers T, et al. Reproductive history in relation to breast cancer risk among Hispanic and non-Hispanic white women. Cancer Causes Control 2008; 19:391.</li>&#xD;&#xA;    <li>Reinier KS, Vacek PM, Geller BM. Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. Breast Cancer Res Treat 2007; 103:343.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Nelson HD, Zakher B, Cantor A, et al. Risk Factors for Breast Cancer for Women Aged 40 to 49 Years. Ann Intern Med 2012; 156:635. Copyright &copy; 2012 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 83694 Version 12.0</div></div></div>"},"83696":{"type":"graphic_table","displayName":"BMI Table PI","title":"How to find your body mass index (BMI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">How to find your body mass index (BMI)</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">&nbsp;</td>\r\n            <td class=\"subtitle1\" colspan=\"7\">Good weights</td>\r\n            <td class=\"subtitle1\" colspan=\"5\">Overweight</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Obesity</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\">BMI, kg/m2</td>\r\n            <td>19</td>\r\n            <td>20</td>\r\n            <td>21</td>\r\n            <td>22</td>\r\n            <td>23</td>\r\n            <td>24</td>\r\n            <td>25</td>\r\n            <td>26</td>\r\n            <td>27</td>\r\n            <td>28</td>\r\n            <td>29</td>\r\n            <td>30</td>\r\n            <td>35</td>\r\n            <td>40</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">Height, inches</td>\r\n            <td class=\"subtitle2\" colspan=\"14\">Weight, pounds</td>\r\n        </tr>\r\n        <tr>\r\n            <td>58\"</td>\r\n            <td>91</td>\r\n            <td>96</td>\r\n            <td>100</td>\r\n            <td>105</td>\r\n            <td>110</td>\r\n            <td>115</td>\r\n            <td>119</td>\r\n            <td>124</td>\r\n            <td>129</td>\r\n            <td>134</td>\r\n            <td>138</td>\r\n            <td>143</td>\r\n            <td>167</td>\r\n            <td>191</td>\r\n        </tr>\r\n        <tr>\r\n            <td>59\"</td>\r\n            <td>94</td>\r\n            <td>99</td>\r\n            <td>104</td>\r\n            <td>109</td>\r\n            <td>114</td>\r\n            <td>119</td>\r\n            <td>124</td>\r\n            <td>128</td>\r\n            <td>133</td>\r\n            <td>138</td>\r\n            <td>143</td>\r\n            <td>148</td>\r\n            <td>173</td>\r\n            <td>198</td>\r\n        </tr>\r\n        <tr>\r\n            <td>60\"</td>\r\n            <td>97</td>\r\n            <td>102</td>\r\n            <td>107</td>\r\n            <td>112</td>\r\n            <td>118</td>\r\n            <td>123</td>\r\n            <td>128</td>\r\n            <td>133</td>\r\n            <td>138</td>\r\n            <td>143</td>\r\n            <td>148</td>\r\n            <td>153</td>\r\n            <td>179</td>\r\n            <td>204</td>\r\n        </tr>\r\n        <tr>\r\n            <td>61\"</td>\r\n            <td>100</td>\r\n            <td>106</td>\r\n            <td>111</td>\r\n            <td>116</td>\r\n            <td>122</td>\r\n            <td>127</td>\r\n            <td>132</td>\r\n            <td>137</td>\r\n            <td>143</td>\r\n            <td>148</td>\r\n            <td>153</td>\r\n            <td>158</td>\r\n            <td>185</td>\r\n            <td>211</td>\r\n        </tr>\r\n        <tr>\r\n            <td>62\"</td>\r\n            <td>104</td>\r\n            <td>109</td>\r\n            <td>115</td>\r\n            <td>120</td>\r\n            <td>126</td>\r\n            <td>131</td>\r\n            <td>136</td>\r\n            <td>142</td>\r\n            <td>147</td>\r\n            <td>153</td>\r\n            <td>158</td>\r\n            <td>164</td>\r\n            <td>191</td>\r\n            <td>218</td>\r\n        </tr>\r\n        <tr>\r\n            <td>63\"</td>\r\n            <td>107</td>\r\n            <td>113</td>\r\n            <td>118</td>\r\n            <td>124</td>\r\n            <td>130</td>\r\n            <td>135</td>\r\n            <td>141</td>\r\n            <td>146</td>\r\n            <td>152</td>\r\n            <td>158</td>\r\n            <td>163</td>\r\n            <td>169</td>\r\n            <td>197</td>\r\n            <td>225</td>\r\n        </tr>\r\n        <tr>\r\n            <td>64\"</td>\r\n            <td>110</td>\r\n            <td>116</td>\r\n            <td>122</td>\r\n            <td>128</td>\r\n            <td>134</td>\r\n            <td>140</td>\r\n            <td>145</td>\r\n            <td>151</td>\r\n            <td>157</td>\r\n            <td>163</td>\r\n            <td>168</td>\r\n            <td>174</td>\r\n            <td>204</td>\r\n            <td>232</td>\r\n        </tr>\r\n        <tr>\r\n            <td>65\"</td>\r\n            <td>114</td>\r\n            <td>120</td>\r\n            <td>126</td>\r\n            <td>132</td>\r\n            <td>138</td>\r\n            <td>144</td>\r\n            <td>150</td>\r\n            <td>156</td>\r\n            <td>162</td>\r\n            <td>168</td>\r\n            <td>174</td>\r\n            <td>180</td>\r\n            <td>210</td>\r\n            <td>240</td>\r\n        </tr>\r\n        <tr>\r\n            <td>66\"</td>\r\n            <td>118</td>\r\n            <td>124</td>\r\n            <td>130</td>\r\n            <td>136</td>\r\n            <td>142</td>\r\n            <td>148</td>\r\n            <td>155</td>\r\n            <td>161</td>\r\n            <td>167</td>\r\n            <td>173</td>\r\n            <td>179</td>\r\n            <td>186</td>\r\n            <td>216</td>\r\n            <td>247</td>\r\n        </tr>\r\n        <tr>\r\n            <td>67\"</td>\r\n            <td>121</td>\r\n            <td>127</td>\r\n            <td>134</td>\r\n            <td>140</td>\r\n            <td>146</td>\r\n            <td>153</td>\r\n            <td>159</td>\r\n            <td>166</td>\r\n            <td>172</td>\r\n            <td>178</td>\r\n            <td>185</td>\r\n            <td>191</td>\r\n            <td>223</td>\r\n            <td>255</td>\r\n        </tr>\r\n        <tr>\r\n            <td>68\"</td>\r\n            <td>125</td>\r\n            <td>131</td>\r\n            <td>138</td>\r\n            <td>144</td>\r\n            <td>151</td>\r\n            <td>158</td>\r\n            <td>164</td>\r\n            <td>171</td>\r\n            <td>177</td>\r\n            <td>184</td>\r\n            <td>190</td>\r\n            <td>197</td>\r\n            <td>230</td>\r\n            <td>262</td>\r\n        </tr>\r\n        <tr>\r\n            <td>69\"</td>\r\n            <td>128</td>\r\n            <td>135</td>\r\n            <td>142</td>\r\n            <td>149</td>\r\n            <td>155</td>\r\n            <td>162</td>\r\n            <td>169</td>\r\n            <td>176</td>\r\n            <td>182</td>\r\n            <td>189</td>\r\n            <td>196</td>\r\n            <td>203</td>\r\n            <td>236</td>\r\n            <td>270</td>\r\n        </tr>\r\n        <tr>\r\n            <td>70\"</td>\r\n            <td>132</td>\r\n            <td>139</td>\r\n            <td>146</td>\r\n            <td>153</td>\r\n            <td>160</td>\r\n            <td>167</td>\r\n            <td>174</td>\r\n            <td>181</td>\r\n            <td>188</td>\r\n            <td>195</td>\r\n            <td>202</td>\r\n            <td>209</td>\r\n            <td>243</td>\r\n            <td>278</td>\r\n        </tr>\r\n        <tr>\r\n            <td>71\"</td>\r\n            <td>136</td>\r\n            <td>143</td>\r\n            <td>150</td>\r\n            <td>157</td>\r\n            <td>165</td>\r\n            <td>172</td>\r\n            <td>179</td>\r\n            <td>186</td>\r\n            <td>193</td>\r\n            <td>200</td>\r\n            <td>208</td>\r\n            <td>215</td>\r\n            <td>250</td>\r\n            <td>286</td>\r\n        </tr>\r\n        <tr>\r\n            <td>72\"</td>\r\n            <td>140</td>\r\n            <td>147</td>\r\n            <td>154</td>\r\n            <td>162</td>\r\n            <td>169</td>\r\n            <td>177</td>\r\n            <td>184</td>\r\n            <td>191</td>\r\n            <td>199</td>\r\n            <td>206</td>\r\n            <td>213</td>\r\n            <td>221</td>\r\n            <td>258</td>\r\n            <td>294</td>\r\n        </tr>\r\n        <tr>\r\n            <td>73\"</td>\r\n            <td>144</td>\r\n            <td>151</td>\r\n            <td>159</td>\r\n            <td>166</td>\r\n            <td>174</td>\r\n            <td>182</td>\r\n            <td>189</td>\r\n            <td>197</td>\r\n            <td>204</td>\r\n            <td>212</td>\r\n            <td>219</td>\r\n            <td>227</td>\r\n            <td>265</td>\r\n            <td>302</td>\r\n        </tr>\r\n        <tr>\r\n            <td>74\"</td>\r\n            <td>148</td>\r\n            <td>155</td>\r\n            <td>163</td>\r\n            <td>171</td>\r\n            <td>179</td>\r\n            <td>186</td>\r\n            <td>194</td>\r\n            <td>202</td>\r\n            <td>210</td>\r\n            <td>218</td>\r\n            <td>225</td>\r\n            <td>233</td>\r\n            <td>272</td>\r\n            <td>311</td>\r\n        </tr>\r\n        <tr>\r\n            <td>75\"</td>\r\n            <td>152</td>\r\n            <td>160</td>\r\n            <td>168</td>\r\n            <td>176</td>\r\n            <td>184</td>\r\n            <td>192</td>\r\n            <td>200</td>\r\n            <td>208</td>\r\n            <td>216</td>\r\n            <td>224</td>\r\n            <td>232</td>\r\n            <td>240</td>\r\n            <td>279</td>\r\n            <td>319</td>\r\n        </tr>\r\n        <tr>\r\n            <td>76\"</td>\r\n            <td>156</td>\r\n            <td>164</td>\r\n            <td>172</td>\r\n            <td>180</td>\r\n            <td>189</td>\r\n            <td>197</td>\r\n            <td>205</td>\r\n            <td>213</td>\r\n            <td>221</td>\r\n            <td>230</td>\r\n            <td>238</td>\r\n            <td>246</td>\r\n            <td>287</td>\r\n            <td>328</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_lgnd\">Body Mass Index (BMI) is a measure of weight in relation to height. It is the most practical way to estimate if a person is underweight, at a healthy weight, overweight, or obese.</div><div id=\"graphicVersion\">Graphic 83696 Version 1.0</div></div></div>"},"83697":{"type":"graphic_figure","displayName":"Waist circumference PI","title":"How to measure your waist circumference","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">How to measure your waist circumference</div><div class=\"cntnt\"><img style=\"width:357px; height:468px;\" src=\"images/PI/83697_waist_circumference_measure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To measure your waist circumference, place the measuring tape around your belly just above your hipbone. Make sure the measuring tape is snug but not too tight. Also, make sure the tape measure is parallel to the floor as it circles your body.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart Lung and Blood Institute, Bethesda MD, October 2000.</div><div id=\"graphicVersion\">Graphic 83697 Version 1.0</div></div></div>"},"83699":{"type":"graphic_diagnosticimage","displayName":"Breast clustered cysts mammogram and ultrasound","title":"Breast clustered cysts mammogram and ultrasound","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Breast clustered cysts mammogram and ultrasound</div><div class=\"cntnt\"><img style=\"width:547px; height:438px;\" src=\"images/RADIOL/83699_Br_clust_cysts_mammogram_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mammogram of the right breast using LMLO projection (A) and LCC projection (B) shows a small soft tissue mass (rings). The ultrasound of the mass shows a cluster of grape like anechoic structures with some internal septations (arrow) in the longitudinal view (C) and in the transverse view (D). These findings are consistent with a diagnosis of septated cyst.</div><div class=\"graphic_footnotes\">LMLO: left mediolateral oblique; LCC: left craniocaudal.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 83699 Version 2.0</div></div></div>"},"83700":{"type":"graphic_diagnosticimage","displayName":"Breast cyst ultrasound - pear shaped","title":"Breast cyst ultrasound - pear shaped","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Breast cyst ultrasound - pear shaped</div><div class=\"cntnt\"><img style=\"width:598px; height:282px;\" src=\"images/RADIOL/83700_Breast_cyst_US_pear_shaped.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound of a palpable mass in the right breast (A) shows a 3 cm pear shaped anechoic structure with back wall enhancement (arrow), through transmission (arrowheads), and no internal enhancement on the Doppler study (B), consistent with a benign simple cyst. The mammogram revealed a non specific soft tissue mass.</div><div class=\"graphic_reference\">Courtesty of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 83700 Version 4.0</div></div></div>"},"83701":{"type":"graphic_diagnosticimage","displayName":"Mammographic image of a density - large cyst","title":"Mammographic image of a density - large cyst","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Mammographic image of a density - large cyst</div><div class=\"cntnt\"><img style=\"width:484px; height:562px;\" src=\"images/RADIOL/83701_Mammogr_img_dens_large_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A BB (radiopaque marker seen as a hyperdense dot on A and B) was placed on a palpable mass. The mammogram that followed shows a solitary ill defined soft tissue mass underlying the BB and surrounded by a ring. A subsequent ultrasound confirmed the cystic nature of the mass.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 83701 Version 3.0</div></div></div>"},"83702":{"type":"graphic_diagnosticimage","displayName":"Breast intraductal papilloma ultrasound","title":"Breast intraductal papilloma ultrasound","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Breast intraductal papilloma ultrasound</div><div class=\"cntnt\"><img style=\"width:597px; height:263px;\" src=\"images/RADIOL/83702_Breast_intrad_papilloma_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound of left breast shows a solitary dilated duct (A, arrow) with a filling defect consisting of soft tissue echoes within the duct (B, overlaid in green). These findings are consistent with a benign papilloma.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 83702 Version 2.0</div></div></div>"},"83703":{"type":"graphic_diagnosticimage","displayName":"Intraductal papilloma as a mammographic density","title":"Intraductal papilloma as a mammographic density","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Intraductal papilloma as a mammographic density</div><div class=\"cntnt\"><img style=\"width:598px; height:464px;\" src=\"images/RADIOL/83703_Intraduc_papil_mamm_density.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mammogram of the left breast using spot craniocaudal projection (A) and a spot lateral view (B) reveal a single, isolated dilated duct (circled). An intraductal mass is not obvious, and was identified on the ultrasound.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 83703 Version 2.0</div></div></div>"},"83705":{"type":"graphic_diagnosticimage","displayName":"Retroareolar dilated ducts - ultrasound","title":"Retroareolar dilated ducts - ultrasound","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Retroareolar dilated ducts - ultrasound</div><div class=\"cntnt\"><img style=\"width:594px; height:282px;\" src=\"images/RADIOL/83705_Retroareolar_dilat_ducts_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The US of the breast is from a 29-year-old lactating woman and shows dilated fluid filled ducts (red arrow) manifesting as branching anechoic structures in the sagittal (A) and transverse planes (B).</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 83705 Version 1.0</div></div></div>"},"83709":{"type":"graphic_table","displayName":"Shoulder girdle ossification centers","title":"Shoulder girdle ossification centers: Age of formation and fusion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Shoulder girdle ossification centers: Age of formation and fusion</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Ossification center</td> <td class=\"subtitle1\">Age ossification centers form (years)</td> <td class=\"subtitle1\">Age by which ossification centers fuse (years)</td> </tr> <tr> <td>Clavicle (medial)</td> <td>18 to 20</td> <td>26 to 30</td> </tr> <tr> <td>Clavicle (lateral)</td> <td>Puberty</td> <td>20</td> </tr> <tr> <td>Scapula (coracoid)</td> <td>First center: 1*<br /> Second center: 15</td> <td> <p>15* (first center), 22 (second center)</p> </td> </tr> <tr> <td>Scapula (acromion)</td> <td>Pre-acromion: Puberty<br /> Meso-acromion: Puberty<br /> Meta-acromion: Puberty</td> <td>22<sup>&#182;</sup></td> </tr> <tr> <td>Scapula (glenoid fossa)</td> <td>First center: 10<br /> Second center: Puberty</td> <td>25</td> </tr> <tr> <td>Scapula (vertebral border)</td> <td>Puberty</td> <td>22</td> </tr> <tr> <td>Scapula (inferior angle)</td> <td>Puberty</td> <td>22</td> </tr> <tr> <td>Humerus (greater tuberosity)</td> <td>3</td> <td>7</td> </tr> <tr> <td>Humerus (lesser tuberosity)</td> <td>5</td> <td>7</td> </tr> <tr> <td>Proximal humeral epiphysis</td> <td>7</td> <td>19</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A third ossification center at the tip of the coracoid process develops in some patients at puberty and occasionally fails to fuse which produces a bipartite coracoid. This condition can be confused with a fracture of the coracoid process.<br />&para; Failure of fusion of the meso-acromion to the meta-acromion results in an os acromiale.</div><div id=\"graphicVersion\">Graphic 83709 Version 2.0</div></div></div>"},"83711":{"type":"graphic_table","displayName":"Phakomatosis pigmentovascularis classification","title":"Classification of phakomatosis pigmentovascularis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of phakomatosis pigmentovascularis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Type I</td>\r\n            <td>Capillary malformation + epidermal nevus</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Type II</td>\r\n            <td>Capillary malformation + dermal melanocytosis +/- nevus anemicus</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Type III</td>\r\n            <td>Capillary malformation + nevus spilus +/- nevus anemicus</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Type IV</td>\r\n            <td>Capillary malformation + dermal melanocytosis + nevus spilus +/- nevus anemicus</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">Original table modified for this publication. Reproduced from: Paller AS, Mancini AJ. Vascular disorders of childhood. In: Hurwitz Clinical Pediatric Dermatology, 3rd ed, Elsevier, 2006. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83711 Version 1.0</div></div></div>"},"83712":{"type":"graphic_diagnosticimage","displayName":"Klebsiella pneumoniae liver abscess","title":"Klebsiella pneumoniae liver abscess","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Klebsiella pneumoniae liver abscess</div><div class=\"cntnt\"><img style=\"width:504px; height:441px;\" src=\"images/ID/83712_Liver_abs_mim_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) of a primary liver abscess due to Klebsiella pneumoniae. The multiloculated appearance can make radiographic distinction from a hepatic tumor difficult. In such cases, diffusion-weighted magnetic resonance imaging may be helpful to better differentiate between abscess and tumor.</div><div class=\"graphic_reference\">Courtesy of Wen-Liang Yu, MD and Yin-Ching Chuang, MD.</div><div id=\"graphicVersion\">Graphic 83712 Version 1.0</div></div></div>"},"83713":{"type":"graphic_diagnosticimage","displayName":"Blastomycosis chest CT","title":"Blastomycosis on chest CT","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Blastomycosis on chest CT</div><div class=\"cntnt\"><img style=\"width:471px; height:162px;\" src=\"images/ID/83713_BlastchestCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blastomycosis in a 69-year-old woman.<BR>(A) High-resolution (1 mm collimation) computed tomography (CT) image at the level of the aortic arch shows small centrilobular nodules (arrows) in the left upper lobe.<BR>(B) CT scan obtained at the level of the basal trunk demonstrates areas of consolidation in the left lower lobe. Also note tree-in-bud opacities (arrows) in both lower lobes.</div><div class=\"graphic_reference\">Reproduced with permission from: Imaging of Pulmonary Infections, MÃ¼ller NL, Franquet T, Lee KS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83713 Version 8.0</div></div></div>"},"83714":{"type":"graphic_picture","displayName":"Blastomycosis chest CT and histopathology","title":"Lung nodule caused by Blastomyces dermatitidis","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Lung nodule caused by Blastomyces dermatitidis</div><div class=\"cntnt\"><img style=\"width:515px; height:327px;\" src=\"images/ID/83714_BlastchestCThisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blastomycosis.<BR>(A) View of the right lower lobe from a computed tomography (CT) image (2.5-mm collimation) shows a triangular nodule in the right lower lobe.<BR>(B) Dynamic CT scans obtained at a similar level to (A) demonstrate marked and persistent enhancement, suggesting an active inflammatory nodule.<BR>(C) Photomicrograph of a wedge resection specimen demonstrates foci of granulomatous inflammation (arrows).<BR>(D) Photomicrograph with Gomori methenamine silver staining reveals yeast forms of <EM>Blastomyces dermatitidis</EM>. The patient was a 69-year-old woman.</div><div class=\"graphic_reference\">Reproduced with permission from: Imaging of Pulmonary Infections, MÃ¼ller NL, Franquet T, Lee KS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83714 Version 7.0</div></div></div>"},"83715":{"type":"graphic_table","displayName":"Differential diagnosis mastoiditis children","title":"Differential diagnosis of mastoiditis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of mastoiditis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Distinguishing clinical features</td> </tr> <tr> <td rowspan=\"4\">Mastoiditis (&#60;2 years)</td> <td>Ear pain (may manifest as irritability)</td> </tr> <tr> <td>Postauricular tenderness, erythema, swelling (obliterating postauricular crease), fluctuance, or mass (poorly circumscribed, immobile) </td> </tr> <tr> <td>Displacement of the auricle (downward and outward)</td> </tr> <tr> <td>Abnormal tympanic membrane</td> </tr> <tr> <td rowspan=\"4\">Mastoiditis (&#62;2 years)</td> <td>Ear pain</td> </tr> <tr> <td>Postauricular tenderness, erythema, swelling (obliterating postauricular crease), fluctuance, or mass (poorly circumscribed, immobile) </td> </tr> <tr> <td>Displacement of the auricle (upward and outward)</td> </tr> <tr> <td>Abnormal tympanic membrane</td> </tr> <tr> <td>Postauricular lymphadenopathy</td> <td>Well-circumscribed and freely mobile mass</td> </tr> <tr> <td>Periauricular cellulitis without otitis externa</td> <td>Normal tympanic membrane</td> </tr> <tr> <td>Periauricular cellulitis with otitis externa</td> <td>Severe pain over the tragus and pinna</td> </tr> <tr> <td rowspan=\"2\">Auricular perichondritis</td> <td>Preservation of the postauricular crease</td> </tr> <tr> <td>Normal tympanic membrane</td> </tr> <tr> <td rowspan=\"2\">Mumps</td> <td>Swelling over the parotid gland rather than the mastoid</td> </tr> <tr> <td>Normal tympanic membrane</td> </tr> <tr> <td>Mastoid tumor</td> <td>Normal tympanic membrane</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83715 Version 2.0</div></div></div>"},"83716":{"type":"graphic_picture","displayName":"Verrucous skin lesion in blastomycosis","title":"Verrucous skin lesion caused by Blastomyces dermatitidis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Verrucous skin lesion caused by Blastomyces dermatitidis</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/ID/83716_Verruc_les_blastomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous lesion with subcutaneous abscesses on the buttock caused by <em>Blastomyces dermatitidis.</em></div><div class=\"graphic_reference\">Reproduced from: Bradsher RW, Bariola JR. Blastomycosis. In: Essentials of Clinical Mycology, 2nd ed, Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (Eds), Springer, New York City 2011; with kind permission from Springer Science + Business Media B.V. Copyright Â© 2011.</div><div id=\"graphicVersion\">Graphic 83716 Version 3.0</div></div></div>"},"83717":{"type":"graphic_picture","displayName":"Ulcerative breast lesion in blastomycosis","title":"Ulcerative breast lesion caused by Blastomyces dermatitidis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ulcerative breast lesion caused by Blastomyces dermatitidis</div><div class=\"cntnt\"><img style=\"width:504px; height:406px;\" src=\"images/ID/83717_Ulc_brst_les_blastomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcerative lesion on the breast caused by <em>Blastomyces dermatitidis.</em> Note the distinct and raised borders.</div><div class=\"graphic_reference\">Reproduced from: Bradsher RW, Bariola JR. Blastomycosis. In: Essentials of Clinical Mycology, 2nd ed, Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (Eds), Springer, New York City 2011; with kind permission from Springer Science + Business Media B.V. Copyright Â© 2011.</div><div id=\"graphicVersion\">Graphic 83717 Version 4.0</div></div></div>"},"83718":{"type":"graphic_picture","displayName":"Ulcerative lesion in blastomycosis","title":"Ulcerative perirectal lesion caused by Blastomyces dermatitidis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ulcerative perirectal lesion caused by Blastomyces dermatitidis</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/ID/83718_Ulcer_les_blastomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive perirectal ulcerative lesion with overlying exudate in a patient who had disseminated blastomycosis.</div><div class=\"graphic_reference\">Reproduced from: Bradsher RW, Bariola JR. Blastomycosis. In: Essentials of Clinical Mycology, 2nd ed, Kauffman CA, Pappas PG, Sobel JD,&nbsp;Dismukes WE&nbsp;(Eds), Springer, New York City 2011; with kind permission from Springer Science + Business Media B.V. Copyright Â© 2011.</div><div id=\"graphicVersion\">Graphic 83718 Version 3.0</div></div></div>"},"83719":{"type":"graphic_picture","displayName":"Subcutaneous nodules in blastomycosis","title":"Subcutaneous nodules caused by Blastomyces dermatitidis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Subcutaneous nodules caused by Blastomyces dermatitidis</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/ID/83719_Subcut_nod_blastomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcutaneous nodules with superficial crusts due to blastomycosis on the thigh of a young man.</div><div class=\"graphic_reference\">Reproduced from: Bradsher RW, Bariola JR. Blastomycosis. In: Essentials of Clinical Mycology, 2nd ed, Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (Eds), Springer, New York City 2011; with kind permission from Springer Science + Business Media B.V. Copyright Â© 2011.</div><div id=\"graphicVersion\">Graphic 83719 Version 3.0</div></div></div>"},"83720":{"type":"graphic_picture","displayName":"Verrucous skin lesions in blastomycosis","title":"Multiple verrucous skin lesions caused by Blastomyces dermatitidis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Multiple verrucous skin lesions caused by Blastomyces dermatitidis</div><div class=\"cntnt\"><img style=\"width:504px; height:303px;\" src=\"images/ID/83720_Ver_lesions_blastomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple verrucous lesions on the forearm of a 20-year-old man with blastomycosis. (Courtesy of Dr. Hector Bonilla.)</div><div class=\"graphic_reference\">Reproduced from: Bradsher RW, Bariola JR. Blastomycosis. In: Essentials of Clinical Mycology, 2nd ed, Kauffman CA, Pappas PG, Sobel JD,&nbsp;Dismukes WE (Eds), Springer, New York City 2011; with kind permission from Springer Science + Business Media B.V. Copyright Â© 2011.</div><div id=\"graphicVersion\">Graphic 83720 Version 3.0</div></div></div>"},"83721":{"type":"graphic_picture","displayName":"Skin lesion in blastomycosis","title":"Verrucous skin lesion caused by Blastomyces dermatitidis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Verrucous skin lesion caused by Blastomyces dermatitidis</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/ID/83721_Skin_lesion_blastomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonpainful, heaped-up lesion due to <em>Blastomyces dermatitidis</em> behind the ear of a 35-year-old man.</div><div class=\"graphic_reference\">Reproduced from: Bradsher RW, Bariola JR. Blastomycosis. In: Essentials of Clinical Mycology, 2nd ed, Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (Eds), Springer, New York City 2011; with kind permission from Springer Science + Business Media B.V. Copyright Â© 2011.</div><div id=\"graphicVersion\">Graphic 83721 Version 3.0</div></div></div>"},"83722":{"type":"graphic_table","displayName":"Liquid/capsule challenge procedures for potassium metabisulfite","title":"Liquid and capsule challenge procedures for potassium metabisulfite (sulfites)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Liquid and capsule challenge procedures for potassium metabisulfite (sulfites)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Food additive</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Interval time</td> <td class=\"subtitle1\">Monitoring</td> </tr> <tr> <td rowspan=\"4\">Potassium metabisulfite</td> <td>Skin prick testing</td> <td> <p>0.001 mg/mL</p> <p>0.01 mg/mL</p> <p>0.1 mg/mL</p> <p>1 mg/mL</p> </td> <td>15 minutes</td> <td>Wheal/erythema</td> </tr> <tr> <td>Intradermal</td> <td>0.02 mL of 0.001 mg/mL solution</td> <td>15 minutes</td> <td>Wheal/erythema</td> </tr> <tr> <td>Oral (solution)</td> <td>1 mg, 10 mg, 25 mg, 50 mg, 100 mg</td> <td>20 minutes in between doses</td> <td>Spirometry prior to each dose and following each dose</td> </tr> <tr> <td>Oral (capsule)</td> <td>1 mg, 10 mg, 25 mg, 50 mg, 100 mg</td> <td>30 minutes in between doses</td> <td>Spirometry prior to each dose and following each dose</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Bush RK, Zoratti E, Taylor SL. Diagnosis of sulfite and aspirin sensitivity. Clin Rev Allergy 1990; 8:159.</div><div id=\"graphicVersion\">Graphic 83722 Version 4.0</div></div></div>"},"83727":{"type":"graphic_table","displayName":"HCC transplantation recs from intl consensus conf","title":"Summary of recommendations for transplantation for hepatocellular carcinoma from an International Consensus Conference","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommendations for transplantation for hepatocellular carcinoma from an International Consensus Conference</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Level of evidence</td> <td class=\"subtitle1\">Strength of recommendation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Assessment of candidates with HCC for liver transplantation</td> </tr> <tr> <td class=\"indent1\"><strong>1.</strong> When considering treatment options for patients with HCC, the BCLC staging system is the preferred staging system to assess the prognosis of patients with HCC.</td> <td>2b (P)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>2.</strong> The TNM system (7th edition), including pathological examination of the explanted liver, should be used for determining prognosis after transplantation with the addition of assessment of microvascular invasion.</td> <td>2b (P)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>3.</strong> Either dynamic CT or dynamic MRI with the presence of arterial enhancement followed by washout on portal venous or delayed imaging is the best non-invasive test to make a diagnosis in cirrhotic patients suspected of having HCC and for preoperative staging.</td> <td>1b (D)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>4.</strong> Extrahepatic staging should include CT of the chest and CT or MRI of the abdomen and pelvis.</td> <td>3b (D)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>5.</strong> Tumor biopsy is not required in cirrhotic patients considered for liver transplantation who have high-quality dynamic CT or MRI findings typical for HCC and a lesion larger than 1 cm according to current AASLD guidelines.</td> <td>1b (D)</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>6.</strong> For patients with lesions smaller or equal to 10 mm, non-invasive imaging does not allow an accurate diagnosis and should not be used to make a decision for or against transplantation.</td> <td>1b (D)</td> <td>Strong</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Criteria for listing candidates with HCC in cirrhotic livers for DDLT</td> </tr> <tr> <td class=\"indent1\"><strong>7.</strong> Liver transplantation should be reserved for HCC patients who have a predicted five-year survival comparable to non-HCC patients.</td> <td>NA</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>8.</strong> Preoperative assessment of the size of the largest tumor or total diameter of tumors should be the main consideration in selecting patients with HCC for liver transplantation.</td> <td>2a (P)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>9.</strong> The Milan criteria are currently the benchmark for the selection of HCC patients for liver transplantation and the basis for comparison with other suggested criteria.</td> <td>2a (P)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>10.</strong> A modest expansion of the number of potential candidates may be considered on the basis of several studies showing comparable survival for patients outside the Milan criteria.</td> <td>3b (P)</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>11.</strong> Patients with worse prognosis may be considered for liver transplantation outside the Milan criteria if the dynamics of the waiting list allow it without undue prejudice to other recipients with a better prognosis.</td> <td>NA</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>12.</strong> &#945;-fetoprotein concentrations add prognostic information in HCC patients and may be used for making decisions regarding transplantation in combination with imaging criteria.</td> <td>2b (P)</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>13.</strong> Biomarkers other than &#945;-fetoprotein cannot yet be used for clinical decision making regarding liver transplantation for HCC.</td> <td>2b (P)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>14.</strong> Indication for liver transplantation in HCC should not rely on microvascular invasion because it cannot be reliably detected prior to transplantation.</td> <td>2b (P)</td> <td>Strong</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Criteria for HCC candidates with non-cirrhotic livers</td> </tr> <tr> <td class=\"indent1\"><strong>15.</strong> The Milan criteria and its modifications are not applicable to patients with HCC developing in a non-cirrhotic liver. Such patients with non-resectable HCC and absence of macrovascular invasion and extrahepatic spread may be considered as appropriate candidates for liver transplantation.</td> <td>4 (P)</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>16.</strong> Patients with HCC in non-cirrhotic liver who were treated by resection, and have intrahepatic recurrence of HCC and no evidence of lymph node or macrovascular invasion, may be considered for salvage transplantation.</td> <td>4 (P)</td> <td>Weak</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Role of downstaging</td> </tr> <tr> <td class=\"indent1\"><strong>17.</strong> Transplantation may be considered after successful downstaging.</td> <td>5 (P)</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>18.</strong> Liver transplantation after successful downstaging should achieve a five-year survival comparable to that of HCC patients who meet the criteria for liver transplantation without requiring downstaging.</td> <td>5 (P)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>19.</strong> Criteria for successful downstaging should include tumor size and number of viable tumors.</td> <td>4 (P)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>20.</strong> &#945;-fetoprotein concentrations before and after downstaging may add additional information.</td> <td>4 (P)</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>21.</strong> Based on existing evidence, no recommendation can be made for preferring a specific locoregional therapy for downstaging over others.</td> <td>NA</td> <td>None</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Managing patients on the waiting list</td> </tr> <tr> <td class=\"indent1\"><strong>22.</strong> Periodic waiting-list monitoring should be performed by imaging (dynamic CT, dynamic MRI, or contrast-enhanced ultrasonography) and &#945;-fetoprotein measurements.</td> <td>5 (P)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>23.</strong> Based on current absence of evidence, no recommendation can be made on bridging therapy in patients with UNOS T1 (&#8804;2 cm) HCC.</td> <td>NA</td> <td>None</td> </tr> <tr> <td class=\"indent1\"><strong>24.</strong> In patients with UNOS T2 (one nodule 2 to 5 cm or three or more nodules each &#8804;3 cm) HCC (Milan criteria) and a likely waiting time longer than six months, locoregional therapy may be appropriate.</td> <td>4 (P)</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>25.</strong> No recommendation can be made for preferring any type of locoregional therapy to others.</td> <td>NA</td> <td>None</td> </tr> <tr> <td class=\"indent1\"><strong>26.</strong> Patients found to have progressed beyond criteria acceptable for listing for liver transplantation should be placed on hold and considered for downstaging.</td> <td>5 (P)</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>27.</strong> Patients with progressive disease in whom locoregional intervention is not considered appropriate, or is ineffective, should be removed from the waiting list.</td> <td>5 (P)</td> <td>Strong</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Role of LDLT</td> </tr> <tr> <td class=\"indent1\"><strong>28.</strong> LDLT is acceptable for HCC patients who have an expected five-year survival similar to comparably staged patients receiving a deceased donor liver. In LDLT, careful attention should be given to psychosocial considerations regarding both donor and recipient.</td> <td>NA</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>29.</strong> LDLT must be restricted to centers of excellence in liver surgery and liver transplantation to minimize donor risk and maximize recipient outcome.</td> <td>NA</td> <td>Strong</td> </tr> <tr> <td class=\"indent1\"><strong>30.</strong> In patients following LDLT for HCC within the accepted regional criteria for DDLT, retransplantation for graft failure is justified.</td> <td>5 (P)</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>31.</strong> In patients following LDLT for HCC outside the accepted regional criteria for DDLT, retransplantation for graft failure using a deceased donor organ is not recommended.</td> <td>5 (P)</td> <td>Strong</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Posttransplant management</td> </tr> <tr> <td class=\"indent1\"><strong>32.</strong> Posttransplant monitoring may include 6 to 12 monthly contrast-enhanced CT or MRI imaging and &#945;-fetoprotein measurements.</td> <td>5 (P)</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>33.</strong> There is currently insufficient evidence from clinical trials to base a recommendation for choosing the type or dose of immunosuppression therapy to influence the incidence of HCC recurrence or its prognosis.</td> <td>NA</td> <td>None</td> </tr> <tr> <td class=\"indent1\"><strong>34.</strong> Based on current evidence, no recommendation can be made on the use of mTOR inhibitors solely to reduce the risk of HCC recurrence outside clinical trials.</td> <td>NA</td> <td>None</td> </tr> <tr> <td class=\"indent1\"><strong>35.</strong> The current evidence does not justify the routine use of adjuvant antitumor therapy after liver transplantation for HCC outside of a controlled clinical trial.</td> <td>NA</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>36.</strong> HCC recurrence after liver transplantation may be treated by surgery for resectable lesions or by locoregional therapy or systemic therapy (including sorafenib) for unresectable lesions.</td> <td>4 (p)</td> <td>Weak</td> </tr> <tr> <td class=\"indent1\"><strong>37.</strong> Liver retransplantation is not appropriate treatment for recurrent HCC.</td> <td>NA</td> <td>Strong</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Level of evidence for each recommendation refers to the Oxford classification.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer; TNM: tumor, node, metastasis; P: prognosis; D: diagnosis; AASLD: American Association for the Study of Liver Diseases; NA: not applicable; OLT: orthotopic liver transplantation; UNOS: United Network for Organ Sharing; LDLT: living donor liver transplantation; DDLT: deceased donor liver transplantation; mTOR: mammalian target of rapamycin.</div><div class=\"graphic_reference\">Reproduced from: Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13:e11. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83727 Version 1.0</div></div></div>"},"83729":{"type":"graphic_table","displayName":"Guidelines for liver transplantation in HCC from the EASL EORTC","title":"Guidelines for liver transplantation in HCC from the European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for liver transplantation in HCC from the European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p>Liver transplantation is considered to be the first-line treatment option for patients with single tumors less than 5 cm or &#8804;3 nodules &#8804;3 cm (Milan criteria) not suitable for resection</p> <strong>(evidence 2A; recommendation 1A)</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Perioperative mortality and one-year mortality are expected to be approximately 3 percent and &#8804;10 percent, respectively</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Extension of tumor limit criteria for liver transplantation for HCC has not been established. Modest expansion of Milan criteria applying the \"up-to-seven\" in patients without microvascular invasion achieves competitive outcomes, and thus this indication requires prospective validation</p> <strong>(evidence 2B; recommendation 2B</strong>)</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Neoadjuvant treatment can be considered for locoregional therapies if the waiting list exceeds six months due to good cost-effectiveness data and tumor response rates, even though impact on long-term outcome is uncertain</p> <strong>(evidence 2D; recommendation 2B)</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Down-staging policies for HCCs exceeding conventional criteria cannot be recommended and should be explored in the context of prospective studies aimed at survival and disease progression end-points</p> <p><strong>(evidence 2D; recommendation 2C)</strong></p> Assessment of downstaging should follow modified RECIST criteria</td> </tr> <tr> <td> <p>Living donor liver transplantation is an alternative option in patients with a waiting list exceeding six to seven months, and offers a suitable setting to explore extended indications within research programs</p> <strong>(evidence 2A; recommendation 2B)</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div class=\"graphic_reference\">Reproduced from: EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56:908. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83729 Version 1.0</div></div></div>"},"83730":{"type":"graphic_diagnosticimage","displayName":"Gastric volvulus on plain chest film","title":"Gastric volvulus on plain chest film","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Gastric volvulus on plain chest film</div><div class=\"cntnt\"><img style=\"width:469px; height:454px;\" src=\"images/SURG/83730_Gastric_volv_plain_abd_film.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph of the chest shows a large central gas bubble in the thoracic cavity reminiscent of a large hiatal hernia (between white arrows).</div><div id=\"graphicVersion\">Graphic 83730 Version 1.0</div></div></div>"},"83731":{"type":"graphic_figure","displayName":"Gastric volvulus","title":"Gastric volvulus","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Gastric volvulus</div><div class=\"cntnt\"><img style=\"width:475px; height:674px;\" src=\"images/SURG/83731_Gastric-volvulus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Organoaxial volvulus results from rotation along the long axis of the stomach from the gastroesophageal junction to the pylorus.<br />(B) Mesenteroaxial rotation occurs with rotation along the transverse axis such that the pylorus rotates above the gastroesophageal junction.<br />(C) Combined volvulus results from a combination of both.</div><div id=\"graphicVersion\">Graphic 83731 Version 3.0</div></div></div>"},"83732":{"type":"graphic_diagnosticimage","displayName":"Organoaxial gastric volvulus","title":"Organoaxial gastric volvulus","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Organoaxial gastric volvulus</div><div class=\"cntnt\"><img style=\"width:600px; height:386px;\" src=\"images/RADIOL/83732_Organoaxial_gastr_volvulus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph of the abdomen (A) shows a large central gas bubble in the thoracic cavity reminiscent of a large hiatal hernia (between arrows). A barium study (B) shows the greater curvature of the stomach (arrowhead) superior to the lesser curvature (dashed arrow). These findings are characteristic of an organoaxial volvulus.</div><div id=\"graphicVersion\">Graphic 83732 Version 2.0</div></div></div>"},"83733":{"type":"graphic_diagnosticimage","displayName":"Gastric volvulus on computed tomography","title":"Gastric volvulus on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric volvulus on computed tomography</div><div class=\"cntnt\"><img style=\"width:394px; height:363px;\" src=\"images/RADIOL/83733_Gastric_volvulus_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography of the lower chest of an elderly female with organoaxial volvulus shows accumulated food and fluid in a distended stomach with evidence of pneumatosis of the stomach wall (arrow). A small gas bubble in the liver represents portal venous air (arrowhead). The patient was decompressed in the operating room and the hernia was repaired.</div><div id=\"graphicVersion\">Graphic 83733 Version 2.0</div></div></div>"},"83734":{"type":"graphic_diagnosticimage","displayName":"Mesenteroaxial gastric volvulus","title":"Mesenteroaxial gastric volvulus on upper GI study and computed tomography","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Mesenteroaxial gastric volvulus on upper GI study and computed tomography</div><div class=\"cntnt\"><img style=\"width:597px; height:250px;\" src=\"images/RADIOL/83734_Mesenteroaxial_gastric_volv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 64-year-old male presented with medication-resistant gastroesophageal reflux disease. Mesenteroaxial gastric volvulus is noted on a barium swallow fluoroscopic examination (A). The distal esophagus (arrow) is in normal position. The antrum of the stomach (small arrowhead panel A and B) has rotated 180 degrees in a cranial direction and the fundus is positioned caudally (large arrowhead A). The mesenteroaxial volvulus is shown on reformatted CT study. A follow-up barium swallow fluoroscopic examination shows normal anatomic positioning of the stomach after the patient underwent fundoplication and gastropexy (C).</div><div class=\"graphic_footnotes\">GI: gastrointestinal; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 83734 Version 2.0</div></div></div>"},"83735":{"type":"graphic_table","displayName":"Dietary sources of iron","title":"Dietary sources of iron","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary sources of iron</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Approximate measure</td> <td class=\"subtitle1\">Iron (mg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">High iron sources </td> </tr> <tr> <td class=\"indent1\">Cream of Wheat (quick or instant)*</td> <td>1/2 cup</td> <td>7.8</td> </tr> <tr> <td class=\"indent1\">Kidney, beef<sup>&#182;</sup></td> <td>2 oz (60 g)</td> <td>5.3</td> </tr> <tr> <td class=\"indent1\">Liver, beef<sup>&#182;</sup></td> <td>2 oz (60 g)</td> <td>5.8</td> </tr> <tr> <td class=\"indent1\">Liver, calf<sup>&#182;</sup></td> <td>2 oz (60 g)</td> <td>9</td> </tr> <tr> <td class=\"indent1\">Liver, chicken<sup>&#182;</sup></td> <td>2 oz (60 g)</td> <td>6</td> </tr> <tr> <td class=\"indent1\">Liverwurst<sup>&#182;</sup></td> <td>2 oz (60 g)</td> <td>3.6</td> </tr> <tr> <td class=\"indent1\">Prune juice</td> <td>1/2 cup</td> <td>5.1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Spinach</td> <td>1/2 cup</td> <td>3.2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Moderate iron sources</td> </tr> <tr> <td class=\"indent1\">All-Bran cereal</td> <td>1/2 cup</td> <td>2.9</td> </tr> <tr> <td class=\"indent1\">Almonds, dried unblanched</td> <td>1/2 cup</td> <td>3</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Dried beans and peas</td> </tr> <tr> <td class=\"sublist2\">Baked beans, no pork</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.5</td> </tr> <tr> <td class=\"sublist2\">Blackeye peas, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">0.8</td> </tr> <tr> <td class=\"sublist2\">Chick peas, dry</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">3.5</td> </tr> <tr> <td class=\"sublist2\">Great northern beans, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.3</td> </tr> <tr> <td class=\"sublist2\">Green peas, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.4</td> </tr> <tr> <td class=\"sublist2\">Lentils, dry</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">3.4</td> </tr> <tr> <td class=\"sublist2\">Lima beans, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.3</td> </tr> <tr> <td class=\"sublist2\">Navy beans, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.3</td> </tr> <tr> <td class=\"sublist2\">Red beans, dry</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">3.5</td> </tr> <tr> <td class=\"sublist2\">Soybeans, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.4</td> </tr> <tr> <td class=\"sublist2\">White beans, dry</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">3.9</td> </tr> <tr> <td class=\"indent1\">Beef, cooked</td> <td>2 oz (60 g)</td> <td>2-3<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Ham, cooked</td> <td>2 oz (60 g)</td> <td>1.3</td> </tr> <tr> <td class=\"indent1\">Lamb, cooked</td> <td>2 oz (60 g)</td> <td>1.9</td> </tr> <tr> <td class=\"indent1\">Peaches, dried</td> <td>1/4 cup</td> <td>2.4</td> </tr> <tr> <td class=\"indent1\">Peanuts, roasted without skins</td> <td>3 1/2 oz (100 g)</td> <td>3.2</td> </tr> <tr> <td class=\"indent1\">Pork, cooked</td> <td>2 oz (60 g)</td> <td>2-3<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Prunes, dried</td> <td>2 large</td> <td>1.1</td> </tr> <tr> <td class=\"indent1\">Scallops</td> <td>2 oz (60 g)</td> <td>1.6</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Turkey, cooked</td> <td>2 oz (60 g)</td> <td>1.7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Approximate iron content of children's favorite foods</td> </tr> <tr> <td class=\"sublist2_start\">Hamburger, small</td> <td class=\"sublist_other_start\">1</td> <td class=\"sublist_other_start\">3</td> </tr> <tr> <td class=\"sublist2\">Large</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">5.2</td> </tr> <tr> <td class=\"sublist2\">Big Mac</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">4.3</td> </tr> <tr> <td class=\"sublist2\">Quarter Pounder</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">5.1</td> </tr> <tr> <td class=\"indent1\">Spaghetti with meatballs</td> <td>1 cup</td> <td>3.3</td> </tr> <tr> <td class=\"indent1\">Frankfurter and beans</td> <td>1 cup</td> <td>4.8</td> </tr> <tr> <td class=\"indent1\">Pork and beans</td> <td>1 cup</td> <td>5.9</td> </tr> <tr> <td class=\"indent1\">Raisins<sup>&#167;</sup></td> <td>5/8 cup</td> <td>3.5</td> </tr> <tr> <td class=\"indent1\">Cereals, fortified</td> <td>1 serving</td> <td>4.5-17.8</td> </tr> <tr> <td class=\"indent1\">Nuts<sup>&#167;</sup></td> <td>1 cup</td> <td>5-7</td> </tr> <tr> <td class=\"indent1\">Seeds, sunflower<sup>&#167;</sup></td> <td>3 1/2 oz (100 g)</td> <td>7.1</td> </tr> <tr> <td class=\"indent1\">Chile con carne</td> <td>1 cup</td> <td>3.6</td> </tr> <tr> <td class=\"indent1\">Beef burrito or tostado</td> <td>1 medium</td> <td>3.4-4.6</td> </tr> <tr> <td class=\"indent1\">Cheese pizza</td> <td>2 slices</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Cheese pizza with beef</td> <td>2 slices</td> <td>4.8</td> </tr> <tr> <td class=\"indent1\">White bread</td> <td>1 piece</td> <td>0.7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Or other fortified cereals which contain 10 mg of iron per ounce or 100 percent RDA per serving.<br />Â¶ As organ meats are generally high in cholesterol, these iron-rich foods should be eaten in moderation.<br />Î Depending on cut, the greatest amounts of iron are generally found in the chuck, flank, and bottom round cuts of beef.<br /><FONT class=lozenge>â</FONT> Depending on cut, the greatest amounts of iron are generally found in the loin, sirloin, tenderloin, and picnic shoulder cuts of pork.<br />Â§ Raisins, nuts, and seeds are not generally recommended for children under age three because of risk of choking.</div><div class=\"graphic_reference\">Data from: Walker WA, Watkins JB (Eds), Nutrition in Pediatrics, 2nd ed, BC Decker, Inc, London 1997.</div><div id=\"graphicVersion\">Graphic 83735 Version 2.0</div></div></div>"},"83736":{"type":"graphic_algorithm","displayName":"Assessing risk factors for hepatic steatosis in HIV","title":"Potentially modifiable factors that contribute to hepatic steatosis in HIV-infected patients","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Potentially modifiable factors that contribute to hepatic steatosis in HIV-infected patients</div><div class=\"cntnt\"><img style=\"width:491px; height:289px;\" src=\"images/ID/83736_Assess_risk_hep_steat_HIV.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: McGovern BH. Hepatic steatosis in HIV/HCV-coinfected patients: time to reevaluate! Gastroenterology 2011; 140:772. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83736 Version 1.0</div></div></div>"},"83737":{"type":"graphic_picture","displayName":"Numerous atypical nevi","title":"Multiple common and atypical nevi","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple common and atypical nevi</div><div class=\"cntnt\"><img style=\"width:363px; height:504px;\" src=\"images/DERM/83737_Numerous_atypical_nevi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous common and atypical nevi are present on the back of this patient.</div><div id=\"graphicVersion\">Graphic 83737 Version 3.0</div></div></div>"},"83739":{"type":"graphic_table","displayName":"Caprini risk assessment model","title":"Modified Caprini risk assessment model for VTE in general surgical patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Caprini risk assessment model for VTE in general surgical patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Risk score</td> </tr> <tr> <td class=\"subtitle2\">1 point</td> <td class=\"subtitle2\">2 points</td> <td class=\"subtitle2\">3 points</td> <td class=\"subtitle2\">5 points</td> </tr> <tr> <td>Age 41 to 60 years</td> <td>Age 61 to 74 years</td> <td>Age &#8805;75 years</td> <td>Stroke (&#60;1 month)</td> </tr> <tr> <td>Minor surgery</td> <td>Arthroscopic surgery</td> <td>History of VTE</td> <td>Elective arthroplasty</td> </tr> <tr> <td>BMI &#62;25 kg/m<sup>2</sup></td> <td>Major open surgery (&#62;45 minutes)</td> <td>Family history of VTE</td> <td>Hip, pelvis, or leg fracture</td> </tr> <tr> <td>Swollen legs</td> <td>Laparoscopic surgery (&#62;45 minutes)</td> <td>Factor V Leiden</td> <td>Acute spinal cord injury (&#60;1 month)</td> </tr> <tr> <td>Varicose veins</td> <td>Malignancy</td> <td>Prothrombin 20210A</td> <td>&nbsp;</td> </tr> <tr> <td>Pregnancy or postpartum</td> <td>Confined to bed (&#62;72 hours)</td> <td>Lupus anticoagulant</td> <td>&nbsp;</td> </tr> <tr> <td>History of unexplained or recurrent spontaneous abortion</td> <td>Immobilizing plaster cast</td> <td>Anticardiolipin antibodies</td> <td>&nbsp;</td> </tr> <tr> <td>Oral contraceptives or hormone replacement</td> <td>Central venous access</td> <td>Elevated serum homocysteine</td> <td>&nbsp;</td> </tr> <tr> <td>Sepsis (&#60;1 month)</td> <td>&nbsp;</td> <td>Heparin-induced thrombocytopenia</td> <td>&nbsp;</td> </tr> <tr> <td>Serious lung disease, including pneumonia (&#60;1 month)</td> <td>&nbsp;</td> <td>Other congenital or acquired thrombophilia</td> <td>&nbsp;</td> </tr> <tr> <td>Abnormal pulmonary function</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Acute myocardial infarction</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Congestive heart failure (&#60;1 month)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>History of inflammatory bowel disease</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Medical patient at bed rest</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Interpretation</td> </tr> <tr> <td class=\"subtitle2\">Surgical risk category*</td> <td class=\"subtitle2\" colspan=\"2\">Score</td> <td class=\"subtitle2\">Estimated VTE risk in the absence of pharmacologic or mechanical prophylaxis (percent)</td> </tr> <tr> <td class=\"centered\">Very low (see text for definition)</td> <td class=\"centered\" colspan=\"2\">0</td> <td class=\"centered\">&#60;0.5</td> </tr> <tr> <td class=\"centered\">Low</td> <td class=\"centered\" colspan=\"2\">1 to 2</td> <td class=\"centered\">1.5</td> </tr> <tr> <td class=\"centered\">Moderate</td> <td class=\"centered\" colspan=\"2\">3 to 4</td> <td class=\"centered\">3.0</td> </tr> <tr> <td class=\"centered\">High</td> <td class=\"centered\" colspan=\"2\">&#8805;5</td> <td class=\"centered\">6.0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VTE: venous thromboembolism; BMI: body mass index.<br />* This table is applicable only to general, abdominal-pelvic, bariatric, vascular, and plastic and reconstructive surgery. See text for other types of surgery (eg, cancer surgery).</div><div class=\"graphic_reference\">From: Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practical guidelines. Chest 2012; 141:e227S. Copyright &copy; 2012. Reproduced with permission from the American College of Chest Physicians.</div><div id=\"graphicVersion\">Graphic 83739 Version 14.0</div></div></div>"},"83741":{"type":"graphic_diagnosticimage","displayName":"Magnetic resonance spectroscopy Canavan disease","title":"Brain magnetic resonance spectroscopy, 1-year old girl with Canavan disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Brain magnetic resonance spectroscopy, 1-year old girl with Canavan disease</div><div class=\"cntnt\"><img style=\"width:504px; height:443px;\" src=\"images/NEURO/83741_Mag_res_spect_can_dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single voxel (8-mL) magnetic resonance spectroscopy of the affected white matter of the brain showing the large N-acetylaspartate peak (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Pradhan S, Goyal G. Teaching NeuroImages: Honeycomb appearance of the brain in a patient with Canavan disease. Neurology 2011; 76:e68. Copyright Â© 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83741 Version 5.0</div></div></div>"},"83742":{"type":"graphic_table","displayName":"Amyloidosis prognostic staging systems","title":"Prognostic staging systems for amyloidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic staging systems for amyloidosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Prognostic model</td> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Risk groups</td> <td class=\"subtitle1\" colspan=\"2\">Survival in patients not undergoing stem cell transplantation</td> <td class=\"subtitle1\" colspan=\"2\">Survival in patients undergoing stem cell transplantation</td> </tr> <tr> <td class=\"subtitle2\">Median in months</td> <td class=\"subtitle2\">Five-year survival rate (percent)*</td> <td class=\"subtitle2\">Median in months</td> <td class=\"subtitle2\">Four-year survival rate (percent)*</td> </tr> <tr> <td rowspan=\"3\">Mayo stage<sup>[1,2]</sup></td> <td>Stage I</td> <td>Cardiac troponin &#60;0.035 mcg/L and NT-proBNP &#60;332 ng/L</td> <td>26</td> <td>28</td> <td>Not reached at 40 months</td> <td>85<sup>&#182;</sup></td> </tr> <tr> <td>Stage II</td> <td>Any one factor high</td> <td>11</td> <td>12</td> <td>Not reached at 40 months</td> <td>75<sup>&#182;</sup></td> </tr> <tr> <td>Stage III</td> <td>Cardiac troponin &#8805;0.035 mcg/L and NT-proBNP &#8805;332 ng/L</td> <td>4</td> <td>8</td> <td>8</td> <td>25<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"4\">Revised Mayo stage<sup>[3]</sup></td> <td>Stage I</td> <td>NT-proBNP &#60;1800 ng/L, cardiac troponin T &#60;0.025 mcg/L, and difference between involved and uninvolved serum free light chains &#60;18 mg/dL</td> <td>55</td> <td>50</td> <td>Not reached</td> <td>87</td> </tr> <tr> <td>Stage II</td> <td>Any one factor high</td> <td>19</td> <td>35</td> <td>97</td> <td>72</td> </tr> <tr> <td>Stage III</td> <td>Any two factors high</td> <td>12</td> <td>20</td> <td>58</td> <td>56</td> </tr> <tr> <td>Stage IV</td> <td>NT-proBNP &#8805;1800 ng/L, cardiac troponin T &#8805;0.025 mcg/L, and difference between involved and uninvolved serum free light chains &#8805;18 mg/dL</td> <td>5</td> <td>15</td> <td>22</td> <td>46</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Estimated from published survival curve if not reported.<br />&para; Survival rate at 40 months.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751.</li>&#xD;&#xA;    <li>Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104:1881.</li>&#xD;&#xA;    <li>Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30:989.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 83742 Version 5.0</div></div></div>"},"83743":{"type":"graphic_diagnosticimage","displayName":"Brain MRI 1-year-old girl Canavan disease","title":"Brain MRI, 1-year-old girl with Canavan disease","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Brain MRI, 1-year-old girl with Canavan disease</div><div class=\"cntnt\"><img style=\"width:468px; height:583px;\" src=\"images/NEURO/83743_Brain_MRI_Canavan_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted (A, B) and T1-weighted (C, D) MRI of the brain showing severe and diffuse T2 hyperintense and T1 hypointense signal changes in the white matter suggesting Canavan disease. Significant involvement of U fibers is present. Multiple round or oval cystic changes within the white matter give a honeycomb appearance. The radial arrangement of these cystic spaces suggests dilatation of Virchow-Robin spaces due to spongiform degeneration of the white matter.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Pradhan S, Goyal G. Teaching NeuroImages: honeycomb appearance of the brain in a patient with Canavan disease. Neurology 2011; 76:e68. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83743 Version 5.0</div></div></div>"},"83748":{"type":"graphic_table","displayName":"Stages of hepatic encephalopathy in young children","title":"Stages of hepatic encephalopathy in infants and children from birth to 48 months of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of hepatic encephalopathy in infants and children from birth to 48 months of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Clinical</td> <td class=\"subtitle1\">Reflexes</td> <td class=\"subtitle1\">Neurological signs</td> </tr> <tr> <td>No encephalopathy<br /> (stage 0)</td> <td>Normal</td> <td>Normal</td> <td>None</td> </tr> <tr> <td>Early <br /> (stage I and II)</td> <td>Inconsolable crying, sleep reversal, inattention to task, child is not acting like self to parents</td> <td>Unreliable/ normal or hyperreflexic</td> <td>Untestable</td> </tr> <tr> <td>Mid <br /> (stage III)</td> <td>Somnolence, stupor, combativeness</td> <td>Unreliable/ hyperreflexic</td> <td>Likely untestable </td> </tr> <tr> <td>Late <br /> (stage IV)</td> <td>Comatose, arouses with painful stimuli (stage IVa) or no response (stage IVb)</td> <td>Absent</td> <td>Decerebrate or decorticate</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 83748 Version 2.0</div></div></div>"},"83762":{"type":"graphic_table","displayName":"Drugs causing lichenoid eruptions","title":"Drugs causing lichenoid eruptions (drug-induced lichen planus)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs causing lichenoid eruptions (drug-induced lichen planus)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Group of drug</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>Antimicrobial substances</td> <td>Aminosalicylate sodium, ethambutol, griseofulvin, ketoconazole, streptomycin, tetracycline, trovafloxacin, isoniazid</td> </tr> <tr> <td>Antihistamines (H<sub>2</sub>-blocker)</td> <td>Ranitidine, roxatidine</td> </tr> <tr> <td>Antihypertensives/antiarrhythmics</td> <td><strong>ACE-inhibitors</strong> (captopril, enalapril), doxazosin, <strong>beta blockers</strong> (propranolol, labetalol, sotalol), <strong>methyldopa</strong>, prazosin, nifedipine, <strong>quinidine</strong></td> </tr> <tr> <td>Antimalarial drugs</td> <td><strong>Chloroquine</strong>, <strong>hydroxychloroquine</strong>, quinine</td> </tr> <tr> <td>Antidepressives/antianxiety drugs/antipsychotics/anticonvulsants</td> <td>Amitriptyline, carbamazepine, chlorpromazine, levomepromazine, methopromazine, imipramine, lorazepam, phenytoin</td> </tr> <tr> <td>Diuretics</td> <td><strong>Thiazide diuretics</strong> (chlorothiazide and hydrochlorothiazide), furosemide, spironolactone</td> </tr> <tr> <td>Antidiabetics</td> <td>Sulfonylureas (chlorpropamide, glimepiride, tolazamide, tolbutamide, glyburide)</td> </tr> <tr> <td>Metals</td> <td><strong>Gold salts</strong>, arsenic, bismuth, mercury, palladium, lithium</td> </tr> <tr> <td>Nonsteroidal-antiinflammatory drugs (NSAIDs)</td> <td>Acetylsalicylic acid, benoxaprofen, diflunisal, fenclofenac, flurbiprofen, ibuprofen, indomethacin, naproxen, sulindac</td> </tr> <tr> <td>Proton pump inhibitors</td> <td>Omeprazole, lansoprazole, pantoprazole</td> </tr> <tr> <td>Lipid lowering drugs</td> <td>Pravastatin, simvastatin, gemfibrozil</td> </tr> <tr> <td>Tumor necrosis factor-alpha antagonists</td> <td>Infliximab, adalimumab, etanercept, lenercept</td> </tr> <tr> <td>Varia</td> <td>Allopurinol, bleomycin, cinnarizine, cyanamide, dapsone, hydroxyurea, hepatitis B-vaccine, imatinib, immunoglobulins, interferon alfa, l-thyroxin, levamisole, mesalamine, methycran, <strong>penicillamine</strong>, procainamide, pyrimethamine, pyrithioxine, <strong>quinacrine</strong>, sildenafil, sulfasalazine, terbinafine, trihexyphenidyl, ursodeoxycholic acid</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The <strong>bolded</strong> drugs are the ones most frequently implicated.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol 1993; 29:249.</LI>&#xD;&#xA;<LI>Shiohara T, Kano Y. Lichen planus and lichenoid dermatoses. In: Dermatology, Bolognia JL (Ed), Mosby, London 2003. p.188.</LI>&#xD;&#xA;<LI>Bork K. Lichenoid eruptions. In: Cutaneous Side Effects of Drugs, Bork K (Ed), WB Saunders, Philadelphia 1988. p.170.</LI></OL>Original figure modified for this publication. Shiohara T, Kano Y. Lichen planus and lichenoid dermatoses. In: Dermatology, 3rd Edition, Bolognia JL, Jorizzo JL, Schaffer JV (Eds), Elsevier, London 2012. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83762 Version 3.0</div></div></div>"},"83763":{"type":"graphic_figure","displayName":"Schematic model of the course of PALF","title":"Schematic model of the natural course and outcome of acute liver failure in children","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Schematic model of the natural course and outcome of acute liver failure in children</div><div class=\"cntnt\"><img style=\"width:554px; height:306px;\" src=\"images/PEDS/83763_Schematic_model_course_PALF.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SIRS: systemic inflammatory response syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 83763 Version 1.0</div></div></div>"},"83764":{"type":"graphic_table","displayName":"Causes of PALF worldwide","title":"Etiology of acute liver failure in children worldwide (final diagnosis as percent of cases in each region)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of acute liver failure in children worldwide (final diagnosis as percent of cases in each region)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">North America and Europe*</td> <td class=\"subtitle1\">Brazil</td> <td class=\"subtitle1\">North Brazil</td> <td class=\"subtitle1\">Argentina</td> <td class=\"subtitle1\">Kolkata</td> <td class=\"subtitle1\">North India</td> <td class=\"subtitle1\">Hong Kong</td> <td class=\"subtitle1\">Chile</td> </tr> <tr> <td>Indeterminate</td> <td class=\"centered\"><span style=\"color: #ff0000;\"><strong>48</strong></span></td> <td class=\"centered\">13</td> <td class=\"centered\">4</td> <td class=\"centered\"><span style=\"color: #ff0000;\"><strong>32</strong></span></td> <td class=\"centered\">0</td> <td class=\"centered\">6</td> <td class=\"centered\"><span style=\"color: #ff0000;\"><strong>75</strong></span></td> <td class=\"centered\"><span style=\"color: #ff0000;\"><strong>44</strong></span></td> </tr> <tr> <td class=\"sublist1_start\">Viral hepatitis</td> <td class=\"sublist_other_start_centered\">6<sup>&#182;</sup></td> <td class=\"sublist_other_start_centered\">&nbsp;</td> <td class=\"sublist_other_start_centered\">&nbsp;</td> <td class=\"sublist_other_start_centered\">&nbsp;</td> <td class=\"sublist_other_start_centered\">&nbsp;</td> <td class=\"sublist_other_start_centered\">&nbsp;</td> <td class=\"sublist_other_start_centered\">&nbsp;</td> <td class=\"sublist_other_start_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hepatitis A</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\"><span style=\"color: #ff0000;\"><strong>80</strong></span></td> <td class=\"sublist_other_centered\">13</td> <td class=\"sublist_other_centered\"><span style=\"color: #ff0000;\"><strong>61</strong></span></td> <td class=\"sublist_other_centered\"><span style=\"color: #ff0000;\"><strong>43</strong></span></td> <td class=\"sublist_other_centered\"><span style=\"color: #ff0000;\"><strong>51</strong></span></td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\"><span style=\"color: #ff0000;\"><strong>37</strong></span></td> </tr> <tr> <td class=\"sublist1\">Hepatitis B</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">4</td> <td class=\"sublist_other_centered\"><span style=\"color: #ff0000;\"><strong>17</strong></span></td> <td class=\"sublist_other_centered\">1</td> <td class=\"sublist_other_centered\"><span style=\"color: #ff0000;\"><strong>20</strong></span></td> <td class=\"sublist_other_centered\">7</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hepatitis E</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\"><span style=\"color: #ff0000;\"><strong>37</strong></span></td> <td class=\"sublist_other_centered\"><span style=\"color: #ff0000;\"><strong>25</strong></span></td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hepatitis A/E</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">10</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hepatitis B/D</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\"><span style=\"color: #ff0000;\"><strong>48</strong></span></td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hepatitis A/C</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">2</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hepatitis A/B</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">4</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hepatitis B/C</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">4</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td>Autoimmune</td> <td class=\"centered\">7</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">11</td> </tr> <tr> <td>Drugs</td> <td class=\"centered\">3</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\"><span style=\"color: #ff0000;\"><strong>25</strong></span></td> <td class=\"centered\">7</td> </tr> <tr> <td>Wilson disease</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Yellow fever</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">9</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>APAP</td> <td class=\"centered\"><span style=\"color: #ff0000;\"><strong>12</strong></span></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Metabolic</td> <td class=\"centered\">10</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Other</td> <td class=\"centered\">11.8<sup>&#916;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Causes of acute liver failure in children worldwide, as percent of cases in each country or region. The most common causes in each region are shown in <strong>bold <span style=\"color: #ff0000;\">red</span></strong> font.</div><div class=\"graphic_footnotes\">* Data from the Pediatric Acute Liver Failure Study Group (PALFSG), from 2000 to 2007.<br />&para; For the PALFSG data, this category includes all viral causes of acute liver failure. In this population, herpes simplex virus (HSV) was the most common viral cause of acute liver failure in infants; Epstein-Barr virus (EBV) and hepatitis A virus (HAV) were the most common viral causes in older children.<br />&Delta; For the PALFSG data, the \"other\" category includes shock/ischemia, gestational alloimmune liver disease (neonatal hemochromatosis), veno-occlusive disease, hemophagocytic syndrome, Budd-Chiari, and \"other diagnosis\".</div><div class=\"graphic_reference\">Modified with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 83764 Version 2.0</div></div></div>"},"83765":{"type":"graphic_table","displayName":"Medications and toxins associated with acute liver failure","title":"Medications and toxins associated with acute liver failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications and toxins associated with acute liver failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Anti-infective</td> </tr> <tr> <td class=\"indent1\">Clavulanic acid/amoxicillin</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td class=\"indent1\">Isoniazid</td> </tr> <tr> <td class=\"indent1\">Minocycline, doxycycline or tetracycline</td> </tr> <tr> <td class=\"indent1\">Quinolone (ciprofloxacin, norfloxacin)</td> </tr> <tr> <td class=\"indent1\">Voriconazole</td> </tr> <tr> <td class=\"indent1\">Ketoconazole</td> </tr> <tr> <td class=\"indent1\">Macrolide (erythromycin, clarithromycin, azithromycin, roxithromycin)</td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin</td> </tr> <tr> <td class=\"indent1\">Rifampin</td> </tr> <tr> <td class=\"indent1\">Others</td> </tr> <tr> <td class=\"subtitle1_single\">Anticonvulsants</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Valproate*</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Felbamate</td> </tr> <tr> <td class=\"indent1\">Others</td> </tr> <tr> <td class=\"subtitle1_single\">Immunomodulators/anti-inflammatory</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> </tr> <tr> <td class=\"indent1\">Nonsteroidal anti-inflammatory drugs</td> </tr> <tr> <td class=\"indent1\">Acetaminophen (APAP)</td> </tr> <tr> <td class=\"indent1\">Biological (ie, infliximab, basiliximab, etc)</td> </tr> <tr> <td class=\"indent1\">Others</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Propylthiouracil (a thionamide)</td> </tr> <tr> <td class=\"indent1\">Halothane</td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> </tr> <tr> <td class=\"sublist2_start\">Antidepressants:</td> </tr> <tr> <td class=\"sublist2\">Trazodone (SSRI)</td> </tr> <tr> <td class=\"sublist2\">Monoamine oxidase inhibitors</td> </tr> <tr> <td class=\"sublist2\">Tricyclic antidepressants</td> </tr> <tr> <td class=\"subtitle1_single\">Recreational drugs</td> </tr> <tr> <td class=\"indent1\">Ecstasy (3,4-methylenedioxyamphetamine, MDMA)</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Solvent-sniffing (glue)</td> </tr> <tr> <td class=\"indent1\">Others</td> </tr> <tr> <td class=\"subtitle1_single\">Complementary, alternative or herbal medications</td> </tr> <tr> <td class=\"indent1\">Pyrrolizidine alkaloids</td> </tr> <tr> <td class=\"indent1\">Germander</td> </tr> <tr> <td class=\"indent1\">Ma huang</td> </tr> <tr> <td class=\"indent1\">Chaparral</td> </tr> <tr> <td class=\"indent1\">Black cohosh root</td> </tr> <tr> <td class=\"indent1\">Pennyroyal</td> </tr> <tr> <td class=\"indent1\">Kava</td> </tr> <tr> <td class=\"indent1\">Others</td> </tr> <tr> <td class=\"subtitle1_single\">Environmental toxins or industrial solvents</td> </tr> <tr> <td class=\"indent1\">Amatoxin (mushrooms from Amanita sp)</td> </tr> <tr> <td class=\"indent1\">Carbon tetrachloride</td> </tr> <tr> <td class=\"indent1\">Trichloroethylene</td> </tr> <tr> <td class=\"indent1\">2-nitropropane</td> </tr> <tr> <td class=\"indent1\">1,2,3-trichloropropane</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SSRI: selective serotonin reuptake inhibitor.<br />* Patients with unsuspected mitochondrial disease (eg, Alpers-Huttenlocher disease, caused by <em>POLG</em> mutations) are particularly at risk for hepatotoxicity from valproate.</div><div class=\"graphic_reference\">Modified with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 83765 Version 3.0</div></div></div>"},"83766":{"type":"graphic_table","displayName":"Metabolic diseases associated with ALF in children","title":"Metabolic diseases that may present as acute liver failure in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Metabolic diseases that may present as acute liver failure in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Condition</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Less than 6 months</td> <td>Galactosemia</td> </tr> <tr> <td>Niemann-Pick type C</td> </tr> <tr> <td>Tyrosinemia</td> </tr> <tr> <td>Glycosylation defect</td> </tr> <tr> <td class=\"divider_bottom\">Mitochondrial disease*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">7 months to 4 years</td> <td>Mitochondrial disease*</td> </tr> <tr> <td>Tyrosinemia</td> </tr> <tr> <td>Hereditary fructose intolerance</td> </tr> <tr> <td class=\"divider_bottom\">Urea cycle defects</td> </tr> <tr> <td rowspan=\"2\">5 years to 18 years</td> <td>Wilson disease</td> </tr> <tr> <td>Mitochondrial disease*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Mitochondrial disease includes fatty acid oxidation defects, respiratory chain defects, and mitochondrial DNA depletion or damage. Mitochondrial disorders, especially Alpers-Huttenlocher disease (caused by <em>POLG</em> mutations), should be particularly suspected in patients presenting with <strong>valproate toxicity</strong>.</div><div class=\"graphic_reference\">Modified with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 83766 Version 4.0</div></div></div>"},"83767":{"type":"graphic_picture","displayName":"Lichenoid drug eruption 1","title":"Lichenoid drug eruption (drug-induced lichen planus)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lichenoid drug eruption (drug-induced lichen planus)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83767_Lichen_drug_erupt_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient with a lichenoid drug eruption, flat erythematous papules are typically distributed on the trunk and upper extremities. Grouped and confluent lesions also can be seen.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83767 Version 6.0</div></div></div>"},"83768":{"type":"graphic_picture","displayName":"Lichenoid drug eruption 2","title":"Lichenoid drug eruption (drug-induced lichen planus)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lichenoid drug eruption (drug-induced lichen planus)</div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/DERM/83768_Lichenoid_drug_erup_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flat erythematous/violaceous papules on the shoulder and upper arm of a patient with lichenoid drug eruption.</div><div id=\"graphicVersion\">Graphic 83768 Version 2.0</div></div></div>"},"83769":{"type":"graphic_picture","displayName":"Lichenoid drug eruption hand","title":"Lichenoid drug eruption involving the dorsum of the hand","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lichenoid drug eruption involving the dorsum of the hand</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83769_Lichen_drug_erupt_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In contrast to lichen planus, the lesions of lichenoid drug eruption are distributed on the extensor aspects of the extremities. In this patient, confluent violaceous papules are located on the dorsal aspect of the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83769 Version 5.0</div></div></div>"},"83770":{"type":"graphic_figure","displayName":"Unintentional injury deaths children","title":"Annual unintentional injury death rates (per 100,000 population) among persons aged â¤19 years, by age group - National Vital Statistics System, United States, 2000-2009","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Annual unintentional injury death rates (per 100,000 population) among persons aged &le;19 years, by age group - National Vital Statistics System, United States, 2000-2009</div><div class=\"cntnt\"><img style=\"width:524px; height:451px;\" src=\"images/PEDS/83770_Unint_injury_deaths_childr.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention (CDC). Vital signs: unintentional injury deaths among persons aged 0-19 years&nbsp;â United States, 2000-2009. MMWR Morb Mortal Wkly Rep 2012; 61:270.</div><div id=\"graphicVersion\">Graphic 83770 Version 2.0</div></div></div>"},"83771":{"type":"graphic_picture","displayName":"Lichenoid drug eruption hyperpigmentation 2","title":"Lichenoid drug eruption (drug-induced lichen planus)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichenoid drug eruption (drug-induced lichen planus)</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/83771_Lichen_drug_erupt_hyppig_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmentation following the resolution of lichenoid drug eruption.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83771 Version 7.0</div></div></div>"},"83772":{"type":"graphic_table","displayName":"Age-specific diagnostic priorities for children with ALF","title":"Age-specific diagnostic priorities for children with acute liver failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Age-specific diagnostic priorities for children with acute liver failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">&#60;3 months of age</td> </tr> <tr> <td>HSV&nbsp;blood PCR (or other testing: HSV IgM, viral culture of blood or CSF, CSF PCR)</td> </tr> <tr> <td>Enterovirus blood PCR (or other testing)</td> </tr> <tr> <td>Lactate, pyruvate (mitochondrial screen)</td> </tr> <tr> <td>Plasma acylcarnitine profile (fatty acid oxidation defects)</td> </tr> <tr> <td>Ferritin (screen for gestational alloimmune liver disease [neonatal hemochromatosis])</td> </tr> <tr> <td>Serum amino acid profile (urea cycle and metabolic)</td> </tr> <tr> <td>Echocardiogram: Cardiac dysfunction</td> </tr> <tr> <td>Abdominal ultrasound with Doppler (vascular and anatomic)</td> </tr> <tr> <td>Confirm newborn screening results (galactosemia and tyrosinemia)</td> </tr> <tr> <td>Confirm maternal hepatitis B serology</td> </tr> <tr> <td class=\"subtitle1_single\">3 months to 4 years</td> </tr> <tr> <td>HBsAg, HAV IgM, EBV VCA IgM or EBV PCR</td> </tr> <tr> <td>HSV and enterovirus PCR (infants, and older children who are immunosuppressed or have&nbsp;herpetic lesions)&nbsp;</td> </tr> <tr> <td>Lactate, pyruvate (mitochondrial screen)</td> </tr> <tr> <td>Autoimmune markers: ANA, ASMA, ALKM, IgG</td> </tr> <tr> <td>Drug history, acetaminophen level</td> </tr> <tr> <td>Plasma acylcarnitine profile (fatty acid oxidation defects)</td> </tr> <tr> <td>Serum amino acids</td> </tr> <tr> <td>Abdominal ultrasound with Doppler (vascular and anatomic)</td> </tr> <tr> <td class=\"subtitle1_single\">5 years to 18 years</td> </tr> <tr> <td>HBsAg, HAV IgM, EBV (EBV VCA IgM or PCR)</td> </tr> <tr> <td>HSV PCR (all patients who are immunosuppressed or have herpetic lesions of the skin, genitalia, or pharynx)&nbsp;</td> </tr> <tr> <td>Autoimmune markers: ANA, ASMA, ALKM, IgG</td> </tr> <tr> <td>Ceruloplasmin</td> </tr> <tr> <td>Drug history, acetaminophen level</td> </tr> <tr> <td>Lactate, pyruvate (screen for mitochondrial disorders)</td> </tr> <tr> <td>Plasma acylcarnitine profile (Fatty acid oxidation defects)</td> </tr> <tr> <td>Serum amino acids</td> </tr> <tr> <td>Abdominal ultrasound with Doppler (vascular and anatomic)</td> </tr> <tr> <td class=\"subtitle1_single\">Additional diagnostic screening tests to consider, directed by history and clinical course</td> </tr> <tr> <td class=\"sublist1_start\">Infectious causes</td> </tr> <tr> <td class=\"sublist1\">Blood culture</td> </tr> <tr> <td class=\"sublist1\">Viral PCR in blood for adenovirus, enterovirus, EBV, HHV-6, parvovirus</td> </tr> <tr> <td class=\"sublist1\">Nasal wash for influenza (infections)</td> </tr> <tr> <td class=\"sublist1\">Hepatitis E antibody</td> </tr> <tr> <td>Serologic tests for celiac disease&nbsp;(eg, tissue transglutaminase)&nbsp;</td> </tr> <tr> <td>Soluble IL2R, ferritin in older patients, triglycerides (hemophagocytic lymphohistiocytosis)</td> </tr> <tr> <td>Echocardiogram (cardiac)</td> </tr> <tr> <td>MRI for tissue iron (gestational alloimmune liver disease [neonatal hemochromatosis])</td> </tr> <tr> <td>Urine succinyl acetone (tyrosinemia)</td> </tr> <tr> <td>Urine orotic acid (urea cycle defects)</td> </tr> <tr> <td>Urine organic acids (metabolic)</td> </tr> <tr> <td>Liver copper, Wilson gene mutation analysis (Wilson)</td> </tr> <tr> <td>Liver biopsy for histology, culture, electron microscopy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HSV: herpes simplex virus; PCR: polymerase chain reaction; HSV: herpes simplex virus; IgM: immunoglobulin M; CSF: cerebrospinal fluid; HBsAg: hepatitis B s antigen; HAV: hepatitis A virus; EBV: Epstein-Barr virus; VCA: viral capsid antigen; ANA: anti-nuclear antibodies; ASMA: anti-smooth muscle antibodies; ALKM: anti-liver-kidney microsomal antibodies; HHV-6: human herpes virus 6; IL2R: interleukin 2 receptor. MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Modified with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 83772 Version 4.0</div></div></div>"},"83773":{"type":"graphic_picture","displayName":"Liver biopsy in a child with indeterminate acute liver failure","title":"Liver biopsy in a child with indeterminate acute liver failure","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Liver biopsy in a child with indeterminate acute liver failure</div><div class=\"cntnt\"><img style=\"width:557px; height:212px;\" src=\"images/PEDS/83773_Liver_biop_acut_liver_fail.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of a liver biopsy in a child with acute liver failure of indeterminate etiology, with falling ALT (1250 IU/L to 275 IU/L), rising total bilirubin (12.5 mg/dL to 25 mg/dL) and rising prothrombin time (rising from 20 to 26 seconds). Histology reveals a dense infiltrate dominated by lymphocytes, but with scattered neutrophils and eosinophils, and with hepatic necrosis and biliary damage.<br />(A) Low power view.<br />(B) High power view.</div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; IU: international unit.</div><div class=\"graphic_reference\">Reproduced with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 83773 Version 2.0</div></div></div>"},"83774":{"type":"graphic_picture","displayName":"Lichenoid drug eruption oral","title":"Oral lichenoid drug eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral lichenoid drug eruption</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/83774_Lichen_drug_erupt_oral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White lesions with a reticular pattern (Wickam striae) can be seen on the tongue and oral mucosa of this patient with oral lichenoid drug eruption.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83774 Version 5.0</div></div></div>"},"83775":{"type":"graphic_figure","displayName":"Categories of idiopathic pediatric acute liver failure","title":"Categories of idiopathic pediatric acute liver failure","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Categories of idiopathic pediatric acute liver failure</div><div class=\"cntnt\"><img style=\"width:596px; height:299px;\" src=\"images/PEDS/83775_Cat_idio_ped_acu_liver_fail.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The etiology of pediatric acute liver failure (PALF) is identified in approximately 55 percent of cases, leaving an indeterminate cause in 45 percent. Indeterminate cases are likely composed of a number separate conditions including immune dysregulation, with the latter condition having a variety of manifestations.</div><div class=\"graphic_footnotes\">%: percent; APAP: acetaminophen (paracetamol).</div><div class=\"graphic_reference\">Modified with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Suchy FJ, Sokol RJ, Balistreri WF, Eds. Liver Disease in Children, 4th Ed. Cambridge University Press, New York, 2012. Copyright &copy; 2012 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 83775 Version 1.0</div></div></div>"},"83777":{"type":"graphic_table","displayName":"Guidelines for safe prehospital transportation","title":"Guidelines for safe prehospital transportation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for safe prehospital transportation</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Condition</td>\r\n            <td class=\"subtitle1\">Restraint options</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Injured, but not ill</td>\r\n            <td>\r\n            <p>Transport in the front seat of the ambulance with the air bags off</p>\r\n            <p>Transport in a forward or rear-facing EMS provider's seat</p>\r\n            <p>Consider delay of transport and continue on scene care until an alternate vehicle is available</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ill or injured, but not requiring continuous/intensive monitoring or interventions</td>\r\n            <td>\r\n            <p>Transport in the EMS provider's seat in a size-appropriate child restraint system or an integrated seat in the EMS provider's seat that is certified by the manufacturer to meet the injury criteria of Federal Motor Vehicle Safety Standards</p>\r\n            <p>Transport on a cot using three horizontal restraints across the child's torso (chest/waist/knees) and one vertical restraint across each of the child's shoulders</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ill or injured, and requiring continuous/intensive monitoring or interventions</td>\r\n            <td>\r\n            <p>Transport the child in a size-appropriate child restraint system that complies with the injury criteria of Federal Motor Vehicle Safety Standards secured appropriately on a cot. If this is not feasible, the following alternatives are recommended:</p>\r\n            <p>Transport on a cot, head first, using three horizontal restraints across the child's torso (chest/waist/knees) and one vertical restraint across each of the child's shoulders. If restraints must be removed, they should be re-secured as quickly as possible; consider stopping the ambulance if interventions require restraint removal.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Condition requires spinal immobilization or lying flat</td>\r\n            <td>\r\n            <p>Transport with a size-appropriate spineboard and secure it to the cot, head first, with a tether at the foot to prevent forward movement AND three horizontal restraints across the child's torso (chest/waist/knees) and one vertical restraint across each of the child's shoulders. If this is not feasible, the following alternative is recommended:</p>\r\n            <p>Transport with a standard spineboard with padding added to make the device fit the child; secure as noted above.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Multiple transport (newborn with mother or multiple children)</td>\r\n            <td>\r\n            <p>Transport each as a single patient. If this is not feasible, the following alternative is recommended:</p>\r\n            <p>Use space available in a non-emergency mode, driving below the maximum legal speed limit.</p>\r\n            </td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">National Highway Traffic Safety Administration (NHTSA). Recommendations for the Safe Transportation of Children in Emergency Ground Ambulances. Public meeting. August 5, 2010. http://www.nhtsa.gov/staticfiles/nti/ems/pdf/EMSconference05aug2010.pdf (Accessed on September 21, 2011).</div><div id=\"graphicVersion\">Graphic 83777 Version 1.0</div></div></div>"},"83778":{"type":"graphic_table","displayName":"Appropriate on scene pediatric prehospital interventions","title":"Appropriate on scene pediatric prehospital interventions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Appropriate on scene pediatric prehospital interventions</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Assessment</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Initiate cardiac monitoring</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Measure pulse oximetry</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Airway and cervical spine immobilization</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Open and maintain the airway </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Suction the airway to remove secretions</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Apply cervical collar and back board immobilization for suspected spinal injury</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Administer racemic or L-epinephrine for severe inspiratory stridor (eg, severe croup)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Place an advanced airway, if unable to maintain airway by other means</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Breathing</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Perform&nbsp;bag-mask ventilation </td>\r\n        </tr>\r\n        <tr>\r\n            <td>Administer beta agonist therapy for reactive airway disease</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Perform needle decompression for tension pneumothorax </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Circulation</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Control external hemorrhage (eg, penetrating trauma to extremity)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Provide cardiopulmonary resuscitation if indicated - at least three cycles</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Perform synchronized cardioversion and defibrillation</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Obtain intravenous or intraosseous access if benefit outweighs delay in transport</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Administer medications indicated for cardiopulmonary arrest - at least one cycle</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Administer IV fluids for shock</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Disability</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Administer glucose for hypoglycemia</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Administer medications to control seizures</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Splint extremities</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Perform eye irrigation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1_single\">Other</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Administer medications (eg, epinephrine, diphenhydramine, and steroids) for allergic or anaphylactic reactions</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Administer hydroxocobalamin for cyanide poisoning (eg, home fires)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Administer pain medication</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83778 Version 1.0</div></div></div>"},"83779":{"type":"graphic_figure","displayName":"Chondromalacia patella PI","title":"Chondromalacia patella","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Chondromalacia patella</div><div class=\"cntnt\"><img style=\"width:486px; height:535px;\" src=\"images/PI/83779_Chondromalacia-patella-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In people with chondromalacia patella, the cartilage (rubbery material) behind the knee cap gets too soft or wears away.</div><div id=\"graphicVersion\">Graphic 83779 Version 1.0</div></div></div>"},"83780":{"type":"graphic_table","displayName":"Sun protection measures","title":"Sun protection measures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sun protection measures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Minimize sun exposure between 10 AM and 4 PM.</td> </tr> <tr> <td>Wear a wide-brimmed hat (4 inches or larger), long-sleeved shirt, and long pants. Choose tightly woven materials or ultraviolet protection factor (UPF) clothing.</td> </tr> <tr> <td>Apply sunscreen when sun exposure is unavoidable. Apply one hour prior to sun exposure to all areas of the skin that are exposed to the sun and reapply frequently (every two hours) and liberally. Use a broad spectrum (UVA and UVB) sunscreen with an SPF of 30 or greater.</td> </tr> <tr> <td>Be aware of the sun exposure risk with high-altitude activities including mountain climbing, biking, hiking, or skiing, in locations near the equator, and on cloudy or overcast days.</td> </tr> <tr> <td>Individuals at high risk for skin cancer, such as outdoor workers, fair-skinned individuals, patients with a history of skin cancer, and patients with atypical mole syndrome, should apply sunscreen daily to exposed skin.</td> </tr> <tr> <td>Infants less than six months of age should be kept out of the sun; children six months and older should be protected with clothing and sunscreens.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83780 Version 2.0</div></div></div>"},"83781":{"type":"graphic_picture","displayName":"Follicular miniaturization in androgenetic alopecia","title":"Follicular miniaturization in androgenetic alopecia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Follicular miniaturization in androgenetic alopecia</div><div class=\"cntnt\"><img style=\"width:504px; height:357px;\" src=\"images/DERM/83781_Follic_mini_andro_alopecia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair follicle miniaturization viewed through a dermatoscope. Progressive reduction in hair follicle caliber is an important feature of androgenetic alopecia. A mixture of normal and miniaturized hairs is present in this patient with androgenetic alopecia.</div><div id=\"graphicVersion\">Graphic 83781 Version 2.0</div></div></div>"},"83782":{"type":"graphic_figure","displayName":"Venn diagram hyperventilation syndrome","title":"Hyperventilation syndrome and overlapping disorders","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Hyperventilation syndrome and overlapping disorders</div><div class=\"cntnt\"><img style=\"width:464px; height:577px;\" src=\"images/PC/83782_Hypervent_syndr_Venn_diag.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperventilation and overlapping clinical pictures. In the assessment of the patient presenting with hyperventilation, one needs to consider the potential contributions of behavioral disorders and seemingly inappropriate dyspnea in the presence of known cardiopulmonary disease. The size of the circles is not meant to imply relative prevalence of the conditions.</div><div id=\"graphicVersion\">Graphic 83782 Version 2.0</div></div></div>"},"83785":{"type":"graphic_picture","displayName":"Cold panniculitis on cheek","title":"Cold panniculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cold panniculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83785_Cold_panniculitis_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous plaque is present on the cheek of this child with cold panniculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83785 Version 3.0</div></div></div>"},"83786":{"type":"graphic_picture","displayName":"Cold panniculitis on thighs","title":"Cold panniculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cold panniculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83786_Cold_pannic_thighs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques are present on the proximal thighs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83786 Version 3.0</div></div></div>"},"83788":{"type":"graphic_table","displayName":"Contraindications to cardiac transplantation","title":"Contraindications to cardiac transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to cardiac transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absolute contraindications</td> </tr> <tr> <td class=\"indent1\">Systemic illness with a life expectancy &#60;2 years despite heart transplantation</td> </tr> <tr> <td class=\"indent1\">Irreversible pulmonary hypertension with pulmonary vascular resistance &#62;3 Wood Units (&#62;240 dynes-sec/cm<sup>5</sup>)<sup>[1]</sup>*</td> </tr> <tr> <td class=\"indent1\">Clinically severe symptomatic cerebrovascular disease</td> </tr> <tr> <td class=\"indent1\">Active substance (drug or alcohol) abuse</td> </tr> <tr> <td class=\"indent1\">Multiple demonstrations of inability to comply with drug therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Multisystem disease with severe extracardiac organ dysfunction</td> </tr> <tr> <td class=\"subtitle1_single\">Relative contraindications</td> </tr> <tr> <td class=\"indent1\">Age &#62;70 years<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Obesity (ie, body mass index &#62;35 kg/m<sup>2</sup>)</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus with poor glycemic control (glycated hemoglobin [HbA1c] &#62;7.5% or 58 mmol/mol) despite optimal effort or end-organ damage other than non-proliferative retinopathy</td> </tr> <tr> <td class=\"indent1\">Irreversible renal dysfunction (eGFR &#60;30 mL/min/1.73 m<sup>2</sup>)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Neoplasm (requires individualized assessment of severity, treatment options, and prognosis)</td> </tr> <tr> <td class=\"indent1\">Infection (requires individualized assessment of severity, treatment options, and prognosis)</td> </tr> <tr> <td class=\"indent1\">Acute pulmonary embolism (within six to eight weeks)</td> </tr> <tr> <td class=\"indent1\">Tobacco use (within 6 months)</td> </tr> <tr> <td class=\"indent1\">Recent past (within 6 months) substance (drug or alcohol) abuse</td> </tr> <tr> <td class=\"indent1\">Inadequate social support or cognitive-behavioral disability that would prevent compliant care</td> </tr> <tr> <td class=\"indent1\">Other conditions that increase the risk of perioperative complications or limit tolerance of immunosuppression (eg, peripheral vascular disease that would limit rehabilitation and is not amenable to revascularization, active peptic ulcer disease, cholelithiasis, diverticulosis, advanced hepatic disease)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patients with PVR up to 5 Wood units can be considered for cardiac transplantation on a case by case basis.<br />&para; While age &gt;70-years-old is a relative contraindication, carefully selected &gt;70-years-old may be considered for transplantation.<br />&Delta; For patients with renal dysfunction, evaluation should be undertaken to exclude reversible causes. Combined heart-kidney transplantation may be offered to those who require transplantation of both organs.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Mancini D, Lietz K. Selection of Cardiac Transplantation Candidates in 2010. Circulation 2010; 122:174. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.</li>&#xD;&#xA;    <li>Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant 2016; 35:1.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 83788 Version 7.0</div></div></div>"},"83789":{"type":"graphic_picture","displayName":"Pancreatic panniculitis","title":"Pancreatic panniculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pancreatic panniculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83789_Pancreatic_panniculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory nodules on the distal leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83789 Version 4.0</div></div></div>"},"83790":{"type":"graphic_picture","displayName":"Subcutaneous fat necrosis of the newborn","title":"Subcutaneous fat necrosis of the newborn","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Subcutaneous fat necrosis of the newborn</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83790_Subcutan_fat_necros_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous nodules and plaques in subcutaneous fat necrosis of the newborn.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83790 Version 3.0</div></div></div>"},"83791":{"type":"graphic_picture","displayName":"Lupus panniculitis","title":"Lupus panniculitis (lupus profundus)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus panniculitis (lupus profundus)</div><div class=\"cntnt\"><img style=\"width:334px; height:504px;\" src=\"images/DERM/83791_Lupus_panniculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous nodules (chest and abdomen) and lipoatrophy (upper arm) in lupus panniculitis.</div><div class=\"graphic_reference\">Copyright Â© Scott Crater, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 83791 Version 6.0</div></div></div>"},"83792":{"type":"graphic_table","displayName":"UNOS priority status for HT","title":"UNOS priority status for heart transplant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">UNOS priority status for heart transplant</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Status 1A</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Reside in the transplant listing center and at least one of the following: </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp; On mechanical ventilation</p> </td> </tr> <tr> <td class=\"indent1\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp; On intraaortic balloon pump, total artificial heart, or&nbsp;extracorporeal&nbsp;membrane oxygentator</td> </tr> <tr> <td class=\"indent1\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp; Hemodynamic monitoring with single high-dose intravenous inotrope or multiple intravenous inotropes (eg, dobutamine &#62;7.5 mcg/kg/min plus milrinone 0.5 mcg/kg/min)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>&nbsp;For 30 days after implantation with a left and/or right ventricular assist device for acute decompensation (need not be admitted to the listing center) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>&nbsp; A candidate with a total artificial heart who has been discharged from the listing center may be listed as Status 1A for 30 days after the discharge. (This provision will expire on December 1, 2012.) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>LVAD with a device-related complication (such as thromboembolism, device infection, mechanical failure, or life-threatening ventricular arrhythmias) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Status 1B</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Infusion of intravenous inotropes or&nbsp;supported by an implanted chronic (left&nbsp;and/or right)&nbsp;mechanical assist device </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>&nbsp;A candidate with a total artificial heart who has been discharged from the listing hospital may be listed as Status 1B at ay point in time after discharge. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Status 2</td> </tr> <tr> <td class=\"indent1\">All candidates who do not meet 1A or 1B requirements</td> </tr> <tr> <td class=\"subtitle2_left\">Status 7</td> </tr> <tr> <td class=\"indent1\"> <p>Temporarily unsuitable to receive a thoracic organ transplant.&nbsp;During the inactive period there is no gain or loss of&nbsp;accrued time.</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Based on guidelines from: Organ Procurement and Transplantation Network (OPTN). Organ Distribution:Allocation of Thoracic Organs. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, November 15, 2011. http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp (Accessed on May 31, 2012).</div><div id=\"graphicVersion\">Graphic 83792 Version 2.0</div></div></div>"},"83793":{"type":"graphic_picture","displayName":"Nail changes in reactive arthritis I","title":"Nail changes in reactive arthritis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Nail changes in reactive arthritis</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/RHEUM/83793_Nail_changes_reactive_arthI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subungual hyperkeratosis, onycholysis, and periungual erythematous scaly plaques are present on the hands of this patient with reactive arthritis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83793 Version 3.0</div></div></div>"},"83796":{"type":"graphic_picture","displayName":"Nail changes in reactive arthritis II","title":"Nail changes in reactive arthritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nail changes in reactive arthritis</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/RHEUM/83796_Nail_change_react_arth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Separation of the distal portion of the nails (onycholysis), accumulation of subungual keratotic debris, and periungual scale and erythema can occur in both reactive arthritis and psoriasis. &nbsp;Arthritis is present in addition to the dystrophic nail changes.</div><div class=\"graphic_reference\">Copyright Â© 2017 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 83796 Version 14.0</div></div></div>"},"83797":{"type":"graphic_picture","displayName":"Palatal erosion in reactive arthritis","title":"Palatal erosion in reactive arthritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Palatal erosion in reactive arthritis</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/RHEUM/83797_Palatal_eros_reac_arthrit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sharply demarcated erosion of the hard palate is shown. This is among the more common of the oral manifestations of reactive arthritis.</div><div class=\"graphic_reference\">Copyright Â© 2017 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 83797 Version 12.0</div></div></div>"},"83802":{"type":"graphic_picture","displayName":"Androgenetic alopecia bitemporal recession","title":"Androgenetic alopecia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Androgenetic alopecia</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83802_Andro_alope_bite_recess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bitemporal hair loss in a man with androgenetic alopecia.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83802 Version 4.0</div></div></div>"},"83803":{"type":"graphic_figure","displayName":"Mitral valve prolapse PI","title":"Mitral valve prolapse","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Mitral valve prolapse</div><div class=\"cntnt\"><img style=\"width:512px; height:453px;\" src=\"images/PI/83803_Mitral-valve-prolapse-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mitral valve prolapse is a condition in which the mitral valve doesnât close normally. The mitral valve is made up of&nbsp;two flaps. In mitral valve prolapse,&nbsp;one or both flaps billow or bulge into the left atrium.&nbsp;In some people, this causes&nbsp;blood&nbsp;to leak backward in the wrong direction.</div><div id=\"graphicVersion\">Graphic 83803 Version 4.0</div></div></div>"},"83804":{"type":"graphic_picture","displayName":"Androgenetic alopecia vertex","title":"Androgenetic alopecia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Androgenetic alopecia</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83804_Androgen_alopec_vertex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair loss on the vertex of the scalp in a man with androgenetic alopecia.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83804 Version 3.0</div></div></div>"},"83805":{"type":"graphic_picture","displayName":"Androgenetic alopecia extensive","title":"Androgenetic alopecia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Androgenetic alopecia</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/83805_Andro_alopecia_exten.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair loss in androgenetic alopecia. Terminal hairs on the occipital scalp are spared.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83805 Version 3.0</div></div></div>"},"83816":{"type":"graphic_figure","displayName":"PET rate of transport","title":"Peritoneal equilibration test (PET): Rate of transport","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Peritoneal equilibration test (PET): Rate of transport</div><div class=\"cntnt\"><img style=\"width:557px; height:655px;\" src=\"images/NEPH/83816_PETrateoftransport.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">D/P: dialysate/plasma ratio.</div><div class=\"graphic_reference\">Data originally published in Peritoneal Dialysis International. Reproduced with permission from: Twardowski ZJ, Nolph KD, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138. Copyright &copy; 1987.</div><div id=\"graphicVersion\">Graphic 83816 Version 3.0</div></div></div>"},"83824":{"type":"graphic_figure","displayName":"Normal range of neutrophil counts for preterm infants","title":"Normal range of neutrophil count for newborn infants with a gestational age between 28 and 36 weeks during the first 72 hours of life","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Normal range of neutrophil count for newborn infants with a gestational age between 28 and 36 weeks during the first 72 hours of life</div><div class=\"cntnt\"><img style=\"width:594px; height:444px;\" src=\"images/PEDS/83824_Norm_neutrophil_preterm_inf.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neutrophils per microL of blood during the first 72 hours after the birth of 28- to 36-week gestation preterm neonates. A total of 8896 values were obtained for the analysis. The 5th percentile, the mean, and the 95th percentile values are shown.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Schmutz N, Henry E, Jopling J, Christensen RD. Expected ranges for blood neutrophil concentrations of neonates: the Manroe and Mouzinho charts revisited. J Perinatol 2008; 28:275. <a href=\"http://www.nature.com/jp/index.html\" target=\"_blank\">http://www.nature.com/jp/index.html</a>. Copyright &copy; 2008.</div><div id=\"graphicVersion\">Graphic 83824 Version 1.0</div></div></div>"},"83826":{"type":"graphic_table","displayName":"Pre-transplant mortality among adults wait-listed for HT","title":"Pre-transplant mortality rates among adult patients wait-listed for a heart transplant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pre-transplant mortality rates among adult patients wait-listed for a heart transplant</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"9%\"></colgroup><colgroup span=\"7\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">18 to 34</td> <td class=\"subtitle1\">35 to 49</td> <td class=\"subtitle1\">50 to 64</td> <td class=\"subtitle1\">65+</td> <td class=\"subtitle1\">Male</td> <td class=\"subtitle1\">Female</td> <td class=\"subtitle1\">All</td> </tr> <tr> <td><strong>1998</strong></td> <td class=\"centered\">24.7</td> <td class=\"centered\">17.5</td> <td class=\"centered\">20.7</td> <td class=\"centered\">28.8</td> <td class=\"centered\">21.0</td> <td class=\"centered\">19.6</td> <td class=\"centered\">20.7</td> </tr> <tr> <td><strong>1999</strong></td> <td class=\"centered\">21.7</td> <td class=\"centered\">18.2</td> <td class=\"centered\">17.7</td> <td class=\"centered\">23.7</td> <td class=\"centered\">19.0</td> <td class=\"centered\">17.2</td> <td class=\"centered\">18.6</td> </tr> <tr> <td><strong>2000</strong></td> <td class=\"centered\">22.0</td> <td class=\"centered\">14.0</td> <td class=\"centered\">16.7</td> <td class=\"centered\">19.1</td> <td class=\"centered\">16.5</td> <td class=\"centered\">16.9</td> <td class=\"centered\">16.6</td> </tr> <tr> <td><strong>2001</strong></td> <td class=\"centered\">20.9</td> <td class=\"centered\">15.2</td> <td class=\"centered\">16.9</td> <td class=\"centered\">20.0</td> <td class=\"centered\">16.7</td> <td class=\"centered\">18.3</td> <td class=\"centered\">17.1</td> </tr> <tr> <td><strong>2002</strong></td> <td class=\"centered\">21.5</td> <td class=\"centered\">14.1</td> <td class=\"centered\">14.9</td> <td class=\"centered\">14.3</td> <td class=\"centered\">15.3</td> <td class=\"centered\">14.6</td> <td class=\"centered\">15.2</td> </tr> <tr> <td><strong>2003</strong></td> <td class=\"centered\">16.4</td> <td class=\"centered\">12.2</td> <td class=\"centered\">15.9</td> <td class=\"centered\">17.0</td> <td class=\"centered\">15.4</td> <td class=\"centered\">14.2</td> <td class=\"centered\">15.2</td> </tr> <tr> <td><strong>2004</strong></td> <td class=\"centered\">15.4</td> <td class=\"centered\">13.8</td> <td class=\"centered\">14.1</td> <td class=\"centered\">20.0</td> <td class=\"centered\">14.7</td> <td class=\"centered\">15.6</td> <td class=\"centered\">14.9</td> </tr> <tr> <td><strong>2005</strong></td> <td class=\"centered\">15.9</td> <td class=\"centered\">13.6</td> <td class=\"centered\">13.6</td> <td class=\"centered\">15.0</td> <td class=\"centered\">13.8</td> <td class=\"centered\">14.7</td> <td class=\"centered\">14.0</td> </tr> <tr> <td><strong>2006</strong></td> <td class=\"centered\">15.5</td> <td class=\"centered\">13.7</td> <td class=\"centered\">14.6</td> <td class=\"centered\">16.9</td> <td class=\"centered\">14.9</td> <td class=\"centered\">14.6</td> <td class=\"centered\">14.8</td> </tr> <tr> <td><strong>2007</strong></td> <td class=\"centered\">12.3</td> <td class=\"centered\">13.2</td> <td class=\"centered\">13.1</td> <td class=\"centered\">16.2</td> <td class=\"centered\">13.7</td> <td class=\"centered\">12.6</td> <td class=\"centered\">13.5</td> </tr> <tr> <td><strong>2008</strong></td> <td class=\"centered\">16.2</td> <td class=\"centered\">13.3</td> <td class=\"centered\">14.6</td> <td class=\"centered\">18.2</td> <td class=\"centered\">15.0</td> <td class=\"centered\">14.8</td> <td class=\"centered\">15.0</td> </tr> <tr> <td><strong>2009</strong></td> <td class=\"centered\">12.6</td> <td class=\"centered\">13.1</td> <td class=\"centered\">13.1</td> <td class=\"centered\">17.3</td> <td class=\"centered\">13.8</td> <td class=\"centered\">13.4</td> <td class=\"centered\">13.7</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Mortality rates listed as deaths per 100 wait-list years.</div><div class=\"graphic_reference\">Data from: Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD: 2011.</div><div id=\"graphicVersion\">Graphic 83826 Version 2.0</div></div></div>"},"83827":{"type":"graphic_table","displayName":"INTERMACS levels of limitation at the time of implant","title":"Interagency registry for mechanically assisted circulatory support (INTERMACS) levels of limitation at the time of implant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interagency registry for mechanically assisted circulatory support (INTERMACS) levels of limitation at the time of implant</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <colgroup span=\"2\" width=\"50%\"></colgroup>\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">INTERMACS profile level</td>\r\n            <td class=\"subtitle1\">Status</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Level 1</td>\r\n            <td>Critical cardiogenic shock</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Level 2</td>\r\n            <td>Progressive decline</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Level 3</td>\r\n            <td>Stable but inotrope dependent</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Level 4</td>\r\n            <td>Recurrent advanced heart failure</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Level 5</td>\r\n            <td>Exertion intolerant</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Level 6</td>\r\n            <td>Exertion limited</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Level 7</td>\r\n            <td>Advanced NYHA Class III</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">Reproduced from: Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009; 28:535. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83827 Version 1.0</div></div></div>"},"83831":{"type":"graphic_picture","displayName":"Ascending colon TB enteritis","title":"Ascending colon tuberculous enteritis","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Ascending colon tuberculous enteritis</div><div class=\"cntnt\"><img style=\"width:511px; height:206px;\" src=\"images/ID/83831_Ascend_colon_tuber_en.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Colonoscopic view of circumferential ulcers involving the cecum and ascending colon due to tuberculosis.<br />(B) Colonoscopic view of longitudinal ulcers (arrows) involving the ascending colon due to Crohn disease.</div><div class=\"graphic_reference\">Courtesy of Harshad Devarbhavi, MD (image A) and Louis M. Wong Kee Song, MD (image B).</div><div id=\"graphicVersion\">Graphic 83831 Version 3.0</div></div></div>"},"83832":{"type":"graphic_picture","displayName":"Ileocecal tuberculous enteritis","title":"Ileocecal tuberculous enteritis","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Ileocecal tuberculous enteritis</div><div class=\"cntnt\"><img style=\"width:513px; height:413px;\" src=\"images/ID/83832_Ileocecal_tube_enter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopic views of histologically confirmed ileocecal tuberculosis with ulcerations (A) and destroyed ileocecal valve (B and C).</div><div class=\"graphic_reference\">Courtesy of Harshad Devarbhavi, MD.</div><div id=\"graphicVersion\">Graphic 83832 Version 1.0</div></div></div>"},"83833":{"type":"graphic_diagnosticimage","displayName":"CT tuberculous enteritis","title":"Tuberculous enteritisÂ â Computed tomography","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Tuberculous enteritis&nbsp;â Computed tomography</div><div class=\"cntnt\"><img style=\"width:517px; height:238px;\" src=\"images/ID/83833_CT_tubercul_enteritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced computed tomography of histologically proven ileocecal tuberculosis showing thickened terminal ileum (arrow), ileocecal valve (thick arrow), and cecum (dashed arrow) with enlarged necrotic ileocecal lymph nodes (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Sudhakar Venkatesh, MD.</div><div id=\"graphicVersion\">Graphic 83833 Version 3.0</div></div></div>"},"83834":{"type":"graphic_table","displayName":"Subcutaneous sliding scale sample","title":"Sample subcutaneous sliding scale using short-acting insulin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample subcutaneous sliding scale using short-acting insulin</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">&nbsp;</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Insulin sensitive</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Usual</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Insulin resistant</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">Glucose values (mg/dL/mmol/L)</td>\r\n            <td class=\"subtitle2\">AC</td>\r\n            <td class=\"subtitle2\">HS</td>\r\n            <td class=\"subtitle2\">AC</td>\r\n            <td class=\"subtitle2\">HS</td>\r\n            <td class=\"subtitle2\">AC</td>\r\n            <td class=\"subtitle2\">HS</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&#60;150/8.3</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">0</td>\r\n        </tr>\r\n        <tr>\r\n            <td>151 to 200/8.4 to 11.1</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">2</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">4</td>\r\n            <td class=\"centered\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td>201 to 250/11.2 to 13.9</td>\r\n            <td class=\"centered\">2</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">4</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">8</td>\r\n            <td class=\"centered\">4</td>\r\n        </tr>\r\n        <tr>\r\n            <td>251 to 300/13.9 to 16.6</td>\r\n            <td class=\"centered\">3</td>\r\n            <td class=\"centered\">1</td>\r\n            <td class=\"centered\">6</td>\r\n            <td class=\"centered\">2</td>\r\n            <td class=\"centered\">12</td>\r\n            <td class=\"centered\">6</td>\r\n        </tr>\r\n        <tr>\r\n            <td>301 to 350/16.7 to 19.4</td>\r\n            <td class=\"centered\">4</td>\r\n            <td class=\"centered\">2</td>\r\n            <td class=\"centered\">8</td>\r\n            <td class=\"centered\">4</td>\r\n            <td class=\"centered\">16</td>\r\n            <td class=\"centered\">8</td>\r\n        </tr>\r\n        <tr>\r\n            <td>351 to 400/19.5 to 22.2</td>\r\n            <td class=\"centered\">5</td>\r\n            <td class=\"centered\">3</td>\r\n            <td class=\"centered\">10</td>\r\n            <td class=\"centered\">6</td>\r\n            <td class=\"centered\">20</td>\r\n            <td class=\"centered\">10</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">AC: before meals; HS: bedtime.</div><div id=\"graphicVersion\">Graphic 83834 Version 1.0</div></div></div>"},"83835":{"type":"graphic_diagnosticimage","displayName":"MRI sacral ala insufficiency fracture","title":"MRI of sacral ala insufficiency fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of sacral ala insufficiency fracture</div><div class=\"cntnt\"><img style=\"width:426px; height:514px;\" src=\"images/EM/83835_MRI_sac_ala_insuf_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiographs and a computed tomography (CT) of the pelvis failed to reveal any fracture in the elder patient for whom the studies were obtained. When her groin and low back pain persisted, this and the accompanying magnetic resonance image (MRI) were obtained. Bone marrow edema consistent with an insufficiency fracture of the sacral ala (arrow) is seen on this T2 image.</div><div class=\"graphic_reference\">Courtesy of Jim Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 83835 Version 2.0</div></div></div>"},"83839":{"type":"graphic_table","displayName":"Classification of toxic hepatocellular injury","title":"Classification of toxic hepatocellular injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of toxic hepatocellular injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical classification</td> </tr> <tr> <td class=\"sublist1_start\">Acute hepatocellular injury</td> </tr> <tr> <td class=\"sublist1\">Injury predominantly to hepatocytes</td> </tr> <tr> <td class=\"sublist1\">Markedly elevated ALT</td> </tr> <tr> <td class=\"sublist1\">Mildly elevated alkaline phosphatase</td> </tr> <tr> <td class=\"sublist1_start\">Cholestatic injury</td> </tr> <tr> <td class=\"sublist1\">Injury to bile ducts or the mechanisms affecting flow of bilirubin from serum to bile</td> </tr> <tr> <td class=\"sublist1\">Disproportionately elevated alkaline phosphatase</td> </tr> <tr> <td class=\"sublist1_start\">Mixed injury</td> </tr> <tr> <td class=\"sublist1\">Features of both acute hepatocellular injury and cholestatic injury</td> </tr> <tr> <td class=\"subtitle1_single\">Pathogenic classification</td> </tr> <tr> <td class=\"sublist1_start\">Intrinsic hepatotoxins</td> </tr> <tr> <td class=\"sublist1\">Direct chemical reactions</td> </tr> <tr> <td class=\"sublist1\">Predictable</td> </tr> <tr> <td class=\"sublist1_start\">Idiosyncratic reactions</td> </tr> <tr> <td class=\"sublist1\">Unpredictable</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase.</div><div id=\"graphicVersion\">Graphic 83839 Version 2.0</div></div></div>"},"83840":{"type":"graphic_table","displayName":"Risk factors for growth impairment in pediatric CKD","title":"Risk factors for growth impairment in children with chronic kidney disease (CKD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for growth impairment in children with chronic kidney disease (CKD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Genetic factors</td> </tr> <tr> <td class=\"sublist1\">Parental heights</td> </tr> <tr> <td class=\"sublist1\">Gender</td> </tr> <tr> <td class=\"sublist1\">Congenital anomalies including syndromes</td> </tr> <tr> <td class=\"sublist1\">Genetic disorders</td> </tr> <tr> <td>Birth-related factors</td> </tr> <tr> <td class=\"sublist1\">Prematurity</td> </tr> <tr> <td class=\"sublist1\">Small for gestational age</td> </tr> <tr> <td class=\"sublist1\">Prolonged neonatal intensive care course</td> </tr> <tr> <td>Age at onset of CKD</td> </tr> <tr> <td>Severity of CKD and residual renal function for children undergoing dialysis</td> </tr> <tr> <td>Anemia</td> </tr> <tr> <td>Metabolic disturbances</td> </tr> <tr> <td class=\"sublist1\">Salt and water metabolism</td> </tr> <tr> <td class=\"sublist1\">Metabolic acidosis</td> </tr> <tr> <td class=\"sublist1\">CKD-mineral and bone disorder</td> </tr> <tr> <td>Malnutrition</td> </tr> <tr> <td class=\"sublist1\">Altered taste sensation</td> </tr> <tr> <td class=\"sublist1\">Anorexia</td> </tr> <tr> <td class=\"sublist1\">Vomiting</td> </tr> <tr> <td class=\"sublist1\">Dietary restrictions</td> </tr> <tr> <td class=\"sublist1\">Nutrient losses in dialysate</td> </tr> <tr> <td class=\"sublist1\">Infections and inflammation</td> </tr> <tr> <td>Protein energy wasting</td> </tr> <tr> <td class=\"sublist1\">Infections and inflammation</td> </tr> <tr> <td class=\"sublist1\">Uremic toxins</td> </tr> <tr> <td class=\"sublist1\">Oxidative stress</td> </tr> <tr> <td class=\"sublist1\">Inflammatory cytokines</td> </tr> <tr> <td class=\"sublist1_start\">Hormonal disturbances</td> </tr> <tr> <td class=\"sublist1\">Somatotropic hormonal axis</td> </tr> <tr> <td class=\"sublist1\">Gonadotropic hormonal axis</td> </tr> <tr> <td class=\"sublist1\">Parathyroid hormone and vitamin D metabolism/action</td> </tr> <tr> <td class=\"sublist1\">Gastrointestinal hormones</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease.</div><div id=\"graphicVersion\">Graphic 83840 Version 2.0</div></div></div>"},"83841":{"type":"graphic_figure","displayName":"Effect of renal function on growth in children with CKD","title":"The effect of baseline renal function on growth from the NAPRTCS registry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The effect of baseline renal function on growth from the NAPRTCS registry</div><div class=\"cntnt\"><img style=\"width:406px; height:490px;\" src=\"images/PEDS/83841_Eff_renal_func_growth_CKD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) demonstrate the impact of renal function on growth in children with chronic renal insufficiency.</div><div class=\"graphic_footnotes\">Height Z score: the number of standard deviations from the mean height for age; GFR: glomerular filtration rate.</div><div class=\"graphic_reference\">Reproduced with permission from: North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2008 Annual Report. Renal transplantation, dialysis, and chronic renal insufficiency. Available at: https://web.emmes.com/study/ped/annlrept/annlrept.html.</div><div id=\"graphicVersion\">Graphic 83841 Version 1.0</div></div></div>"},"83842":{"type":"graphic_figure","displayName":"Standarized height score by age at transplant","title":"Standarized height score (Z-score) by age at transplant from the NAPRTCS registry","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Standarized height score (Z-score) by age at transplant from the NAPRTCS registry</div><div class=\"cntnt\"><img style=\"width:601px; height:376px;\" src=\"images/PEDS/83842_Indextransplantfuncgraft.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Height Z-score: the number of standard deviations from the mean height for age; NAPRTCS: North American Pediatric Renal Trials and Collaborative Studies.</div><div class=\"graphic_reference\">Reproduced with permission from: North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2010 Annual Transplant Report. Available at: <A spellcheck=true href=\"https://web.emmes.com/study/ped/annlrept/annlrept.html\" target=_blank>https://web.emmes.com/study/ped/annlrept/annlrept.html</A>. This graphic appeared unchanged as Exhibit 6.2 in the 2014 Annual Transplant Report.</div><div id=\"graphicVersion\">Graphic 83842 Version 2.0</div></div></div>"},"83843":{"type":"graphic_figure","displayName":"Height velocity in children on hemodialysis","title":"Height velocity based on duration of dialysis and age in children on hemodialysis from the NAPRTCS registry","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Height velocity based on duration of dialysis and age in children on hemodialysis from the NAPRTCS registry</div><div class=\"cntnt\"><img style=\"width:601px; height:368px;\" src=\"images/PEDS/83843_Ht_vel_child_hemodialysis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Height Z score: the number of standard deviations from the mean height for age; NAPRTCS: North American Pediatric Renal Trials and Collaborative Studies.</div><div class=\"graphic_reference\">Reproduced with permission from: North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2011 Annual Dialysis Report. Available at: https://web.emmes.com/study/ped/annlrept/annlrept.html.</div><div id=\"graphicVersion\">Graphic 83843 Version 1.0</div></div></div>"},"83844":{"type":"graphic_figure","displayName":"Height velocity in children on peritoneal dialysis","title":"Height velocity based on duration of dialysis and age in children on peritoneal dialysis from the NAPRTCS registry","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Height velocity based on duration of dialysis and age in children on peritoneal dialysis from the NAPRTCS registry</div><div class=\"cntnt\"><img style=\"width:599px; height:368px;\" src=\"images/PEDS/83844_Ht_vel_child_peri_dialysis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Height Z score: the number of standard deviations from the mean height for age; NAPRTCS: North American Pediatric Renal Trials and Collaborative Studies.</div><div class=\"graphic_reference\">Reproduced with permission from: North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2011 Annual Dialysis Report. Available at: https://web.emmes.com/study/ped/annlrept/annlrept.html.</div><div id=\"graphicVersion\">Graphic 83844 Version 2.0</div></div></div>"},"83845":{"type":"graphic_figure","displayName":"Anatomy of L-TGA and normal heart","title":"Anatomy of a normal heart and L-transposition of the great arteries","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Anatomy of a normal heart and L-transposition of the great arteries</div><div class=\"cntnt\"><img style=\"width:542px; height:400px;\" src=\"images/PEDS/83845_Normal-heart_L-TGA.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RA: right atrium; RV: right ventricle; Ao: aorta; LV: left ventricle; LA: left atrium; PT: pulmonary trunk.</div><div id=\"graphicVersion\">Graphic 83845 Version 1.0</div></div></div>"},"83846":{"type":"graphic_figure","displayName":"Classification systems for truncus arteriosus","title":"Classification systems for truncus arteriosus","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Classification systems for truncus arteriosus</div><div class=\"cntnt\"><img style=\"width:533px; height:718px;\" src=\"images/PEDS/83846_ClassificationsystemsforTA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left: Type I to IV, by Collett and Edwards (1949). Of note, type IV is no longer&nbsp;considered a variant of truncus arteriosus but rather it is categorized as pulmonary atresia.&nbsp;Right: Types A1 to A4, by Van Praagh and Van Praagh (1965).</div><div class=\"graphic_reference\">Reproduced with permission from: Cabalka AK, Edwards WD, Dearani JA. Truncus arteriosus. In: Heart Disease in Infants, Children, and Adolescents Including the Fetus and Young Adult, 7th ed, Allen HD, Shaddy RE, Driscoll DJ, Feltes TF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83846 Version 6.0</div></div></div>"},"83849":{"type":"graphic_picture","displayName":"Measles rash PI","title":"Measles rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measles rash</div><div class=\"cntnt\"><img style=\"width:332px; height:240px;\" src=\"images/PI/83849_Measles_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measles is an infection that causes a red rash on the face and body. It is caused by the measles virus. The spots in the rash can form red patches.</div><div class=\"graphic_reference\">Copyright Dr. Michael Bennish; reproduced with his permission.</div><div id=\"graphicVersion\">Graphic 83849 Version 1.0</div></div></div>"},"83850":{"type":"graphic_figure","displayName":"Carotid sinus PI","title":"Carotid sinus","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Carotid sinus</div><div class=\"cntnt\"><img style=\"width:472px; height:550px;\" src=\"images/PI/83850_Carotid-sinus-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The carotid sinus is located in 1 of the arteries that brings blood to the brain. This artery is called the internal carotid artery.</div><div id=\"graphicVersion\">Graphic 83850 Version 1.0</div></div></div>"},"83851":{"type":"graphic_diagnosticimage","displayName":"Large cyst imaged on breast MRI","title":"Large cyst imaged on breast MRI","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Large cyst imaged on breast MRI</div><div class=\"cntnt\"><img style=\"width:598px; height:350px;\" src=\"images/RADIOL/83851_Large_cyst_imaged_br_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The T2 weighted image (A) shows a T2 bright mass in the central right breast (arrow). The T1 weighted fat saturated precontrast image (B) shows a T1 hypointense signal (arrowhead) and on the postcontrast image, there is no enhancement (C). These findings are characteristic of a cyst.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 83851 Version 2.0</div></div></div>"},"83853":{"type":"graphic_figure","displayName":"Metabolic pathways that regulate HDL","title":"Metabolic pathways that regulate HDL","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Metabolic pathways that regulate HDL</div><div class=\"cntnt\"><img style=\"width:612px; height:464px;\" src=\"images/PC/83853_Meta_path_high_dens_lipopr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Metabolic pathways that regulate HDL.</div><div class=\"graphic_footnotes\">HDL: high-density lipoprotein; LRP: lipoprotein receptor-related protein; SR-BI: scavenger receptor class B type I; LDL: low-density lipoprotein; LDLR: LDL receptor; CETP: cholesteryl ester transfer protein; TG: triglycerides; CE: cholesterol efflux.</div><div class=\"graphic_reference\">Reproduced with permission from: Rosenson RS, Brewer HB Jr, Davidson SW, et al. Cholesterol Efflux and Atheroprotection : Advancing the Concept of Reverse Cholesterol Transport. Circulation 2012; 125:1905. Copyright Â© 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83853 Version 6.0</div></div></div>"},"83854":{"type":"graphic_table","displayName":"Osteoporosis medicines PI","title":"Medicines to treat or prevent osteoporosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicines to treat or prevent osteoporosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Sample US brand names</td> <td class=\"subtitle1\">How it's taken</td> </tr> <tr> <td rowspan=\"4\"><strong>Bisphosphonates</strong></td> <td>Alendronate</td> <td>Fosamax, Binosto</td> <td> <p>1 pill a day or 1 pill a week</p> <p>You can also&nbsp;take this as a&nbsp;liquid&nbsp;or a pill that can dissolve in water</p> </td> </tr> <tr> <td>Risedronate</td> <td>Actonel, Atelvia</td> <td>1 pill a day, 1 pill a week, or 1 pill a month</td> </tr> <tr> <td>Ibandronate</td> <td>Boniva</td> <td>1 pill a month, or 1&nbsp;injection given in a vein every 3 months</td> </tr> <tr> <td>Zoledronic acid</td> <td>Reclast</td> <td>1&nbsp;injection given in a vein&nbsp;every year</td> </tr> <tr> <td rowspan=\"2\"><strong>\"Estrogen-like\" medicines (SERMs)</strong></td> <td>Raloxifene</td> <td>Evista</td> <td>1 pill a day</td> </tr> <tr> <td>Bazedoxifene&nbsp;and conjugated equine estrogens</td> <td>Duavee&nbsp;</td> <td>1 pill a day</td> </tr> <tr> <td rowspan=\"4\"><strong>Hormone medicines</strong></td> <td>Estrogen-progestin therapy</td> <td>Prempro, Premphase, Climara Pro, others</td> <td>1 pill a day, or a patch you wear on your skin that is changed 1 time a week</td> </tr> <tr> <td>Estrogen therapy</td> <td>Premarin, Cenestin, Climara,&nbsp;Menostar, Vivelle-Dot, &nbsp;others</td> <td>1 pill a day, or a patch you wear on your skin that is changed either 1 or 2 times a week</td> </tr> <tr> <td>Birth control pills (for women before menopause)</td> <td>Many different brand names</td> <td>1 pill a day</td> </tr> <tr> <td>Testosterone (for men with testosterone deficiency)</td> <td>Many different forms and brand names</td> <td>Depends on form</td> </tr> <tr> <td><strong>Parathyroid hormone <span style=\"color: black;\">(PTH)</span></strong></td> <td><span style=\"color: black;\">Teriparatide</span></td> <td><span style=\"color: black;\">Forteo</span></td> <td><span style=\"color: black;\">1 injection under the skin every day</span></td> </tr> <tr> <td><span style=\"color: black;\"><strong>Parathyroid hormone-related protein&nbsp;(PTHrP) analog</strong></span></td> <td><span style=\"color: black;\">Abaloparatide</span></td> <td><span style=\"color: black;\">Tymlos</span></td> <td><span style=\"color: black;\">1 injection under the skin every day</span></td> </tr> <tr> <td><strong>Denosumab</strong></td> <td>Denosumab</td> <td>Prolia</td> <td>1&nbsp;injection under the skin&nbsp;2 times a year</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83854 Version 4.0</div></div></div>"},"83855":{"type":"graphic_picture","displayName":"Melasma PI","title":"Melasma on the cheek","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melasma on the cheek</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/PI/83855_Melasma_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melasma is a skin condition that causes brown patches on the face. This picture shows melasma on a woman's cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83855 Version 3.0</div></div></div>"},"83856":{"type":"graphic_picture","displayName":"Classic KS PI","title":"Classic Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/83856_Class_Kaposis_sarcoma_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a photograph of classic Kaposi sarcoma on the lower leg and foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83856 Version 6.0</div></div></div>"},"83857":{"type":"graphic_picture","displayName":"AIDS-related KS PI","title":"AIDS-related Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AIDS-related Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/PI/83857_Kaposis_sarcoma_nose_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows Kaposi sarcoma on the nose.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83857 Version 5.0</div></div></div>"},"83859":{"type":"graphic_figure","displayName":"Map MDR-TB I","title":"Distribution of percentage of new tuberculosis cases with multidrug-resistant tuberculosis (MDR-TB)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Distribution of percentage of new tuberculosis cases with multidrug-resistant tuberculosis (MDR-TB)</div><div class=\"cntnt\"><img style=\"width:590px; height:365px;\" src=\"images/ID/83859_Map_MDR_TB_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figures are based on the most recent year for which data have been reported, which varies among countries.</div><div class=\"graphic_reference\">Reproduced, with the permission of the publisher, from the Global Tuberculosis Report 2013. Geneva, World Health Organization, 2013. (Figure 4.2, <a href=\"http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf\" target=_blank>http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf</a>, Accessed on November 18, 2013.)</div><div id=\"graphicVersion\">Graphic 83859 Version 2.0</div></div></div>"},"83860":{"type":"graphic_figure","displayName":"Map MDR-TB II","title":"Percentage of previously treated tuberculosis patients with multidrug-resistant tuberculosis (MDR-TB)","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Percentage of previously treated tuberculosis patients with multidrug-resistant tuberculosis (MDR-TB)</div><div class=\"cntnt\"><img style=\"width:577px; height:363px;\" src=\"images/ID/83860_Map_MDR_TB_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figures are based on the most recent year for which data have been reported, which varies among countries. The high percentages of previously treated tuberculosis cases with multidrug-resistant tuberculosis in Bahrain, Bonaire - Saint Eustatius and Saba, Cook Islands, Iceland, Sao Tome and Principe, and Lebanon refer to only a small number of notified cases (&lt;10).</div><div class=\"graphic_reference\">Reproduced, with the permission of the publisher, from the Global Tuberculosis Report 2013. Geneva, World Health Organization, 2013. (Figure 4.3, <a href=\"http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf\" target=_blank>http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf</a>, Accessed on November 18, 2013.)</div><div id=\"graphicVersion\">Graphic 83860 Version 2.0</div></div></div>"},"83861":{"type":"graphic_figure","displayName":"Port placement for laparoscopic proctocolectomy","title":"Port placement for laparoscopic proctocolectomy","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Port placement for laparoscopic proctocolectomy</div><div class=\"cntnt\"><img style=\"width:485px; height:601px;\" src=\"images/SURG/83861_Port-placement-for-laparoscopic-proctocolectomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83861 Version 4.0</div></div></div>"},"83862":{"type":"graphic_figure","displayName":"Orbital cellulitis PI","title":"Orbital cellulitis","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Orbital cellulitis</div><div class=\"cntnt\"><img style=\"width:474px; height:508px;\" src=\"images/PI/83862_Orbital_cellulitis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Orbital cellulitis is a rare but dangerous infection that affects the tissue behind the orbital septum.</div><div id=\"graphicVersion\">Graphic 83862 Version 2.0</div></div></div>"},"83863":{"type":"graphic_picture","displayName":"Ileocolic pedicle laparoscopic view","title":"Ileocolic pedicle laparoscopic view","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ileocolic pedicle laparoscopic view</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/SURG/83863_Ileoc_pedi_laparos_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the dissection of the mesentery overlying the ileocolic pedicle. The procedure is being performed laparoscopically.</div><div id=\"graphicVersion\">Graphic 83863 Version 1.0</div></div></div>"},"83864":{"type":"graphic_picture","displayName":"Laparoscopic mobilization of the ascending colon","title":"Laparoscopic mobilization of the ascending colon ","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Laparoscopic mobilization of the ascending colon </div><div class=\"cntnt\"><img style=\"width:501px; height:375px;\" src=\"images/SURG/83864_Lapar_mobil_ascend_colon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the mobilization of the ascending colon in the avascular plane. This procedure is being performed laparoscopically.</div><div id=\"graphicVersion\">Graphic 83864 Version 1.0</div></div></div>"},"83865":{"type":"graphic_picture","displayName":"Laparoscopic mobilization of the transverse colon","title":"Laparoscopic mobilization of the transverse colon","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Laparoscopic mobilization of the transverse colon</div><div class=\"cntnt\"><img style=\"width:576px; height:394px;\" src=\"images/SURG/83865_Laparosc_mobil_trans_colon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows laparoscopic mobilization of the transverse colon by dividing the greater omentum. The specimen is distal to the gastroepiploic arcade.</div><div id=\"graphicVersion\">Graphic 83865 Version 1.0</div></div></div>"},"83866":{"type":"graphic_picture","displayName":"Laparoscopic mobilization of the superior hemorrhoidal artery","title":"Laparoscopic mobilization of the superior hemorrhoidal artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic mobilization of the superior hemorrhoidal artery</div><div class=\"cntnt\"><img style=\"width:352px; height:240px;\" src=\"images/SURG/83866_Lap_mobili_sup_hem_art.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the laparoscopic transection of the superior hemorrhoidal vessels.</div><div id=\"graphicVersion\">Graphic 83866 Version 1.0</div></div></div>"},"83867":{"type":"graphic_figure","displayName":"Placement of laparoscopic monitors at head of table","title":"Placement of laparoscopic monitors at head of table","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Placement of laparoscopic monitors at head of table</div><div class=\"cntnt\"><img style=\"width:502px; height:655px;\" src=\"images/SURG/83867_Monitors-at-head-of-table.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the location of the ports and monitors in preparation for performing an intra-abdominal procedure.</div><div id=\"graphicVersion\">Graphic 83867 Version 1.0</div></div></div>"},"83868":{"type":"graphic_figure","displayName":"Placement of laparoscopic monitors at foot of table","title":"Placement of laparoscopic monitors at foot of table","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Placement of laparoscopic monitors at foot of table</div><div class=\"cntnt\"><img style=\"width:502px; height:617px;\" src=\"images/SURG/83868_Monitors-at-foot-of-table.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration shows the monitors placed at the foot of the table in preparation for a laparoscopic pelvic dissestion.</div><div id=\"graphicVersion\">Graphic 83868 Version 1.0</div></div></div>"},"83869":{"type":"graphic_picture","displayName":"Laparoscopic visualization of the left ureter","title":"Laparoscopic visualization of the left ureter","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Laparoscopic visualization of the left ureter</div><div class=\"cntnt\"><img style=\"width:504px; height:344px;\" src=\"images/SURG/83869_Lapar_visual_left_ureter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left ureter is visualized laparoscopically.</div><div id=\"graphicVersion\">Graphic 83869 Version 1.0</div></div></div>"},"83870":{"type":"graphic_picture","displayName":"Uvular edema caustic ingestion","title":"Uvular edema and tongue burns from caustic ingestion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uvular edema and tongue burns from caustic ingestion</div><div class=\"cntnt\"><img style=\"width:440px; height:441px;\" src=\"images/PEDS/83870_Uvular_edema_caus_ingest.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 83870 Version 1.0</div></div></div>"},"83871":{"type":"graphic_picture","displayName":"Uvular edema tonsillectomy","title":"Uvular edema after tonsillectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uvular edema after tonsillectomy</div><div class=\"cntnt\"><img style=\"width:392px; height:504px;\" src=\"images/PEDS/83871_Uvular_edema_tonsillect.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 83871 Version 1.0</div></div></div>"},"83872":{"type":"graphic_picture","displayName":"Laparoscopic ligation of the superior hemorrhoidal artery","title":"Laparoscopic ligation of the superior hemorrhoidal artery","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Laparoscopic ligation of the superior hemorrhoidal artery</div><div class=\"cntnt\"><img style=\"width:502px; height:341px;\" src=\"images/SURG/83872_Lapar_ligat_hem_art.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pictures shows the ligation of the proximal end of the superior hemorrhoidal artery.</div><div id=\"graphicVersion\">Graphic 83872 Version 1.0</div></div></div>"},"83873":{"type":"graphic_picture","displayName":"Placement of laparoscopic instruments for total colectomy","title":"Placement of laparoscopic instruments for total colectomy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Placement of laparoscopic instruments for total colectomy</div><div class=\"cntnt\"><img style=\"width:504px; height:358px;\" src=\"images/SURG/83873_Port_place_hand_asst_lapr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the placement of the laparoscopic instruments in preparation for performing a total colectomy.</div><div id=\"graphicVersion\">Graphic 83873 Version 2.0</div></div></div>"},"83874":{"type":"graphic_figure","displayName":"Laparoscopic mobilization of rectum in avascular space","title":"Laparoscopic mobilization of rectum in avascular space","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Laparoscopic mobilization of rectum in avascular space</div><div class=\"cntnt\"><img style=\"width:533px; height:484px;\" src=\"images/SURG/83874_Laparoscopic-mobilization-of-rectum-in-avascular-space.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration depicts the laparoscopic dissection of the rectum in the avascular space, posterior to the mesorectum.</div><div id=\"graphicVersion\">Graphic 83874 Version 2.0</div></div></div>"},"83883":{"type":"graphic_waveform","displayName":"Early repolarization 12 lead ECG","title":"Early repolarization 12 lead ECG","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Early repolarization 12 lead ECG</div><div class=\"cntnt\"><img style=\"width:542px; height:286px;\" src=\"images/CARD/83883_Early_repolar_12_lead_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early repolarization manifest as inferior J-point slurring and lateral J-point notching, each &gt;1 mm in two contiguous leads.</div><div id=\"graphicVersion\">Graphic 83883 Version 2.0</div></div></div>"},"83884":{"type":"graphic_figure","displayName":"Action potentials in early repolarization","title":"Action potentials in early repolarization","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Action potentials in early repolarization</div><div class=\"cntnt\"><img style=\"width:522px; height:307px;\" src=\"images/CARD/83884_Act_pot_earl_repolar.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A disproportionately abbreviated epicardial action potential compared with the endocardial action potential&nbsp;causes J-point elevation.</div><div id=\"graphicVersion\">Graphic 83884 Version 1.0</div></div></div>"},"83885":{"type":"graphic_picture","displayName":"Urine sediment showing a waxy cast","title":"Urine sediment showing a waxy cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urine sediment showing a waxy cast</div><div class=\"cntnt\"><img style=\"width:342px; height:390px;\" src=\"images/NEPH/83885_Urine_sediment_waxy_cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Ringsrud KM, Linne JJ. Urinalysis and Body Fluids: A Colortext and Atlas, Mosby, Amsterdam 1995. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83885 Version 1.0</div></div></div>"},"83886":{"type":"graphic_picture","displayName":"Urine sediment showing a transitional epithelial cell","title":"Urine sediment showing a transitional epithelial cell","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Urine sediment showing a transitional epithelial cell</div><div class=\"cntnt\"><img style=\"width:500px; height:503px;\" src=\"images/NEPH/83886_Urine_sed_trans_epith.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bradley M. Urine crystals: Identification and significance. Lab Med 1982; 13:348. Copyright &copy; 1983-2012 American Society for Clinical Pathology. Copyright &copy; 1983-2012 Laboratory Medicine.</div><div id=\"graphicVersion\">Graphic 83886 Version 1.0</div></div></div>"},"83889":{"type":"graphic_table","displayName":"Agents for pediatric sedation (not intravenous route)","title":"Commonly used agents for pediatric procedural sedation in children without IV access","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used agents for pediatric procedural sedation in children without IV access</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>Sedation with these agents can result in significant respiratory depression and other adverse effects. Children should receive appropriate monitoring by personnel skilled in pediatric resuscitation until full recovery has occurred. Please refer to UpToDate topics on procedural sedation in children for more details.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Onset (minutes)</td> <td class=\"subtitle1\">Duration (minutes)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Nitrous oxide (N<sub>2</sub>0)</td> <td>50 to 70 percent N<sub>2</sub>0 administered with oxygen typically delivered through a demand valve system with scavenging capability</td> <td>&#60;0.5</td> <td>Recovery typically within 3 to 5 minutes of cessation of N<sub>2</sub>0 delivery</td> <td> <ul> <li>Primarily used in children older than 4 years of age. </li> <li>Provides amnesia, mild to moderate anxiolysis, mild to moderate sedation, and mild analgesia. </li> <li>Common adverse effects: Vomiting and dysphoria. </li> <li>Clinicians must know how to test and use the equipment in use in their facility. In addition, equipment must be carefully maintained and periodically tested to ensure adequate safety. </li> <li>Relatively contraindications and precautions: Nausea and vomiting. </li> <li>Absolutely contraindications: Pregnancy and conditions with trapped gas within body cavities (eg, bowel obstruction, pneumothorax, middle ear infection). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Midazolam</td> <td> <p>0.25 to 0.5 mg/kg PO or SL, maximum 20 mg</p> <p>0.2 to 0.3 mg/kg IN, maximum 10 mg*</p> Buccal dosing is as for IN</td> <td>20 to 30</td> <td>30 to 60</td> <td> <ul> <li>Midazolam has poor oral bioavailability (15 to 35 percent). IN, SL, and buccal has bioavailability approaching 70 to 80 percent during gradual administration. </li> <li>Provides amnesia, mild anxiolysis, and mild sedation for procedures that do not require full immobility (eg, laceration repair with local topical anesthesia). </li> <li>Flumazenil can reverse effects but should be avoided in patients with seizure disorder or who are chronically maintained on benzodiazepines. </li> <li>Common adverse effects: Respiratory depression and apnea, especially if combined with opioids or other sedatives; paradoxical reactions, including hyperactivity, aggressive behavior, and inconsolable crying. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Dexmedetomidine</td> <td>2.5 mcg/kg IN</td> <td>20 to 30</td> <td>30 to 45</td> <td> <ul> <li>Provides amnesia, mild anxiolysis, and mild sedation. </li> <li>Common adverse events: Bradycardia or hypertension with IV administration, not described with IN use. </li> <li>Relative contraindications and precautions: Children with dehydration or reduced cardiac output. </li> <li>Absolute contraindications: Patients receiving digoxin or other medications acting on sinus node or with sinus node dysfunction. </li> </ul> </td> </tr> <tr> <td>Ketamine</td> <td>4 mg/kg IM</td> <td>5 to 10</td> <td>30 to 60</td> <td> <ul> <li>Provides sedation AND analgesia for moderately to severely painful procedures. </li> <li>Common adverse events: Vomiting, emergence reaction, frequency of vomiting is reduced by premedication with ondansetron (0.15 mg/kg, typical dose 4 mg) or by co-administration of propofol. </li> <li>Laryngospasm and apnea occur rarely and are more common with intramuscular administration. </li> <li>Relative contraindications and precautions: Age younger than 12 months, active pulmonary infections (including URI), known or suspected cardiac disease, suspected increased intracranial pressure (eg, head trauma with signs or symptoms, intracranial mass, or hydrocephalus), glaucoma or acute eye injury (open globe), porphyria, thyroid disease, or seizures. </li> <li>Absolute contraindications: Age younger than 3 months or patients with known or suspected psychosis. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PO: oral; SL: sublingual; IN: intranasal; IM: Intramuscular.<br />* Pretreatment with lidocaine spray (10 mg/puff) one minute prior to intranasal midazolam decreases nasal mucosal irritation. Intranasal preparation is not commercially available in the USA; 5 mg/mL injectable solution may be given IN.</div><div id=\"graphicVersion\">Graphic 83889 Version 6.0</div></div></div>"},"83890":{"type":"graphic_figure","displayName":"Signal averaged ECG in early repolarization","title":"Signal averaged ECG in early repolarization","html":"<div class=\"graphic\"><div style=\"width: 643px\" class=\"figure\"><div class=\"ttl\">Signal averaged ECG in early repolarization</div><div class=\"cntnt\"><img style=\"width:623px; height:372px;\" src=\"images/CARD/83890_Signal_averaged_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Signal averaged ECG in a patient with ER demonstrating normal parameters (filtered QRS duration 124 ms, duration of high frequency low amplitude signal less than 40 microvolts of 37 ms, and root mean square voltage in the terminal 40 ms of 19 microvolts).</div><div id=\"graphicVersion\">Graphic 83890 Version 1.0</div></div></div>"},"83891":{"type":"graphic_waveform","displayName":"Early repol 12 lead ECG","title":"Early repolarization 12 lead electriocardiogram (ECG)","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Early repolarization 12 lead electriocardiogram (ECG)</div><div class=\"cntnt\"><img style=\"width:564px; height:324px;\" src=\"images/CARD/83891_Early_repol_12_lead_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked inferior and lateral ER of 3 mm.</div><div id=\"graphicVersion\">Graphic 83891 Version 2.0</div></div></div>"},"83895":{"type":"graphic_algorithm","displayName":"Approach for the acute management of ventricular arrhythmia","title":"Approach for the acute management of ventricular arrhythmia","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Approach for the acute management of ventricular arrhythmia</div><div class=\"cntnt\"><img style=\"width:534px; height:440px;\" src=\"images/CARD/83895_Appr_ventricular_arrhythmia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An algorithmic approach for the acute management of ventricular arrhythmia associated with genetic disorders.</div><div class=\"graphic_footnotes\">VF: ventricular fibrillation; PMVT: polymorphic ventricular tachycardia, possible torsade de pointes.</div><div id=\"graphicVersion\">Graphic 83895 Version 2.0</div></div></div>"},"83901":{"type":"graphic_table","displayName":"WHO and ENSAT classification of ACC","title":"World Health Organization and European Network for the Study of Adrenal Tumors classification of adrenocortical carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization and European Network for the Study of Adrenal Tumors classification of adrenocortical carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage*</td> <td class=\"subtitle1\">UICC/WHO 2004</td> <td class=\"subtitle1\">ENSAT</td> </tr> <tr> <td class=\"centered\">I</td> <td class=\"centered\">T1, N0, M0</td> <td class=\"centered\">T1, N0, M0</td> </tr> <tr> <td class=\"centered\">II</td> <td class=\"centered\">T2, N0, M0</td> <td class=\"centered\">T2, N0, M0</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">III</td> <td class=\"centered\">T3, N0, M0</td> <td class=\"centered\">T3-4, N0, M0</td> </tr> <tr> <td class=\"centered\">T1-2, N1, M0</td> <td class=\"centered\">T1-4, N1, M0 </td> </tr> <tr> <td class=\"centered\" rowspan=\"3\">IV</td> <td class=\"centered\">T3, N1, M0</td> <td class=\"centered\">Any M1</td> </tr> <tr> <td class=\"centered\">T4, N0-1, M0</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">Any M1</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UICC: Union Internationale contre le Cancer; WHO: World Health Organization; ENSAT: European Network for the Study of Adrenal Tumors.<br />* T1: tumor â¤5 cm; T2: tumor &gt;5 cm; T3: tumor infiltration in surrounding tissue; T4: tumor invasion in adjacent organs (ENSAT - also venous tumor thrombus in vena cava or renal vein); N0: no positive lymph nodes; M0: no distance metastases; N1: positive lymph nodes; M1: presence of distant metastasis.</div><div class=\"graphic_reference\">Reproduced from: Zini L, Porpiglia F, Fassnact M. Contemporary management of adrenocortical carcinoma. Eur Urol 2011; 60:1055. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83901 Version 2.0</div></div></div>"},"83902":{"type":"graphic_table","displayName":"Occurrence and age of onset in VHL","title":"Clinical manifestations of von Hippel-Lindau disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of von Hippel-Lindau disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Ages at diagnosis</td> <td class=\"subtitle1\">Most common ages at dx</td> <td class=\"subtitle1\">Frequency in patients CNS</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">CNS</td> </tr> <tr> <td class=\"indent1\">Retinal hemangioblastomas</td> <td>0-68 yrs</td> <td>12-25 yrs</td> <td>25-60 percent</td> </tr> <tr> <td class=\"indent1\">Endolymphatic sac tumors</td> <td>12-46 yrs</td> <td>24-35 yrs</td> <td>10-25 percent</td> </tr> <tr> <td class=\"indent1\">Cerebellar hemangioblastomas</td> <td>9-78 yrs</td> <td>18-25 yrs</td> <td>44-72 percent</td> </tr> <tr> <td class=\"indent1\">Brainstem hemangioblastomas</td> <td>12-36 yrs</td> <td>24-35 yrs</td> <td>10-25 percent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Spinal cord hemangioblastomas</td> <td>12-66 yrs</td> <td>24-35 yrs</td> <td>13-50 percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Viscera</td> </tr> <tr> <td class=\"indent1\">Renal cell carcinoma or cysts</td> <td>16-67 yrs</td> <td>25-50 yrs</td> <td>25-60 percent</td> </tr> <tr> <td class=\"indent1\">Pheochromocytomas*</td> <td>4-58 yrs</td> <td>12-25 yrs</td> <td>10-20 percent<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Pancreatic tumor or cyst</td> <td>5-70 yrs</td> <td>24-35 yrs</td> <td>35-70 percent</td> </tr> <tr> <td class=\"indent1\">Epididymal cystadenomas</td> <td>17-43 yrs</td> <td>14-40 yrs</td> <td>25-60 percent of males*</td> </tr> <tr> <td class=\"indent1\">Adnexal papillary cystadenoma of mesonephric origin (broad ligament cystadenoma)</td> <td>16-64 yrs</td> <td>16-46 yrs</td> <td>Estimated 10 percent of females</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Includes the 20 percent of lesions that occur outside the adrenal gland, also called paragangliomas.<br />Â¶ Frequency of pheochromocytoma varies widely depending on genotype.</div><div class=\"graphic_reference\">Courtesy of, Dr. Eric Jonasch, MD.</div><div id=\"graphicVersion\">Graphic 83902 Version 4.0</div></div></div>"},"83904":{"type":"graphic_picture","displayName":"Vegetative pyoderma gangrenosum","title":"Vegetative pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Vegetative pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/83904_Veget_pyoderm_gangrenos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ulcer with a verrucous surface is present on the ankle.</div><div id=\"graphicVersion\">Graphic 83904 Version 1.0</div></div></div>"},"83905":{"type":"graphic_diagnosticimage","displayName":"RA PIP soft tissue swelling x-ray","title":"Soft tissue swelling and periarticular osteopenia of proximal interphalangeal joints in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Soft tissue swelling and periarticular osteopenia of proximal interphalangeal joints in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/RADIOL/83905_RA_PIP_soft_tiss_swell_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiographs of the hand are magnified at the proximal interphalangeal joints of the third and fourth fingers showing soft tissue swelling (arrows) and periarticular osteopenia (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 83905 Version 2.0</div></div></div>"},"83906":{"type":"graphic_diagnosticimage","displayName":"MRI non-retracted partial tear of hamstring tendons","title":"MRI of non-retracted partial tear of hamstring tendons","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">MRI of non-retracted partial tear of hamstring tendons</div><div class=\"cntnt\"><img style=\"width:598px; height:227px;\" src=\"images/RADIOL/83906_MRI_nonretrac_tear_hamstr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI of the thighs using Fast STIR sequence in the coronal plane (A, with arrows in same image B) reveals a fluid collection (arrow) in the proximal insertion of the hamstrings on to the ischial tuberosity (arrowhead). The dashed arrow points to the hamstring tendon. These findings demonstrate a high grade detachment without gross retraction.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; STIR: Short-TI Inversion Recovery.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD and Patrick Casey, MD.</div><div id=\"graphicVersion\">Graphic 83906 Version 2.0</div></div></div>"},"83907":{"type":"graphic_picture","displayName":"Giant cell (temporal) arteritis multinuc giant cells","title":"Multinucleated giant cells in giant cell (temporal) arteritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Multinucleated giant cells in giant cell (temporal) arteritis</div><div class=\"cntnt\"><img style=\"width:504px; height:337px;\" src=\"images/RHEUM/83907_Giant_cell_art_multi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of superficial temporal artery involved by giant cell (temporal) arteritis. Two multinucleated giant cells near the internal elastic lamina have phagocytized small particles of elastic tissue (arrows).</div><div class=\"graphic_reference\">Courtesy of Gene G Hunder, MD.</div><div id=\"graphicVersion\">Graphic 83907 Version 2.0</div></div></div>"},"83908":{"type":"graphic_picture","displayName":"Giant cell (temporal) arteritis inflam infiltrate","title":"Inflammatory infiltrate in giant cell (temporal) arteritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Inflammatory infiltrate in giant cell (temporal) arteritis</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/RHEUM/83908_Giant_art_inflam_infil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power view of a superficial temporal artery involved by giant cell (temporal) arteritis. The hypocellular thickening of the intima produces&nbsp;luminal narrowing (yellow arrow). The inflammatory infiltrate is most marked in the media near the internal elastic lamina (black arrow). A small branch of the temporal artery is also involved (red arrow).</div><div class=\"graphic_reference\">Courtesy of Gene G Hunder, MD.</div><div id=\"graphicVersion\">Graphic 83908 Version 4.0</div></div></div>"},"83909":{"type":"graphic_picture","displayName":"Proctocolectomy extraction via perineum","title":"Proctocolectomy extraction via perineum","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Proctocolectomy extraction via perineum</div><div class=\"cntnt\"><img style=\"width:485px; height:504px;\" src=\"images/SURG/83909_Procto_extra_via_perineum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the extraction of the total proctocolectomy through the perineum. This procedure was performed laparoscopically.</div><div id=\"graphicVersion\">Graphic 83909 Version 3.0</div></div></div>"},"83910":{"type":"graphic_picture","displayName":"Thrombosed artery in giant cell (temporal) arteritis","title":"Thrombosed lumen of superficial temporal artery in giant cell (temporal) arteritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Thrombosed lumen of superficial temporal artery in giant cell (temporal) arteritis</div><div class=\"cntnt\"><img style=\"width:504px; height:339px;\" src=\"images/RHEUM/83910_Thromb_art_giant_arterits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial temporal artery specimen. Prior to biopsy, palpation of this region of the artery revealed a slightly tender, cord-like structure without pulse. Histologic examination showed an intense mural inflammatory infiltration with a thrombosed lumen.</div><div class=\"graphic_reference\">Courtesy of Gene G Hunder, MD.</div><div id=\"graphicVersion\">Graphic 83910 Version 3.0</div></div></div>"},"83911":{"type":"graphic_table","displayName":"Valvular disease and other medical criteria for contraception","title":"Valvular disease and other US medical eligibility criteria for contraceptive use: Summary of classifications for hormonal contraceptive methods and intrauterine devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Valvular disease and other US medical eligibility criteria for contraceptive use: Summary of classifications for hormonal contraceptive methods and intrauterine devices</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <colgroup span=\"16\" width=\"6%\"></colgroup>\r\n    <tbody>\r\n        <tr class=\"divider_bottom\">\r\n            <td colspan=\"16\">Health-care providers can use the summary table as a quick reference guide to the classifications for hormonal contraceptive methods and intrauterine contraception and to compare classifications across these methods. See the full appendix for each method for clarifications to the numeric categories, as well as for summaries of the evidence and additional comments.</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_single\" colspan=\"16\">BOX. Categories for classifying hormonal contraceptives and IUDs</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\">\r\n            <p>1 = A condition for which there is no restriction for the use of the contraceptive method.</p>\r\n            <p>2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.</p>\r\n            <p>3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.</p>\r\n            <p>4 = A condition that represents an unacceptable health risk if the contraceptive method is used.</p>\r\n            </td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle1\">Condition</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">COC/P/R</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">POP</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">DMPA</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Implants</td>\r\n            <td class=\"subtitle1\" colspan=\"4\">LNG-IUD</td>\r\n            <td class=\"subtitle1\" colspan=\"3\">Cu-IUD</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Personal characteristics and reproductive history</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Pregnancy</strong></td>\r\n            <td colspan=\"2\">Not applicable*</td>\r\n            <td colspan=\"2\">Not applicable*</td>\r\n            <td colspan=\"2\">Not applicable*</td>\r\n            <td colspan=\"2\">Not applicable*</td>\r\n            <td colspan=\"4\">4*</td>\r\n            <td colspan=\"3\">4*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" rowspan=\"3\"><strong>Age</strong></td>\r\n            <td colspan=\"2\">Menarche to &#60;40 yrs = 1</td>\r\n            <td colspan=\"2\">Menarche to &#60;18 yrs = 1</td>\r\n            <td colspan=\"2\">Menarche to &#60;18 yrs = 2</td>\r\n            <td colspan=\"2\">Menarche to &#60;18 yrs = 1</td>\r\n            <td colspan=\"4\">Menarche to &#60;20 yrs = 2</td>\r\n            <td colspan=\"3\">Menarche to &#60;20 yrs = 2</td>\r\n        </tr>\r\n        <tr>\r\n            <td colspan=\"2\">&#8805;40 yrs = 2</td>\r\n            <td colspan=\"2\">18-45 yrs = 1</td>\r\n            <td colspan=\"2\">18-45 yrs = 1</td>\r\n            <td colspan=\"2\">18-45 yrs = 1</td>\r\n            <td colspan=\"4\">&#8805;20 yrs = 1</td>\r\n            <td colspan=\"3\">&#8805;20 yrs = 1</td>\r\n        </tr>\r\n        <tr>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&#62;45 yrs = 1</td>\r\n            <td colspan=\"2\">&#62;45 yrs = 2</td>\r\n            <td colspan=\"2\">&#62;45 yrs = 1</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Parity</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Nulliparous</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Parous</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Postpartum</strong> (nonbreastfeeding women)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. &#60;21 days</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. 21 days to 42 days</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. With other risk factors for VTE (such as age &#8805;35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, BMI &#8805;30, postpartum hemorrhage, postcesarean delivery, preeclampsia or smoking)</td>\r\n            <td colspan=\"2\">3<sup>&#916;</sup></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Without other risk factors for VTE</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. &#62;42 days</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Postpartum</strong> (breastfeeding women<sup>&#9674;</sup>)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. &#60;21 days</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. 21 to &#60;30 days</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. With other risk factors for VTE (such as age &#8805;35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, BMI &#8805;30 kg/m<sup>2</sup>, postpartum hemorrhage, postcesarean delivery, preeclampsia or smoking)</td>\r\n            <td colspan=\"2\">3<sup>&#916;</sup></td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Without other risk factors for VTE</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. 30-42 days</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. With other risk factors for VTE (such as age &#8805;35 years, previous VTE, thrombophilia, immobility, transfusion at delivery, BMI &#8805;30, postpartum hemorrhage, postcesarean delivery, preeclampsia or smoking)</td>\r\n            <td colspan=\"2\">3<sup>&#916;</sup></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Without other risk factors for VTE</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">d. &#62;42 days</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Postpartum</strong> (breastfeeding or nonbreastfeeding women, including post-Cesarean section)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. &#60;10 min after delivery of the placenta</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. 10 min after delivery of the placenta to &#60;4 wks</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. &#8805;4 wks</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">d. Puerperal sepsis</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">4</td>\r\n            <td colspan=\"3\">4</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Postabortion</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. First trimester</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"4\">1*</td>\r\n            <td colspan=\"3\">1*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Second trimester</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. Immediate postseptic abortion</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"4\">4</td>\r\n            <td colspan=\"3\">4</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Past ectopic pregnancy</strong></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>History of pelvic surgery</strong> (see postpartum, including Cesarean section)</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Smoking</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Age &#60;35 yrs</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">b. Age &#8805;35 yrs</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. &#60;15 Cigarettes/day</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. &#8805;15 Cigarettes/day</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Obesity</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. &#8805;30 kg/m<sup>2</sup> BMI</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Menarche to &#60;18 yrs and &#8805;30 kg/m<sup>2</sup> BMI</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>History of bariatric surgery</strong><sup>&#167;</sup></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Restrictive procedures: decrease storage capacity of the stomach (vertical banded gastroplasty, laparoscopic adjustable gastric band, laparoscopic sleeve gastrectomy)</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent2\">b. Malabsorptive procedures: decrease absorption of nutrients and calories by shortening the functional length of the small intestine (Roux-en-Y gastric bypass, biliopancreatic diversion)</td>\r\n            <td colspan=\"2\">\r\n            <p>COCs: 3</p>\r\n            <p>P/R: 1</p>\r\n            </td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Cardiovascular disease</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Multiple risk factors for arterial cardiovascular disease</strong> (such as older age, smoking, diabetes, and hypertension)</td>\r\n            <td colspan=\"2\">3/4*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Hypertension</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Adequately controlled hypertension</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">b. Elevated blood pressure levels (properly taken measurements)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. Systolic 140-159 mmHg or diastolic 90-99 mmHg</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Systolic &#8805;160 mmHg or diastolic &#8805;100 mmHg<sup>&#167;</sup></td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. Vascular disease</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>History of high blood pressure during pregnancy</strong> (where current blood pressure is measurable and normal)</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Deep venous thrombosis (DVT)/pulmonary embolism (PE)</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">a. History of DVT/PE, not on anticoagulant therapy</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">\r\n            <p>i. Higher risk for recurrent DVT/PE (&#8805;1 risk factors)</p>\r\n            <ul>\r\n                <li>History of estrogen-associated DVT/PE </li>\r\n                <li>Pregnancy-associated DVT/PE </li>\r\n                <li>Idiopathic DVT/PE </li>\r\n                <li>Known thrombophilia, including antiphospholipid syndrome </li>\r\n                <li>Active cancer (metastatic, on therapy, or within 6 mos after clinical remission), excluding non-melanoma skin cancer </li>\r\n                <li>History of recurrent DVT/PE </li>\r\n            </ul>\r\n            </td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Lower risk for recurrent DVT/PE (no risk factors)</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Acute DVT/PE </td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">c. DVT/PE and established on anticoagulant therapy for at least 3 mos</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">\r\n            <p>i. Higher risk for recurrent DVT/PE (&#8805;1 risk factors)</p>\r\n            <ul>\r\n                <li>Known thrombophilia, including antiphospholipid syndrome </li>\r\n                <li>Active cancer (metastatic, on therapy, or within 6 mos after clinical remission), excluding non-melanoma skin cancer </li>\r\n                <li>History of recurrent DVT/PE </li>\r\n            </ul>\r\n            </td>\r\n            <td colspan=\"2\">4*</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Lower risk for recurrent DVT/PE (no risk factors)</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">d. Family history (first-degree relatives)</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">e. Major surgery</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. With prolonged immobilization</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Without prolonged immobilization</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">f. Minor surgery without immobilization</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Known thrombogenic mutations</strong><sup>&#167;</sup> (eg, factor V Leiden; prothrombin mutation; protein S, protein C, and antithrombin deficiencies)</td>\r\n            <td colspan=\"2\">4*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"4\">2*</td>\r\n            <td colspan=\"3\">1*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Superficial venous thrombosis</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Varicose veins</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Superficial thrombophlebitis</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" rowspan=\"2\"><strong>Current and history of ischemic heart disease</strong><sup>&#167;</sup></td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td>Continuation</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td>Continuation</td>\r\n            <td colspan=\"2\">Initiation</td>\r\n            <td colspan=\"2\">Continuation</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td colspan=\"2\">4</td>\r\n            <td>2</td>\r\n            <td>3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td>2</td>\r\n            <td>3</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" rowspan=\"2\"><strong>Stroke</strong><sup>&#167;</sup> (history of cerebrovascular accident)</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td>Continuation</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td>Continuation</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td colspan=\"2\">4</td>\r\n            <td>2</td>\r\n            <td>3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td>2</td>\r\n            <td>3</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Known hyperlipidemias</strong></td>\r\n            <td colspan=\"2\">2/3*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"4\">2*</td>\r\n            <td colspan=\"3\">1*</td>\r\n        </tr>\r\n        <tr>\r\n            <td style=\"background-color: #ff9;\" class=\"indent1\" colspan=\"16\"><strong>Valvular heart disease</strong></td>\r\n        </tr>\r\n        <tr style=\"background-color: #ff9;\">\r\n            <td class=\"indent2\">a. Uncomplicated</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr style=\"background-color: #ff9;\">\r\n            <td class=\"indent2\">b. Complicated<sup>&#167;</sup> (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis)</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Peripartum cardiomyopathy</strong><sup>&#167;</sup></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">a. Normal or mildly impaired cardiac function (New York Heart Association Functional Class I or II: patients with no limitation of activities or patients with slight, mild limitation of activity) (1)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. &#60;6 mos</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. &#8805;6 mos</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent2\">b. Moderately or severely impaired cardiac function (New York Heart Association Functional Class III or IV: patients with marked limitation of activity or patients who should be at complete rest) (1)</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Rheumatic diseases</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Systemic lupus erythematosus</strong><sup>&#167;</sup></td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td>Continuation</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"2\">Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Positive (or unknown) antiphospholipid antibodies</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td>3</td>\r\n            <td>3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"4\">3</td>\r\n            <td>1</td>\r\n            <td colspan=\"2\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Severe thrombocytopenia</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td>3</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2*</td>\r\n            <td>3*</td>\r\n            <td colspan=\"2\">2*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. Immunosuppressive treatment</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td>2</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">d. None of the above</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td>2</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td>1</td>\r\n            <td colspan=\"2\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Rheumatoid arthritis</strong></td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"3\">Continuation</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"2\">Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. On immunosuppressive therapy</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2/3*</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>2</td>\r\n            <td colspan=\"3\">1</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">1</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent2\">b. Not on immunosuppressive therapy</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Neurologic conditions</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Headaches</strong></td>\r\n            <td>Initiation</td>\r\n            <td>Continuation</td>\r\n            <td>Initiation</td>\r\n            <td>Continuation</td>\r\n            <td>Initiation</td>\r\n            <td>Continuation</td>\r\n            <td>Initiation</td>\r\n            <td>Continuation</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"3\">Continuation</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Non-migrainous (mild or severe)</td>\r\n            <td>1*</td>\r\n            <td>2*</td>\r\n            <td>1*</td>\r\n            <td>1*</td>\r\n            <td>1*</td>\r\n            <td>1*</td>\r\n            <td>1*</td>\r\n            <td>1*</td>\r\n            <td>1*</td>\r\n            <td colspan=\"3\">1*</td>\r\n            <td colspan=\"3\">1*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">b. Migraine</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\" colspan=\"16\">i. Without aura</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist4\">- Age &#60;35 yrs</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">3*</td>\r\n            <td class=\"sublist_other\">1*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\" colspan=\"3\">2*</td>\r\n            <td class=\"sublist_other\" colspan=\"3\">1*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist4\">- Age &#8805;35 yrs</td>\r\n            <td class=\"sublist_other\">3*</td>\r\n            <td class=\"sublist_other\">4*</td>\r\n            <td class=\"sublist_other\">1*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\">2*</td>\r\n            <td class=\"sublist_other\" colspan=\"3\">2*</td>\r\n            <td class=\"sublist_other\" colspan=\"3\">1*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. With aura (at any age)</td>\r\n            <td>4*</td>\r\n            <td>4*</td>\r\n            <td>2*</td>\r\n            <td>3*</td>\r\n            <td>2*</td>\r\n            <td>3*</td>\r\n            <td>2*</td>\r\n            <td>3*</td>\r\n            <td>2*</td>\r\n            <td colspan=\"3\">3*</td>\r\n            <td colspan=\"3\">1*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Epilepsy</strong><sup>&#167;</sup></td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent1\" colspan=\"16\">If on treatment, see Drug interactions section below</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Depressive disorders</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent1\"><strong>Depressive disorders</strong></td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"4\">1*</td>\r\n            <td colspan=\"3\">1*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Reproductive tract infections and disorders</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Vaginal bleeding patterns</strong></td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"3\">Continuation</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Irregular pattern without heavy bleeding</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td>1</td>\r\n            <td colspan=\"3\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Heavy or prolonged bleeding (includes regular and irregular patterns)</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td>1*</td>\r\n            <td colspan=\"3\">2*</td>\r\n            <td colspan=\"3\">2*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Unexplained vaginal bleeding</strong> (suspicious for serious condition)</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"3\">Continuation</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"2\">Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">Before evaluation</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td>4*</td>\r\n            <td colspan=\"3\">2*</td>\r\n            <td>4*</td>\r\n            <td colspan=\"2\">2*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Endometriosis</strong></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Benign ovarian tumors</strong> (including cysts)</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Severe dysmenorrhea</strong></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Gestational trophoblastic disease</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Decreasing or undetectable &#946;-hCG levels</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">3</td>\r\n            <td colspan=\"3\">3</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Persistently elevated &#946;-hCG levels or malignant disease<sup>&#167;</sup></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">4</td>\r\n            <td colspan=\"3\">4</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Cervical ectropion</strong></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Cervical intraepithelial neoplasia</strong></td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" rowspan=\"2\"><strong>Cervical cancer</strong> (awaiting treatment)</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"3\">Continuation</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"2\">Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td>4</td>\r\n            <td colspan=\"3\">2</td>\r\n            <td>4</td>\r\n            <td colspan=\"2\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Breast disease</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Undiagnosed mass</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Benign breast disease</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. Family history of cancer</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">d. Breast cancer<sup>&#167;</sup></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. Current</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"4\">4</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Past and no evidence of current disease for 5 yrs</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"4\">3</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Endometrial hyperplasia</strong></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" rowspan=\"2\"><strong>Endometrial cancer</strong><sup>&#167;</sup></td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"3\">Continuation</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"2\">Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>4</td>\r\n            <td colspan=\"3\">2</td>\r\n            <td>4</td>\r\n            <td colspan=\"2\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Ovarian cancer</strong><sup>&#167;</sup></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Uterine fibroids</strong></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Anatomical abnormalities</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Distorted uterine cavity (any congenital or acquired uterine abnormality distorting the uterine cavity in a manner that is incompatible with IUD insertion)</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">4</td>\r\n            <td colspan=\"3\">4</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Other abnormalities (including cervical stenosis or cervical lacerations) not distorting the uterine cavity or interfering with IUD insertion</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Pelvic inflammatory disease (PID)</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Past PID (assuming no current risk factors of STIs)</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"3\">Continuation</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"2\">Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. With subsequent pregnancy</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>1</td>\r\n            <td colspan=\"3\">1</td>\r\n            <td>1</td>\r\n            <td colspan=\"2\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Without subsequent pregnancy</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>2</td>\r\n            <td colspan=\"3\">2</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Current PID</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>4</td>\r\n            <td colspan=\"3\">2*</td>\r\n            <td>4</td>\r\n            <td colspan=\"2\">2*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>STIs</strong></td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"3\">Continuation</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"2\">Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Current purulent cervicitis or chlamydial infection or gonorrhea</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>4</td>\r\n            <td colspan=\"3\">2*</td>\r\n            <td>4</td>\r\n            <td colspan=\"2\">2*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Other STIs (excluding HIV and hepatitis)</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>2</td>\r\n            <td colspan=\"3\">2</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. Vaginitis (including <em>Trichomonas vaginalis</em> and bacterial vaginosis)</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>2</td>\r\n            <td colspan=\"3\">2</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">d. Increased risk for STIs</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>2/3*</td>\r\n            <td colspan=\"3\">2</td>\r\n            <td>2/3*</td>\r\n            <td colspan=\"2\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>HIV/AIDS</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"3\">Continuation</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"2\">Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>High risk for HIV</strong></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>2</td>\r\n            <td colspan=\"3\">2</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>HIV infection</strong><sup>&#167;</sup></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td>2</td>\r\n            <td colspan=\"3\">2</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>AIDS</strong><sup>&#167;</sup></td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td>3</td>\r\n            <td colspan=\"3\">2*</td>\r\n            <td>3</td>\r\n            <td colspan=\"2\">2*</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent2\">Clinically well on ARV therapy</td>\r\n            <td colspan=\"8\">If on treatment, see Drug interactions section below</td>\r\n            <td>2</td>\r\n            <td colspan=\"3\">2</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Other Infections</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Schistosomiasis</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Uncomplicated</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Fibrosis of the liver (if severe, see Cirrhosis)<sup>&#167;</sup></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Tuberculosis</strong><sup>&#167;</sup></td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"3\">Continuation</td>\r\n            <td>Initiation</td>\r\n            <td colspan=\"2\">Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Nonpelvic</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td>1</td>\r\n            <td colspan=\"3\">1</td>\r\n            <td>1</td>\r\n            <td colspan=\"2\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Pelvic</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td>4</td>\r\n            <td colspan=\"3\">3</td>\r\n            <td>4</td>\r\n            <td colspan=\"2\">3</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\">If on treatment, see Drug interactions section below</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent1\"><strong>Malaria</strong></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Endocrine conditions</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Diabetes</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. History of gestational disease</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">b. Nonvascular disease</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. Noninsulin-dependent</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Insulin-dependent<sup>&#167;</sup></td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. Nephropathy/retinopathy/ neuropathy<sup>&#167;</sup></td>\r\n            <td colspan=\"2\">3/4*</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">d. Other vascular disease or diabetes of &#62;20 yrs' duration<sup>&#167;</sup></td>\r\n            <td colspan=\"2\">3/4*</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Thyroid disorders</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Simple goiter</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Hyperthyroid</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent2\">c. Hypothyroid</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Gastrointestinal conditions</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Inflammatory bowel disease (IBD)</strong> (ulcerative colitis, Crohn disease)</td>\r\n            <td colspan=\"2\">2/3*</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Gallbladder disease</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">a. Symptomatic</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. Treated by cholecystectomy</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Medically treated</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">iii. Current</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Asymptomatic</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>History of cholestasis</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Pregnancy-related</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Past COC-related</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Viral hepatitis</strong></td>\r\n            <td>Initiation</td>\r\n            <td>Continuation</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"4\">&nbsp;</td>\r\n            <td colspan=\"3\">&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Acute or flare</td>\r\n            <td>3/4*</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Carrier</td>\r\n            <td>1</td>\r\n            <td>1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. Chronic</td>\r\n            <td>1</td>\r\n            <td>1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Cirrhosis</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Mild (compensated)</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Severe<sup>&#167;</sup> (decompensated)</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"4\">3</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Liver tumors</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\" colspan=\"16\">a. Benign</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">i. Focal nodular hyperplasia</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent3\">ii. Hepatocellular adenoma<sup>&#167;</sup></td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"4\">3</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent2\">b. Malignant<sup>&#167;</sup> (hepatoma)</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td colspan=\"4\">3</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Anemias</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Thalassemia</strong></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Sickle cell disease</strong><sup>&#167;</sup></td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent1\"><strong>Iron-deficiency anemia</strong></td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Solid organ transplantation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\"><strong>Solid organ transplantation</strong><sup>&#167;</sup></td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"2\">&nbsp;</td>\r\n            <td colspan=\"3\">Initiation</td>\r\n            <td>Continuation</td>\r\n            <td colspan=\"2\">Initiation</td>\r\n            <td>Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Complicated: graft failure (acute or chronic), rejection, cardiac allograft vasculopathy</td>\r\n            <td colspan=\"2\">4</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"3\">3</td>\r\n            <td>2</td>\r\n            <td colspan=\"2\">3</td>\r\n            <td>2</td>\r\n        </tr>\r\n        <tr class=\"divider_bottom\">\r\n            <td class=\"indent2\">b. Uncomplicated</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"2\">2</td>\r\n            <td colspan=\"4\">2</td>\r\n            <td colspan=\"3\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"16\">Drug interactions</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"9\"><strong>Antiretroviral therapy</strong> (see appendix M)</td>\r\n            <td colspan=\"3\">Initiation</td>\r\n            <td>Continuation</td>\r\n            <td colspan=\"2\">Initiation</td>\r\n            <td>Continuation</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Nucleoside reverse transcriptase inhibitors (NRTIs)</td>\r\n            <td colspan=\"2\">1*</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"3\">2/3*</td>\r\n            <td>2*</td>\r\n            <td colspan=\"2\">2/3*</td>\r\n            <td>2*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"3\">2/3*</td>\r\n            <td>2*</td>\r\n            <td colspan=\"2\">2/3*</td>\r\n            <td>2*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. Ritonavir-boosted protease inhibitors</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"3\">2/3*</td>\r\n            <td>2*</td>\r\n            <td colspan=\"2\">2/3*</td>\r\n            <td>2*</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Anticonvulsant therapy</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine)</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Lamotrigine</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\" colspan=\"16\"><strong>Antimicrobial therapy</strong></td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">a. Broad-spectrum antibiotics</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">b. Antifungals</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">c. Antiparasitics</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">d. Rifampicin or rifabutin therapy</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">3*</td>\r\n            <td colspan=\"2\">1</td>\r\n            <td colspan=\"2\">2*</td>\r\n            <td colspan=\"4\">1</td>\r\n            <td colspan=\"3\">1</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_lgnd\">The section highlighted in yellow addresses valvular heart disease. Other sections are included since patients with valvular heart disease frequently have other relevant conditions.</div><div class=\"graphic_footnotes\">COC: combined oral contraceptive; P: combined hormonal contraceptive patch; R: combined hormonal vaginal ring; POP: progestin-only pill; DMPA: depot medroxyprogesterone acetate; IUD: intrauterine device; LNG-IUD: levonorgestrel-releasing IUD; Cu-IUD: copper IUD; BMI: body mass index (weight [kg]/height [m<SUP>2</SUP>]); DVT: deep venous thrombosis; VTE: venous thromboembolism; CHC: combined hormonal contraceptive; PE: pulmonary embolism; hCG: human chorionic gonadotropin; PID: pelvic inflammatory disease; STI: sexually transmitted infection; HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase.<BR>* Consult the appendix for this contraceptive method for a clarification to this classification.<BR>&#916; Clarification: For women with other risk factors for VTE, these risk factors might increase the classification to a \"4\"; for example, smoking, deep venous thrombosis/pulmonary embolism, known thrombogenic mutations, and peripartum cardiomyopathy.<BR><FONT class=lozenge>&#9674;</FONT> The breastfeeding recommendations are divided by month in <EM>US Medical Eligibility Criteria for Contraceptive Use, 2010</EM>. They have been divided by days for purposes of integration with the postpartum recommendations.<BR>&#167; Condition that exposes a woman to increased risk as a result of unintended pregnancy.</div><div class=\"graphic_reference\">Updated information reproduced from: Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period. MMWR Morb Mortal Wkly Rep 2011; 60:878. Original table published in: US Medical Eligibility Criteria for Contraceptive Use 2010, with data adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition.</div><div id=\"graphicVersion\">Graphic 83911 Version 2.0</div></div></div>"},"83912":{"type":"graphic_picture","displayName":"Thoracic aorta in giant cell (temporal) arteritis","title":"Histopathology of thoracic aorta in giant cellÂ (temporal)Â arteritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathology of thoracic aorta in giant cell&nbsp;(temporal)&nbsp;arteritis</div><div class=\"cntnt\"><img style=\"width:504px; height:333px;\" src=\"images/RHEUM/83912_Thorac_aort_cell_arter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power view of the thoracic aorta from a patient with giant cell (temporal) arteritis. A patchy lymphocytic infiltrate (arrow) is present in various areas of the artery wall, typical of giant cell (temporal)&nbsp;arteritis.</div><div class=\"graphic_reference\">Courtesy of Gene G Hunder, MD.</div><div id=\"graphicVersion\">Graphic 83912 Version 2.0</div></div></div>"},"83913":{"type":"graphic_picture","displayName":"Ileal J pouch construction and identification of the apex","title":"Ileal J pouch construction and identification of the apex","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Ileal J pouch construction and identification of the apex</div><div class=\"cntnt\"><img style=\"width:498px; height:373px;\" src=\"images/SURG/83913_Ileal_J_constr_id_apex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the construction of the J-pouch. A suture is used to mark the apex of the loop of ileum.</div><div id=\"graphicVersion\">Graphic 83913 Version 2.0</div></div></div>"},"83914":{"type":"graphic_picture","displayName":"Ileal J pouch construction by securing loop of ileum to ileum","title":"Ileal J pouch construction by securing loop of ileum to ileum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ileal J pouch construction by securing loop of ileum to ileum</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/SURG/83914_Ileal_J_constr_sec_loop_il.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83914 Version 1.0</div></div></div>"},"83915":{"type":"graphic_picture","displayName":"Ileal pouch construction with enterotomies and linear stapling","title":"Ileal pouch construction with enterotomies and linear stapling","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Ileal pouch construction with enterotomies and linear stapling</div><div class=\"cntnt\"><img style=\"width:501px; height:375px;\" src=\"images/SURG/83915_Ileal_pouch_const_ent_stap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows an enterotomy made on the antimesenteric surface of the proximal limb and another near the distal limb of the ileum. A linear stapler is inserted and a pouch constructed between the limbs.</div><div id=\"graphicVersion\">Graphic 83915 Version 2.0</div></div></div>"},"83916":{"type":"graphic_picture","displayName":"Ileal J pouch eversion","title":"Ileal J pouch eversion","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Ileal J pouch eversion</div><div class=\"cntnt\"><img style=\"width:502px; height:375px;\" src=\"images/SURG/83916_Ileal_j_pouch_eversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows eversion of the ileal anal pouch and the mucosal lining on the outer surface.</div><div id=\"graphicVersion\">Graphic 83916 Version 2.0</div></div></div>"},"83917":{"type":"graphic_picture","displayName":"Ileal J pouch construction with inversion of the pouch","title":"Ileal J pouch construction with inversion of the pouch","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Ileal J pouch construction with inversion of the pouch</div><div class=\"cntnt\"><img style=\"width:503px; height:374px;\" src=\"images/SURG/83917_Ileal_J_const_inv_pouch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the completion of the construction of the ileal pouch. The mucosal surface has been inverted back into its normal position.</div><div id=\"graphicVersion\">Graphic 83917 Version 2.0</div></div></div>"},"83918":{"type":"graphic_picture","displayName":"Ileal pouch anal anastomosis visualized through the anus","title":"Ileal pouch anal ananstomosis visualized through the anus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ileal pouch anal ananstomosis visualized through the anus</div><div class=\"cntnt\"><img style=\"width:504px; height:390px;\" src=\"images/SURG/83918_Ileal_pouch_anal_anast_vis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the ileal pouch anal anastomosis through the anus.</div><div id=\"graphicVersion\">Graphic 83918 Version 2.0</div></div></div>"},"83919":{"type":"graphic_picture","displayName":"Ileoanal hand-sewn pouch anastomosis","title":"Ileoanal hand-sewn pouch anastomosis","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Ileoanal hand-sewn pouch anastomosis</div><div class=\"cntnt\"><img style=\"width:502px; height:382px;\" src=\"images/SURG/83919_Ileo_hand_sew_pouch_anas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the hand-sewn completed ileoanal pouch anastomosis.</div><div id=\"graphicVersion\">Graphic 83919 Version 2.0</div></div></div>"},"83920":{"type":"graphic_picture","displayName":"Small congenital nevus","title":"Small congenital nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small congenital nevus</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/83920_Small_congenital_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small (&lt;1.5 cm) congenital nevus on the buttock of a child.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83920 Version 4.0</div></div></div>"},"83921":{"type":"graphic_table","displayName":"Viral versus bacterial sinusitis","title":"Characteristic features of viral versus bacterial rhinosinusitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristic features of viral versus bacterial rhinosinusitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Viral rhinosinusitis</td> <td class=\"subtitle1\">Bacterial rhinosinusitis</td> </tr> <tr> <td>Fever</td> <td>Fever is typically absent, but when present <strong>occurs early (in first 24 hours)</strong>, is low-grade, and resolves within the first&nbsp;two days</td> <td>In severe presentation, temperature may be &#8805;39&#176;C (102.2&#176;F) for &#62;3 days; in worsening presentation, fever may develop or recur on Day 6 to 7 of illness after initial improvement</td> </tr> <tr> <td>Nasal discharge</td> <td>Peaks on Days 3 to 6 of illness and then steadily improves</td> <td>Fails to improve or worsens over time</td> </tr> <tr> <td>Cough</td> <td>Peaks on Days 3 to 6 of illness and then steadily improves</td> <td>Fails to improve or worsens over time</td> </tr> <tr> <td>Ill-appearance</td> <td>Absent</td> <td>May occur (in severe presentation)</td> </tr> <tr> <td>Severe headache</td> <td>Absent</td> <td>May be a sign of severe illness or complication</td> </tr> <tr> <td>Clinical course</td> <td>Symptoms peak in severity on Says 3 to 6 and then improve</td> <td>Symptoms are present for &#8805;10 days <strong>without improvement</strong></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83921 Version 2.0</div></div></div>"},"83922":{"type":"graphic_table","displayName":"Medicines that can cause AIN PI","title":"Medicines that can cause acute interstitial nephritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicines that can cause acute interstitial nephritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of drug&nbsp;and generic name(s)</td> <td class=\"subtitle1\">Brand names in US</td> <td class=\"subtitle1\">Used to treat</td> </tr> <tr> <td colspan=\"3\"><strong>Pain relievers</strong></td> </tr> <tr> <td> <p>Nonsteroidal drugs (also called NSAIDs):&nbsp; examples&nbsp;include&nbsp;ibuprofen, naproxen&nbsp;and diclofenac.</p> </td> <td>Advil&#174;, Aleve&#174;, Voltaren&#174;, many others</td> <td> <p>Aches and pains</p> <p>Inflammation</p> <p>Fever&nbsp;</p> <p>Arthritis pain</p> </td> </tr> <tr> <td>Celecoxib</td> <td>Celebrex&#174;</td> <td>Arthritis pain</td> </tr> <tr> <td colspan=\"3\"><strong>Acid lowering medicines</strong></td> </tr> <tr> <td>Cimetidine</td> <td>Tagamet HB&#174;</td> <td rowspan=\"3\"> <p>Heart burn</p> <p>Indigestion</p> <p>Acid reflux</p> <p>Stomach ulcer</p> </td> </tr> <tr> <td>Omeprazole</td> <td>Prilosec OTC&#174;</td> </tr> <tr> <td>Lansoprazole</td> <td>Prevacid 24 hour&#174;</td> </tr> <tr> <td colspan=\"3\"><strong>Antibiotics</strong></td> </tr> <tr> <td>Penicillins</td> <td>Bicillin&#174;, Pfizerpen&#174;, others</td> <td rowspan=\"6\">Infections<br /> <br /> </td> </tr> <tr> <td>Cephalosporins: examples include cephalexin and cefuroxime</td> <td>Keflex&#174;, Ceftin&#174;, many others</td> </tr> <tr> <td>Ciprofloxacin</td> <td>Cipro&#174;</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole (also called co-trimoxazole)</td> <td>Bactrim&#8482; DS, Septra&#174; DS</td> </tr> <tr> <td>Rifampin</td> <td>Rifadin&#174;</td> </tr> <tr> <td>Indinavir</td> <td>Crixivan&#174;</td> </tr> <tr> <td colspan=\"3\"><strong>Diuretics (also called \"water pills\")</strong></td> </tr> <tr> <td>Furosemide</td> <td>Lasix&#174;</td> <td rowspan=\"2\"> <p>Excess fluid in the body</p> <p>Heart failure</p> </td> </tr> <tr> <td>Bumetanide</td> <td>Bumex&#174;</td> </tr> <tr> <td>Hydrochlorothiazide (also called HCTZ) </td> <td>Microzide&#174;</td> <td>High blood pressure</td> </tr> <tr> <td colspan=\"3\"><strong>Ulcerative colitis medicines</strong></td> </tr> <tr> <td>Mesalamine (also called mesalazine), balsalazide, sulfasalazine, olsalazine</td> <td>Apriso&#8482;, Asacol&#174;, Canasa&#174;, Lialda&#174;, Pentasa&#174;, Roawasa&#174;, Colazal&#174;, Dipentum&#174;</td> <td>Ulcerative colitis</td> </tr> <tr> <td colspan=\"3\"><strong>Other</strong></td> </tr> <tr> <td>&nbsp;Allopurinol&nbsp;&nbsp;&nbsp;&nbsp;</td> <td>Zyloprim&#174;, Aloprim&#174;</td> <td>Gout</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83922 Version 1.0</div></div></div>"},"83923":{"type":"graphic_figure","displayName":"Tissue Doppler echo with velocity and strain plots","title":"Tissue Doppler echocardiographic image with longitudinal velocity, strain rate, and strain curves","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Tissue Doppler echocardiographic image with longitudinal velocity, strain rate, and strain curves</div><div class=\"cntnt\"><img style=\"width:456px; height:622px;\" src=\"images/CARD/83923_Tissue_dopp_ech_rate_plot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An echocardiographic apical four chamber tissue Doppler image of a normal subject (left panel). The yellow line represents an ultrasound scan line with velocities from two points (V1 and V2) separated by length (L) used to determine strain rate. The right panels show a representative longitudinal velocity curve (top), a strain rate curve (middle), and a strain curve (bottom) from the same cardiac cycle in this individual.</div><div id=\"graphicVersion\">Graphic 83923 Version 2.0</div></div></div>"},"83925":{"type":"graphic_figure","displayName":"Mechanisms for urate secretion by the proximal tubule","title":"Mechanisms for urate secretion by the proximal tubule","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Mechanisms for urate secretion by the proximal tubule</div><div class=\"cntnt\"><img style=\"width:475px; height:388px;\" src=\"images/NEPH/83925_Mech_ur_secret_prox_tube.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urate enters the cell at the basolateral membrane via exchange with alpha-ketoglutarate, mediated by OAT1 and OAT3. At the apical membrane, urate is secreted via MRP4, ABCG2, NPT1 (SLC17A1), and/or NPT4 (SLC17A3). SLC13A1 is a sodium-dependent transporter that drives basolateral urate uptake.</div><div id=\"graphicVersion\">Graphic 83925 Version 4.0</div></div></div>"},"83926":{"type":"graphic_figure","displayName":"Mechanisms for urate reabsorption by the proximal tubule","title":"Mechanisms for urate reabsorption by the proximal tubule","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Mechanisms for urate reabsorption by the proximal tubule</div><div class=\"cntnt\"><img style=\"width:508px; height:386px;\" src=\"images/NEPH/83926_Mech_urat_reabs_prox_tube.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sodium-dependent anion transport by SLC5A8 and SLC5A12 increases intracellular concentrations of anions that exchange with luminal urate (URAT1/OAT10/OAT4). GLUT9 is the presumptive exit pathway for urate at the basolateral membrane but may also traffic to the apical membrane.</div><div id=\"graphicVersion\">Graphic 83926 Version 1.0</div></div></div>"},"83927":{"type":"graphic_table","displayName":"Effects of antihypertensive treatment in the elderly","title":"Effects of antihypertensive treatment in the elderly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effects of antihypertensive treatment in the elderly</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">HYVET</td> <td class=\"subtitle1\">SHEP</td> <td class=\"subtitle1\">STOP</td> <td class=\"subtitle1\">Syst-Eur</td> <td class=\"subtitle1\">Syst-China</td> </tr> <tr> <td>Mean treatment BP reduction, SBP/DBP, mmHg</td> <td>-29/-13</td> <td>-27/-9</td> <td>-29/-17</td> <td>-23/-7</td> <td>-20/-5</td> </tr> <tr> <td>Stroke,<br /> percent reduction</td> <td>-30 percent</td> <td>-32 percent</td> <td>-47 percent</td> <td>-42 percent</td> <td>-38 percent</td> </tr> <tr> <td>Coronary disease,<br /> percent reduction</td> <td>-23 percent*</td> <td>-27 percent</td> <td>-13 percent</td> <td>-30 percent</td> <td>+6 percent</td> </tr> <tr> <td>Heart failure,<br /> percent reduction</td> <td>-64 percent</td> <td>-55 percent</td> <td>-51 percent</td> <td>-29 percent</td> <td>-58 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SHEP: Systolic Hypertension in the Elderly Program; STOP: Swedish Trial in Old Patients; HYVET: Hypertension in Very Elderly Trial; Sys-Eur: European Systolic Hypertension in the Elderly; Syst-China: Chinese Trial on Isolated Systolic Hypertension in Elderly.<br />* Percentage of cardiovascular mortality reduction.</div><div class=\"graphic_reference\">Reproduced from: Burney B, Bakris G. Hypertension and its management in the elderly. Semin Nephrol 2009; 29:604. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83927 Version 1.0</div></div></div>"},"83928":{"type":"graphic_picture","displayName":"M perstans microfilariae","title":"<EM>Mansonella perstans</EM> microfilariae","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\"><EM>Mansonella perstans</EM> microfilariae</div><div class=\"cntnt\"><img style=\"width:515px; height:260px;\" src=\"images/ID/83928_M_persta_microfil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microfilariae of <EM>Mansonella perstans</EM> are unsheathed and measure 190 to 200 micrometers in stained blood smears and 180 to 225 micrometers in 2%&nbsp;formalin. The tail is blunt, and nuclei extend to the tip of the tail. Microfilariae circulate in the blood.<br />(A) Microfilariae of <EM>M. perstans</EM> in a thick blood smear stained with Giemsa from a patient from Cameroon.<br />(B) Microfilaria of <EM>M. perstans</EM> in a thin blood smear from the same specimen as (A).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Mansonellosis. Available at: <A href=\"http://www.cdc.gov/dpdx/mansonellosis/index.html\">http://www.cdc.gov/dpdx/mansonellosis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 83928 Version 6.0</div></div></div>"},"83929":{"type":"graphic_figure","displayName":"M ozzardi lifecycle","title":"Mansonella ozzardi lifecycle","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Mansonella ozzardi lifecycle</div><div class=\"cntnt\"><img style=\"width:568px; height:420px;\" src=\"images/ID/83929_M_ozzardi_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a blood meal, an infected anthropod (midges, genus <EM>Culicoides</EM>, or blackflies, genus <EM>Simulium</EM>) introduces third-stage filarial larvae onto the skin of the human host, where they penetrate into the bite wound <STRONG>(1)</STRONG>. They develop into adults that commonly reside in subcutaneous tissues <STRONG>(2)</STRONG>. Adult worms are rarely found in humans. The size range for female worms is 65 to 81 mm in length and 0.21 and 0.25 mm in diameter but unknown for males. Adult worms recovered from experimentally infected Patas monkeys measured 24 to 28 mm in length and 70 to 80 micrometers in diameter (males) and 32 to 62 mm in length and 0.13 to 0.16 mm in diameter (females). Adults produce unsheathed and nonperiodic microfilariae that reach the blood stream <STRONG>(3)</STRONG>. The arthropod ingests microfilariae during a blood meal <STRONG>(4)</STRONG>. After ingestion, the microfilariae migrate from the arthropod's midgut through the hemocoel to the thoracic muscles <STRONG>(5)</STRONG>. There the microfilariae develop into first-stage larvae <STRONG>(6)</STRONG>. The third-stage infective larvae migrate to arthropod's proboscis <STRONG>(8)</STRONG> and can infect another human when the arthropod takes a blood meal <STRONG>(1)</STRONG>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Mansonellosis. Available at: <A href=\"http://www.cdc.gov/dpdx/mansonellosis/index.html\">http://www.cdc.gov/dpdx/mansonellosis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 83929 Version 3.0</div></div></div>"},"83930":{"type":"graphic_picture","displayName":"M ozzardi microfilariae","title":"<EM>Mansonella ozzardi</EM> microfilariae","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\"><EM>Mansonella ozzardi</EM> microfilariae</div><div class=\"cntnt\"><img style=\"width:515px; height:260px;\" src=\"images/ID/83930_M_ozzard_microfil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microfilariae of <EM>Mansonella ozzardi</EM> in thick blood smears stained with Giemsa. Microfilariae of <EM>M. ozzardi</EM> are unsheathed and measure 160 to 205 micrometers in stained blood smears and 200 to 255 micrometers in 2%&nbsp;formalin. The tail tapers to a point, and the nuclei end well before the end of the tail. The end of the tail is also bent in a small hook-like shape. Microfilariae circulate in the blood.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Mansonellosis. Available at: <A href=\"http://www.cdc.gov/dpdx/mansonellosis/index.html\">http://www.cdc.gov/dpdx/mansonellosis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 83930 Version 5.0</div></div></div>"},"83931":{"type":"graphic_picture","displayName":"M streptocerca microfilariae","title":"<EM>Mansonella streptocerca </EM>microfilariae","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Mansonella streptocerca </EM>microfilariae</div><div class=\"cntnt\"><img style=\"width:504px; height:245px;\" src=\"images/ID/83931_M_strepto_microfilariae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microfilaria of <EM>Mansonella streptocerca</EM> fixed in 2% formalin and stained with hematoxylin. Microfilariae of <EM>M. streptocerca</EM> are unsheathed and measure 180 to 240 micrometers. The tail is been into a hook-like shape, and the nuclei extend to the end of the tail. Microfilariae are found in skin and do not circulate in the blood.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Mansonellosis. Available at: <A href=\"http://www.cdc.gov/dpdx/mansonellosis/index.html\">http://www.cdc.gov/dpdx/mansonellosis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 83931 Version 4.0</div></div></div>"},"83932":{"type":"graphic_table","displayName":"Recommended monitoring during mitotane","title":"Recommended monitoring during mitotane treatment*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended monitoring during mitotane treatment*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Interval</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Mitotane blood level</td> <td>Every four to six weeks<sup>&#182;</sup></td> <td>Target: 14 to 20 mg/L.</td> </tr> <tr> <td>Adverse effects</td> <td>At every visit (initially, every four weeks; after six months, every eight weeks)</td> <td>Gastrointestinal adverse effects: Use antiemetics (eg, metoclopramide or a 5-HT3 blocker) or loperamide.</td> </tr> <tr> <td>ACTH</td> <td>Suspected glucocorticoid deficiency or excess</td> <td> <p>CNS side effects (ataxia, confusion, speech or visual problems): Interrupt therapy or reduce dosage. Glucocorticoid status is difficult to determine.</p> Target: ACTH in the normal range or slightly above. Because of an increased glucorticoid clearance, high-dose glucocorticoid replacement is needed (most patients require at least 50 mg hydrocortisone per day).</td> </tr> <tr> <td>Serum sodium and potassium </td> <td>At every visit</td> <td>&nbsp;</td> </tr> <tr> <td>24-hour urine free cortisol</td> <td>At every visit</td> <td>Aim for mid-normal range.</td> </tr> <tr> <td>GOT, GPT, bilirubin, GGT</td> <td>Initially, every four weeks; after six months, every eight weeks</td> <td>GGT is invariably elevated without clinical consequences. If other liver enzymes are rapidly increasing (greater than threefold of baseline), there is risk of liver failure: Stop mitotane.</td> </tr> <tr> <td>TSH, fT3, fT4</td> <td>Every three to four months</td> <td>Disturbance of thyroid hormones is frequent. Thyroid hormone replacement is recommended in patients with clinical symptoms of hypothyroidism and low fT4 values.</td> </tr> <tr> <td>Testosterone</td> <td>Every three to four months</td> <td>Hypogonadism frequently occurs. Replacement should be initiated in men with symptoms of hypogonadism.</td> </tr> <tr> <td>Renin</td> <td>Every six months</td> <td>If renin is elevated, add fludrocortisone.</td> </tr> <tr> <td>Cholesterol (HDL, LDL), triglycerides</td> <td>Every three to four months (in an adjuvant setting)</td> <td>If LDL or HDL cholesterol are highly elevated, consider treatment with statins.</td> </tr> <tr> <td>Blood count</td> <td>Every three to four months</td> <td>Check for relevant leucopoenia, thrombocytopoenia, and anaemia (rare).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTH: corticotropin; CNS: central nervous system;&nbsp;GOT: glutamic-oxaloacetic transaminase; GPT: glutamate pyruvate transaminase; GGT: gamma glutamyltransferase; TSH: thyroid-stimulating hormone; fT3: free&nbsp;triiodothyronine; fT4: free thyroxine;&nbsp;HDL: high-density lipoprotein; LDL: low-density lipoprotein.<br />* Adapted from: Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a revised TNM classification. Cancer 2009; 115:243.<br />Â¶ In the first three months, mitotane blood levels should be checked every two to three weeks. After reaching a plateau, the interval can be extended.</div><div class=\"graphic_reference\">Original figure modified for this publication. Zini L, Porpiglia F, Fassnact M. Contemporary management of adrenocortical carcinoma. Eur Urol 2011; 60:1055. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83932 Version 5.0</div></div></div>"},"83933":{"type":"graphic_diagnosticimage","displayName":"Hemorrhagic ovarian cyst","title":"Hemorrhagic ovarian cyst","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hemorrhagic ovarian cyst</div><div class=\"cntnt\"><img style=\"width:504px; height:290px;\" src=\"images/OBGYN/83933_Hemorr_ovarian_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound image in a 38-year-old female shows a complex ovarian cyst (cursors) that contains a reticular pattern of internal echoes. This appearance is classic for a hemorrhagic ovarian cyst.</div><div class=\"graphic_reference\">Courtesy of Dr. Douglas Brown.</div><div id=\"graphicVersion\">Graphic 83933 Version 2.0</div></div></div>"},"83934":{"type":"graphic_table","displayName":"Causes of dyspnea in palliative care and potential treatments","title":"Causes of dyspnea in palliative care and potential treatments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of dyspnea in palliative care and potential treatments</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease process</td> <td class=\"subtitle1\">Potential interventions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Airway obstruction</td> </tr> <tr> <td class=\"indent1\">Airway obstruction by tumor or by lymphadenopathy</td> <td>Airway laser/cautery*, stent*, radiation therapy (RT)*, resection*, glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Bronchoconstriction (COPD, asthma)</td> <td>Bronchodilators, glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Retained or excess secretions</td> <td>Anticholinergic agents</td> </tr> <tr> <td class=\"indent1\">Vocal cord paralysis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Obstructive sleep apnea</td> <td>Continuous positive airway pressure (CPAP) at night</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pulmonary parenchymal</td> </tr> <tr> <td class=\"indent1\">Widespread tumor metastases</td> <td>RT*, chemotherapy*, glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Pneumonia, aspiration</td> <td>Antibiotics, pulmonary toilet, aspiration precautions</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> <td>Diuretics, ACE inhibitors, etc</td> </tr> <tr> <td class=\"indent1\">Pericardial disease, tamponade</td> <td>Pericardiocentesis*</td> </tr> <tr> <td class=\"indent1\">Lymphangitic tumor</td> <td>Diuretics, glucocorticoids, chemotherapy*</td> </tr> <tr> <td class=\"indent1\">Lung resection (eg, lobectomy, pneumonectomy)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pneumonitis caused by antineoplastic therapy</td> <td>Glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Radiation pneumonitis and fibrosis</td> <td>Glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Interstitial lung disease</td> <td>Glucocorticoids</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pulmonary vascular</td> </tr> <tr> <td class=\"indent1\">Venous thromboembolism</td> <td>Anticoagulation*, thrombolysis*, inferior vena cava filter*</td> </tr> <tr> <td class=\"indent1\">Sinusoidal obstruction syndrome (veno-occlusive disease)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tumor thromboembolism</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pulmonary hypertension</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Superior vena cava syndrome</td> <td>Glucocorticoids, RT*, chemotherapy*, stent*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pleural</td> </tr> <tr> <td class=\"indent1\">Pleural effusion (eg, malignant, drug-induced)</td> <td>Indwelling pleural catheter with intermittent drainage; pleurodesis</td> </tr> <tr> <td class=\"indent1\">Pleural tumor</td> <td>RT*, chemotherapy*</td> </tr> <tr> <td class=\"indent1\">Pneumothorax</td> <td>Chest tube</td> </tr> <tr> <td class=\"indent1\">Pleural effusion due to lung entrapment by tumor</td> <td>Indwelling pleural catheter with intermittent drainage as guided by symptoms*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inspiratory muscle weakness</td> </tr> <tr> <td class=\"indent1\">Cachexia</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Electrolyte imbalance</td> <td>Adjust electrolytes</td> </tr> <tr> <td class=\"indent1\">Neuromuscular disease, including paraneoplastic syndromes</td> <td>Noninvasive positive pressure ventilation (NPPV)*</td> </tr> <tr> <td class=\"indent1\">Steroid myopathy</td> <td>Physical therapy, reduce dose of glucocorticoids</td> </tr> <tr> <td><strong>Diaphragmatic paralysis, phrenic nerve paralysis</strong></td> <td>NPPV*, diaphragmatic pacing*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Decreased chest wall compliance</td> </tr> <tr> <td class=\"indent1\">Restriction post thoracotomy</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Restriction due to advanced chest wall tumor (eg, inflammatory breast cancer)</td> <td>RT*, chemotherapy*</td> </tr> <tr> <td class=\"indent1\">Massive ascites</td> <td>Drainage*, including indwelling catheter with intermittent drainage</td> </tr> <tr> <td class=\"indent1\">Massive abdominal organomegaly</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Obesity</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Systemic</td> </tr> <tr> <td class=\"indent1\">Anemia</td> <td>Red blood cell transfusion*</td> </tr> <tr> <td class=\"indent1\">Acidosis</td> <td>Correct metabolic abnormalities</td> </tr> <tr> <td class=\"indent1\">Arrhythmias</td> <td>Usual treatments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neuropsychiatric</td> </tr> <tr> <td class=\"indent1\">Pain</td> <td>Opioids</td> </tr> <tr> <td class=\"indent1\">Depression</td> <td>Antidepressants, cognitive behavioral therapy</td> </tr> <tr> <td class=\"indent1\">Anxiety, including hyperventilation</td> <td>Anxiolytic medication, cognitive behavioral therapy</td> </tr> <tr> <td class=\"indent1\">Respiratory panic</td> <td>Anxiolytics, antidepressants, cognitive behavioral therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RT: radiation therapy; COPD: chronic obstructive pulmonary disease; ACE: angiotensin converting enzyme; NPPV: noninvasive positive pressure ventilation.<br />* Decisions regarding all therapies and disease-modifying treatments must be made in light of the expected burdens and benefits and be consistent with the patient's long-term and short-term goals of care.</div><div id=\"graphicVersion\">Graphic 83934 Version 3.0</div></div></div>"},"83936":{"type":"graphic_table","displayName":"Lichenoid drug eruption histology differential","title":"Histologic features in lichenoid drug eruption and lichen planus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic features in lichenoid drug eruption and lichen planus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Differential criteria</td> <td class=\"subtitle1\">Lichen planus</td> <td class=\"subtitle1\">Lichenoid drug eruption</td> </tr> <tr class=\"divider_bottom\"> <td>Cornified layer</td> <td>Compact hyperorthokeratosis, seldom a moderate degree of parakeratosis</td> <td>Focal parakeratosis; cytoid bodies in the cornified layer</td> </tr> <tr class=\"divider_bottom\"> <td>Epidermis</td> <td>Thickened stratum granulosum at acrosyringia and acrotrichia, irregular saw-tooth-like acanthosis, necrotic keratinocytes in the lower epidermal layers</td> <td>Thickened stratum granulosum possible, however, with focal interruption of the granular layer, cytoid bodies in the granular layer, necrotic keratinocytes scattered in all epidermal layers</td> </tr> <tr> <td>Dermis</td> <td>Mostly a superficial dermal inflammatory infiltrate; seldom eosinophils</td> <td>More often a deep dermal inflammatory infiltrate (especially in non-photodistributed lichenoid drug eruption); admixture of eosinophils and plasma cells possible*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Presence of plasma cell is a regular finding in biopsies from mucous membranes independently of the origin of dermatosis.</div><div id=\"graphicVersion\">Graphic 83936 Version 1.0</div></div></div>"},"83937":{"type":"graphic_picture","displayName":"Lichenoid interface dermatitis","title":"Lichenoid interface dermatitis","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Lichenoid interface dermatitis</div><div class=\"cntnt\"><img style=\"width:517px; height:345px;\" src=\"images/DERM/83937_Lichen_inter_derm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichenoid interface dermatitis resembling that of idiopathic lichen planus.<br />(A) Compact hyperorthokeratosis, thickened stratum granulosum and irregular acanthosis of the epidermis together with a superficial lichenoid lymphocytic infiltrate (hematoxylin-eosin, x100).<br />(B and C) Higher magnification with necrotic keratinocytes up to the mid-epidermal layers (hematoxylin-eosin, x200).</div><div id=\"graphicVersion\">Graphic 83937 Version 3.0</div></div></div>"},"83938":{"type":"graphic_table","displayName":"Common antibiotic and anticoagulant lock solutions","title":"Final concentrations of common antibiotic lock solutions with anticoagulant for treatment of catheter-related bloodstream infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Final concentrations of common antibiotic lock solutions with anticoagulant for treatment of catheter-related bloodstream infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Antibiotic and concentration</td> <td class=\"subtitle1\">Heparin concentration (units/mL)</td> <td class=\"subtitle1\">Maximum dwell time<br /> (duration of stability)</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td rowspan=\"2\">For gram-positive activity</td> <td>Cefazolin 5 mg/mL</td> <td>5000</td> <td>24 hours</td> <td>[1]</td> </tr> <tr> <td>Vancomycin&nbsp;5 mg/mL</td> <td>5000</td> <td>72 hours</td> <td>[2]</td> </tr> <tr> <td rowspan=\"2\">For gram-negative activity</td> <td>Ceftazidime 10 mg/mL</td> <td>5000</td> <td>72 hours</td> <td>[3]</td> </tr> <tr> <td>Gentamicin 1 mg/mL</td> <td>2500</td> <td>72 hours</td> <td>[4]&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Combinations for both gram-positive and gram-negative activity</td> <td>Cefazolin 10 mg/mL and gentamicin 5 mg/mL</td> <td>5000</td> <td>48 hours</td> <td>[5]</td> </tr> <tr> <td>Vancomycin 10 mg/mL and gentamicin 5 mg/mL</td> <td>5000</td> <td>48 hours</td> <td>[5]&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table lists clinically useful antibiotics in combination with heparin at doses for which there are optimal stability and/or in vitro efficacy data. If lower doses of heparin are used, the antibiotic dose often must be decreased as well to maintain stability. Antibiotic lock solutions for the treatment of catheter-related bloodstream infections should&nbsp;be used in conjunction with systemic antibiotic therapy.&nbsp;Antibiotic concentrations may decrease to subtherapeutic levels in the distal lumen of the catheter when dwell times exceed 48 hours, but, for hemodialysis catheters, it is reasonable to allow the solution to dwell during the interval between sessions, up to 72 hours. If the line must be accessed for alternate use during the dwell time, the lock solution should be removed and later replaced anew.</div><div class=\"graphic_footnotes\"><EM></EM>&nbsp;</div><div class=\"graphic_reference\">References:<br /><br /><OL>&#xD;&#xA;<LI>Bookstaver PB, Williamson JC, Tucker BK, et al. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. Ann Pharmacother 2009; 43:210.2. </LI>&#xD;&#xA;<LI>LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 2007; 22:2239.3. </LI>&#xD;&#xA;<LI>Vercaigne LM, Sitar DS, Penner SB, et al. Antibiotic-heparin lock: in vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy 2000; 20:394.4. </LI>&#xD;&#xA;<LI>Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002; 61:1136.5. </LI>&#xD;&#xA;<LI>Vercaigne LM, Zelenitsky SA, Findlay I, et al. An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters. J Antimicrob Chemother 2002; 49:693.</LI></OL></div><div id=\"graphicVersion\">Graphic 83938 Version 3.0</div></div></div>"},"83939":{"type":"graphic_table","displayName":"Antibiotic lock solutions without anticoagulant","title":"Final concentrations of antibiotic lock solutions without anticoagulant for treatment of catheter-related bloodstream infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Final concentrations of antibiotic lock solutions without anticoagulant for treatment of catheter-related bloodstream infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic and concentration</td> <td class=\"subtitle1\">Maximum dwell time<br /> (duration of stability)</td> <td class=\"subtitle1\">&nbsp;Reference</td> </tr> <tr> <td>Amikacin 1 mg/mL</td> <td>48 hours</td> <td>&nbsp;[1]</td> </tr> <tr> <td>Aztreonam 83.3 mg/mL</td> <td>12 hours</td> <td>&nbsp;[2]</td> </tr> <tr> <td>Cefepime 1 mg/mL</td> <td>48 hours</td> <td>&nbsp;[1]</td> </tr> <tr> <td>Cefepime 10 mg/mL</td> <td>48 hours</td> <td>&nbsp;[1]</td> </tr> <tr> <td>Ceftazidime 5 mg/mL</td> <td>48 hours</td> <td>&nbsp;[1]</td> </tr> <tr> <td>Ceftriaxone 83.3 mg/mL</td> <td>12 hours</td> <td>&nbsp;[2]</td> </tr> <tr> <td>Ciprofloxacin 5 mg/mL</td> <td>48 hours</td> <td>&nbsp;[3]</td> </tr> <tr> <td>Daptomycin 5 mg/mL*</td> <td>72 hours</td> <td>&nbsp;[4]</td> </tr> <tr> <td>Gentamicin 13.3 mg/mL</td> <td>12 hours</td> <td>&nbsp;[2]</td> </tr> <tr> <td>Minocycline 2 mg/mL</td> <td>4 hours</td> <td>&nbsp;[5]</td> </tr> <tr> <td>Nafcillin 83.3 mg/mL</td> <td>12 hours</td> <td>&nbsp;[2]</td> </tr> <tr> <td>Rifampicin 5 mg/mL</td> <td>48 hours</td> <td>&nbsp;[3]</td> </tr> <tr> <td>Teicoplanin 10 mg/mL</td> <td>48 hours</td> <td>&nbsp;[3]</td> </tr> <tr> <td>Tigecycline 2 mg/mL</td> <td>4 hours</td> <td>&nbsp;[5]</td> </tr> <tr class=\"divider_bottom\"> <td>Vancomycin 5 mg/mL</td> <td>72 hours</td> <td>&nbsp;[4]</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Combinations</td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Daptomycin 2 mg/mL* and rifampin 2 mg/mL</td> <td>4 hours</td> <td>&nbsp;[5]</td> </tr> <tr> <td class=\"indent1\">Linezolid 2 mg/mL and rifampin 2 mg/mL</td> <td>4 hours</td> <td>&nbsp;[5]</td> </tr> <tr> <td class=\"indent1\">Minocycline 2 mg/mL and rifampin 2 mg/mL</td> <td>4 hours</td> <td>&nbsp;[5]</td> </tr> <tr> <td class=\"indent1\">Tigecycline 2 mg/mL and rifampin 2 mg/mL</td> <td>4 hours</td> <td>&nbsp;[5]</td> </tr> <tr> <td class=\"indent1\">Vancomycin 2 mg/mL and rifampin 2 mg/mL</td> <td>4 hours</td> <td>&nbsp;[5]</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table lists&nbsp;clinically useful antibiotic solutions that do not contain an anticoagulant and can be used in patients who have a contraindication to heparin. Otherwise, solutions containing both an antibiotic and an anticoagulant are&nbsp;preferred. The doses included have optimal stability and/or in vitro data to support their use. Antibiotic lock solutions for the treatment of catheter-related bloodstream infections should be used in conjunction with systemic antibiotic therapy. Antibiotic concentrations may decrease to subtherapeutic levels in the distal lumen of the catheter when dwell times exceed 48 hours, but, for hemodialysis catheters, it is reasonable to allow the solution to dwell during the interval between sessions, up to 72 hours. If the line must be accessed for alternate use during the dwell time, the lock solution should be removed and later replaced anew.</div><div class=\"graphic_footnotes\">* Daptomycin solution contained 50 mg/L of calcium, which is necessary for antibiotic activity.</div><div class=\"graphic_reference\">References:&nbsp;<br /><br /><OL>&#xD;&#xA;<LI>Lee MY, Ko KS, Song JH, Peck KR. In vitro effectiveness of the antibiotic lock technique (ALT) for the treatment of catheter-related infections by Pseudomonas aeruginosa and Klebsiella pneumoniae. J Antimicrob Chemother 2007; 60:782. </LI>&#xD;&#xA;<LI>Andris DA, Krzywda EA, Edmiston CE, et al. Elimination of intraluminal colonization by antibiotic lock in silicone vascular catheters. Nutrition 1998; 14:427. </LI>&#xD;&#xA;<LI>Lee JY, Ko KS, Peck KR, et al. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. J Antimicrob Chemother 2006; 57:1110. </LI>&#xD;&#xA;<LI>LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 2007; 22:2239. </LI>&#xD;&#xA;<LI>Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51:1656.</LI></OL></div><div id=\"graphicVersion\">Graphic 83939 Version 2.0</div></div></div>"},"83941":{"type":"graphic_figure","displayName":"Interpretation of Z-scores for growth parameters","title":"Interpretation of Z-scores for growth parameters","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Interpretation of Z-scores for growth parameters</div><div class=\"cntnt\"><img style=\"width:599px; height:259px;\" src=\"images/PEDS/83941_Interp_Zscores_growth_param.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Length (recumbent) is generally measured for children younger than two years of age, and height (standing) is measured for those two years and older.<br />Â¶ A child in this range is very tall. Tallness is rarely a problem, unless it is so excessive that it may indicate an endocrine disorder such as a growth hormone-producing tumor. Refer a child in this range for assessment if you suspect an endocrine disorder (eg, if parents of normal height have a child who is excessively tall for his or her age).<br />Î A child whose weight-for-age falls into this range may have a growth problem, but this is better assessed from a weight-for-length/height or body mass index (BMI)-for-age.<br /><FONT class=lozenge>â</FONT> A plotted point above 1 shows possible risk. A trend towards the 2 z-score line shows definite risk.<br />Â§ It is possible for a stunted or severely stunted child to become overweight.<br />Â¥ This is referred to as very low weight in IMCI training modules.<SUP>[1]</SUP></div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Integrated Management of Childhood Illness, in-service training. WHO, Geneva, 1997.</LI></OL>Reprinted with permission from: World Health Organization. Training course on child growth assessment. WHO, Geneva 2008. Copyright Â© 2008 World Health Organization. Full publication available at: <A href=\"http://www.who.int/childgrowth/training/module_c_interpreting_indicators.pdf\" target=_blank>http://www.who.int/childgrowth/training/module_c_interpreting_indicators.pdf</A>.</div><div id=\"graphicVersion\">Graphic 83941 Version 2.0</div></div></div>"},"83942":{"type":"graphic_algorithm","displayName":"Management of single magnet ingestion","title":"Algorithm for management of single magnet ingestion","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of single magnet ingestion</div><div class=\"cntnt\"><img style=\"width:586px; height:408px;\" src=\"images/PEDS/83942_Manage_magnet_ingest_small.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* If magnet might be or is known to be a high-powered type (neodymium, or \"rare earth\" type).<br />&Delta; Radiographs do not reliably distinguish between single and multiple magnets, since it is possible for magnets to stick together or overlap on a single view and be misdiagnosed as a single magnet.<br /><span class=\"lozenge\">&loz;</span> The following \"magnet precautions\" should be for any child who has ingested one or more magnets: Remove any magnetic objects nearby, avoid clothes with metallic buttons and belts with buckles, and ensure that no other metal objects or magnets are in the child's environment that could be accidentally ingested. Maintain these precautions until magnet has passed out of the gastrointestinal tract.</div><div class=\"graphic_reference\">Modified with permission from: Hussain SZ, Bousvaros A, Gilger M, et al. Management of ingested magnets in children. J Pediatr Gastroenterol Nutr 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 83942 Version 4.0</div></div></div>"},"83944":{"type":"graphic_table","displayName":"Iodinated intravascular contrast agents","title":"Iodinated intravascular contrast agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Iodinated intravascular contrast agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">United States trade name</td> <td class=\"subtitle1\">Anion</td> <td class=\"subtitle1\">Cation</td> <td class=\"subtitle1\">Osmolality<br /> (m0sm/kg H<sub>2</sub>O)</td> <td class=\"subtitle1\">Iodine<br /> (mg/mL)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Nonionic</td> </tr> <tr> <td class=\"indent1\">Iodixanol</td> <td>Visipaque 270</td> <td>N/A</td> <td>N/A</td> <td>290</td> <td>270</td> </tr> <tr> <td class=\"indent1\">Iodixanol</td> <td>Visipaque -320</td> <td>N/A</td> <td>N/A</td> <td>290</td> <td>320</td> </tr> <tr> <td class=\"indent1\">Iopromide</td> <td>Ultravist 150</td> <td>N/A</td> <td>N/A</td> <td>328</td> <td>150</td> </tr> <tr> <td class=\"indent1\">Ioversol 34%</td> <td>Optiray 160</td> <td>N/A</td> <td>N/A</td> <td>355</td> <td>160</td> </tr> <tr> <td class=\"indent1\">Iohexol</td> <td>Omnipaque 180</td> <td>N/A</td> <td>N/A</td> <td>388</td> <td>180</td> </tr> <tr> <td class=\"indent1\">Iopamidol 40.8%</td> <td>Isovue -200</td> <td>N/A</td> <td>N/A</td> <td>413</td> <td>200</td> </tr> <tr> <td class=\"indent1\">Iopromide</td> <td>Ultravist 240</td> <td>N/A</td> <td>N/A</td> <td>483</td> <td>240</td> </tr> <tr> <td class=\"indent1\">Ioversol 51%</td> <td>Optiray 240</td> <td>N/A</td> <td>N/A</td> <td>502</td> <td>240</td> </tr> <tr> <td class=\"indent1\">Iohexol 51.8%</td> <td>Omnipaque 240</td> <td>N/A</td> <td>N/A</td> <td>520</td> <td>240</td> </tr> <tr> <td class=\"indent1\">Iopamidol 51%</td> <td>Isovue -250</td> <td>N/A</td> <td>N/A</td> <td>524</td> <td>250</td> </tr> <tr> <td class=\"indent1\">Ioxilan 62.3%</td> <td>Oxilan 300</td> <td>N/A</td> <td>N/A</td> <td>607</td> <td>300</td> </tr> <tr> <td class=\"indent1\">Iopromide</td> <td>Ultravist 300</td> <td>N/A</td> <td>N/A</td> <td>607</td> <td>300</td> </tr> <tr> <td class=\"indent1\">Iopamidol 61.2%</td> <td>Isovue 300</td> <td>N/A</td> <td>N/A</td> <td>616</td> <td>300</td> </tr> <tr> <td class=\"indent1\">Ioversol 64%</td> <td>Optiray 300</td> <td>N/A</td> <td>N/A</td> <td>651</td> <td>300</td> </tr> <tr> <td class=\"indent1\">Iohexol 64.7%</td> <td>Omnipaque -300</td> <td>N/A</td> <td>N/A</td> <td>672</td> <td>300</td> </tr> <tr> <td class=\"indent1\">Ioversol 68%</td> <td>Optiray 320</td> <td>N/A</td> <td>N/A</td> <td>702</td> <td>320</td> </tr> <tr> <td class=\"indent1\">Iopromide</td> <td>Ultravist 370</td> <td>N/A</td> <td>N/A</td> <td>774</td> <td>370</td> </tr> <tr> <td class=\"indent1\">Ioversol 74%</td> <td>Optiray 350</td> <td>N/A</td> <td>N/A</td> <td>792</td> <td>350</td> </tr> <tr> <td class=\"indent1\">Iopamidol 75.5%</td> <td>Isovue -370</td> <td>N/A</td> <td>N/A</td> <td>796</td> <td>370</td> </tr> <tr> <td class=\"indent1\">Iohexol 75.5%</td> <td>Omnipaque -350</td> <td>N/A</td> <td>N/A</td> <td>844</td> <td>350</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Ionic</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Conray 30</td> <td>Iothalamate</td> <td>Meglumine</td> <td>600</td> <td>141</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Hexabrix</td> <td>Ioxaglate</td> <td>Meglumine sodium</td> <td>Approximately 600</td> <td>320</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Cholografin</td> <td>Iodipamide</td> <td>Meglumine</td> <td>664</td> <td>257</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Conray 43</td> <td>Iothalamate</td> <td>Meglumine</td> <td>1000</td> <td>202</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Conray</td> <td>Iothalamate</td> <td>Meglumine</td> <td>1400</td> <td>282</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>MD-76 R</td> <td>Diatrizoate</td> <td>Meglumine sodium</td> <td>1551</td> <td>370</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Conray -325</td> <td>Iothalamate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>325</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 83944 Version 15.0</div></div></div>"},"83945":{"type":"graphic_figure","displayName":"Cauda equina PI","title":"Cauda equina syndrome","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Cauda equina syndrome</div><div class=\"cntnt\"><img style=\"width:470px; height:687px;\" src=\"images/PI/83945_Cauda-equina-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cauda equina is a bundle of nerves that spread out from the bottom of the spinal cord (see label). Cauda equina syndrome happens when some of the nerves in the cauda equina get squeezed or damaged.</div><div id=\"graphicVersion\">Graphic 83945 Version 2.0</div></div></div>"},"83947":{"type":"graphic_figure","displayName":"Hypospadias PI","title":"Hypospadias","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Hypospadias</div><div class=\"cntnt\"><img style=\"width:478px; height:659px;\" src=\"images/PI/83947_Hypospadias_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a penis with hypospadias, the hole that urine comes out of can be close to the tip (A), somewhere along the shaft of the penis (B), or down by the testicles (C).</div><div id=\"graphicVersion\">Graphic 83947 Version 3.0</div></div></div>"},"83948":{"type":"graphic_figure","displayName":"Intra-aortic balloon inflation and deflation timing","title":"Intra-aortic balloon inflation and deflation timing","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Intra-aortic balloon inflation and deflation timing</div><div class=\"cntnt\"><img style=\"width:469px; height:560px;\" src=\"images/CARD/83948_Intraaortballooninfldefl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The timing of balloon inflation and deflation is adjusted in the 1:2 mode. The inflation point is moved rightward (later) until it occurs in late diastole, and the dicrotic notch is uncovered. The inflation timing is moved progressively earlier in the cardiac cycle until the dicrotic notch on the central aortic tracing just disappears. Examples of early, late, and correct inflation are shown in the top two tracings. Similarly, the deflation knob is moved leftward (earlier) and then slowly advanced toward the right (later in the cardiac cycle) until the end-diastolic pressure dips 10 to 15 mmHg below the patient's unassisted diastolic pressure. This will produce a maximal lowering of the patient's unassisted systolic pressure. Examples of early, late, and correct deflation timing are shown in the bottom two traces.</div><div class=\"graphic_reference\">Reproduced with permission from: Burkhof D, Moscucci M, Henriques JPS. Percutaneous Circulatory Support: Intra-aortic Balloon Counterpulsation, Impella, Tandem Heart, and Extracorporeal Bypass. In: Grossman &amp; Baim's Cardiac Catheterization, Angiography, and Intervention, 8th ed, Moscucci M (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright Â© 2013 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 83948 Version 6.0</div></div></div>"},"83949":{"type":"graphic_diagnosticimage","displayName":"Avulsion fracture associated with jersey finger","title":"Avulsion fracture associated with jersey finger","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Avulsion fracture associated with jersey finger</div><div class=\"cntnt\"><img style=\"width:596px; height:369px;\" src=\"images/RADIOL/83949_Xray_jersey_finger.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiograph of the right ring (fourth) finger in the AP (A), lateral (B), and oblique (C) projections reveals a severe avulsion fracture (red arrows) of the base of the distal phalanx at the insertion point of the flexor digitorum profundus muscle reminiscent of the injury associated with the jersey finger.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 83949 Version 3.0</div></div></div>"},"83950":{"type":"graphic_picture","displayName":"Erythema nodosum PI","title":"Erythema nodosum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PI/83950_Erythema_nodosum_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema nodosum causes painful red or purple bumps on the legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 83950 Version 3.0</div></div></div>"},"83951":{"type":"graphic_table","displayName":"Insulin algorithm 1","title":"Insulin algorithm: Regular insulin, example 1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Insulin algorithm: Regular insulin, example 1</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <colgroup span=\"3\" width=\"33%\"></colgroup>\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\" colspan=\"2\">Blood glucose values</td>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Change in dose, units of regular insulin</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">mg/dL</td>\r\n            <td class=\"subtitle2\">mmol/L</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&#60;70</td>\r\n            <td>&#60;3.9</td>\r\n            <td>- 2 R</td>\r\n        </tr>\r\n        <tr>\r\n            <td>70 to 140</td>\r\n            <td>4.4 to 6.7</td>\r\n            <td>&#177; 0 R</td>\r\n        </tr>\r\n        <tr>\r\n            <td>141 to 160</td>\r\n            <td>7.8 to 8.9</td>\r\n            <td>+ 1 R</td>\r\n        </tr>\r\n        <tr>\r\n            <td>161 to 200</td>\r\n            <td>8.9 to 11.1</td>\r\n            <td>+ 2 R</td>\r\n        </tr>\r\n        <tr>\r\n            <td>201 to 240</td>\r\n            <td>11.4 to 13.3</td>\r\n            <td>+ 3 R</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&#62;240</td>\r\n            <td>&#62;11.3</td>\r\n            <td>+ 4 R</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83951 Version 1.0</div></div></div>"},"83952":{"type":"graphic_table","displayName":"Insulin algorithm 2","title":"Insulin algorithm: Regular insulin, example 2","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Insulin algorithm: Regular insulin, example 2</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <colgroup span=\"3\" width=\"33%\"></colgroup>\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\" colspan=\"2\">Blood glucose values</td>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Change in dose, units of regular insulin</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">mg/dL</td>\r\n            <td class=\"subtitle2\">mmol/L</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&#60;80</td>\r\n            <td>&#60;4.4</td>\r\n            <td>- 1 R</td>\r\n        </tr>\r\n        <tr>\r\n            <td>80 to 120</td>\r\n            <td>4.4 to 6.7</td>\r\n            <td>&#177; 0 R</td>\r\n        </tr>\r\n        <tr>\r\n            <td>121 to 140</td>\r\n            <td>6.7 to 7.8</td>\r\n            <td>+ 0.5 R</td>\r\n        </tr>\r\n        <tr>\r\n            <td>141 to 160</td>\r\n            <td>7.8 to 8.9</td>\r\n            <td>+ 1 R</td>\r\n        </tr>\r\n        <tr>\r\n            <td>161 to 200</td>\r\n            <td>8.9 to 11.1</td>\r\n            <td>+ 1.5 R</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&#62;200</td>\r\n            <td>&#62;11.1</td>\r\n            <td>+ 2 R</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83952 Version 1.0</div></div></div>"},"83953":{"type":"graphic_table","displayName":"Insulin algorithm lispro","title":"Insulin algorithm: Lispro insulin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Insulin algorithm: Lispro insulin</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <colgroup span=\"3\" width=\"33%\"></colgroup>\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\" colspan=\"2\">Blood glucose values</td>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Change in dose, units of insulin lispro</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">mg/dL</td>\r\n            <td class=\"subtitle2\">mmol/L</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&#60;80</td>\r\n            <td>&#60;4.4</td>\r\n            <td>- 2 units</td>\r\n        </tr>\r\n        <tr>\r\n            <td>80 to 120</td>\r\n            <td>4.4 to 6.7</td>\r\n            <td>&#177; 0 units</td>\r\n        </tr>\r\n        <tr>\r\n            <td>121 to 140</td>\r\n            <td>6.7 to 7.8</td>\r\n            <td>+ 1 units</td>\r\n        </tr>\r\n        <tr>\r\n            <td>141 to 160</td>\r\n            <td>7.8 to 8.9</td>\r\n            <td>+ 2 units</td>\r\n        </tr>\r\n        <tr>\r\n            <td>161 to 200</td>\r\n            <td>8.9 to 11.1</td>\r\n            <td>+ 3 units</td>\r\n        </tr>\r\n        <tr>\r\n            <td>&#62;200</td>\r\n            <td>&#62;11.1</td>\r\n            <td>+ 4 units</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 83953 Version 1.0</div></div></div>"},"83962":{"type":"graphic_table","displayName":"CAILS","title":"Composite Assessment of Index Lesion Severity for Mycosis Fungoides and Sezary Syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composite Assessment of Index Lesion Severity for Mycosis Fungoides and Sezary Syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Clinical sign and degree or size (scale of 0 to 8)</td> <td class=\"subtitle1\" colspan=\"5\">Index lesion</td> </tr> <tr> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> <td class=\"subtitle2\">5</td> </tr> <tr> <td>Erythema</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Scaling</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Plaque elevation</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hypo- or hyperpigmentation</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Lesion size*</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td align=\"right\"><strong>Subtotal:</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td align=\"right\"><strong>Total (sum of subtotals):</strong></td> <td colspan=\"5\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Composite Assessment of Index Lesion Severity cannot be used as skin assessment in global response score. Suggestions for improvement include using actual size of lesion versus categorical score for size and eliminating pigmentation as a clinical parameter.</div><div class=\"graphic_footnotes\">* Lesion size (cm<SUP>2</SUP>): 0: no measurable area; 1: &gt;0 to &#8804;4; 2: &gt;4 to &#8804;10; 3: &gt;10 to &#8804;16; 4: &gt;16 to &#8804;25; 5: &gt;25 to &#8804;35; 6: &gt;35 to &#8804;45; 7: &gt;45 to &#8804;55; 8: &gt;55 to &#8804;70; 9: &gt;70 to &#8804;90; 10: &gt;90 to &#8804;110; 11: &gt;110 to &#8804;130; 12: &gt;130 to &#8804;155; 13: &gt;155 to &#8804;180; 14: &gt;180 to &#8804;210; 15: &gt;210 to &#8804;240; 16: &gt;240 to &#8804;270; 17: &gt;270 to &#8804;300; 18: &gt;300.</div><div class=\"graphic_reference\">From: Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S&eacute;zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol; 29(18), 2011:2598-2607. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83962 Version 1.0</div></div></div>"},"83963":{"type":"graphic_table","displayName":"mSWAT","title":"Modified Severity Weighted Assessment Tool for Mycosis Fungoides and Sezary Syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Severity Weighted Assessment Tool for Mycosis Fungoides and Sezary Syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Body region</td> <td class=\"subtitle1\" rowspan=\"2\">Percent BSA in body region</td> <td class=\"subtitle1\" colspan=\"3\">Assessment of involvement in patient's skin</td> </tr> <tr> <td class=\"subtitle2\">Patch*</td> <td class=\"subtitle2\">Plaque<sup>&#182;</sup></td> <td class=\"subtitle2\">Tumor<sup>&#916;</sup></td> </tr> <tr> <td>Head</td> <td class=\"centered\">7</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Neck</td> <td class=\"centered\">2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Anterior trunk</td> <td class=\"centered\">13</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Arms</td> <td class=\"centered\">8</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Forearms</td> <td class=\"centered\">6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hands</td> <td class=\"centered\">5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Posterior trunk</td> <td class=\"centered\">13</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Buttocks</td> <td class=\"centered\">5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Thighs</td> <td class=\"centered\">19</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Legs</td> <td class=\"centered\">14</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Feet</td> <td class=\"centered\">7</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Groin</td> <td class=\"centered\">1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1_start\" align=\"right\"><strong>Subtotal of lesion BSA:</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\" align=\"right\">Weighting factor:</td> <td class=\"sublist_other_centered\">&nbsp;</td> <td class=\"sublist_other_centered\">x1</td> <td class=\"sublist_other_centered\">x2</td> <td class=\"sublist_other_centered\">x4</td> </tr> <tr> <td align=\"right\"><strong>Subtotal lesion BSA x weighting factor:</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Modified Severity Weighted Assessment Tool score equals summation of each column line.</div><div class=\"graphic_footnotes\">BSA: body surface area; mSWAT: modified Severity Weighted Assessment Tool.<br />* Any size lesion without induration or significant elevation above the surrounding uninvolved skin; poikiloderma may be present.<br />Â¶ Any size lesion that is elevated or indurated; crusting, ulceration, or poikiloderma may be present.<br />Î Any solid or nodular lesion â¥1 cm in diameter with evidence of deep infiltration in the skin and/or vertical growth.</div><div class=\"graphic_reference\">From: Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S&eacute;zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol; 29(18), 2011:2598-2607. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 83963 Version 2.0</div></div></div>"},"83964":{"type":"graphic_picture","displayName":"Partial nail avulsion 2","title":"Partial nail avulsion","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Partial nail avulsion</div><div class=\"cntnt\"><img style=\"width:498px; height:476px;\" src=\"images/DERM/83964_Part_nail_avulsion_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83964 Version 1.0</div></div></div>"},"83965":{"type":"graphic_figure","displayName":"Nail biopsy diagram","title":"Diagram of the nail biopsy techniques","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Diagram of the nail biopsy techniques</div><div class=\"cntnt\"><img style=\"width:488px; height:526px;\" src=\"images/DERM/83965_Nail_biopsy_diagram.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83965 Version 1.0</div></div></div>"},"83966":{"type":"graphic_picture","displayName":"Split-nail complication","title":"Split-nail complication","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Split-nail complication</div><div class=\"cntnt\"><img style=\"width:504px; height:449px;\" src=\"images/DERM/83966_Split_nail_complication.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83966 Version 1.0</div></div></div>"},"83967":{"type":"graphic_diagnosticimage","displayName":"Healing pubic ramus fractures","title":"Healing pubic ramus fractures","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Healing pubic ramus fractures</div><div class=\"cntnt\"><img style=\"width:504px; height:396px;\" src=\"images/EM/83967_Heal_pubic_ram_fract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph of the pelvis was obtained at the six-week follow-up visit of an elderly woman who sustained insufficiency fractures of the pubic rami. Note the callous formation (arrows) at the left superior pubic root and the the inferior pubic ramus fracture sites.</div><div class=\"graphic_reference\">Courtesy of Jim Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 83967 Version 2.0</div></div></div>"},"83968":{"type":"graphic_figure","displayName":"Glycolysis PK deficiency","title":"Alterations of glycolysis in pyruvate kinase deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alterations of glycolysis in pyruvate kinase deficiency</div><div class=\"cntnt\"><img style=\"width:330px; height:494px;\" src=\"images/HEME/83968_GlycolysisPKdeficien.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This highly simplified outline of glycolysis demonstrates that in PK deficiency, metabolic intermediates upstream to the PK enzyme accumulate, including phosphoenolpyruvate and&nbsp;2,3 BPG. Elevated levels of 2,3 BPG ameliorate the consequences of anemia by altering the hemoglobin oxygen dissociation curve, increasing oxygen delivery to the tissues.<br />Note: Hexokinase catalyzes the formation of glucose-6 P from glucose. As this step is upstream of the Rappaport-Leubering shunt, levels of 2,3-BPG are low in subjects with hexokinase deficiency, in contrast to that noted in PK deficiency.</div><div class=\"graphic_footnotes\">PK: pyruvate kinase; 2,3 BPG: 2,3 bisphosphoglycerate.</div><div id=\"graphicVersion\">Graphic 83968 Version 4.0</div></div></div>"},"83969":{"type":"graphic_diagnosticimage","displayName":"BK virus decoy cells","title":"Urine cytology specimen demonstrating the findings associated with polyomavirus-associated nephropathy","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Urine cytology specimen demonstrating the findings associated with polyomavirus-associated nephropathy</div><div class=\"cntnt\"><img style=\"width:513px; height:430px;\" src=\"images/ID/83969_BK_virus_decoy_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Urine cytology specimen depicting scattered \"decoy cells\" with ground-glass, homogeneous nuclear inclusions (Papanicolaou, Ã1000).<br />(B) Urine cytology specimen depicting vesicular variant decoy cells with enlarged nuclei with clumped, irregular chromatin (Papanicolaou, Ã1000).<br />(C) Urine cytology specimen with tubular casts containing numerous compacted<br />decoy cells indicative of polyomavirus-associated nephropathy (Papanicolaou, Ã400).</div><div class=\"graphic_reference\">Reproduced with permission from: Bechert CJ, Schnadig VJ, Payne DA, Dong J. Monitoring of BK viral load in renal allograft recipients by real-time PCR assays. Am J Clin Pathol 2010; 133:242. Copyright &copy; 2010 American Society for Clinical Pathology.</div><div id=\"graphicVersion\">Graphic 83969 Version 3.0</div></div></div>"},"83972":{"type":"graphic_diagnosticimage","displayName":"Salter-Harris type II distal femoral fracture","title":"Salter-Harris type II distal femoral fracture","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Salter-Harris type II distal femoral fracture</div><div class=\"cntnt\"><img style=\"width:513px; height:426px;\" src=\"images/EM/83972_Salter_Harr_II_distal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure A shows a displaced Salter-Harris II distal femoral fracture extending through the physis (arrows). Figure B shows post-operative healing with restored alignment.</div><div class=\"graphic_reference\">Courtesy of Kimberly Stone, MD.</div><div id=\"graphicVersion\">Graphic 83972 Version 1.0</div></div></div>"},"83975":{"type":"graphic_table","displayName":"Hypothermia PI","title":"Hypothermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypothermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Body temperature</td> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Common symptoms</td> </tr> <tr> <td>98.6&#176;F (37&#176;C)</td> <td>(Normal body temperature)</td> <td>&nbsp;</td> </tr> <tr> <td>90 to 95&#176;F (32 to 35&#176;C)</td> <td>Mild hypothermia</td> <td>Shivering, goose bumps, bluish skin, confusion, trouble speaking, memory problems</td> </tr> <tr> <td>82 to 90&#176;F (28 to 32&#176;C)</td> <td>Moderate hypothermia</td> <td>Shivering stops, feeling very sleepy, seeing things that are not there (hallucinations)</td> </tr> <tr> <td>Less than 82&#176;F (28&#176;C)</td> <td>Severe hypothermia</td> <td>Stiffness, passing out, coma, breathing stops, heart stops</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Normal body temperature is around 98.6Â°F (37Â°C). Hypothermia is when body temperature drops below 95Â°F (35Â°C). This table shows the temperatures at which hypothermia is called mild, moderate, and severe, and lists some of the symptoms that happen with each stage.</div><div id=\"graphicVersion\">Graphic 83975 Version 1.0</div></div></div>"},"83976":{"type":"graphic_picture","displayName":"Nail matrix punch biopsy","title":"Punch biopsy of the nail matrix","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Punch biopsy of the nail matrix</div><div class=\"cntnt\"><img style=\"width:576px; height:374px;\" src=\"images/DERM/83976_Nail_matrix_punch_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission of Informa Healthcare, from An Atlas of Diseases of the Nail, Rich P, Scher RK, New York, 2003; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 83976 Version 4.0</div></div></div>"},"83977":{"type":"graphic_picture","displayName":"Nail lateral longitudinal excision","title":"Lateral longitudinal excision of the nail","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral longitudinal excision of the nail</div><div class=\"cntnt\"><img style=\"width:393px; height:504px;\" src=\"images/DERM/83977_Nail_lateral_long_excis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83977 Version 2.0</div></div></div>"},"83980":{"type":"graphic_picture","displayName":"Nail tangential excision","title":"Nail tangential excision","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Nail tangential excision</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/DERM/83980_Nail_tangential_excis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83980 Version 1.0</div></div></div>"},"83981":{"type":"graphic_picture","displayName":"Nail map paper and cassette","title":"Nail map paper and cassette","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nail map paper and cassette</div><div class=\"cntnt\"><img style=\"width:504px; height:357px;\" src=\"images/DERM/83981_Nail_map_paper_cassette.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 83981 Version 1.0</div></div></div>"},"83996":{"type":"graphic_figure","displayName":"TAPVC PI","title":"Total anomalous pulmonary venous connection","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Total anomalous pulmonary venous connection</div><div class=\"cntnt\"><img style=\"width:536px; height:526px;\" src=\"images/PI/83996_TAPVC_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heart has 4 main sections, or \"chambers.\" The top 2 chambers are called the right atrium and left atrium. The bottom 2 chambers are called the right ventricle&nbsp;and left ventricle. Each of these chambers has a valve (shown in gray) that keeps blood flowing in 1 direction. When the heart is working normally, blood comes in from the body through the right atrium and into the right ventricle. From there it goes to the lungs, where it picks up oxygen. Then the blood comes back through the left atrium, into the left ventricle, and out to the body through a blood vessel called the aorta (shown in red). When a baby has a total anomalous pulmonary venous connection, the blood from the lungs does not return to the left atrium. Instead, it returns to the right atrium, or another vein in the body and then into the right atrium.</div><div id=\"graphicVersion\">Graphic 83996 Version 2.0</div></div></div>"}};